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Abstract 
	  
The aim of this project is to study the use of Staphylococcus carnosus as an 
alternative host in whole-cell biocatalysis, using the NADPH-dependent conversion 
of cyclic ketones by cyclohexanone monooxygenase (CHMO) as the model 
system.  
The use of whole cells in industrial biocatalysis has been actively 
researched due to their promise as biological factories that can perform complex 
reactions in environments where the use of isolated enzymes would not be 
feasible. However, the majority of whole-cell processes rely on a small range of 
organisms that, while been extensively characterized and easily engineering to 
express enzyme biocatalysts, have some inherent limitations that hinder their 
application to many industrial processes. Thus. There is a need to find novel 
microorganisms that can fill in the shortcoming of those conventional strains.       
In this project, a flexible shuttle vector was constructed to allow for the 
cloning and expression of CHMO in both E. coli and S. carnosus by using a dual 
promoter system in which one of the promoters could be replaced. Higher levels of 
CHMO expression were achieved in E. coli strains cloned with the shuttle vector 
compared to an expression vector used in previous studies. No biocatalyst 
expression was detected in S. carnosus. The shuttle vector was subsequently 
modified to allow for the quantitative characterization of different synthetic 
promoters based on the gemone of S. carnosus. A novel in-silico promoter 
selection methodology based on the codon bias was developped to allow for the 
rational selection of potential genomics promoters. Two synthetic promoters based 
on sequences upstream of ribosomal proteins rplK and rplJ were subsequently 
shown to allow for protein expression in both E. coli and S. carnosus. The stronger 
of these two promoter was inserted into the CHMO expression vector, but the 
resulting construct did not manage to express detectable levels of the biocatalyst in 
S. carnosus. It was thus concluded that S. carnosus was not a suitable host for 
biocatalysis with CHMO, and further studies with other enzymes would have to be 
conducted to access its suitability as a general biocatalytic host.  
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Chapter 1: Introduction to 
the project 
	  
	  
1.1- Biocatalysis as an Emergent Technology  
 
Biocatalysis as a field revolves around the idea of using biological systems 
to perform chemical reactions, either through the use of isolated enzymes or 
microorganisms. By necessity, the biocatalytic approach relies on our 
understanding of the biological systems that make up organic life, and 
subsequently allows us to take inspiration from these systems in the design and 
application of biocatalysis.   
The idea of biocatalysis as a distinct field in which biological entities are 
purposely engineered for use in human-constructed processes is fairly recent when 
compared to the much longer history of the subconscious use of 
biotransformations in processes that permeate our lives. The very familiar process 
of beer production is one of the oldest examples of an accidental biotransformation 
by using microorganisms in the production of beverages. The oldest records date 
from 6000 BC in the “Fertile Crescent” when Sumerians and Babylonians were 
practicing the art of brewery. Another example of these early biocatalysts is the use 
of yeast in bread baking by the Egyptians (Liese et al. 2008). These examples 
illustrate the crucial role that biocatalysis fulfilled throughout history in shaping what 
we produce and how we produce it.  
It was only in the second half of the 19th century, with the discovery of the 
enantioselective fermentation of tartaric acid by Louis Pasteur in 1857 (Gal 2008), 
that biocatalysis became an active field of research. Louis Pasteur’s discovery not 
only shed light on the use of microbial systems for the production of chemical 
compounds, but also highlighted how biological systems introduced chirality into a 
chemical reaction. This promoted a surge of research into biotransformations that 
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culminated in Fischer giving the first description of enzymes as biological machines 
capable of performing reactions in a stereo-selective manner, by means of the very 
well known lock-and-key metaphor (Reggelin 2005; Bornscheuer & Buchholz 
2005).   
The lock-and-key metaphor proved to be an apt description of the 
mechanisms underlying the activity of enzymes. But it wasn’t until Eduard Buchner 
published a series of studies on alcohol fermentation in the 1870s that enzymes as 
entities that could perform chemical reactions in the absence of living cells was 
widely considered (Bornscheuer & Buchholz 2005). Numerous studies since have 
described how enzymes select compounds on the basis of their stereochemistry 
and efficiently produce compounds of high optical purity (Thomas et al. 2002; 
Wohlgemuth 2010).   
Thus, as the focus of scientific research shifted to enzyme biochemistry, and 
the knowledge of an ever-growing repertoire of enzyme-mediated reactions 
deepened, the notion of using biological systems as machines for chemical 
synthesis started to permeate a broad range of different research and industrial 
fields (Illanes 2008; Bornscheuer & Buchholz 2005).  
The introduction of biocatalysts opened up a new golden age of discovery 
and technological improvements. More efficient processes for the production of 
commercial compounds were instituted, while novel biochemical processes were 
created by exploiting a ever-increasing catalogue of enzyme catalysts. (Otten et al. 
2010; Thomas et al. 2002; Pollard & Woodley 2007; Coward-Kelly & Chen 2007).  
It is perhaps apt to draw a parallel between the current state of biocatalysis 
and that moment in history when Louis Pasteur first described the fermentation of 
tartaric acid.  As his discoveries changed the state of scientific knowledge and 
challenged the status quo at the time, so now is the field of biocatalysis pushing 
the boundaries of current science, by changing the landscape in with we create 
products and commodities, and by presenting new and exciting ways of expanding 
our biotechnological capabilities.    
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1.1.1- Biocatalysis in the Chemical industry 
 
The chemical industry is an area with a strong impact in a broad range of 
commercial products used in everyday life, including pharmaceuticals, fragrances, 
detergents, textiles and biofuels (Sanchez & Demain 2010). The importance of this 
industry has led to increasing demand for long-term sustainable processes and the 
production of more specialized products, both of which are difficult to achieve using 
the tradition chemical approach.  While chemical processes can achieve very high 
yields, they often require high-energy inputs, the use of potentially harmful 
solvents, and result in the production of large quantities of by-products, which 
require efficient separation (Thomas et al. 2002). 
In this context, biocatalysis has become a highly attractive alternative to the 
traditional approach. Many enzymes are flexible catalysts that can accept a wide 
range of substrates, and are able to produce optically active compounds with high 
enantio- and regio-selectivity in a rapid fashion. This solves several problems of 
the conventional chemical industry. Firstly, biocatalysis allows for the use of 
renewable and cheap feedstocks and does not require the numerous protection of 
vulnerable groups and  their subsequent de-protection steps of chemical processes 
In addition, the highly selective reactions involved in biocatalysis bypass the need 
to develop complex downstream processes for the separation of unwanted bi-
products. Biocatalysis also provides answer to the more recent and increasingly 
important concern of creating “greener” industrial processes (Woodley et al. 2008). 
An example of the relevance of the stereo- and regio- selectivity of enzyme 
biocatalysts for the chemical industry is the production of pharmaceutical 
compounds such as neuraminic acid, a precursor to the anti-influenza drug 
Zanamivir, which is produced by N-acetyl-D-neuraminic acid aldolase (Liese & 
Villela Filho 1999). The chiral complexity of the substrates and products involved in 
this reaction would require several protection and de-protection steps during 
chemical synthesis, while the aldolase can carry out the reaction in a single step 
without protection. Another example of the advantages of biocatalysts is the use of 
peroxidases for production of phenolic resins, which are used in numerous 
industries as molding materials, circuit component s, coatings and adhesives, 
among others (A. Schmid et al. 2001). The chemical synthesis of these resins 
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involves the condensation of formaldehyde with several phenol-type, but the 
toxicity of the former compound as led to a shift of the process into the direct 
enzymatic polymerization of phenols (Dordick et al. 1987). In this case, the 
peroxidase allows for conversion to occur in milder condition than the chemical 
counterparts by using hydrogen peroxide as the oxidant, thereby removing the 
toxic pollutant from the process waste.  
In 2011, it was estimated that the overall industrial biocatalytic market 
accounted for more than 500 products, excluding diagnostics and pharmaceuticals, 
with the bulk of the biocatalytic processes being focused on detergent production 
and food processing (Sanchez & Demain 2010). Several enzymes are currently 
routinely used as additives in detergents for stain removal, the most common being 
the serine proteases from Bacillus species due to their stability under high 
temperatures and alkaline pH (Maurer 2004). More recently, second-generation 
enzymes such as amylases, cellulases and mannanases that are better for the 
removal of specific stains have been developed (Kirk et al. 2002). Detergent 
production remains the largest application of enzyme catalysts in chemical industry 
due to the commercial scale of detergent use (Figure 1).  
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Figure	  1-­‐	  Enzyme	  market	  distribution	  for	  the	  Chemical	  Industry	  in	  2003	  (Sanchez	  &	  Demain	  2010).	  	  
 
The application of biocatalysts to the food industry is more diverse, ranging 
from flavor production to food preservation. As previously mentioned, microbial 
biocatalysts have historically played a very crucial role in beer brewing and bread 
baking.  With the development of technologies for enzyme screening and 
purification, several other food processes have since been put in the charge of 
biocatalysts. For instance, the production of the low-calorie sweetener Aspartame, 
which is applied to a broad range of products from soft drinks to ready-made 
meals, and is composed of the two natural amino acids L-aspartic acid and L-
phenylalanine.  is catalyzed by the thermophilic zinc protease thermolysin 
(Bommarius & Riebel 2005). This enzyme not only has an optimal temperature of 
50- 60 oC, but it also allows for a tight control over the regio- and enantio- 
selectivity of the reaction. Another compound that is used as a sweetener, D-
fructose, is converted from D-glucose by a xylose isomerase that is active at 70 oC 
in packed bed reactors (Schoemaker et al. 2003). Microbial and fungal proteases 
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are also involved in food processing as substitutes for calf rennet for the milk 
clotting process in cheese production (Shieh et al. 2009; Vishwanatha et al. 2010). 
The use of engineered enzymes as substitutes for the coagulating mammalian 
proteins chymosin and pepsin in the calf rennet improves the cheese 
manufacturing process in two major ways: it solves the bottle-neck of limited 
enzyme supplies found in the calf stomach extracts, as well as preventing heath 
risks related to bovine spongiform encephalopathy or scrapie (Jacob et al. 2011). 
Finally, Gram-positive bacteria such as Staphylococcus carnosus are used in the 
curing of raw meat for the preservation of colour, flavor production, and prevention 
of spoilage by pathogenic organisms (Gøtterup et al. 2008; Simonová et al. 2006).    
Several other industrial areas employ biocatalysts to a lesser extent. In 
textile industries the scouring step of cotton processing, which revolves around the 
removal of cell-wall components on cellulose fibers, conventionally involves high 
temperatures and alkaline conditions. This can be avoided by using microbial and 
fungal pectinases, which allow for the process to be performed in a single step 
under milder process conditions (Tzanov et al. 2001). In the production of animal 
feed-stocks, fungal, bacterial and yeast phytases are used to release phosphorus 
from phytates found in plant-derived feed (Haefner et al. 2005), which cannot be 
digested by monogastric animals . Since phytates account for 60 to 80% of 
phosphorous in plant-derived feedstock, the use of enzymes that complement for 
deficiencies in mammalian digestive systems is essential in order to provide a 
sufficient diet in the food. In addition, the present of phytates in the human diet has 
been related to negative heath effects. As a anionic compound, phytate, will bind to 
several positively charged mineral ions and proteins, thus affecting the uptake of 
essential dietary minerals like zinc and calcium as well as the activity of proteins 
they bind to (Greiner & Konietzny 2006). Therefore, there is also a health-related 
interest in the use of phytases in animal feedstocks and food industries.  
Despite the clear advantages of biocatalysis, there are still problems that 
prevent the application of several promising biocatalysts in large-scale industrial 
processes. One of the problems is that a number of chemicals and polymers 
produced in chemical processes are not soluble in aqueous solutions and require 
reactions to be performed in organic solvents. While several enzymes have been 
found to be sufficiently stable and show activity in hydrophobic environments, there 
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is a big proportion of proteins that are not active in such environments (Schmid et 
al. 2001).  Another bottleneck is the struggle of biocatalytic reactions to achieve the 
high yields of traditional chemical processes, either due to enzyme instability or the 
need for co-factor regeneration. The successful transition of biocatalysts into the 
chemical industry is dependent on how cost-competitive the biocatalytic processes 
are when compared to the more conventional chemical counterparts (Sanchez & 
Demain 2010). Thus, biocatalytic processes that perform bellow industrial 
standards are handicapped, as they often require a lengthy optimization process. 
This in itself becomes a problem, as many companies are unwilling to invest high 
sums of money into novel processes that require specialized training and the 
extensive development and optimization of processes prior to application (Thomas 
et al. 2002). On the other hand, the advent of the genomic era has opened a 
window to the discovery of novel biocatalysts that can operate in more extreme 
environments, while also sponsoring developments in genetic engineering 
techniques that allowed for the optimization of current biocatalysts. These 
technological advances will be discussed in more detail in a later section.  
 
1.1.2- Biocatalysis in the Medical Sciences 
 
Biocatalysis also plays a very important role in the development of new- 
generation therapeutics. As the bank of natural compounds available for 
therapeutic use dwindles and becomes less effective against a growing number of 
pathologies, the pharmaceutical industry has led the search for novel small 
molecules that are either based on the natural counterparts or purely novel 
synthetic compounds (Newman & Cragg 2012). Enzymes, with their tightly defined 
regio- and enantio-selectivity, are ideal catalysts for the construction of complex 
structures with several chiral centers and active groups.    
In fact, the relevance of biocatalysis to drug discovery cannot be better 
exemplified than by one of the great medical developments in the 20th century, the 
discovery of penicillin. This discovery was made by Alexander Fleming, who 
reported in 1929 the anti-bacterial effects of a substance secreted by a Penicillium 
mold on several pathogenic bacterial cultures (Fleming 1979), later named 
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penicillin.  The fermentation studies on Penicillium notatum conducted by Florey 
and colleagues at both the Sir William Dunn School of Pathology at Oxford 
university and the Northern Regional Research Laboratory of the US Department 
of Agriculture constituted the first instance of an antibiotic produced in large scale 
through the action of a fungal micro-organism (Kardos & Demain 2011). The 
realization that microorganisms could be used for the development of anti-bacterial 
drugs highlighted the potential of biological systems as sources for drug discovery, 
and opened up a new era for therapeutic-directed biocatalysts.  
Since the major breakthrough in the discovery of penicillin, biocatalyst 
systems have been recognized as sources of natural products for therapeutic uses. 
Thus, several bacterial and fungal microorganisms have been employed in the 
pharmaceutical industry due to their native ability to produce bioactive secondary 
metabolites that exert a major impact on several diseases and medical conditions. 
One example is the anti-cancer antibiotic daunorubicin, which is produced naturally 
by Streptomyces peucetius (Demain & Sanchez 2009). This anthracycline acts by 
interlacing DNA strands, which prevents transcription, and triggering cell-death 
through Topoisomerase II DNA digestion. It has been found to be very effective 
against several types of cancer, including leukemia, lymphoma, and lung cancer. 
Another important group of natural metabolites was found in the fermentation broth 
of Streptomyces avermitilis (Campbell 2012). These compounds, named 
avermectins, are 16-membered macrocyclic ketones that have a strong toxic 
activity towards parasitical nematodes, but are non-toxic to most other organisms 
(Dent et al. 1997). 
Biocatalysts have also been extensively used in pathways for the synthesis 
of synthetic compounds. In fact, biocatalysis has been the major driving force 
behind the expansion of the repertoire of bioactive compounds that replace the 
dwindling effective natural products available to drug manufacture. The production 
of the anti-hypertensive drug Omapatrilat is a clear example of how biocatalysts 
are integrated into drug synthesis. This compound is a complex chiral molecule 
that can be used to treat hypertension and congestive heart failure by inhibiting 
both the angiotensin-converting enzyme and an endopeptidase involved in the 
stimulus of the production of cGMP and consequent vaso-dilatation (Seymour et al. 
1991) by blocking the activation of the cGMP cyclase. One intermediate in this 
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drug symnthesis, (S)- 6- hydroxynorleucine, is synthesized through the activity of 
four enzymes. First a D amino acid oxidase and catalase are used to make 2-keto-
6hydroxyhexanoic acid which in turn is acted upon by glutamate dehydrogenase 
making (S)-6-hydroxynorleucine. The reaction uses ammonia and the coenzyme is 
NADH.  The NADH is regenerated by using glucose and a glucose dehydrogease 
from Bacillus megaterium. (Patel et al. 2003). The use of these enzymes solves 
some of the problems of chirality and multiple sensitive functional groups present in 
Omapatrilat. Perhaps a more relevant example of high-impact biocatalysis of 
synthetic drugs is the production of an intermediate to the neuraminidase inhibitor 
Tamiflu® from Roche. This intermediate compound, shikimic acid, is also an 
intermediate of aromatic amino acid synthesis, and through pathway engineering 
strains of E. coli were created to allow for the bulk production of this compound 
(Panke & Wubbolts 2005; Escalante et al. 2010).  
One class of enzyme catalysts that has been the focus of intensive research 
in the context of therapeutics is cytochrome P450s (CYP) (Figure 2). These 
enzymes are haeme-containing monooxygenases that catalyze a variety of 
different oxidation reactions on a broad range of substrates, including active 
secondary metabolites of human metabolism, such as hormones and signaling 
molecules, as well as intermediates of drug metabolism (Urlacher & Girhard 2012). 
Thus, the pharmaceutical relevance of these enzymes stems not only from the fact 
that they are able to catalyze a large repertoire of processes, but also because 
they interact directly with bioactive compounds such as steroids and xenobiotics. 
Correspondingly, a number of drug synthesis processes using microbial p450s 
have been established. For instance, the production of Pravastanin, (an HMG-CoA 
reductase inhibitor that suppresses cholesterol biosynthesis), from compactin by a 
Streptomyces sp. cytochrome P450 has been developed into a lucrative 
commercial process (Urlacher & Eiben 2006).  
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Figure	  2-­‐	  Industrially	  relevant	  oxidations	  and	  hydroxylations	  conducted	  by	  cytochrome	  P450s	  from	  
different	  native	  organisms:	  CYP170A1	  from	  Streptomyces	  coelicolor	  A3(2)	  converts	  epi-­‐isozizaene	  into	  the	  
antibiotic	  albaflavenone	  	  (reaction	  1)	  (Urlacher	  &	  Girhard	  2012)	  ;	  CYP19,	  which	  is	  abundant	  in	  the	  human	  
liver,	  catalysises	  the	  conversion	  of	  testosterone	  into	  estradiol	  (reaction	  2),	  which	  can	  be	  subsequently	  
converted	  into	  anti-­‐cancer	  compounds	  (Tsuchiya	  et	  al.	  2005);	  the	  anti-­‐cholesterol	  drug	  pravastatin	  can	  be	  
economically	  produced	  using	  a	  CYP	  from	  the	  soil	  bacteria	  Streptomyces	  sp.	  Y-­‐110	  (reaction	  3)	  (Park	  et	  al.	  
2003). 
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Human CYPs have also been extensively researched as potential 
therapeutic biocatalysts due to the fact that they are native to the end users of the 
pharmaceutical industry.  Several pharmaceutical companies have successfully 
cloned and expressed human CYPs in microbial and yeast systems for large-scale 
synthesis of bioactive metabolites. One example is Novartis, which tested 14 
human CYPs from E. coli systems for synthesis of bioactive metabolites from more 
than 60 different compounds (Schroer et al. 2010). The results highlight the 
versatility of this class of enzymes, as several of them were able to synthesize 
metabolite building blocks that could be later used in drug production. More recent 
therapeutic strategies focus on the use of CYP as prodrug activators for treatment 
of cancer cells, thus using the target cells as the centers of biocatalytic focus. For 
instance, the human CYP2B6 was delivered to cancer cell culture via a retroviral 
vector and was shown to successfully activate the prodrug cyclophosphamide 
(CPA) into a more active compound that damaged DNA in the cell, thus inhibiting 
tumor growth (Kan et al. 2001). This approach to chemotherapy offers several 
advantages to the conventional methods, as it allows for the specific targeting of 
the toxicity of drugs to cells that express the recombinant CYP, where they are 
activated. Additionally, human recombinant CYP expression is not in itself toxic to 
cells, and will not trigger a native immune response.  
The examples given above are just a sub-section of the pharmaceutical 
processes that hinge on enzyme catalysts or whole-cell systems. The heavy 
investment of companies and academic research has promoted a bloom in the 
number as well as the types of biocatalysts, which in turn paved the way to the 
production of more complex bioactive metabolites and drug compounds. 
Correspondingly, the impact on the pharmaceutical industry on healthcare is 
partially dependent on breakthroughs made in the field of biocatalysis. Recently, 
several approaches have been adopted not only to find several novel biocatalysts 
of medical importance, but also to change the nature of biocatalysts so that they 
can perform a broader range chemical reaction, and subsequently grant access to 
a wider variety of drug compounds. These approaches will be discussed in the next 
section.  
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1.2- Enzyme versus Whole-Cell Biocatalytic 
Systems:   
 
In the examples mentioned above, both isolated enzyme system and whole-
cell systems were discussed in equal measure. However, there is a clear 
distinction between these systems that cannot be ignored, as they do not stand on 
equal footing for every chemical process that would require a biocatalyst. 
Therefore it is worth spending some time analyzing both systems in parallel and 
compare their advantages and disadvantages.  
Enzymes are powerful biological machines, optimized to catalyze a wide 
variety of reactions in a enantio- and stereo- selective manner, while producing 
optically pure products in a single reaction that does not require large inputs of 
energy and hazardous chemical compounds (Bommarius & Riebel 2005; Thomas 
et al. 2002). Thus, the use of these machines in-vitro in vitro offers a very attractive 
alternative to conventional organic chemistry, which normally relies on several 
steps and cannot provide pure products in a very straightforward manner. A very 
relevant example in the context of this PhD project is the use of enzyme biocatalyst 
for Baeyer-Villiger oxidations in industry. As it will be discussed in more detail later 
in this chapter, Baeyer-Villiger oxidations refer to reactions in which an oxygen 
atom is introduced into the structure of ketones near the carbonyl groups, resulting 
in the production of esters, or lactones in the case of cyclic ketones (Mihovilovic et 
al. 2002). In the chemical process, peracids or hydrogen peroxide are used as the  
reagent for the reaction, but the use of these compounds poses a major challenge 
for industrial scale Baeyer-Villiger oxidations due to their reactivity and toxicity 
(Kamerbeek et al. 2003). By contrast, the use of enzyme catalysts not only 
simplifies the reaction process by removing the need for protection and de-
protection steps to prevent by-product formation with the use of reagents, but also 
presents a greener alternative to the use of large volumes of hazardous 
compounds.   
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In many chemical processes, isolated enzymes are seen as the preferred 
biocatalysts over whole-cell systems. One of the major advantages of isolated 
enzyme systems is the low degree of system complexity, when compared with 
whole-cell systems with secondary metabolic pathways and several potential 
mass-transfer barriers. In this respect, working with enzyme biocatalysts leads to a 
simplification of design for any catalysis process (de Carvalho 2011). Another 
related advantage of isolated-enzyme systems is the turnover of products, which 
are not dependent on mass-transfer limitations across the cellular membrane, and 
therefore often result in higher yields (Burton et al. 2002).  
The major downside of isolated-enzyme system is the stability of the 
biocatalysts that operate under stringent microenvironments. Devoid of the 
homeostatic environment of the intracellular space, enzymes become highly 
susceptible to small shifts in reaction conditions such as temperature, pH, and non-
conventional solvents (Illanes et al. 2012). Correspondingly, several strategies 
have been developed in the attempt to solve this problem. One of these strategies 
that has been greatly aided by advances in sequencing technology, is the 
metagenomic approach, whereupon libraries of metagenomes are screened for 
enzyme biocatalysts that are inherently optimized for a specific process. One such 
approach is the screening of DNA from extremophile organisms for the 
identification of biocatalysts such as lipases and proteases that are stable in 
organic solvents (Gupta & Khare 2009).  
Recent developments in the field of genetic engineering have also allowed 
for synthetic approaches that focus on the optimization of existing biocatalysts 
instead of searching for novel enzymes. One of these methodologies, directed 
evolution, relies on the use of site directed mutagenesis or genetic recombination 
to create large libraries of iterations from an single enzyme catalyst, which are 
subsequently screened for increased stability, higher activity, or even novel 
substrate specificity (Goldsmith & Tawfik 2012; de Carvalho 2011). The great 
advantage of this strategy, and the reason why it is currently one of the preferred 
methodologies for optimization of a biocatalytic process, is the fact that a large 
number of active iterations can be created without a comprehensive understanding 
of how protein sequence and function are co-related. Of course, in many practical 
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cases, a prior understanding of the enzyme’s mechanism of action and structure 
greatly improve the chances of creating an active library of optimized iterations.  
Another strategy largely employed in industry to increase the stability of 
biocatalysts is enzyme immobilization, either through cross-linking onto a support, 
or through absorption or entrapment onto a carrier. While there is no universal rule 
to predict how different biocatalysts will behave after immobilization, in many cases 
this strategy has been shown to increase the overall structural stability of the 
biocatalyst, its tolerance to pH and temperature, and to increase activity (Singh et 
al. 2013). An added advantage of immobilization is the easy downstream 
separation of the reacting biocatalyst from the finished product.   
While the development of several genetic, genomic, and process strategies 
allowed for the optimization of enzyme biocatalytic systems and even the creation 
of novel ones, stability is not the only difficulty in working with these systems. 
There are numerous cases of highly desirable biocatalysts that require co-factors 
such as NAD(P)H and FAD for efficient catalysis, which are often very expensive 
compounds to produce and subsequently constitute a large economical cost in a 
industrial-scale process.  Aside from a couple of examples where hybrid 
biocatalysts were created by coupling an active enzyme with a co-factor 
regeneration domain (Torres Pazmiño et al. 2009), co-factor regeneration is still a 
major limitation to the development of economically viable processes for this type 
of biocatalyst.  Many methodologies used to tackle this problem rely on two 
enzyme systems, whereupon the activity of the primary biocatalyst is 
complemented with a second protein and substrate that recycles the co-factors. 
Some recently developed recycling systems involve the use of enzyme catalytic 
loops such as glucose-6-phosphate dehydrogenase and formate dehydrogenase 
systems to regenerate NADPH (Mihovilovic et al. 2002). Another closed-loop 
catalytic system involve the use of an alcohol dehydrogenase that converts the 
alcohol substrate into a ketone, reducing NADP+ in the process (Willetts 1997).  
The problem with such two enzyme systems is the need to supply in situ conditions 
that are compatible with both enzymes, which considerably increases the 
complexity of the system.  
Other types of biocatalysts that are not easily adapted to isolated-enzyme 
systems are membrane-associated proteins, which require the physical contact to 
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structures analogous to cellular lipid membranes. A more crucial limitation of 
membrane bound biocatalysts is the challenge of purifying the protein from the 
membrane without a significant loss of activity, which often requires complex and 
cost-demanding protocols (Lin & Guidotti 2009).   
While enzyme catalysis have warranted much of the attention due to their 
immediacy as biological machines and the flexibility that they offer, it is often easy 
to forget that the first steps into the area of biocatalysis were taken by whole-cell 
systems. Here, we will only briefly discuss the advantages and disadvantages of 
these systems over isolated biocatalysts, in order to re-iterate the importance of 
whole-cell biocatalytic systems as viable options for industrial and research 
biocatalysis. A more in-depth discussion of these systems will follow in the next 
sections.  
Working with whole-cell systems offers a different approach that bypasses 
crucial hurdles of isolated enzyme biocatalysis.  On one hand, cells have natural 
recycling systems and thus do not require the use of expensive co-factors or 
secondary protein catalytic systems to replenish co-factors. On the other hand, use 
of host cells avoids the need for protein purification and problems with protein 
instability, as the biocatalysts are expressed and maintained in a tightly controlled 
intracellular micro-environment that is physically protected from external changes 
(Kuhn et al. 2010).  As mentioned above, these factors represent major difficulties 
for the development of cost-efficient biocatalytic processes, particularly on the 
industrial scale. Whole-cell systems are also self-recycling, by which it is 
understood that the expressed biocatalysts are in a constant cycle of renewal that 
is concomitant with the metabolic activity of the host. It follows that the biocatalyst 
recycling step in a whole-cell biocatalytic process is easily achieved by re-growing 
the host cells (Pollard & Woodley 2007).  Therefore, there is an argument to the 
lower cost of using whole-cell systems as direct catalysts when compared to the 
costs of protein purification, the R&D needed for stability optimization, and the 
recycling strategies often associated with isolated-biocatalyst systems.  
However, whole-cell systems also have major drawbacks, particularly the 
added complexity of whole cells compared to the isolated enzyme systems in 
terms of the number of factors the affect the yields of a given biocatalytic process. 
For instance, the presence of several metabolites as well as the desired products 
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in the fermentation broth requires more extensive downstream processes to extract 
the products to the desired degree of purity.  In addition to increasing the number 
of undesired compounds in the output of the biocatalytic process, some cellular 
metabolic pathways might directly compete with the desired biocatalytic reactions, 
resulting in a decreased yield through the degradation of the products or further 
conversions of the latter into undesirable by-products. One such example is the 
use of baker’s yeast strains to perform Baeyer-Villiger oxidations with 
cyclohexanone monooxygenase from Acinetobacter sp. NCIB 9871.  While the 
biocatalytic conversions were mostly successful, the presence of native proteins 
that competed with the Baeyer-Villiger oxidation by reducing the ketone substrates 
ultimately argued against the use of baker’s yeast as suitable hosts (Stewart et al. 
1996; Kayser 2009).  
Another crucial limitation of whole-cell biocatalytic processes is that in 
several cases these systems struggle to achieve product yield that could be 
deemed acceptable for industrial processes (Pollard & Woodley 2007). The 
problem here is two fold. On one hand, the ability of the lipid cell wall to maintain 
the homeostatic nature of the intracellular microenvironment works as a 
permeability barrier against the diffusion of certain biocatalytic substrates that are 
either too hydrophobic, hydrophilic, or large to cross from the extracellular broth to 
the space where biocatalysis occurs. Recent attempts to counter-act this limitation 
relied upon genetic manipulation of cell wall synthetic pathways (Ni & Chen 2004), 
which manage to increase the permeability of the membrane to large hydrophilic 
compounds. On the other hand, some substrates and products are inherently toxic 
to cells, and therefore cannot be present in the biocatalytic environment above the 
toxicity threshold, which in many cases results in very low overall yields. 
Consequently, in these biocatalytic processes strategies are employed to regulate 
the concentration of the toxic compounds throughout the reaction, either through 
establishing a chemostat, where substrate and product are continually added and 
removed, or through the use of in situ resins with high affinities to the toxic 
compounds (Lye & Woodley 1999; Woodley et al. 2008).  
It is clear from this brief analysis of the two type of biocatalytic systems that 
there is no straightforward answer as to which one is the best. The choice between 
isolated enzymes and whole-cell biocatalysts will largely depend on the type of 
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biocatalytic process, its operation conditions and the biocatalysts’ requirements. In 
processes where reaction conditions are mild and a fast turnover is required the 
use of isolated-biocatalysts might be favored, whereas in situations where the 
biocatalysts are not stable or require co-factor regeneration the use of whole-cell 
systems might be more economically viable. For the sake of this PhD project, the 
subsequent sections of this chapter will focus primarily on the discussion of whole-
cell systems. However, we do not wish to prioritize the later over isolated-enzyme 
systems, but rather show that whole-cell biocatalysis is a viable option in the 
context of this project’s topic.  
 
 
1.2.1- Conventional Hosts employed in Biotechnology 
  
The current range of microorganisms used for biotechnology is as large as it 
is wide reaching, aided as it has been by advances in Genetic Engineering 
techniques as well as the genomic foot printing of several species, which has 
allowed for an easier characterization and manipulation of such species. Numerous 
gram-negative and gram-positive bacteria, as well as fungi and mammalian cells 
are routinely employed as hosts for pharmaceuticals production, as components in 
biofuel refineries, as preservers in ripening agents in food industry, among others 
roles.  
However, despite this diversity, the gram-negative bacteria Escherichia coli 
can be still singled-out as the most widely used host in biotechnological processes, 
for both historical and practical reasons.  Historically, E. coli is the best-
characterized organism other than humans. Having been discovered and cultured 
in 1855 by the German bacteriologist Escherich in the fauna of the human colon, E. 
coli was routinely used as a model for biochemical studies before any other strain 
(Waites et al. 2009). It was also the first organism to produce human insulin as a 
genetically engineered therapeutic agent approved for human use, in 1982 (Glazer 
& Nikaido 2007).  In practical terms, E. coli strains are organisms that can grow 
rapidly under temperate conditions, with a doubling time of 30 to 20 minutes, and 
achieve high biomass yields using simple and cheap carbon sources like glucose 
(Yang et al. 2011). In addition, as the production of human insulin showed, E. coli 
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strains have a great versatility in the nature of proteins they can stably express. 
This capacity, together with the vast repertoire of genetic systems developed for 
heterologous protein expression and the ease of genomic engineering, have made 
E. coli into the staple host system in many industrial processes (Lee 2009).  
One such process is the production of amino acids, which are routinely used 
in human nutrition and consequently are in high demand. The use of bacteria as 
biocatalytic factories for the production of these compounds is preferable to the use 
of chemical processes, not only because amino acids are natural by-products of 
metabolic pathways in many bacterial strains, but also these strains permit the use 
of cheaper and milder reaction processes. Genetically engineering E. coli strains, 
in which specific metabolic genes have been knocked-out or up-regulated, are 
routinely used for the production of individual amino acids as more economically 
viable alternatives to chemical synthesis. For instance, the industrial production of 
L-threonine is dependent on the use of genetically modified E. coli strains in which 
the pathways for the production of this amino acid are up-regulated, and 
consequently can achieve yields of 100 g/L (Breuer et al. 2004). Another example 
of a mainstream industry in which E. coli is actively used is the production of 
Inosine-5’-phosphate (5’-IMP), which is a main flavor enhancer. In this case, a E. 
coli strain expressing an acid phosphatase/phosphotransferase gene from 
Escherichia blattae is used to achieve yields of 156 g/L of 5’-IMP (Ishige et al. 
2005), making it the most efficient and economically viable means of producting 
this compound. Other examples range from the production of chiral alcohols as 
single drugs to the production of novel carotenoids through pathway engineering 
(Ishige et al. 2005; Beloqui et al. 2008).  
However, E. coli is not a perfect industrial workhorse, and the realization of 
its limitations has been a major driving force in the search for alternative hosts. 
Genomic engineering has been very useful in partially mitigating many problems of 
E. coli –mediated processes, but some of the limitations cannot be easily bypassed 
through genetics. These include the inability to perform post-translational 
glycosylation, which is required for many mammalian proteins (Lee 2009), and 
inability to survive in extreme conditions, such as in organic solvent-based medium 
or at extreme temperatures. For instance, processes for the the production of 
biofuels like ethanol often involve the use of high temperatures, which facilitate 
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extraction of the product, and high concentrations of solvent, both conditions 
excluding the use of most E. coli strains in preference to extremophiles 
likeThermoanaerobacterium saccharolyticum (Shaw 2008). In other biocatalytic 
processes, as in Baeyer-Villiger oxidations of cyclic ketones (see section 1.6), the 
substrates and products of the process are toxic to E. coli strains due to 
accumulation in the cell membrane.  
Many of the limitations mentioned above have been bypassed by employing 
another equally successful group of microorganisms, collectively designated as 
yeasts. These predominantly unicellular eukaryotic fungi are perhaps the oldest 
organisms use in the production of human commodities such as bread and 
beverages, and therefore have advantage over E. coli of having been adapted for 
human use over millennia, (Waites et al. 2009). In addition, yeast like 
Saccharomyces cerevisiae are as well characterized and easily manipulated the E. 
coli counterparts, with an equal kit of tools for genetic engineering and protein 
expression being available commercially. They also have the added advantage of 
being more closely related to human and other mammalian cells in genetic terms, 
and therefore are able to express proteins that are not stably expressed in their E. 
coli counterparts. Thus, yeasts like S. cerevisiae and Pichia pastoris are major 
contributors to key industries such as the production of alcoholic beverages, fuel 
ethanol, and human proteins, including antibodies and insulin (Waites et al. 2009).  
However, despite their advantages, neither E. coli nor yeast strains are able 
to cover the myriad of biocatalytic processes that would benefit from the use of 
microbial hosts. Thus, as the biomedical and chemical industries shift to a pro-
biocatalyst age, there is a ever-pressing impetus to expand the repertoire of 
microorganisms that can be efficiently adapted and optimized to existing industries, 
as well as provide the backdrop to the discovery novel processes.    
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1.3- Staphylococcus carnosus as an 
Alternative Host for Biocatalysis 
 
The name Staphylococcus (greek- staphyle: “bunch of grapes”; coccus: 
“grape”) was first used by Sir Alexander Ogston in 1882 to describe a new form of 
micrococci involved in pyogenic abscesses in humans (Cohen 1972). As the name 
indicates, this type of bacteria was distinct from other types because it formed 
clusters (Figure 3).  
 
 
Figure 3- Staphylococcus aureus organised into grape-like structures (Reproduced from the 
Centers for Disease Control and Prevention’s Public Health image Library, image #6486) 
). 
 
The definition proposed by Ogston for the genus Staphylococcus is still 
used today, albeit complemented by biochemical, genomic, and proteomic 
analysis. In the 1920s staphylococci species were re-classified as part of the genus 
Micrococcus under the argument that there were insufficient distinctions between 
the two species. Only in 1955 was the genus Staphylococcus separated from other 
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cluster-forming cocci on the basis of growth and production of lactic acid from 
glucose under anaerobic conditions.  
Genetic data came to add another criterion to the separation, as 
staphylococci have lower GC genome content (30-40%) than the other genus. 
Recently, due to the development of new technologies for DNA and biochemical 
analysis, together with increasing database for genome sequences, a more 
extensive characterization of the genus Staphylococcus has been achieved, and 
some species that were previously considered under other genus are now been re-
classified as staphylococci (Schleifer & Fischer 1982; Suzuki et al. 2012). 
The species Staphylococcus carnosus was first isolated from meat 
fermentation products, hence the name, and was subsequently characterized 
incorrectly as part of the genus Micrococcus, a classification based on phenotypic 
traits. DNA analysis and DNA fingerprinting techniques came to play a crucial role 
in the re-classification of the species by dividing the family Macrococcaceae into 
two genetically distinct genera; Micrococcus and Staphylococcus. These 
techniques also led to the characterization of S. carnosus as a separate species 
from other coagulase-negative staphylococci found also in fermented meat, such 
as Staphylococcus piscifermentas, and Staphylococcus xylosus (Pantůcek et al. 
1999).   
Schleifer and Fischer (1982) describe this novel species as a 1 to 3 mm 
diameter cocci colonies that can occur as a single or in pairs, Gram-positive as 
classified by Gram staining, and not showing motility or spore forming ability. They 
also characterized S. carnosus as a facultative anaerobe, producing equal 
amounts of D- and L- lactate from glucose during anaerobic growth.  
As a Gram-positive bacterium, the intracellular space of S. carnosus is 
enclosed in a single inwards facing lipid membrane and outwards facing 
peptidoglycan wall that confers the physical robustness of Gram-positive bacteria. 
The peptidoglycan wall is a defining structure of Gram-positive bacteria, as it is 
substantially thicker (20-80 nm) than Gram-negative counterparts (7-8nm), and 
acts as the initial permeability and physical barrier between the extracellular and 
intracellular environments, as opposed to Gram-negative bacteria where it lies 
between the two lipid membranes (vollmer et al. 2008). S. carnosus exhibits 
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several phenotypic and genotypic characteristics that are considered highly 
desirable for whole-cell biocatalysis.  
 
1.3.1- The Staphylococcal Cell Wall 
	  
The general structure of the peptidoglycan wall is a mesh composed of 
layers of alternating beta- 1.4 linked N-acetylmuramic acid (NAM) and N-
acetylglucosamine acid dimers (NAG). Layers are further cross-linked via peptide 
stems that are connected to the N-acetylmuramic acid residue. In addition, the 
muramic acid can also serve as an anchor for wall teichoic acids (Xia et al. 2010) 
(Figure 4).  
 
	  
Figure 4- diagram showing composition of gram-positive bacterial cell wall (anon). 
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1.3.2- Non-pathogenicity  
 
The Staphylococcus genus is made up of 36 species, most of which can be 
found as colonizing bacteria in the skin and respiratory tracks of various higher 
mammals, including humans.  In addition to being inherent to the bacterial fauna 
present in our bodies, some species, such as Staphylococcus aureus and 
Staphylococcus epidermis are aggressive invaders that can cause severe human 
infections. Of particular note are MRSA and VRSA (methillin resistant- and 
vancomycin resistant- Staphylococcus aureus), which constitute the main causes 
of skin, pulmonary, and prosthetic-device related infections in hospital patients due 
to their resistance to antibiotic treatment (Rosenstein & Götz 2010). It is therefore 
understandable that much of the scientific interest in this genus has been driven by 
the need to find novel, effective treatments for these diseases.  
Staphylococcus carnosus stands apart from most of the other species of the 
genus, partly because it is not normally found in the bacterial fauna of higher 
mammals, and partly because it is a non-pathogenic bacterium, despite its 
phylogenetic proximity with the more pathogenic strains of the genus. The answer 
to these divergences can be found in the genetic comparison between the different 
species.  
The S. carnosus genome is 2.57 Mb long, 86% of which encodes for 
functional genes. Despite the small size of this genome relative to other 
staphylococci, S. carnosus shares 50 % of its gene products with other pathogenic 
species like S. aureus, S. epidermis, S. saprophyticus, and S. haemolyticus (Götz 
et al. 2004). These orthologous genes are organized in core region around the 
origin of replication that maintains an highly conserved gene structure across the 
different species. While 25% of the shared gene products do not have a known 
function, it is assumed that this conserved region encodes mainly for housekeeping 
genes, which are involved in essential metabolic processes and therefore are 
required for efficient metabolic functions in the different species.  
The point at which S. carnosus starts to diverge from its pathogenic cousins 
is in the absence of toxin genes that characterize the pathogenicity of the other 
	   37	  
species. Superantigens like the toxic shock syndrome toxin-1 (TSST1), which is 
one of the main toxins involved in food poisoning, or the pore-forming Parton-
Valentine leukocidin (PVR), do not have any corresponding homologs in the 
genome of S. carnosus (Götz et al. 2004). Additionally, it does not contain any 
adhesion proteins, such as fribronectin and fibrinogen-binding adhesins, which are 
essential for tissue invasion and biofilm formation. It is possible that the absence of 
these proteins explains why S. carnosus does not occur as a natural component of 
bacterial fauna of higher mammals.  
However, the latter is not completely devoid of virulence-associated genetic 
elements. In fact, 41 proteins from a group of 187 S. aureus COL proteins 
associated with pathogenicity and antibiotic resistance are shared with S. carnosus 
(Becker et al. 2007). Since these shared proteins are not pathogenic in S. 
carnosus, it has been hypothesized that their function is more directly related to 
general regulatory pathways that are also involved in the expression of toxic 
genes.  
Additionally, the genome of S. carnosus contains genomic islands that are 
characterized by a lower GC content and were possibly horizontally transferred 
from other genomes. These islands contain several genes of unknown function that 
share a weak homology with pathogenicity-associated genes. For instance, one of 
these genes codes for putative IgG-binding protein with 30% with protein A from S. 
aureus, but it is clear from experimental studies that S. carnosus does not exhibit 
IgG binding capacity. Similarly, there are also 2 putative exotoxin genes present in 
these clusters, despite the fact that S. carnosus does not excrete toxins 
(Rosenstein et al. 2009). It is clear that these genes are non-functional as 
pathogenic markers, either because they exert a different function despite the 
homologies, or because their expression in S. carnosus is disrupted. 
Aside from the lack of toxic genes, S. carnosus also contains very few 
mobile elements such as genomic islands or IS elements that are commonly found 
in the genomes of pathogenic staphylococci, and are associated to the quick 
adaptability of these species to host’s environment or to conferring antibiotic 
resistance. For instance, an IS element in VRSA (vaconmycin resistant S. aureus) 
designated IS256 has been found to be inserted into the promoter region of a two-
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component regulatory system involved in antibiotic resistance. This insertion 
results in the overexpression of proteins of the regulatory system, probably by 
disrupting the promoter’s repression mechanism, which in turn increases the 
resistance of VRSA to vancomycin and other antibiotics (Becker et al. 2007). The 
absence of these IS elements in S. carnosus argue for a more stable, albeit less 
adaptable bacterial system.  
	  
1.3.3- Industrial Applications 
	  
Historically, S. carnosus was first isolated from cured meat products, so it is 
very likely that this bacterium was being unintentionally used as starter culture in 
the meat curing process for many years before the industrial use of bacteria in food 
processing was even acknowledged.  
In the traditional curing processes no starter cultures are added, and instead 
the flavor and aroma are achieved by adding a mixture of salt and sugars. 
However, economic pressures and the desire to control fermentation conditions 
have driven industry into the use of starter cultures as a means to enhance product 
consistency and decrease fermentation times (Masson et al. 1999). 
The industrial curing of raw sausages involves the use of lactic acid 
producing bacteria such as Lactobacillus or Pediococcus, together with other 
starter cultures such as Staphylococcus and Micrococcus. S. carnosus is regularly 
used as a starter culture in Greek, Italian and Turkish sausage production because 
of its ability to maintain the color of fermented meat, to produce flavor and aroma, 
and to reduce nitrate into ammonia (Masson et al. 1999; Søndergaard & Stahnke 
2002). 
The curing process varies from country to country, but it generally involves a 
pre-inactivation step (aging), a fermentation step, and a drying and storage step. 
Throughout the several stages, the pH of the sausage is dropped from 6 to 
between 5 and 4, a decrease that correlates with the increase in lactic acid 
production by lactic bacteria during the fermentation step. A useful side-effect to 
the production of lactic acid and subsequent decrease of the environment pH 
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throughout the curing process is that it works to prevent the settling of pathogenic 
bacteria. Individual stages in the process also require the use of unique 
temperatures and humidity, such that temperature and water activity vary greatly 
throughout the duration of the process. In addition to these varying factors, meat is 
often cured in environments with high salt, nitrate and nitrite concentrations.  
Therefore, as a starter culture, S. carnosus has the advantage of being 
highly adaptable to the various osmotic, temperature, and chemical pressures of 
the environment in which it coexists. Sondergaard and Stahnke (2002) showed that 
while there is a positive interaction between temperature and pH on the growth of 
starter cultures, high salt concentrations seems to have a negative effect on most 
cultures except for S.carnosus, which has optimum growth at 10% w/v NaCl. The 
resistance to high salt concentration can be explained genetically, as S. carnosus 
contains several systems of osmoprotection, as well as five sodium ion/proton 
antiporters and homologs to macheno-sensitive ion channels (Rosenstein et al. 
2009).   
S. carnosus is crucial for  development of flavor, aroma, and preservation of 
appearance during the drying stage of the process. Several studies indicate that 
flavor and aroma emerge from common products of S. carnosus catabolism of 
branched-chain-amino-acids (BCAA) and aromatic amino-acids. In particular, the 
production of the corresponding methyl-branched aldehydes, acids and esters from 
the catabolism of leucine seems to have a strong impact on aroma.  Two distinct 
pathways for the production of these compounds have been proposed (Masson et 
al. 1999; Madsen et al. 2002), and both involve the conversion  of leucine into α-
ketoisocaproic acid as the starting point.    
Another group of compounds produced by S. carnosus in the course of raw-
meat curing that seem to have influence on the flavor of meat products are 
methylketones, which are formed from the β-oxidation of free fatty acids (Talon & 
Montel 1997; Talon et al. 1998) . This metabolic capacity to produce ketones from 
fatty acids may serve a double purpose: as well as contributing to the flavour of the 
cured meat, the reaction leads to the decrease of free fatty acids which might be 
available for chemical oxidation. Chemical oxidation through interaction of fatty 
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acids with peroxide species is believed to be the main factor affecting rancidity of 
meat products (Montel et al. 1998). 
In addition to flavor and aroma production, S. carnosus plays a crucial role 
in the development and maintenance of red pigmentation during the curing 
process. The red pigmentation of cured meat products is maintained through the 
addition of nitrate into the fermentation mix, which is reduced to the highly reactive 
nitrite during curing. In turn nitrite is converted to nitric oxide (NO), which reacts 
with the haeme group of the meat’s myoglobin (MbFeII), forming the pink-red 
pigmented structure nitromyoglobin (MbFeIINO) (Talon et al. 1999). Nitrite also 
offers other beneficial side effects to the overall cured product, as it prevents the 
oxidation of lipids, which is normally associated with rancidity, and prevents the 
colonization of pathogenic bacteria. S. carnosus  naturally reduces nitrate into 
nitrite under anaerobic conditions as part of the fermentation process, in which 
nitrate is used as the electron acceptor during nitrate respiration. Two enzymes 
that are sequentially expressed under low oxygen conditions, nitrate reductase and 
nitrite reductase, are responsible for this reaction, as well as the subsequent 
reduction of nitrite into ammonia (Gøtterup et al. 2008). While S. carnosus cannot 
convert nitrite into nitric oxide, the reduction of former into ammonia only occurs 
once the nitrate concentration in solution is exhausted. Therefore, nitric oxide 
conversion can happen concurrently to the reduction of nitrate, by using either 
reducing agents like ascorbate, or other starter cultures that can perform the 
reaction (Hammes et al. 2012). By naturally reducing nitrate/nitrite into ammonia, 
S. carnosus also works as regulatory agent that controls the concentration of these 
compounds in the cured product, and therefore prevents the potential hazardous 
affects of nitrate/nitrite accumulation, which have been associated with the 
production of carcinogenic substances.	  	  
	  
1.3.4- Host for Genetic Engineering: 
	  
In recent years, the development of various expression systems for S. 
carnosus that allow for the production of heterologous proteins and the export of 
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these proteins to the cell surface has promoted the idea of employing this food-
grade staphylococcus in the study of antigenic determinants and virulence factors 
of other pathogenic Gram-positive bacteria that are phylogenetically related, such 
as S. aureus. In particular, the possibility of creating live vaccines, i.e bacteria that 
express a single inactive antigenic marker in the cell surface, have attracted the 
scientific community to the advantage of S. carnosus as a host organism 
(Samuelson et al. 1995; Hansson et al. 2002). 
Gotz et al. (Keller et al. 1983) were the first to study the production of 
plasmid vectors for cloning in the  S. carnosus strain TM300, based upon the 
chloramphenicol resistance vector pC194 originally isolated from S. aureus (Figure 
5), as well as the tetracycline resistance vector pMK148 (Horinouchi & Weisblum 
1982). Subsequently, several chimeric versions of these vectors were produced 
specifically for the use in S. carnosus (Demleitner & Götz 1994). In particular, the 
vector pLipPS1, constructed with the lipase gene from Staphylococcus hyicus, and 
its corresponding membrane excretion pro-peptide signal, was used as the 
parental vector systems for the expression of membrane-bound and extracellular 
proteins in S. carnosus.  
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Figure 5- Map for the pC194 (ATCC® 37034™) plasmid. The area highlighted corresponds to 
the chloramphenicol resistance gene. The pCT20 vector was constructed by ligating a HindIII 
segment of pMK 148 into the unique HindIII site of pC194  (reproduced with the permission 
of the ATCC® website- www.atcc.org/). 
 
Inspired by the development of new cloning and expression strategies 
directed at staphylococcus species, several research groups started to study the 
use of S. carnosus and S. xylosus as live vaccines. Samuelson et. al  (Samuelson 
et al. 1995) created the first surface display expression vector  by ligating a 
derivative of pLipPS1, pLipPS17, with the E. coli plasmid pRIT28. The resulting 
hybridized vector, which contained the lipase promoter and both the signal peptide 
and peptide sequences of the lipase gene, was linked with an ABP (albumin 
binding protein) sequence from the streptococcal protein G, and a cell wall 
anchoring sequences (from staphylococcal protein A). The resulting plasmid, 
pSPPmABPXM, was able to express, secrete and display ABP in S. carnosus, and 
induced a positive antibody response when tested through immunogold electron 
microscopy analysis. This vector was the first proof of concept for use of 
staphylococcal strains as vaccine display systems.  
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The positive immunization response achieved in this initial study led to the 
generation of  “second generation” S. carnosus vaccine delivery systems that could 
induce an even greater immune response by co-displaying a fusion product from 
surface bound antigens and adhesion proteins of the targeted cells from the 
infected hosts. For instance, the co-expression of cholera toxin B subunit, which 
targets the molecule monosialoganglioside GM1 of mucosal surfaces, with an 
antigen on the surface of staphylococcal strains was shown to promote a stronger 
IgG response than antigen-presenting staphycocci that did not co-express 
adhesion proteins (Liljeqvist et al. 1997). 
More recently, Williams et al. managed to create a derivative of 
pSPPmABPXM to allow for the intracellular expression of a broader range of 
heterologous proteins, by cleaving off the sequence involved in the export and 
anchoring of recombinant proteins to the cell wall (Williams et al. 2002).This shuttle 
vector, pNW21 (Figure 6), was then used to express the S. aureus hysA gene 
encoding for the putative virulent determinant hyaluronate lyase, which was shown 
to accumulate intracellularly in the cell. 
 
 
Figure 6- pNW21 vector, containing both origins of replication for E.coli and 
Staphylococcus, a multi-cloning site (MCS), a chloramphenicol resistance gene (cat), and a 
ampicillin resistance gene (bla) (Reproduced from Plasmid, vol. 47 (3), Williams et al., 
Expression of the S. aureus hysA gene in S. carnosus from a modified E. coli–
staphylococcal shuttle vector, pg. 241-245, Copyright © 2002, with permission from 
Elsevier.) 
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To summarize, S. carnosus is a unique bacterial strain that shows promise 
as an efficient biocatalytic host. On one hand, its ability to grow in very acidic, 
water deprived environments with high salt concentrations, and the physical 
resilience of its cell wall, argue for an higher adaptability to adverse conditions 
when compared to more conventional Gram-negative strains such as E. coli. One 
can envision the possibility of applying S. carnosus biocatalytic systems to one-pot 
catalysis processes, in which the whole-cell system catalyzes one or more reaction 
steps in parallel to the chemical catalysis of the remaining steps in the process.  In 
addition, S. carnosus has already been validated as safe-to-use, industrially 
relevant bacteria strain, which argues for a greater ease in scaling up and 
optimizing whole-cell biocatalytic processes performed with this strain. Finally, the 
development of genetic expression systems for staphylococcal species has 
increased the value of S. carnosus as a strain for biocatalytic expression by 
creating a precedent for the efficiently cloning and expression of different 
heterologous proteins. Therefore, we think there was an argument to be made for 
the use of S. carnosus as a host for biocatalysis, and the aim of this project was to 
pursue validation for this argument.    
 
 
1.5- The Model Biocatalyst: Cyclohexanone 
Monooxygenase 
 
When evaluating the efficiency of bacterial strains as biocatalytic hosts, the 
choice of biocatalyst is mainly dependent on the characteristics of the host. The 
general question is whether S. carnosus is a good whole-cell biocatalytic host, but 
this question is not very useful to define the important parameters that characterize 
S. carnosus. Rather, more specific questions need to be answered: can S. 
carnosus express a biocatalyst, does S. carnosus allow for biocatalysis to take 
place efficiently, and does S. carnosus offer a clear advantage over other 
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conventional species? These questions define what parameters need to be 
evaluated, and in consequence the best biocatalyst to use for testing these 
parameters.  
Cyclohexanone monooxygenase (CHMO) from Acinetobacter sp. strain 
NCIB 9871 was chosen as the most suitable to answer these questions for a 
number of reasons. CHMO is a Baeyer-Villiger monooxygenase that requires the 
co-factors FAD and NADPH for catalysis, and therefore there is a clear motivation 
to use this enzyme in the context of whole-cell biocatalysis.  In addition, some of 
the substrates and products catalyzed by this enzyme are of industrial relevance, 
but have been shown to be toxic to other bacterial strains in high concentrations. 
This poses a challenge to many whole-cell biocatalytic processes using CHMO, as 
efficient turnovers are largely dependent on the tolerance of the host strain.  
More Importantly, CHMO-mediated biocatalysis has already been tested in 
a range of bacterial host strains, including E. coli and bakers yeast. On one hand, 
these precedents show that the enzyme can be efficiently expressed in different 
genetic environments. The body of literature on the use of CHMO in whole-cell 
systems is crucial to the characterization of the advantages and disadvantages of 
S. carnosus as a host when compared to other bacterial strains.   
 
1.5.1- Baeyer-Villiger Monooxygenases and their 
Importance for the Biotechnology Industry 
	  
Baeyer-Villiger monooxygenases (BVMOs) are a sub-class of oxygenases 
that can perform Baeyer-Villiger oxygenation (BV oxygenation) reactions.  The BV 
reaction was first discovered in 1899 by Adolf Baeyer and Victor Villiger (van 
Beilen et al. 2003) and describes the oxidation of linear, aryl and alkyl ketones into 
esters, and cyclic ketones into lactones.  
In organic chemistry, BV oxygenation reactions are achieved by using 
nucleophilic compounds, the most common of which are peroxy-acids, which are 
involved in the nucleophilic attack on the carbonyl group of the substrate. The 
“Criegee intermediate” formed by this attack is labile and therefore will decay, 
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promoting the insertion of one oxygen atom between the carbonyl group and the 
adjacent carbon atom (Figure 7).   
 
 
Figure	  7-­‐	  Baeyer-Villiger oxidation of a ketone, using a peroxy-acid as the nucleophile 
compound that attack the carboxyl group, forming a Criegee intermediate. This intermediate 
subsequently decays, and the nucleophilic oxygen is introduced into the carbon structure of 
the ketone (taken from http://en.wikipedia.org/wiki/File:Baeyer-
Villiger_oxidation_(mechanism).png). 
 
The industrial relevance of BV oxygenations relies on the fact that they are 
applicable to a large group of carbonyl compounds, and the reactions are highly 
stereo-specific and have a very predictable regiochemistry (Willetts 1997).  An 
example of the importance of BV oxygenations in industry is the production of β-
amino acids, which are important building blocks for peptides with enhanced 
resistance to proteolytic activity. These peptides, called β-peptides, can be 
formulated to work as drugs that are not so easily degraded or rejected by the 
body. In 2010 Rehdorf et al. reported the conversion of racemic N-protected β-
amino ketones by different BV monooxygenases into “normal” β-amino acids, the 
normal products from the chemical catalysis of these ketones, as well as 
“abnormal” β-amino acids that cannot be obtained through chemical processes 
(2010). Another example is ε-caprolactone, the lactone product from the catalysis 
of cyclohexanone by CHMO, which is a constituent for highly specialized polymers 
such as polycaprolactone, which is used as a degradable biomaterial (Woodruff & 
Hutmacher 2010). 
One of main challenges for the chemical industry in the application of BV 
oxygenation reactions is the use of oxidizing agents that are difficult to handle and 
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pose a health and environmental risk. In particular, peroxy-acids are shock-
sensitive and explosive, making large-scale production a high-risk process. To 
counter-act this difficulty, alternative oxidative agents such as metal catalysts and 
organocatalytic compounds that use hydrogen peroxide and oxygen as oxidants 
have been established with moderate success (Kamerbeek et al. 2003).  More 
importantly, peroxy-acids are powerful oxidative agents and can produce 
undesirable bi-products. The lack of enantioselectivity in chemical oxygenations 
remains the biggest issue for industry, and greatly contributes to the increasing 
interest in using biocatalytic processes as a more efficient, enantioselective and 
“greener” alternative. 
The presence of enzymes capable of performing BV reactions was first 
reported in the 1940s in fungi that were involved in the biotransformation of 
steroids (Fraaije & Janssen 2007). The group of organisms capable of BV 
oxygenation was subsequently extended to Gram-positive and Gram-negative 
bacteria, plants, and shellfish (Kamerbeek et al. 2003). In these organisms, 
Baeyer-Villiger monooxygenases (BVMOs) were found to be involved in a broad 
range of functions, including toxin production, iridoids and steroids synthesis, and 
growth on aliphatic ketones and aromatic compounds.  
The isolation of some of these proteins has led to the division of BVMOs into 
two discrete groups. Type I BVMOs were defined as flavin-dependent proteins 
composed of a single peptide chain that require NADPH and oxygen to perform 
oxygenation. These proteins are able to perform both the reduction of the flavin co-
factor by NADPH and the BV oxygenation in the same active site (de Gonzalo et 
al. 2010).  Examples of type I BVMOs include cyclohexanone monooxygenase 
(CHMO), which is the primary focus of our project, and phenylacetone 
monooxygenase (PAMO), the crystal structure of which has now been published 
(Fraaije & Janssen 2007). By contrast, type II BVMOs are composed of two distinct 
sub-units: a reductase subunit that uses NADPH to reduce the flavin co-factor; and 
a second subunit that performs the actual BV oxygenation reaction. The increased 
structural and functional complexity of this group might give insights into the 
rareness of the latter amongst the organisms so far studied (Fraaije & Janssen 
2007). 
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1.5.2- The Discovery of Cyclohexanone Monooxygenase 
	  
Cyclohexanone Monooxygenase (CHMO) was first isolated by Chen et al. 
from Acinetobacter sp. strain NCIB 9871 (1988), and subsequently sequenced as 
an 542- amino-acid protein with the capacity of performing ketone-to-lactone 
conversions in an oxygen- and NADPH-dependent fashion.  Iwaki et al. later 
corrected the sequence and the protein was identified as a 60.9 KDa monomer 
upon purification (Iwaki et al. 2002).  The natural role of CHMO in Acinetobacter  
sp. NCIB 9871 is to degrade cyclohexanol into adipate (Mihovilovic et al. 2002). 
CHMO catalyzes the oxygenation of cyclic ketones through a mechanism very 
similar to that involved in chemical BV-reactions (Mihovilovic et al. 2003). In the 
first step, the bound flavin (FAD) is reduced by NADPH. The resulting enzyme-
NADP+ complex then reacts with oxygen and forms the flavin-peroxide nucleophile 
that performs the nucleophilic attack on the ketone substrate. In the final stage of 
the reaction, water is eliminated to convert the FAD into the original oxidized form, 
and NADP+ is released thereby ending the reaction cycle (Figure 8).  
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Figure	  8-­‐ Mechanism of Baeyer-Villiger monooxygenase-mediated oxygenation showing the 
two distinct pathways which depend n the action of the reduced FAD as a nucleophile or 
electrophile (Reproduced from Advanced Synthesis & Catalysis, vol. 345 (6-7), Kamerbeek et 
al., Baeyer-Villiger Monooxygenases, an Emerging Family of Flavin-Dependent Biocatalysis, 
Copyright © 2003, with permission from John Wiley and Sons.).     	  
 
The natural role of CHMO in Acinetobacter sp. NCIB 9871 is to degrade 
cyclohexanol into adipate, but it has since been tested against more than 100 non-
natural prochiral and racemic substrates, achieving high regio- and 
enantioselectivity in most cases (Mihovilovic et al. 2002). These include mesomeric 
prochiral cyclohexanones with several side-chain substitutions, cyclobutanones, 
and prochiral bicyclic substrates with varying functional groups.  
One of the most studied reactions is the conversion of bicyclo (3.2.0) hept-2-
ene-6-one , because it demonstrates the capacity of CHMO to produce regio-
enantiomers (Figure 9). In addition to producing two regioisomers in a 1:1 
proportion from this ketone, CHMO also achieves a high level of enantiomeric 
purity for both lactones (Alphand et al. 2003). 
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Figure 9- CHMO-mediated  asymmetric oxygenation of racemic bicyclo (3.2.0) hept-2-ene-6-
one 1 into its regioisomer lactones.      
 
Due to its versatility, CHMO has attracted a great deal of research as well 
as commercial interest, which led to it being the most highly characterized type-I 
Baeyer-Villiger monooxygenase. It has also been one of the first in this class of 
enzymes to be used for biocatalysis in vitro and in vivo, and has a proven potential 
as a potent biocatalyst in both cases.  
 
1.5.3- Relation between Structure and Mechanism of 
CHMO  
	  
More recently, Ahmad Mirza et al. were able to produce two different 
conformational crystal structures of CHMO from Rhodococcus sp. strain HI-31 
containing both co-factors FAD and NADP+ (Figure 10) (Mirza et al. 2009). From 
the crystallography results, the protein was shown to be a single peptide organized 
into three domains: the flavin binding domain, which is contained within the termini 
of the protein sequence; a NADPH binding domain that in enclosed in the middle of 
the protein; and an helical domain composed of the segments within the NADPH 
domain which is believed to contain crucial residues that make up the substrate 
binding pocket.  This modular arrangement showed high level of homology with the 
crystal structure of phenylacetone monooxygenase (PAMO), which had been 
previously solved (Malito et al. 2004).  
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The two different conformations of the CHMO are believed to represent 
different time points in the BV oxygenation reaction cycle, and comparison of the 
two has given insight into the role of the domains in the reaction mechanism. The 
active site has been pinpointed to a cavity near the flavin ring made up of the 
segments from the three domains. The trigger for the oxidation to occur was 
subsequently attributed to a slight conformational change in the NADPH domain 
that “pushes” the co-factor into a pocket located in close proximity to the FAD.  
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 Figure	  10- Structure of CHMO in the  FAD and NADP+ binding conformation. The dark-blue 
area represents the NADPbinding-domain; the wheat coloured area represents the FAD-
binding domain. The figure shows the binding site enclosed in between the two domains, 
with the yellow and orange areas corresponding to the fexible loop regions also interacting 
with the compounds in the active site (reproduced with permission of Mirza et al., Journal of 
the American Chemical Society, Crystral Structures of Cyclohexanone Monooxygenase 
Reveal Complex Domain Movements and a Sliding Cofactor, Copyright © 2009, American 
Chemical Society.).        
 
Some key residues involved in the reaction have also been identified. The 
arginine residue in position 239, which in contained in a flexible loop, interacts with 
NADPH directly and is probably involved in the insertion of nicotinamide ring into 
the pocket. Another residue that plays a crucial role in the lateral movement of 
NADPH is the tryptophan residue in position 492, also situated in a flexible region. 
This residue appears to play a role in the active site pocket, as deletion of the latter 
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results in the impairment of the enzyme activity (Mirza et al. 2009). Finally, an 
highly conserved region amongst type I BVMOs composed of the motif 
FXGXXHXXXWP at the start of NADPH domain is believed to coordinate the 
NADPH molecule into optimal position for the reduction of FAD during reaction 
cycle. 
	  
1.5.4- The Use of CHMO in Whole-Cell Systems 
	  
While the use of isolated-enzyme systems results in higher product yield 
and easier downstream processing, working with purified BV monooxygenases is 
not a straightforward process. Since these enzymes are NADPH- dependent, 
bioconversions at large-scale would require an efficient co-factor recycling system 
that would be both energy- and cost-intensive. In this case, the use of whole cells 
as biocatalytic hosts ends up being a more practical and economical option.  
The wild-type Acinetobacter strain in which CHMO is naturally expressed is 
a class 2 pathogen, and thus using this organism for industrial applications is 
undesirable. To solve this problem, alternative, commercially viable strains of other 
species have been genetically engineered to express stable and active enzyme. 
Currently there is a large body of work documenting the construction and 
characterization of several whole-cell biocatalytic systems that allow for CHMO-
mediated biocatalysis. 
Cheesman et al. (2001) were able to express CHMO in both E. coli and 
Saccharomyces cerevisiae, obtaining a final protein yield of 7.3 mg for 3 L of yeast 
cultures and 12.9 mg for each liter of E. coli cultures. More recent studies were 
able to work on the optimization of CHMO expression in the E. coli system, 
obtaining yields of 60 mg- 80 mg of CHMO per liter of cells (Alphand et al. 2003).  
In a more biocatalytic-oriented study, Stewart et al. (1996) were also able to 
express the Acinetobacter wild type CHMO in bakers yeast and use the cells to 
perform BV oxygenations. Cyclohexanone was oxidized by the actively growing 
yeast cells into caprolactone with a reaction yield of 79%, and with minimal side-
ractions (2.5%). The side- reduction of ketones by the indigenous metabolism of 
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the yeast seemed to be suppressed by the over-expression of CHMO. In spite of 
the importance of these studies in establishing micro-organisms suitable for the 
expression and bioconversion with this biocatalyst, large-scale studies were 
necessary to validate the industrial applications of these whole-cell systems.    
Doig et al. (2001) were the first group to report and characterize the large-
scale production of CHMO in E. coli (O’Sullivan et al. 2001). This was cloned using 
the vector pQR239, which expresses CHMO under an L-arabinose inducible 
system, and grown in volumes up to 300 L. Fermentation done on the 1.5 L scale, 
with optimal growth conditions, gave a final dry cell concentration of 5.5 g/L and the 
CHMO specific activity in the lysates of the cell broth was measured to be 630 U / 
gram of dried cells (1 U is the amount of protein that catalyzes the substrate-
induced oxidation of 1 µmol of NADPH per minute). This represented a 50-fold 
increase of activity compared to the enzyme expressed in the native Acinetobacter 
strain. In the 300 L scale, similar cell concentrations were obtained when using the 
same growth conditions, but the specific CHMO activity measured in the lysates 
was significantly lower, at 500 U / gram of dried cells. This discrepancy was 
attributed to plasmid instability at the larger scale, where there is a greater 
percentage of cells that lose the protein expression vector in the course of the 
fermentation.  
In a subsequent study, Doig et al. (2002) tested the biocatalytic potential of 
the E. coli strain expressing CHMO in the BV oxygenation of bicyclo(3,2,0)hept-2-
en-6-one into its resulting lactone regiomers (Doig et al. 2002).  Again, the optimal 
conditions were determined at the 1.5 L scale and subsequently scaled up to large 
fed-batch fermentations. On this scale, final cell density reached 5 g of dried cell 
weight per liter of broth, with a maximum whole-cell biocatalytic activity of 55 U/ 
gram of dried cells for conversion of the ketone substrate, while the enzyme 
specific activity in the lysates of the cell broth were measured to be 10 times higher 
(Doig et al. 2003). More recently, Baboo et al. (2012) used automated microwell 
technology to characterize the oxidation of 7 different ketones by the same E. coli 
strain, including cyclohexanone and Bicyclo[3.2.0]hept-2-en-6-one.   
	   55	  
1.6- Limitations of CHMO Whole-cell 
Biocatalytic Systems:  
	  
The studies on CHMO expression and biocatalysis in bacterial and yeast 
strains were very important not only to characterize the successful implementation 
of CHMO as a biocatalyst in the context of whole-cell systems, but also to highlight 
the limitations of these systems. In the context of this PhD project, an 
understanding of the nature of these limitations is crucial to establish the 
parameters to study when determining the efficiency of alternative hosts.  
Therefore, it is worthwhile to briefly discuss both the cellular and enzymatic factors 
that hinder the performance of the CHMO whole-cell biocatalysis in E. coli. 
 
(i) Optimal enzymatic pH and cell wall diffusion rates  
 
One limitation that was briefly touched upon above was the lower activity 
observed for whole-cell biocatalysis of ketones when compared with the specific 
enzyme activity in lysates. This shortcoming in whole-cell biocatalysis was largely 
attributed to the difference between the pH of the intracellular microenvironment 
and the optimal pH for CHMO oxidation. Again, Doig et al. (2003) were the first to 
document this difference by showing that the activity rates of sonicated samples 
from bacterial cultures expressing CHMO sharply increased as the pH of the 
reaction buffer was shifted from a neutral to a more alkaline pH, with optimal 
activity being recorded for a pH of 9. The diffusion rate of the substrates across the 
membrane was also considered to contribute to the lower biocatalytic activities, 
albeit to a lesser degree.  
Since the intracellular pH and membrane permeability are factors inherent 
and essential to the physiology of the E. coli bacterial host, these factors cannot be 
easily changed to suit the requirements of the biocatalyst without compromising the 
general metabolic activity of the host.   
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(ii) Oxygen availability  
 
The availability of molecular oxygen to feed the BV oxygenation reaction 
can also be a limiting factor in the context of whole cell systems. This is due to the 
fact that, in addition to the stoichiometric requirement of oxygen for the CHMO-
mediated oxidation reaction, cells also require oxygen for metabolic activity. Since 
the electron-transport chain, which is responsible for the metabolic energy 
production, exerts a higher catalytic pressure for the use of available oxygen in 
comparison to CHMO, BV oxygenation rates decrease in actively growing cells as 
the oxygen is primarily recruited to the metabolic pathways (Figure 11). 
In a attempt to overcome this problem, Adam Walton & Stewart (2002; 
2004) performed whole-cell CHMO-mediated oxygenations of cyclohexanone using 
non-growing cells. The reasoning behind the study was that non-dividing cells do 
not require large quantities of oxygen for metabolic purposes, and consequently 
will not exert such a high pressure on oxygen availability for BV oxygenation. 
Contrary to this assumption, the study reported that actively growing cells were 
more efficient biocatalytic units than the non-growing counterparts. However, the 
lower activity of non-growing cultures was offset by a higher cellular density, which 
resulted in an over-all 20-fold improvement of the volumetric productivity when 
operating in non-growing conditions.  
The difference between biocatalytic efficiencies of growing and non-growing 
cultures could be tied to the differences in cell density. On the upside, resting 
cultures do not have a high oxygen consumption, but this is counteracted by the 
higher densities, which result in less oxygen availability per individual cell. 
Therefore, it seems the best solution to counter-act oxygen limitation is to prevent 
the creation of an oxygen limiting environment by close monitoring of fermenter 
DOT and oxygen tension during fermentation and bioconversion, as well as tightly 
controlling cell densities (Baldwin & Woodley 2006). 
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Figure	  11- Model showing the affect of biocatalyst on oxygen demand. As biocatalyst 
concentration reaches point B, the oxygen demand is increased but the rate of biocatalysis 
wont increase from (a) to (b) unless oxygen supply is increased to counteract the overall 
oxygen demand (ii). This increase will result in an increase of biocatalysis rate to (c) 
(Reproduced from Biotechnology & Bioengineering, vol. 95(3), Baldwin et al., On oxygen 
limitation in a whole cell biocatalytic Baeyer-Villiger oxidation process, Copyright © 2006, 
with permission from John Wiley and Sons.). 
 
(iii) Substrate/Product toxicity  
	  
Biocatalyst inhibition through substrate and product toxicity is the most 
relevant limitation when scaling up a whole-cell biocatalytic process, as large 
quantities of the reactants will kill the host cell. In the case of the CHMO-
expressing E. coli system, several substrates and their respective products have 
been shown to severely hinder the biocatalytic process when concentrations rise 
above very low concentration thresholds. In particular, the substrate 
bicyclo[3.2.0]hept-2-en-6-one greatly inhibits the biocatalytic process at 
concentrations above 0.4 g/L, while its lactone products,  (−)-(1S,5R)-2-
Oxabicyclo[3.3.0]oct-6-en-3-one and (−)-(1R,5S)-3-oxabicyclo[3.3.0]oct-6-en-2-
one, kill off the activity of the cells above concentrations of 5 g/L (Doig et al. 2003). 
	   58	  
It is now generally accepted that the toxicity exhibited by some CHMO 
substrates and products is due the lipophilic character of these compounds, which 
will accumulate in the lipid membrane of the cell and cause severe changes in the 
structure and function (Sikkema et al. 1995). In extreme cases, this accumulation 
will lead to loss of membrane integrity, thereby compromising the viability of the 
cell.  
The aggressive nature of many of the CHMO substrates and products 
characterized thus far towards the bacterial host pose a challenge to the 
application of CHMO whole-cell biocatalytic processes in an industrial setting, 
where high yields of product are expected. The toxicity of these compounds 
demands techniques that allow for a tight control over the accumulation of 
substrate and product in the reaction medium. One of the proposed options to 
tackle this issue is the application of in situ product removal (ISPR) systems, such 
as resins, during the biocatalytic process (Figure 12) (Lye 1999).  
 
 
 
Figure	  12- Schematics of whole-cell bioconversion using an absorbent resin for product 
feeding and substrate removal (Reproduced by permission from Macmillan Publishers Ltd: 
Nature Protocols, Hilker et al. 2008, Copyright © 2008.). 
 
ISPR systems involve resins that interact with the reactants through 
covalent or non-covalent interactions and that can discriminate between the 
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stereoisomers and molecules with different functional groups. The use of resins 
that can bind specifically to the substrates and products is an appealing idea, as 
they can work as simultaneous substrate feeding and product recovery system, 
with the ready-made product displacing the bound substrate. In this manner, the 
reactants concentrations can be maintained below the toxicity threshold in the 
reaction medium. An added benefit of this system is the simplification of the 
subsequent product recovery process, which can be done by extracting the resins 
from the medium. Finally ISPR systems can also be used to shift unfavorable 
reaction equilibriums by maintaining concentration gradient directed toward product 
formation. In turn, the artificial gradient created by the ISPR system protects the 
unwanted degradation of substrates and products by decreasing the residence 
time of these compounds in the intracellular space of the host and the reaction 
medium (Woodley et al. 2008). So far, only a couple of studies have focused on 
the implementation of IPSR systems in CHMO-mediated biocatalytic processes. In 
2001 Simpson et al. were able to successfully apply molecularly imprinted 
polymeric (MIP) resins for in situ feeding of bicyclo(3,2,0)hept-2-en-6-one and 
recovery of the respective regioisomers. In this study, two commercially available 
resins, XAD-4 and Optipore L-493, were added to a preparative scale vessel with 
cell concentration of 17 g/L, and allowed for the bioconversion of the ketone 
substrate at concentrations up to 20 g/L. This represents a considerable 
improvement compared to the 0.4 g/L ketone limit established for bioconversions 
without ISPR systems. By adjusting the ratio of resin to substrate, this process was 
subsequently scaled up to allow for the conversion of 1 kilogram of 
bicyclo(3,2,0)hept-2-en-6-one at a concentration, with a final lactone yield of 60% 
(Hilker et al. 2005). Despite the significant loss of product due to the non-optimal 
extraction process, the ketone and lactone concentrations were maintained below 
the toxicity threshold, thus ensuring that the cell viability was not compromised 
during the biocatalytic process.  
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1.7- Conclusions 
	  
1.7.1- The purpose of the project 
 
Throughout this chapter I have attempted to give a broad picture of the 
current state of art in biocatalysis in order to provide a backdrop to this project.  
Indeed, it should be now clear that whole-cell biocatalysis is a concept that 
still stirs the imagination with its massive potential. The advent of Synthetic Biology 
and the development of techniques that allow for a straight-forward, rational and 
systematic approach to cell engineering have promoted a renewed interest in the 
power of prokaryotic and eukaryotic organisms as biological factories. 
However, genetic and metabolic engineering is only part of the solution. The 
creation of engineered iterations of known and industrially proven cellular strains is 
a powerful tool to increase flexibility and improve yield, but the changes that are 
being artificially introduced are not trivial and might create a burden for the host 
system, while not necessarily covering for limitations that are host-specific.  
It is narrow-minded to think that the production of efficient whole-cell 
systems can only be achieved through genetic engineering. This argument would 
be neglecting one of the reasons why whole-cell biocatalysis can be 
advantageous, and that is the vast diversity that nature offers. There is a very big 
repertoire of bacterial and yeast species that have not yet been studied in this 
context. It is therefore premature to assume that the current cell-systems being 
used in the biocatalytic industry are the best suited for whole-cell biocatalysis.  
An effort should be made by researchers (that are not directly limited by 
profit margins and therefore can take risks) to step out of the comfort zone and 
look for alternative strains that offer clear advantages for biocatalytic processing. 
The prospecting of natural alternatives to the conventions of whole-cell biocatalysis 
could, in the long run, be more a cost- and time- effective way to achieve efficient 
cell-biocatalysts, with the valuable side-effect of increasing the repertoire of 
biocatalysts and strains to choose from. 
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This conviction is at the center of this project, but it is not rejecting the value 
of synthetic biology and genetic engineering as essential pieces in this jigsaw that 
is designing an efficient biocatalytic process. Indeed, some level of genetic 
engineering must always be done in order to introduce a new biocatalytic system 
into a host, or to enhance the native capability of the host to perform biocatalysis.  
 
1.7.2- Challenges of the Project 
	  
Searching for and accessing alternative hosts for biocatalysis is not a risk-
free procedure. The huge library of known microorganisms that have not been 
used in the context of biocatalysis makes for a difficult choice when deciding the 
group of alternative hosts to study.  
In addition, the myriad of factors involved in biocatalytic processes make up 
for a complex system of interactions that hampers the ability to predict strain 
performances, more so if the strain has not been characterized previously. 
In the case of this project, S. carnosus was chosen because it showed 
promising phenotypical and biochemical features, such as an high tolerance to 
harsh environments, and the potential to accept compounds more readily because 
of the different membrane composition. However, there is no guarantee that these 
native features actually have a positive effect on whole-cell biocatalysis.  
The novelty in using S. carnosus as biocatalytic host creates its own 
challenge, as there are no known examples or procedures to follow in the 
literature. As a result, the choice of conditions in which S. carnosus can work as an 
efficient host will rely heavily in educated guesses.   Another challenge is that there 
are very few genetic tools available to introduce novel biocatalytic processes into 
S.carnosus. Most of vectors designed for use in S. carnosus were designed for 
diagnostic purposes, and as a result are based on the expression of heterologous 
proteins that are then secreted and displayed on the surface of cells.  These 
vectors are not useful when the biocatalytic process occurs in intracellular space.  
In addition, only a couple of promoters have been studied in these genetic 
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systems, and therefore we have very limited knowledge of how to modulate and 
enhance biocatalyst expression in S.carnosus. 
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Chapter 2: Material and 
Methods 
	  
2.1- Materials 
 
2.1.1- Media, Buffers, and Selective Antibiotics 
 
Most buffers used for the plasmid purification and gel extraction were part of 
the kits from QIAGEN: 
• P1 - resuspension buffer:  50 mM Tris-Cl, pH 8.0; 10 mM EDTA; 100 
µg/ml RNase  A. 
• P2- lysis buffer: 200 mM NaOH, 1% SDS (w/v) 
• N3- neutralization buffer: confidential 
• P3-neutralization buffer: 3.0 M potassium acetate, pH 5.5 
• EB - solubilisation buffer : 50 mM Tris-Cl, pH 8.0  
• PE - wash buffer: confidential 
• QC- wash buffer:  1.0 M NaCl; 50mM MOPS, pH 7.0; 15% 
isopropanol   
• QBT- Equilibrium buffer: 750 mM MOPS, pH 7.0; 15% isopropanol; 
0.15% Triton X-100 
• QF- Elution buffer: 1.25 M NaCl; 50 mM Tris-Cl, pH 8.5; 15% 
isopropanol   
• PB- binding buffer: confidential 
• QG –solubilisation buffer: confidential 
For protocols of cell lysis and DNA extraction from S. carnosus cultures, 
the following specific buffers and chemical solutions were used: 
	   64	  
• Cell lysis buffer L1: 50 mM Tris-HCl buffer, pH7.4; 30 - 60 mg/ml 
Lysozyme from chicken egg white (Sigma-Aldrich)  
• Cell lysis buffer L2: 50 mM Tris-HCl buffer, pH7.4; 60 mg/ml 
Lysozyme from chicken egg white (Sigma-Aldrich); 1 µg/ml Lysostaphin from 
Staphylococcus staphylolyticus (Sigma-Aldrich) 
• Cell lysis buffer L3: 50 mM Tris-HCl buffer, pH7.4; 1 µg/ml 
Lysostaphin from Staphylococcus staphylolyticus (Sigma-Aldrich) 
• Solubilisation buffer: 50 mM Tris-Cl, pH 8.0  
• SDS solution: 3% (w/v) SDS; 0.2 M NaOH 
• 3 M sodium acetate, pH 4.8 
• 7. 5 M ammonium acetate with 0.5 mg/ml Ethidium bromide (Sigma-
Aldrich) 
• Phenol:Chloroform:Isoamyl Alcohol 25:24:1 Saturated with 10 mM 
Tris, pH 8.0, 1 mM EDTA (Sigma-Aldrich) 
• Ethanol (99%) 
• Ethanol (70%) 
• Isopropanol (98%)  
For DNA electrophoresis, the following buffers were used:  
• TBE Running buffer: 89 mM Tris-Borate, 2 mM EDTA buffer 1X (Sigma-
Aldrich) 
• Stacking gel: TBE buffer 1X (Sigma-Aldrich); 0.7-1% agarose (Sigma-
Aldrich) ; 5 to 10 µl Ethidium bromide from a stock solution of 1% (w/ v) (Sigma-
Aldrich). 
For SDS-PAGE, the following buffers were used:  
• 50 mM phosphate buffer saline (PBS) (pH 7.4): containing 3.5X of 1 
MPotassium Phosphate (dibasic) and 1X of 1 M Potassium Phosphate 
(monobasic). 
• Protein loading buffer (2X) stock solution: 0.8 g of SDS; 0.4 ml of β-
mercaptoethanol (Sigma-Aldrich); 8 mg of Coomassie Brilliant Blue G-250 (Thermo 
Scientific); 4 ml of 100% glycerol for every 10 ml of solution. 
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• Protogel 30% (National Diagnostics): acrylamide/ methylene 
bisacrylamide solution (37.5:1 ratio). 
• 4X Resolving buffer (National Diagnostics): gel of 0.375 M Tris-HCL, 
and 0.1% SDS, pH 8.8.  
• ProtoGel Stacking buffer (National Diagnostics): gel of 0.125 M Tris-
HCL and 0.1% SDS, pH 6.8. 
• N,N,N′,N′-Tetramethylethylenediamine (Sigma-Aldrich) 
• 10 % (w/v) ammonium persulfate  
 
Growth media were used for the inoculation and fermentation of cell 
cultures, production of selective agar plates, and for culture storage: 
• Nutrient Broth no. 2 (Oxoid) agar: La-Lemco powder 10g/L; Peptone 
10g/L; sodium chloride 5g/L, pH 7.5; 2% (w/v) Agar granulated (BD) in water. 
• B2 Medium:  2.5 % (w/v) Yeast Extract (DB); 2.5% (w/v) NaCl (DB); 
1% (w/v) Casein Hydrolysate (DB), 0.5% (w/v) Glucose (DB), 0.1% (w/v) K2HPO4 
(DB) in water. 
• LB medium: 10 g/L Tryptone (DB); 5 g/L Yeast Extract (DB); 10 g/L 
NaCl (DB) 
• Nutrient Broth Agar: 25 g/L Nutrient Broth no. 2 (Oxoid), 2% (w/v) 
DIFCO™ Agar (DB) in water. 
• -80 oC storage solution: 10-50 % Glycerol in water.  
 
2.1.2- Restriction and Ligation Enzymes  
 
A list of single and combinations of restriction enzymes used to create the 
restriction maps and digestion for ligation together with the buffers used in reaction 
can be found below. The reaction buffers used are in accordance with the 
guidelines in the NEB website (http://www.neb.uk.com/):  
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• EcoRI (NEB) ; EcoRI reaction buffer 1X (NEB), containing 100 mM 
Tris-HCl buffer (pH 7.5), 50 mM NaCl, 10 mM MgCl2, and 0.025% Triton®  X-100.   
• XhoI (NEB); NEBuffer 2 1X (NEB), containing 10 mM Tris-HCl buffer 
(pH 7.9), 50 mM NaCl, 10 mM MgCl2, and 1 mM DTT. 
• PstI (NEB);  NEBuffer 3 1X (NEB), containing 50 mM Tris-HCl buffer 
(pH 7.9), 100 mM NaCl, 10 mM MgCl2, and 1 mM DTT. 
• SacI (NEB);  NEBuffer 1 1X (NEB) containing 10 mM Bis-Tris-
Propane-HCl buffer (pH 7), 10 mM MgCl2, and 1 mM DTT; BSA 1X (NEB), 
containing 20 mM KPO4 buffer (pH 7), 50 mM NaCl, 0.1 mM EDTA, and 5% 
glycerol. 
• NdeI (NEB); NEBuffer 4 1X (NEB), containing 20 mM Tris-Acetate 
buffer (pH 7.9), 50 mM Potassium Acetate, 10 mM Magnesium Acetate, and 1 mM 
DTT.  
• EcoRI (NEB); XhoI (NED); EcoRI reaction buffer 1X (NEB) 
• EcoRI (NEB); HindIII (NEB); EcoRI reaction buffer 1X (NEB) 
• EcoRI (NEB); PstI (NEB); EcoRI reaction buffer 1X (NEB) 
• EcoRI (NEB); NdeI (NEB); EcoRI reaction buffer 1X (NEB) 
• XhoI (NEB); HindIII (NEB): NEBuffer 2 1X (NEB) 
• XhoI (NEB); NdeI (NEB); NEBuffer 2 1X (NEB) 
• XhoI (NEB); PstI (NEB); NEBuffer 3 1X (NEB) 
• PstI (NEB); HindIII (NEB); NEBuffer 3 1X (NEB) 
• SacI (NEB); NdeI (NEB); NEBuffer 4 1X (NEB) 
• SacI (NEB); HindIII (NEB); NEBuffer 2 1X (NEB) 
 
The ligase used for the plasmid ligations were the T4 ligase from NEB with 
the corresponding reaction buffer 10X (1X containing 50 mM Tris-HCl buffer pH 
7.5, 10 mM MgCl2, 1mM ATP, and 10 mM DTT), and the Quick-Stick Ligase 
(Bioline), with the corresponding Quick-stick Buffer 10X (1X containing 66 mM Tris-
HCl pH 7.6, 10 mM MgCl2, 1 mM Dithiothreitol, 1 mM ATP, and 7.5% Polethylene 
glycol (PEG 6000)). 
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2.1.3- Strains and Vector Constructs 
	  
E. coli DH5α (F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG 
Φ80dlacZΔM15 Δ(lacZYA-argF)U169, hsdR17(rK- mK+), λ–) and TOP10 (F- mcrA 
Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 nupG recA1 araD139 Δ(ara-
leu)7697 galE15 galK16 rpsL(StrR) endA1 λ-) were used for vector purification, 
production of competency and vector transformation. This strains were proived by 
John Ward’s lab and commercially. S. carnosus TM300 (wild-type) was used 
throughout the transformation and protein expression studies. This strain was 
provided by the Leibniz Institute DSMZ-German Collection of Microorganisms and 
Cell Cultures (DSMZ). 
E. coli plasmids used for ligations and restriction digests were pNW21 
(created in John Wards lab) and pTTQ18 (Stark 1987). The S. carnosus vector 
used for the ligation reactions was the pCT20 (a variant from pC194), ordered from 
DSMZ (German Resource Centre for Biological Material). E. coli vector pJ201 
(supplied by John Ward’s lab) was used as the source for the gentamicin 
resistance gene. The pQR239 vector (provided by Frank Baganz’s lab) was used 
as the source for the CHMO gene.  
 
 
2.2- Molecular Biology Techniques  
	  
2.2.1- Plasmid DNA Extraction 
	  
Extraction and purification of plasmid DNA from E. coli strains was achieved 
with spin columns miniprep kits (Qiagen). This kit uses lysis and ionic buffers to 
break the cells and columns that bind to the plasmid DNA through gravitational 
force, separating it from the cell debris. The following protocol was used:  
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• Colonies of E. coli clones were grown in Falcon tubes containing 5ml 
of NB2 or TB medium and the necessary selective antibiotic (100 µg/ml of 
ampicillin; or 15 µg/ml of gentamicin) for 16 hours (overnight), in a Inova 4330 
(New Brunswick) shaking incubator set with a constant temperature of 370C and a 
shaking speed of 250 rpm.  
• The resulting bacterial cultures were collected from the growth 
medium by centrifugation using a centrifuge 5810R (Eppendorf) (5 minutes (min), 
16 639 g, 4 0C) with a rotor for 50 ml falcon tubes, and resuspended in 250 µl of P1 
buffer, which were subsequently transferred to 1.5 ml sterile eppendorf tubes.  
• Cell lysis was induced by addition of 250 µl of P2 buffer.  
• 350 µl of N3 buffer was subsequently added after 5 minutes of 
incubation at room temperature to neutralize the lytic reaction, and to induce 
aggregation of large macromolecules that could inhibit subsequent DNA 
purification.  
• The neutralized samples were centrifuged on a bench top 
accuSpin™ Micro centrifuge (1 min, 17 000 g) in order to fractionate the soluble 
content from the aggregated cell debris, and the resulting supernatant was loaded 
unto a solid phase extraction column that binds to DNA between 100bp and 20 Kb.  
• The supernatant samples were washed through the columns using 
centrifugal force (1 min, 17 000 g), and the resulting flow-through was discarded. 
The plasmid DNA bound to the columns was subsequently washed twice, first with 
500 µl of PB buffer, followed by 750 µl of PE buffer. These washing steps were 
done to clean the DNA samples from impurities, such as protein and lipid 
structures, that might have attached to the columns during the first flow-through of 
the supernatants. In both steps, centrifugal force (1 min, 17 000 g) was used to 
wash the buffers through the solid phase of the columns.  
• After the washing steps, the plasmid DNA samples were eluted in 50 
µl of EB buffer from the columns into 1.5 ml eppendorf tubes by centrifugal force (1 
min, 17 000 g). Final DNA concentrations were measured using a Nanodrop 2000 
spectrophotometer (Nanodrop) at a wavelength of 260 nm.    
 
For S. carnosus, the kits mentioned above were not very efficient, 
recovering less than 5ng/ul of plasmid DNA per 5ml of overnight culture. Instead, 
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two different methods were used for plasmid extraction from the staphylococcal 
cultures. 
The first protocol was based on a previously developed methodology by 
Sullivan et al. (O'Sullivan & Klaenhammer 1993), which involved a phenol-
chloroform gradient to extract the plasmid  from cells debris. The following modified 
extraction protocol was used:  
• Colonies of S. carnosus strains containing plasmid constructs were 
grown in Falcon tubes containing 5 ml of B2 or NB2 medium with the necessary 
selective antibiotic (15 µg/ml of ampicillin; or 15 µg/ml of gentamicin) for 16 hours, 
using a shaking incubator set with the temperature of 370C and shaking speed of 
250 rpm.  
• Resulting cultures were collected from the growth broth via 
centrifugation (5 min, 16 639 g, 4 0C), and subsequently resuspended in 250 µl of a 
25% sucrose solution containing 30 to 60 mg/ml of lysozyme. The resuspended 
samples were incubated for 15 minutes in a 37 0C water-bath. 
• 250 µl of the Qiagen lysis buffer P2 was added to samples, which 
were subsequently incubated for a further 7 minutes at room temperature. 
• The lysis reaction was stopped by adding 300 µl of 3 M sodium 
acetate (pH 4.8), which was cooled to a temperature of 4 0C prior to addition. In 
addition to neutralizing the lytic process, the sodium acetate solution also induces 
the aggregation of large cell fragments, in a similar fashion to the N3 buffer. 
• After aggregation, the samples were centrifuged (10 min, 17 000 g) 
and the supernatants were transferred to 1.5ml sterile Eppendorf tubes, to which 
650 µl of 98% isopropanol was added.  
• After mixing, the samples were centrifuged for a further 15 minutes, 
resulting in a white pellet that was resuspended in a solution containing 320 µl of 
sterile water, 200 µl of 7.5 M ammonium acetate with 0.5 mg/ml of ethidium 
bromide, and 350 µl of phenol/chloroform.  
• The samples were vigorously mixed to produce homogenous 
solutions, which were centrifuged (1 min, 17 000 g) in order to promote DNA 
separation from the other soluble debris through a solvent gradient.  
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• The upper phase of the gradient was collected and transferred to a 
new sterile 1.5 ml eppendorf tube, to which 1 ml of ethanol was added to wash the 
DNA.   
• After another round of centrifugation (1 min, 17 000 g), pellets of 
DNA, which formed in the bottom of the tube, were washed a second time with 
70% ethanol, subsequently dried in a 55 0C incubator for 15 min.    
• DNA samples were finally resuspended in 50 µl of EB buffer. 
Concentrations were measured using a nanodrop spectrophotometer at 260 nm.  
 
The second protocol used for plasmid extraction from staphylococcal 
cultures was a simplified version of the phenol-chloroform extraction protocol, in 
which the solid phase QIAGEN column technology was used for DNA purification 
after pre-treatment of cultures with a lysozyme/lysostaphin solution:  
 
• Overnight cultures were collected via centrifugation (5810R, 5 min, 
16 639 g, 4 0C), resuspended in 250 µl of one of three different lysis buffers (L1, 
L2, and L3), and transferred into 1.5 ml sterile eppendorf tubes. The resulting 
samples were incubation for 1 or 2 hours in a 37 0C water-bath.  
• 250 µl of P2 lysis buffer was subsequently added to samples, which 
were incubated for a further 5 minutes at room temperature.  
• Lysis neutralization and aggregation of unwanted cell debris was 
induced by adding 350 µl of N3 buffer.  
• After centrifugation (1 min, 17 000 g) , the resulting supernatants 
were loaded unto Qiagen spin columns, and the plasmid DNA was subsequently 
purified the Qiagen purification protocol described for E. coli.  
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2.2.2- DNA assembly techniques  
 
(i) DNA restriction and purification 
	  
The different vector constructs were produced by site-specific ligation of 
endonuclease-restricted fragments. For most ligation protocols done in this project, 
the DNA fragments were cut with different endonucleases (REs) at the ends, to 
allow for directional ligation of the different fragments.  
The restriction protocols were conducted prior to the ligation reactions to 
either extract DNA fragments from plasmids, or to produce the appropriate ends in 
amplified products and vectors. Restriction digest were also performed after 
ligation to check for ligation products and produce diagnostic restriction maps.  
In all cases, restriction reactions were performed by adding a volume of 
endonuclease below 5% of total reaction volume into a 1.5 ml sterile Eppendorf 
tube containing 10- 50 µl of DNA. In the case of reactions with a mix of different 
endonucleases, the combined volume for the enzymes did not exceed 5% of the 
total volume of reaction, above which concentration the solution in which the 
endonucleases are stored becomes inhibitory to the restriction reactions.  In 
addition, 1/10  volume the corresponding reaction buffer (10X) (see section 2.1.2), 
was also added to provide the required co-factors for reaction to occur. Finally, 
sterile water was added to the reaction mix to make up for the rest of the total 
reaction volume, if necessary. As an example, a 20 µμl restriction digest of 10  µμl of 
plasmid DNA would be made up in the following fashion:  
 𝑅𝑒𝑎𝑐𝑡𝑖𝑜𝑛  𝑚𝑖𝑥   20µμl= 10µμl  plasmid  DNA+   1µμl  RE+ 2  µμl  RE  buffer   10X + 7  µμl  H2O   
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Restriction reactions were incubated in a 37 0C water-bath for 2 to 4 hours, 
depending on the restriction rates of the different REs, and subsequently stopped 
by heat-shock treatment (10 min, 65 0C heat-block). All the endonucleases used in 
this study produced single-stranded overhangs upon excision of the target 
restriction sites.  
Prior to ligation, restricted DNA samples have to be separated from the 
inactivated reaction mix, which otherwise could interfere with the ligation process.  
This was done either by gel extracting the DNA fragments from an agarose gel, or 
in the case no fragment fractionation was needed, by using Qiagen PCR 
purification kit. These kits are optimized to purify amplified DNA fragments from the 
enzymatic mixes used during polymerase chain reaction (PCR) protocols. 
Therefore, the kits are also suitable to wash away the mix of inactivated REs and 
reaction buffer impurities from the restricted DNA material. For purification by 
Qiagen purification kit, the following protocol was used: 
• 5 volumes of PB buffer were added to 1 sample volume, contained 
within a 1.5 ml sterile Eppendorf tube. For example, for 50 µl of DNA restriction 
sample, 250µl of PB buffer were used.  
• The resulting mix was loaded unto a Qiagen purification column, 
which similarly to the Qiagen miniprep columns contains a solid phase that binds to 
plasmid DNA in solution through centrifugal force. 
• The mix was washed through the column by centrifugation (1 min, 13 
000 rpm), with the resulting flow-through being discarded.  
• The column was subsequently washed with 750 µl of PE buffer to 
wash away cell debris impurities that might have been absorbs into the solid matrix 
of the column.  
• The plasmid DNA was eluted in 20 µl of EB buffer by centrifugal force 
(1 min, 17 000 g), and its final concentration was checked through a nanodrop 
spectrophotometer set for a wavelength of 260 nm.         
The process of plasmid DNA purification through the use of the Qiagen 
purification kit not only generated samples of high purity, but also resulted in a 
reduction of the sample’s volume, consequently increasing the final concentration 
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of the DNA product. In the case of the example given above, an initial sample 
volume of 50 µl was reduced to a final volume of 20 µl. By contrast, the alternative 
method of DNA purification, gel extraction, often results in a loss of final sample 
concentration, but is a requirement for the purification of heterogeneous samples. 
This protocol is described in the next section.  
 
(ii) Ligation of purified fragments 
 
Ligation protocols were performed with a variety of different commercially 
available DNA ligases and operating conditions, which were partly dependent on 
the type of ligase. T4 ligases provided from New England Biolabs and Invitrogen 
were used alternately in most ligations protocols involving fragments with single 
stranded overhangs. In addition, the Quick-Stick Ligase, from Bioline, was also 
used as a faster alternative to the standard protocols in ligation steps that did not 
require a long incubation stage.  
Prior to ligation, the different restricted fragments were mixed together 
following specific molar ratios between the fragments. Depending of these ratios, 
the volumes of the different fragments to be added together were calculated using 
the following equation (1): 
 
𝑛𝑔  𝑖𝑛𝑠𝑒𝑟𝑡 = !"  !"  !"#$%&∗!"#$  !"  !"#$%&    !"#$  !"  !"#$%&   ∗𝑚𝑜𝑙𝑎𝑟  𝑟𝑎𝑡𝑖𝑜   𝑣𝑒𝑐𝑡𝑜𝑟: 𝑖𝑛𝑠𝑒𝑟𝑡     (1) 
 
Where insert refers to the smaller of the fragments, and vector corresponds 
to the larger fragment. Alternately, vector often referred to the DNA fragment 
containing the selection and replication genes. For instance, in the case of the 
ligation between pTTQ18 and the synthetic linker (see Chapter 4, section 4.4), the 
former is considered to be the vector due to its larger size, and the fact that it 
contains the ampicillin resistance gene and the origin of replication. The sizes of 
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the different fragments are expressed as kilo-bases (Kb), and the amounts referred 
to in nano-grams (ng).  
Various molar ratios were tested during the ligation protocols in order to find 
the optimal ratio between the different fragments. For ligations involving DNA 
fragments with single-stranded overhangs, the molar ratios 1:1 (vector/insert), 1:3 
(vector/insert) and 1:6 (vector/insert) were used. For blunt-end ligations, higher 
ratios of 1:6 (vector/insert) and 1:10 (vector/insert) were used in order to increase 
the probability of ligation between the phosphorylated ends of different fragments, 
as opposed to re-ligation of homologous molecules.  
The components of the different ligation reactions were as follows:  
 
• For the T4 ligase from NEB:  
 𝑇𝑜𝑡𝑎𝑙  𝑣𝑜𝑙𝑢𝑚𝑒   10  µμl= x  µμl  of  vector+ y  µμl  of  insert+ 1  µμl  Reaction  buffer   10X+ 10−   1+ 𝑥 + 𝑦 µμl  𝑜𝑓  𝐻2𝑂 
 
• For the T4 ligase from Invitrogen: 𝑇𝑜𝑡𝑎𝑙  𝑣𝑜𝑙𝑢𝑚𝑒   20  µμl= x  µμl  of  vector+ y  µμl  of  insert+ 5  µμl  Reaction  buffer   4X + 20−   5+ 𝑥 + 𝑦 µμl  𝑜𝑓  𝐻2𝑂 
• For the Quick-Stick ligase from Bioline: 𝑇𝑜𝑡𝑎𝑙  𝑣𝑜𝑙𝑢𝑚𝑒   10  µμl= x  µμl  of  vector+ y  µμl  of  insert+ 1  µμl  Reaction  buffer   10X + 10−   1+ 𝑥 + 𝑦 µμl  𝑜𝑓  𝐻2𝑂 
 
Volumes of the vector and insert fractions were derived from the molar 
ratios of reactions and concentrations of the different DNA samples. Ligation 
reactions were routinely incubated in a 37 0C water-bath for 1 to 2 hours, with the 
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exception of reactions involving the Quick-Stick ligase, which were incubated for 5 
minutes. Alternatively, T4 ligase reactions were also incubated in a 4 0C 
refrigerator for 16 hours in order to lower the reaction kinetics in cases were the 
turn-overs were undesirable, such as in blunt-end ligations. After ligation, reactions 
were heat-shocked in a 65 0C heat-block for 10 minutes in order to kill the activity 
of the ligase, and subsequently transformed into competent cells.      
 
2.2.3- Gel Electrophoresis and DNA Extraction  
	  
Screening of ligation products and separation of different sizes DNA 
fragments in restriction digests was achieved by agarose gel electrophoresis. This 
technique works on the basis on size and charge of DNA molecules by establishing 
an electric current around an agarose polymer gel, which promotes migration of 
charged molecules through the matrix. Molecules will run through the gel at 
different speeds depending on their size: larger DNA fragments have a bigger 
surface-area of contact with the agarose matrix, and therefore move at a slower 
rate, while smaller fragments have a lower probability of getting entangled in the 
gel matrix. The same principle can be applied to the separation of different 
geometries. For instance, super-coiled plasmid DNA will migrate faster than its 
open circularized variant due to the smaller surface area. On the other hand, 
linearized plasmid DNA, which has been excised once with restriction 
endonucleases, will exhibited the size expected for that DNA molecule, i.e. a 7.5 kb 
sized linearized plasmid will migrate to the corresponding size on an agarose gel 
relative to a ladder control. 
Agarose is a polysaccharide polymer made up of sub-units of agarobiose 
that dissolves in near-boiling water, forming a gel after the cooling process. The 
gels used in this PhD project were made up of either 100 ml or 50 ml of TBE buffer 
containing 1% of agarose (w/v). It was important for all the agarose gels to contain 
the same percentage of agarose, as this percentage is directly related to the size 
of the resulting gel pores, and consequently to the resolution of the gel.  
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Gel casting was done by heating up the agarose/ TBE solution to boiling-
point for 1 minutes, and subsequently pouring the hot liquid into a plastic mold. The 
size and number of wells was determined by different well combs available as part 
of the mold. In addition, to allow for the visualization of the DNA fragments after 
electrophoresis, 5 to 10 µl of 1% (w/v) ethidium bromide was mixed into the cooling 
gel sample. After casting, gels were loaded into a electrophoresis tank containing 
positive and negative electrodes and subsequently immersed in TBE buffer.  
Prior to loading on the gels, DNA samples were mixed with a dyed loading 
buffer, which allowed for the samples to be loaded into the submerged wells and 
for the monitoring of the diffusion rates of samples during electrophoresis. After 
sample loading, the gel tank was sealed and an electric current established 
through connecting the electrodes to a powerPac from BioRad with a set voltage. 
All the agarose electrophoresis experiments were conducted with a electric current 
voltage of 120 Volts (V).  
After electrophoresis, the bands for the different DNA fragments were 
visualized using a Sygene Bio-imaging system containing a fluorescence UV 
transilluminator and a capture camera. Photographs of the different agarose gels 
were taken for subsequent analysis of the DNA samples.   
As mentioned in the previous sections, some ligation steps required the 
separation of a heterogeneous restricted DNA sample and subsequent gel 
extraction of the desired fragments prior to the ligation reaction. The QIAGEN gel 
extraction kits were routinely used for the purification of DNA fragments from 
agarose gels. This type of kit, like the other kits already described, relies on a the 
use of a solid phase matrix that binds to DNA upon contact. As with other kits, a 
accuSpinTM Micro centrifuge was used to apply the centrifugal force required for 
the flow of samples and wash-buffers through the matrix.  
The following gel extraction protocol was used to extract DNA fragments 
from agarose gels: 
• The desired bands were first excised from the agarose gel by using a 
scalpel and a benchtop UV transilluminator to enable the identification of the 
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correct bands.  Exposure of the agarose gel to the UV was minimized to prevent 
UV-mediated damage to the DNA.  
• The excised bands were subsequently transferred to sterile 1.5 ml 
eppendorf tubes, which had been pre-weighted. The weight of the bands 
(expressed in mg) was then calculated by subtracting the weight of the empty 
tubes to the total weight of the tubes containing the agarose bands.  
• 3 volumes of QG buffer were subsequently added to 1 volume of gel 
(where 100 µl corresponds 100 mg of gel), and the resulting samples were 
incubated in a heat-block at 50 0C for 10 minutes in order for the bands to dissolve 
completely.  
• 1 gel volume of Isopropanol was then added to the samples, which 
were subsequently loaded into the QIAquick spin columns. The columns were 
centrifuged (1 minute, 17 000 g) to bind the DNA to the solid matrix, and the 
resulting flow-through was discarded.  
• Two washing steps were subsequently performed on the columns, in 
which 750 µl of PE buffer were added to the columns and retained for 5 minutes in 
contact with the DNA-bound matrix. The washing buffer was subsequently washed 
via centrifugation (2 minutes, 17 000 g) and resulting flow-through discarded.  
• The DNA was subsequently eluted from the columns, through 
centrifugation (1 minute, 17 000 g), in a final volume of 20 µl of EB buffer. DNA 
concentrations were checked through a Nanodrop 2000 spectrophotometer with a 
wavelength of 260 nm.    
 
2.2.4- Amplification of DNA Fragments using PCR   
 
Polymerase chain reaction (PCR) was used to amplify fragments from low 
concentration DNA samples, and to add specific endonuclease restriction sites at 
the ends of genes. PCR works through repeating thermal cycles that allow for short 
sequence primers to anneal to the sequences to be amplifies and for enzymatic 
replication to occur. Each cycle involved three distinct steps. In the first step the 
double stranded (ds) template DNA is melted at 98 0C to producesingle-stranded 
(ss) targets for primer annealing. The second step involves decreasing the sample 
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temperature to the optimal annealing temperature of the primers to the target 
sequence. Primers are designed complement the boundaries of both forward and 
reverse strands of the sequence in order to create ds DNA products.  In the final 
step, enzymatic replication from the 3’ end of the primers is triggered by using DNA 
polymerases that are activated at a specific temperature. As this cycle is repeated, 
the replication product from the previous chapter is used as a template for a new 
replication cycle, resulting in an exponential increase in the concentration of the 
original template.  
The TC512 gradient thermal cycler (TECNE) was used for all the PCR 
experiments conducted throughout this PhD project. This instrument allows for the 
set-up of a temperature gradient across different samples in the same reaction, 
which was very useful to test for the optimal annealing temperature for a given pair 
of primers. The general cycle program used was the following:  
• Melting step at 98 0C for 10 seconds. 
• Annealing step at tm (annealing temperature) of the primers +/- 5 0C.  
• Replication step at 72 0C, using the PhusionR High-fidelity DNA. 
Polymerase (NEB). 
 
This was repeated for 30 cycles, after which a final replication step was 
performed at 720C for 10 minutes. The temperature used for the annealing steps 
depended on the tm calculated for each primers, which was done using the NEB 
web calculator (https://www.neb.com/tools-and-resources/interactive-tools/tm-
calculator). The PhusionR High-fidelity DNA Polymerase (NEB) was for the 
replication of the amplified fragments due to the fact that it has a lower error rate 
than other polymerases in the market.  
All the primers used in the PCR experiments were designed to contain a 
sequence of 20 to 25 nucleotides complementary to the ends of the DNA fragment 
of interest. In addition, in cases where new restriction sites were introduced to the 
ends of the template sequence, restriction site overhangs that did not anneal with 
the sequence were introduced at the 5’-end of the primer. When possible, primers 
were also designed to have similar tm so that the same annealing temperature 
would be optimal for both primers. The following sets of primers were used:  
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• Primers for the pCT20 fragment: 
Forward strand (tm= 61 0C)  
5- ACAGACAGGACAAAATCGATTTTTAC- 3 
Reverse strand (tm= 61 0C)  
5- AGACATCCAAAAATCCGTATTTTGAT- 3 
 
• Primers for the CHMO gene:  
Forward strand (tm= 67 0C) 
5- CCCCTCGAGATGTCACAAAAAATGGATTT- 3 
Reverse strand (tm= 76 0C) 
5- GGCTGCAGTTAGGCATTGGCAGGTTGCT- 3 
 
• Primers for the GenR gene: 
 Forward strand (tm= 71 0C) 
5- CTCGAGATGTTACGCAGCAGCAACG- 3 
Reverse strand (tm= 74 0C) 
5- GCATGCTTAGG TGGCGGTACT TGGGT- 3 
 
PCR samples were prepared by mixing 1 µl of template DNA with a reaction 
mix containing the PhusionR High-fidelity DNA polymerase, the corresponding 
reaction buffer, the set of primers for the amplification process, and the free 
deoxyribonucleotides. The resulting DNA mix was loaded unto 250 µl sterile 
eppendorf prior to  
PCR. For a 50 µl reaction, the following volumes of the different components 
were added: 
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• 1 µl of DNA template. 
• 1 µl of 10 mM (milliMolar) dNTPs. 
• 2.5 µl of each primer (to a final concentration of 0.5 µM) 
• 0.5 µl of Phusion® High Fidelity Polymerase 
• 10 µl of High Fidelity buffer (5X)(NEB)  
• 32.5 µl sterile H2O 
The different components were thoroughly mixed to ensure that the reaction 
sample was homogenous. The different primers were provided by Eurofins MWG 
Operon.   
	  
2.2.5-  In-silico Design of Promoters for Heterologous 
Protein Expression.  
 
The in-silico design of the promoters used for the expression of 
heterologous proteins in S. carnosus was done through several cycles of criteria 
formulation, data gathering and processing, construction of designs, and re-
evaluation of these designs after experimental testing. 
In a first stage of each design cycle, a set of criteria were formulated for the 
nature of the promoter that would be advantageous to the expression of 
heterologous proteins in S. carnosus. These criteria include: the type of expression 
system, constitutive or regulated; the restriction map of the promoter region; the 
source DNA for the promoter; the expression strength of the promoter. The 
formulation of the desirable criteria were not dependent on what prior knowledge 
existed on each of the criteria, but rather used as a set of broad directives to guide 
the promoter screening and design strategy.  
The second stage in this process was data acquisition and processing. This 
entailed the use of several online databases for the acquisition of raw DNA 
libraries, which would then be processed and filtered for promoter sequences using 
several DNA manipulation and prediction software. We used the genome 
sequence of S. carnosus as the main source for the construction of the DNA 
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libraries, which is readily accessible from the NCBI database 
(http://www.ncbi.nlm.nih.gov/genome/?term=Staphylococcus%20carnosus) . The 
use of the staphylococcal genome as a source for promoters,  as opposed to 
relying on promoter databases such as the Registry of Standard Biological Parts, 
seemed more desirable for several key reasons: the promoter databases readily 
available for use focus on promoters for more conventional bacterial systems like 
E. coli and S. subtilis , which have been previously shown to have limited use in 
Gram-positive staphylococcal systems; the selection of promoter sequences from 
the staphylococcal genome ensures that the latter are inherently adapted to work 
in S. carnosus as a biocatalytic host.  However, there are also inherent risks with 
the choice not to operate with established databases. One of these risks is that, 
apart from a couple of promoters already characterized in the literature, there is 
very little background knowledge about the promoter systems in staphylococcal 
species, and therefore the uncertainty of selecting promoters with the desired traits 
is higher.  
In the first round of promoter design, a DNA library were constructed from 
the genome of S. carnosus on the basis of the expression of the genes 
downstream from the selected sequences. Our approach was to only include 
sequences preceding genes that exhibited an high level of overall expression in the 
native organism. This decision was taken under the assumption that, while there is 
not a linear correlation between level of protein expression and transcription of the 
corresponding gene, it is more likely that an highly level of protein expression is 
correlated to a high level of gene expression. Subsequently, these genes are more 
likely to be under the influence of strong promoters. 
Since most of the data on the proteomics of staphylococci has not been 
done on S. carnosus, we used the statistical web-server tool CAIcal (Puigbò et al. 
2008) for the prediction of highly expressed genes on the basis of their codon 
composition. The analysis done by CAIcal is based upon the codon adaptation 
index (CAI), first introduced by Sharp and Li (1987)  as a measurement of codon 
bias of a gene relative to a reference set. CAI quantifies the similarities between 
the codon usage in a gene and that of the reference set, and can be 
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mathematically be expressed as the geometric mean of the codon biases for each 
codon in a gene, following equation 2:  
𝐶𝐴𝐼 = 𝑒𝑥𝑝 !!    𝑙𝑜𝑔  (𝑤 𝑙 )!!!!     (2)  
Where L is the total number of codons in the gene, and w is the codon bias 
of each of the codons, which is mathematical expressed as the ratio between the 
frequency of that codon and the frequency of the optimal codon for the 
synonymous amino acid (equation 3), which in turn is determined from the 
reference set: 𝑤! = !!!!"#$       (3) 
The codon frequencies for each codon in a set of genes were also 
calculated using CAIcal, while the codon usage frequencies of the reference set 
were taken from the Codon Usage Database (http://www.kazusa.or.jp/codon/) 
The different promoters were designed by using several DNA manipulation 
software. The software SerialCloner was the main tool used for the selection of 
manipulation of DNA sequences, sequence alignments and analysis of the 
restriction maps. This software also allowed for the simulation of the ligation steps 
required for the insertion of each of the designed promoters into the vector 
construct. Other web-based tools were also used to facilitate the manipulation of 
the DNA sequences: DNA Massager 
(http://www.attotron.com/cybertory/analysis/seqMassager.htm) was used to easily 
reverse-complement sequences, while the NEBcutter 
(http://tools.neb.com/NEBcutter2/) was used as a restriction site database and as a 
tool to check compatibility between different restriction sites.  In the first round of 
promoter design, sequences were lifted directly from the S. carnosus genome and 
ordered commercially as synthetic genes, using the provider DNA 2.0. For the 
subsequent runs of promoter design experiments, we took a modular approach to 
the design strategy, by independently searching for the different components of the 
promoter: -35 and -10 transcription elements, ribosomal binding site (RBS), and 
regulatory elements.  These promoters were then physically constructed through 
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the assembly of short overlapping oligos, which in turn had been provided by 
Eurofins.  
The last stages of the in-silico design strategy were the implementation of 
the designs into a common vector construct, in which the biocatalyst or reporter 
gene was placed under the expression of the design promoter, and validation of 
the design through analysis of the experimental data with the resulting ligation. 
Depending on the experimental results in the protein expression assays, the 
promoter design was either validated as an efficient expression system, or re-
evaluated through a second cycle of in-silico design strategy.  
 
2.2.6- Production of Competent Cells 
	  
E. coli TOP10 made chemically competent by using a protocol previously 
devised by Pope et al. (Pope & Kent 1996). Following this protocol, 1 ml of 5 ml 
overnight cultures was transferred to 250 ml baffled shake flasks containing 50 ml 
of NB2 medium. The resulting inoculates were grown in Inova 4330 shaking 
incubators (New Brunswick) at 37 0C and 250 rpm, until the optical density  (OD) of 
cultures reached 0.7. Cultures were then transferred into Falcon tubes, and the 
biomass collected by centrifugation (centrifuge 5810 R, 5 min, 16 639 g, 4 0C). The 
pellets were subsequently resuspended in half volume of ice-cold 0.1 M CaCl2, and 
stored in ice for 30 minutes. After this period, cells were re-pelleted by 
centrifugation (centrifuge 5810 R, 5 min , 1 238 g, 4 0C), and resuspended in 2.5 
ml of 0.1 M CaCl2, which was used directly in the transformation protocols  or 
fractionated into 100 µl aliquots containing 10 % (w/v) glycerol and stored at  -70 
0C. It was important to maintain the temperature of bacterial cultures below room 
temperature in order to prevent potentially harmful stress responses from the cells 
during the incubation with CaCl2. In addition, the re-suspension of cultures was 
done gently in order to minimize shear damage. 
Transformation of E. coli chemically competent cells was done by mixing 5 
to 10 µl of DNA with 100 µl  cell aliquots, and subsequently storing the mix on ice 
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for 30 minutes. Samples were subsequently heat-shocked in a 42 0C water-bath for 
30 seconds and then quickly stored on ice for another 2 minutes. After heat-shock 
treatment, 0.5 ml of NB2 medium was added to samples, which were subsequently 
incubated for 1 hour at 37 0C and 250 rpm. The resulting cultures were plated unto 
2% (w/v) agar plates containing 100 µg/ml of ampicillin or 15 µg/ml gentamicin, 
depending on selective gene present on the plasmid DNA. Plates were incubated 
for 24 hours at 37 0C. 
For transformation of S. carnosus cultures, electrocompetent cells were 
produced by following an optimized version of the protocol developed by Löfblom 
et al. (Löfblom et al. 2007). In the optimized protocol, staphylococcal aliquots from 
5 ml overnight cultures grown on B2 medium were transferred to falcon tubes 
containing 5 ml of B2 medium until the final OD600 of the solution reached 0.5. The 
resulting inoculate were grown for 2 hours at 37 0C and 250 rpm, subsequently 
incubated for 15 minutes in ice to stop bacterial growth, and the biomass collected 
by centrifugation (5 min, 16 639 rpm, 4 0C).  The cultures are subsequently washed 
twice with 2.5 ml and 250 µl of ice-cold water by centrifugation (10 min, 16 639 
rpm, 4 0C). The washed pellets were resuspended in a final volume of 50 µl of a 
10% (w/v) glycerol solution and used directly for transformation.  
An MicroPulserTM electroporator (BioRad) was used for the transformation of 
electrocompetent S. carnosus. Aliquots of electocompetent cells were mixed with 
10 µl of DNA and incubated at room temperature for 30 minutes. The mixed 
samples were subsequently transferred to 0.2 cm (centimeter) electroporation 
cuvettes (BioRad), and electroporated using a single 1.1 ms (milliseconds)  pulse 
with a voltage  of 2.1 Kv (kilo-volts) cm-1 .  Electroporated samples were 
subsequently resuspended in 0.5 ml of B2 medium, and incubated for 2 hours at at 
37 0C and 250 rpm. The resulting cultures were plates unto 2% (w/v) agar plates 
containing 15 µg/ml of chloramphenicol or gentamicin, depending on the selective 
gene present in the DNA. Plates were incubated for 48 hours at 37 0C. 
An alternative method that did not involve the pre-production of competent 
cells was also used. This protocol was previously developed by Lin et al. (L. Lin et 
al. 2010), and involved mixing 500 µl aliquots from 5ml overnight cultures grown in 
B2 medium with 10 µl of DNA and sonicating the resulting sample at an high 
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amplitude. A Soniprep 150 Plus sonicators (MSE, 23 KHz (Kilohertz) was used for 
the sonication process, at an amplitude of 20 microns for 45 seconds. An equal 
volume of B2 medium was subsequently added to the samples, which were 
incubated for 4 hours at 37 0C and 250 rpm.  The resulting cultures were spread 
unto agar plates containing 15 µg/ml of chloramphenicol or gentamicin. Plates 
were subsequently incubated for 48 hours at 37 0C. 
 
2.2.7- Plasmid Stability Assays 
 
The plasmid stability assays were conducted on both plasmid containing E. 
coli and S. carnosus cultures using the same protocol. Cultures were first grown 
overnight in 5 ml of NB2 medium containing the corresponding antibiotic, after 
which 100 µl aliquots of the cultures were inoculated into falcon tubes containing 5 
ml of fresh NB2 medium. The inoculates were then grown for 72 hours in the 
absence of antibiotic in an Inova 4330 shaking incubator at 37 0C and 250 rpm, 
with 100 µl of inoculate being transferred to falcon tubes containing 5 ml of fresh 
medium after every 24 hours.  
Samples were taken twice during each 24 hours period, and subsequently 
plated unto both antibiotic containing 2% (w/v) agar plates and plates without 
antibiotic. Prior to being spread on the plates, samples were diluted so that the 
number of colonies growing on the plates did not exceed 102 magnitudes. Plates 
were incubated overnight at 37 0C, and results from the assay were expressed as 
percentage of surviving plasmid-containing (pl) colonies, which could be calculated 
from the fraction between number of colonies grown in antibiotic selective plates 
and in plates without antibiotic (equation 4):	  	  
	  
	  %  𝑝𝑙  𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 =    !.!"  !"#"$%&'  !"  !"#$%!"#!$  !"#$%&!.!"  !"#"$%&'  !"  !"!!!"#"$%&'"  !"#$%& ∗ 100	  	  	  	  	  	  	  	  	  	  (4)	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2.3- Biocatalytic Techniques:  
	  
2.3.1- General Growth Kinetics 
 
Most studies performed on E. coli and S. carnosus strains were conducted 
in non-baffled conical shake flasks of working volume of 1/5 of the total flask 
volume. Shake flasks were invariably incubated using a Inova 4330 shaking 
incubator, with conditions being set at a constant temperature of 37 0C and shaking 
speed of 250 rpm, unless specifically specified. It is important that conditions were 
maintained constant between different batches and bacterial strains since it 
facilitated comparison of growth, expression and biocatalytic performance between 
the different cultures. During incubation, the optical density (OD) of growing 
bacterial cultures was measured routinely by loading a 1 ml sample unto a cuvette 
and measuring the OD in spectrophotometer set-up to record the absorbance of 
samples at a wavelength of 600 nm.  
The OD measurements of growing cultures were used to plot growth curves, 
and from the latter determine simple kinetics of bacterial strains under growing 
conditions. We mainly focused on the lag-time, maximum growth, and the 
maximum growth rate. The lag-time (ΔTlag) specifies the time between start of 
incubation and beginning of exponential phase, and is calculated as the difference 
between the observed time (Tobs) that takes for cultures to reach a specific density 
(xi) from the start of incubation (x0) and the time it would take if the lag phase was 
absent (Tpred), i.e. if bacterial cultures grew in exponential phase from the start of 
incubation (equation 5):  ∆𝑇!"#(ℎ) = 𝑇!"# − 𝑇!"#$ ⇔ ∆𝑇!"# = 𝑇!"# − !"#! !!!!"#! !!!     (5) 
 
Where R is the exponential growth rate. 
The maximum growth (Gmax) refers to the point at which the bacterial 
cultures reach the highest density (xmax), and can be calculated using equation 6: 𝐺!"# = 𝑥!"# − 𝑥!    (6) 
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Finally, the maximum bacterial growth rate (µmax) refers to the maximum rate 
of cell division, which also corresponds to the exponential growth rate (R), and 
expressed using the following equation (equation 7):   
 𝑅  (ℎ!!) = !"#! !!!!"#! !!!!!!!    (7) 
 
Where x2 and x1 refer to the densities at different points of the exponential 
phase, with the corresponding times T1 and T2. All the different kinetic factors were 
determined following the Monod model for bacterial growth kinetics (Monod 2003).  
For the specific cases where different containers where used for bacterial 
growth, i.e. overnight incubation of colonies and rapid DNA screening via a 96-well 
plate, no kinetic factors were calculated. This was due to the fact that the 
experiments performed under the latter conditions were qualitative, and therefore it 
was not essential to acquire quantitative data on the general kinetics of bacterial 
growth.   
 
2.3.2- Measurement of Dry Cell Weight (DCW) 
 
The dry cell weight (DCW) of cell cultures was determined from the 
calibration of dry mass as a function of optical density (OD) of bacterial cultures. 
This calibration was performed by drying bacterial cultures with different OD on 
0.22 micron nylon filters from Millipore, which had in turn been previously dried for 
5 days in a 50 0C incubator. The long drying period was performed to stabilize the 
weight of the filter and to ensure that the latter did not vary throughout the cell 
drying protocol.  
Cells were inoculated overnight in 5 ml of growth medium contained within a 
shake flask and later transferred into a 500 ml shake flask containing 100 ml of 
growth medium with the respective selective antibiotic. Cultures were incubated in 
a shaking incubator for 24 hours at a temperature of 37 0C and shaking speed of 
250 rpm, with 5 ml samples being taken at different cell densities. The cultures 
from these samples were subsequently drained onto the filters by applying a 
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vacuum to the output of the filter. After successful filtration, filters were stored in 
non-sealed pretty dishes and incubated in the 50 0C incubator until the dry weight 
of the bacterial cultures stabilized. As a control, clean medium was also filtered 
unto the same type of filters and dried in parallel to the bacterial cultures.  This 
control was necessary to measure the contribution of medium salts that are not 
evaporated during the desiccation stages to the overall dry weight of cells cultures. 
Both controls and working samples were analyzed in triplicates, in order to 
calculate the degree of confidence of the results. 
The final bacterial dry weight for each corresponding OD600 was calculated 
as (equation 8):  
 𝐹𝑖𝑛𝑎𝑙  𝐷𝐶𝑊  (𝑔) = 𝑇𝑜𝑡𝑎𝑙  𝑤𝑒𝑖𝑔ℎ𝑡 − 𝑤𝑒𝑖𝑔ℎ𝑡  𝑜𝑓  𝑓𝑖𝑙𝑡𝑒𝑟 + 𝑤𝑒𝑖𝑔ℎ𝑡  𝑜𝑓  𝑐𝑜𝑛𝑡𝑟𝑜𝑙      
(8) 
 
The final dry weight of cultures can be converted to dry cell weight 
concentration (CDCW) by using equation 9:  
 𝐶!"#   (𝑔. 𝐿!!) = !"#$%  !"#!"#$%&  !"  !"#$"%&      (9)  
 
The final step was the calibration of CDCW against its corresponding OD600, 
resulting in a linear correlation, which could be used to calculate the dry cell weight 
of a culture at given OD600.  
For E. coli cultures, this linear correlation was expressed using equation 10:  
 𝐶!"#   (𝑔. 𝐿!!) = 0.25 ∗ 𝑂𝐷!""   (10) 
 
While for S. carnosus it was expressed using equation 11: 
 𝐶!"#(𝑔. 𝐿!!) = 0.25 ∗ 𝑂𝐷!""    (11) 
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2.3.3- SDS-PAGE Analysis of Protein Fractions 
 
Protein extracts from bacterial cultures were examined via SDS 
polyacrylamide gel electrophoresis (PAGE). This technique is based upon the 
stimulated migration and fractionation of charged macromolecules through a 
polyacrylamide gel by applied an electric field across the length of the gel. In a 
native PAGE, migration is largely determined by the electrophoretic mobility of the 
macromolecules, i.e. the size, conformation and charge of different proteins.  
In SDS-PAGE, sodium dodecyl sulfate (SDS) is added to the samples prior 
to loading on the gel in order to linearize proteins by disrupting non-covalent bonds 
within the protein and to impart a negative charge to the latter, which is evenly 
distributed per unit of mass. In this case, migration of a group of macromolecules 
through the gel is mainly dependent upon the sizes of the different proteins, as 
SDS negates both shape and charge of the proteins. As the electric field is 
established across the gel, samples migrate towards the positive electrode 
(anode), and separation of the different proteins contained within the latter occurs 
due to the different speeds at which differently sized protein migrate towards the 
anode.  
Samples used for SDS-PAGE analysis of protein extracts were prepared 
from 50 ml bacterial cultures grown in 250 ml conical shake flasks with selective 
antibiotic, on Inova 4330 shaking incubators set up with a constant temperature of 
37 0C and rotation speed of 250 rpm. After collection of the cultures via 
centrifugation (16 639 rpm, 5 min, 4 0C), pellets were resuspended in 5 ml of either 
50 mM phosphate buffer saline (PBS) ( pH 7.4) or 50 mM Tris-HCl buffer (pH 7). 
The resuspended cultures were subsequently lysed through the use of a French® 
Pressure Cell Press (Thermo) with a 30 ml maximum capacity stainless steel 
pressure cylinder and a 1 inch Piston, which had been stored beforehand at 4 0C to 
ensure that the temperature of the samples did not rise above the threshold for 
protein stability during the homogenization process. Samples were also stored on 
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ice throughout every step of the protocol after collection to minimize any 
compromise to the stability of proteins within the cells.  
During French press homogenization, liquid samples are loaded unto a 
pressure cylinder and compressed by the use of an external hydraulic pump that 
drives a piston into the cylinder, building up a pressurized environment inside the 
cylinder. As a valve is slowly opened at the outlet of the cylinder, cells suffer 
severe shear stress from decompression, resulting in the disruption of cell 
membrane.  
To ensure efficient cell lysis, E. coli samples were submitted to two round of 
homogenization at a final pressure of 1800 bar, while S. carnosus cultures were 
submitted to three round under the same conditions.  
The soluble and insoluble fractions of the lysates were subsequently 
separated using a bench top centrifuge (16 639 g, 5 min, 4 0C) and aliquots were 
taken from each fraction individually for loading unto the SDS-PAGE 
polyacrylamide gel. Aliquots from the soluble fraction were taken directly from the 
supernatant of lysates and mixed with protein loading buffer, while the insoluble 
fraction was first resuspended in an equal volume of PBS or Tris-HCl buffer before 
mixing with the loading buffer. In turn, the protein loading buffer was aliquoted from 
a 2X stock solution containing 0.8 g of SDS, 0.4 ml of β-mercaptoethanol,  8 mg of 
Coomassie blue G-250, and 4 ml of 100% (w/v) glycerol for every 10 ml of solution.  
After mixing of the loading buffer with the supernatant and pellet extracts, 
the samples were heated to 95 0C in order to facilitate the linearization of protein 
structures by SDS and β-mercaptoethanol, and to melt down any cell aggregates 
that might otherwise hinder the loading of the samples into the polyacrylamide gel. 
The samples were subsequently spun down in a benchtop centrifuge at maximum 
speed for 1 minute to separate any remaining aggregates, and loaded onto the 
polyacrylamide gel.  
The polyacrylamide gel was prepared in distinct phases: the running phase 
and staking phase (Figure 13). The running phase is the first to be settled onto a 
glass cassette, and as the name implies it is the phase where the samples migrate 
and are fractioned into distinct bands according to size. It was prepared through a 
mixture of 2 different liquid buffers supplied by National Diagnostics, ProtoGel 30% 
and Resolving Buffer (4X), and distilled water.   
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Figure	  13-­‐	  Diagram	  representing	  the	  different	  layers	  of	  an	  SDS-­‐PAGE	  gel	  
(http://www.siumed.edu/).	   
 
The Protogel 30% is the component of the mix that contains the 
polymerizing acrylamide monomer and bisacrylamide, and depending on the 
desired final percentage of acrylamide on the gel, different volumes of the buffer 
are added to different dilution volumes of distilled water. By contrast the volume of 
resolving buffer remains constant regardless of the final gel percentage. The 
percentage of acrylamide in the resolving phase determines the size of the pores 
through which the linearized proteins migrate through, and consequently 
determines the overall resolution of the gel. Therefore, it was very important to 
maintain the acrylamide percentage of the constant throughout the multiple SDS-
PAGE assays conducted in the protein studies in order to ensure that results from 
different assays were comparable.  To achieve a resolving phase with a 
percentage of 12%, we mixed 40 ml of ProtoGel 30% with 33.9 ml of distilled water 
and 25 ml of resolving buffer. Acrylamide is capable of spontaneous 
autopolymerization upon hydration, forming long single-chain polymers. However, 
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this form of polymerization is slow, and results in a viscous solution rather than a 
solid phase due to the fact that the polymers are not cross-linked. Therefore, prior 
to loading the mixture unto the gel cassette, a small volume of the chemical 
initiators ammonium persulfate (APS) (1% v/v) and TEMED (0.1% v/v) were added 
to speed up polymerization and to trigger cross-linking between acrylamide 
polymers and bisacrylamide molecules present in the ProtoGel 30%. After addition 
of initiators, the resolving gel mixture was poured into the gel glass cassette, which 
was set up vertically to allow the gel to settle through gravitational pull.  
The stacking phase was prepared in a similar fashion, by mixing 1.3 ml of 
ProtoGel 30% with 6.1 ml of distilled water and 2.5 ml of stacking buffer (4X). In 
this case the volumes of distilled water and ProtoGel 30% are not variable, since 
the percentage of acrylamide in the stacking gel does not contribute to the overall 
resolution of the results. TEMED (0.01 ml) and APS (0.05ml) were also added for 
reasons stated previously. Once the resolving phase was solidified, the 
polymerizing stacking phase was poured on top, and sample wells were molded 
through the use of a flat comb with broad indentations, which was subsequently 
removed once the stacking phase was completely settled.  
The resulting polyacrylamide gel was loaded into a transparent plastic 
chamber containing the electrode circuit, and immersed in a SDS-PAGE running 
buffer that had been previously diluted from a 10X stock solution.  Pre-treated 
pellet and supernatant samples were subsequently loaded into the immersed wells, 
and electrophoresis is started by applying an electric current via a powerPac from 
BioRad that had been connected to the electrophoresis apparatus. In all the SDS-
PAGE assays conducted throughout this project, the electric current was set to 
amplitude of 35 mAmps and a electrophoresis running time of 50 minutes.  
The last step in the SDS-PAGE protocol is the staining and de-staining of 
the protein gel, which is necessary for the visualization of protein bands on the gel. 
The staining solution we used was a Coomassie Brilliant Blue based stain, which 
binds non-specifically to proteins. In the staining protocol, we added varying 
volumes of the staining solution to the protein gel, which had been removed from 
the glass cassette after electrophoresis and placed in shallow plastic container. 
Staining was achieved by heating the immersed gel in the microwave at maximum 
power for 1 minute, or alternatively by gently mixing the immersed gel for 30 
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minutes on a revolving table. De-staining was achieved through several washing 
steps in which the gel was re-immersed in a variable volumes of distilled water and 
subsequently heated in the microwave at maximum power for 5 minutes.  
The gels were visualized by using a light-box contained within a sealed 
chamber with a capture camera on top. 
 
2.3.4- NADPH Oxidation Assays 
	  
The activity of intracellularly expressed biocatalyst was readily detected in 
the lysates of bacteria hosts by measuring the oxidation rates of NADPH. During 
the conversion or cyclohexanone into ε-caprolactone, CHMO uses NADPH as a 
source of electrons, and therefore enzymatic activity can be correlated to the 
amount of NADPH oxidation over time. Since NAPDH absorbs at 340 nm, the rates 
of oxidation can be measured as the decay in absorbance of samples containing 
lysates and reaction buffer at 340 nm as a function of time.  
The bacterial lysates were prepared by growing overnight inoculates in 250 
ml shake flasks containing 50 ml of growth media with the corresponding selective 
antibiotic. After 8 hours of growth in an INOVA 4330 shaking incubator at 37 oC 
and 250 rpm, cells were harvested by centrifugation at (5810 R, 16 639 g for 5 
minutes, 4 0C), using a bench top centrifuge 5810 from Eppendorf with a rotor for 
50 ml Falcon tubes.  Before cell harvesting, the optical density of the cultures was 
measured using a spectrophotometer at 600 nm in order to calculate the dry cell 
weight of the pellets. The cell pellets were then resuspended in 5 ml of 50 mM Tris-
HCl (pH 9) buffer, and subsequently lysed via mechanical homogenization using a 
French press. The same method was used for the mechanical lysis of both S. 
carnosus and E. coli cultures, with cells being loaded onto the pressure cylinder 
and submitted to 1800 bar twice. After homogenization, soluble lysate was 
separated from the insoluble cell debris via centrifugation (16 639 g, 5 min, 4 0C), 
and subsequently aliquoted into 0.2 ml samples that were used directly in the 
NADPH oxidation assays. All cultured samples were stored in ice throughout the 
protocol to ensure that the cells were in a dormant state and no unwanted 
enzymatic activity occurred during cell lysis. Storing samples at low temperatures 
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also increased the stability of soluble proteins that were released to the 
supernatant upon lysis.  
The NADPH oxidation assays were performed following an protocol 
established by Doig et al. (2002).  Lysate aliquots were loaded into 1 ml cuvettes 
containing 0.8 ml of reaction buffer, which had been prepared beforehand and 
stored at 4 0C. The reaction buffer was composed of 50 mM Tris- HCl (pH 9), 0.161 
mM of NADPH, and 7.14 g/L of BSA (Bovine Serum Albumin). The cuvettes 
containing the mixture were subsequently loaded into a spectrophotometer with 
temperature control set to 30 0C, and the rates of oxidation of NADPH were 
measured at an absorbance of 340 nm for 2 minutes in the absence of the 
biocatalytic substrate cyclohexanone. This rate corresponds to the basal activity of 
the proteins in the lysate, as there is always a percentage of intracellular proteins 
that oxidize NADPH. After the first 2 minutes,  a varying concentration of 
cyclohexanone (2- 8 mM) is added to the reaction cuvettes from a stock solution of 
1 M, and the NADPH oxidation is measured for another 2 minutes. The resulting 
oxidation rates corresponded to the sum of activities from the intracellular active 
contents of the cell and the biocatalytic activity of CHMO in the conversion of 
cyclohexanone to caprolactone. From these results we were able to calculate the 
specific activity of CHMO in the lysates.  
Unfortunately, we were unable to find a protocol that could give an accurate 
measurement of the amount of CHMO in the lysates: We were unable to purify 
active protein from cell extracts; Bradford assays would only give a rough estimate 
and lacked the sensitivity to detect small variations in biocatalyst concentration, 
which considering the difficulties in pinpointing CHMO overexpression in SDS-
PAGE gels, was not very useful as a measurement of precise amounts of the 
protein. Therefore, the specific enzymatic activity was expressed as amount of 
NADPH oxidized per minute per gram of dried cell weight (DCW).  
Specific enzymatic activity was calculated using the following steps : 
• The NADPH oxidation rate (ω basal) (equation 12) from the lysate 
basal activity was first subtracted from the overall NADPH oxidation rate (ω total) 
(equation 13) after the addition of the biocatalytic substrate, in order to obtain 
oxidation rate resulting from the biocatalytic activity of CHMO (ω CHMO) (equation 
14):  
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   𝜔!"#"$(𝑎𝑏𝑠.𝑚𝑖𝑛!!) = 𝐴𝑏𝑠!!! − 𝐴𝑏𝑠!!!     (12) 𝜔!"!#$  (𝑎𝑏𝑠.𝑚𝑖𝑛!!) =    𝐴𝑏𝑠!!! − 𝐴𝑏𝑠!!!     (13) 𝜔!"#$(𝑎𝑏𝑠.𝑚𝑖𝑛!!) =   𝜔!"!#$ − 𝜔!"#"$    (14) 
 
• The values of absorbance can be translated to amount of NADPH by 
using the extension coefficient (ε) of NADPH at a wavelength of 340 nm (equation 
15):  
 𝐶  (𝑚𝑜𝑙. 𝐿!!) = !"#!∗  !                   (15) 
 
C = concentration (mol.L-1) 
ε = extension coefficient = 6.23 x 103  L.mol-1.cm-1  for NADPH at 340 nm  
l = light path length (1 cm) 
The concentration of NADPH can be in turn converted to the amount of 
NADPH (m) present in the 1ml reaction sample (equation 16):  
 𝑚  (𝑚𝑜𝑙) = 𝐶 ∗ 10!!      (16) 
 
• Finally, the specific enzymatic rate of CHMO (µCHMO) in the lysates 
was expressed using the following equation 17:  𝜇!"#$   (𝑚𝑜𝑙.𝑚𝑖𝑛!!.𝑔 𝐷𝐶𝑊 !!) = !!"#$!      (17) 
 
Where G is the dry cell weight of the cultures from which the lysates were 
extracted, and can be calculated for each 0.2 ml aliquot using equation 18: 
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𝐺  (𝑔 𝐷𝐶𝑊 ) = (!!"##∗!"#$%&  !"  !"#$"%&'  (!"!"))∗!.!!      (18) 
 
Where the constant factors 0.2 and 5 correspond to the concentration of 
volume that occurs as cell cultures are pelleted from the 50 ml volume and 
resuspended in 5 ml of Tris-HCl buffer. Both factors are in the equation expressed 
as milliliters (ml), and therefore required prior conversion into litters (L) in order to 
correspond to the units of the concentration of cells grown in the shake flasks 
(Ccell), which in turn was calculated using equation 19:  
 𝐶!"##   (𝑔 𝐷𝐶𝑊 . 𝐿!!) = 𝑂𝐷 ∗ 𝐶!"!!      (19) 
 
COD=1 = concentration of cells when the optical density (OD) is 1, which had 
been determined previously.  
Alternately, the units of Ccell could be converted to grams (g) per milliliter 
(ml), which in the end was preferred in order to simplify equation 9. 
 
2.3.5- Whole-Cell and Resting-Cell Biocatalysis Assays 
 
In order to access the efficiency of E. coli and S. carnosus strains to work as 
efficient biocatalysis host, whole-cell biocatalytic assays were performed on both 
actively growing bacterial cultures and cultures that have been resuspended in 
non-growing medium and subsequently maintained in the stationary phase.  
The reasoning behind performing biocatalysis on actively growing cells was 
to access the overall performance of CHMO biocatalysis when the cell metabolic 
machinery is consuming oxygen, which is a competing resource. Moreover, the 
analysis of biocatalytic rates during bacterial growth would allow us to access the 
optimal OD for transferring the cell cultures to non-growing medium, i.e. the OD at 
which the bacterial cultures exhibited the highest activity rates. These assays were 
performed by transferring an overnight bacterial inoculate into 250 ml Falcon tube 
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containing 50 ml of growing media, the corresponding selective antibiotic, and a 
non-inhibitory concentration of cyclohexanone, which ranged from 10 mM to 20 
mM  (taken from a stock solution of 1 M cyclohexanone). Cultures were grown for 
24 hours in a INOVA 4330 shaking incubator at 37 0C and 250 rpm, with samples 
being taken at different time points for the subsequent measurement of 
cyclohexanone and caprolactone content via gas chromatography (GC), and for 
measurements of optical density (OD). Samples were taken in triplicates in order to 
determine the confidence range of the results.  
For the resting-state biocatalytic assays, cells were grown as previously 
described in the absence of biocatalytic substrate until the end of exponential 
phase, or at the point at which the biocatalytic rates are optimal (determined from 
the actively growing cell experiments), which for most bacterial cultures 
corresponded to a bacterial growth of 8 hours. Cells where subsequently harvested 
via centrifugation (16 639 g, 5 min, 4 0C) and resuspended in 5 ml of phosphate 
buffer saline (pH 7.4) containing 10 g/L of glycerol, as a carbon source to allow for 
basal cellular activity, and 10-20 mM of cyclohexanone. Incubation of cultures 
under these conditions was performed in a shaking incubator at 37 0C and 250 rpm 
during   Samples were taken at specific time points for subsequent GC analysis of 
substrate/product contents.  
In both the active-growing and resting-state biocatalytic assays, the whole-
cell biocatalytic activity rate (µcell) was calculated using a modified version of 
equation 8 (equation 20):  
 
𝜇!"##   (𝑚𝑜𝑙. ℎ!!.𝑔 𝐷𝐶𝑊 !!) = !"#$%&' !"#!$%&$' ∗!"#.    !"  !"#$"%&  !∗!"#$     (20) 
 
Where G is calculated using a modified version 9, in which the constant 
factor 0.2 and 5 are removed. This is due to the fact that the G in both active and 
resting-state assays is the same, and therefore no correction of the value due to 
change in final volume is required. Despite the concentration step performed on 
cell cultures prior to resting-state biocatalysis, the final mass of cultures does not 
change with the reduction of volume.   
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2.3.6- GC Analysis of Whole-Cell Biocatalytic Samples 
	  
The detection of cyclohexanone and ε-caprolactone in samples taken from 
the biocatalytic assays was done on a autosystem XL-2 gas chromatograph 
(Perkin- Elmer). Gas chromatography (GC) is a technique for analytical chemical 
studies that relies on the separation of different vaporized compounds as they are 
carried through a liquid stationary phase with a specific length and polarity. The GC 
chromatograph set-up is generally composed of three main components: an inlet, 
where the samples are introduced through a syringe and vaporized. The vaporized 
analytes are subsequently transported by a gas stream, designated the mobile 
phase, through a column that contains a liquid stationary phase. As the samples 
are carried through this column, the various analyte components will be retained in 
the stationary phase to differing degrees. The interaction of the different 
compounds with the stationary phase causes each compound to be eluted through 
the column at different times. At the output of the column, a detector is used to 
measure the amount of analytes as they exit the system.  
The different retention times of compounds, i.e. the time in which they are 
retained within the stationary phase, are what determines the analytical power of 
the GC system, as the identification of specific compounds is dependent on the 
ability to discern the retention times of different analytes. In turn, retention time is 
dependent on two major parameters: the polarity of the stationary phase, and the 
temperature of the oven in which the column is contained. The polarity of the 
stationary phase determines the level of interaction between compounds and the 
column, while the temperature of the controlled column environment dictates the 
rate at which different compounds are carried through the column. Similar polarities 
between the stationary phase and sample analytes result in increased retention 
time of the latter, thereby slowing the analysis process; on the other hand, 
increased diffusion rates of samples through the column decrease the residence 
time of the analytes in the column. The interplay between these factors determines 
the resolution of the GC system. In addition, column length and diameter also 
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affect resolution by increasing or decreasing the general residence time of samples 
in the column.  
In the experimental set-up used throughout this PhD project, 1 µl fractions of 
samples from the whole-cell biocatalytic assays were loaded by an in-built syringe 
into a splitless injector set at 280 0C, and subsequently carried through a Heliflex 
AT-1701 column 30 m (length) X 0.54 mm (diameter). Helium was used as the 
mobile phase, and set at a constant pressure of 27 Psi (pounds per square inch). 
The oven temperature was initially set for 50 0C and maintained constant for 2 
minutes after injection of the samples. This temperature was subsequently 
increased at a rate of 20 0C min-1 until a final temperature of 260 0C, which was 
maintained for another 2 minutes. A FID (flame ionization detector)  fuelled by 
hydrogen and air and set at a temperature of  280 0C was used for the detection of 
the different biocatalytic compounds, which were displayed as peaks in a 2D 
spectra as a function of retention time.  
Cyclohexanone, which has a boiling temperature of 155.6 0C, was expected 
to have a lower retention time than ε-caprolactone, which has a boiling temperature 
of 253 0C. Accordingly, in all the GC assays, both compounds could be easily 
differentiation, with the cyclohexanone peak appearing at a retention time of 
around 2.7 minutes after injection, and the caprolactone peak appearing 6.7 
minutes after injection.  
The concentrations of the different compounds were derived from the area 
of the corresponding peaks, which is linearly proportional to the amount of 
compound in the injected sample. To do so, calibration of the GC protocol was 
performed for both cyclohexanone and ε-caprolactone in the beginning of each GC 
analysis, In these calibration protocols, a range of set concentrations for each 
compound were loaded into the GC chromatograph, and the peak area generated 
by each concentration was subsequently measured and plotted against the latter. 
Figure 14 shows the 2D spectra for the calibration of cyclohexanone, in which an 
increase in the concentration of the compound resulted in a proportional increase 
in the area of the peak.  Results obtained from the calibration experiment were 
subsequently used to derive the quantitative relationship between peak area and 
compound concentration, plotted as calibration curves, from which the 
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concentration of cyclohexanone and ε-caprolactone in the biocatalytic samples was 
calculated using equation 21: 
 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑   (𝑚𝑜𝑙. 𝐿!!) = 𝑚 ∗ 𝑝𝑒𝑎𝑘  𝑎𝑟𝑒𝑎      (21) 
	  
Where m is the slope obtained from the calibration curves of cyclohexanone 
and ε-caprolactone.	  	  
	  
	  
 
 
Figure 14- 2 D spectra from a calibration experiment done with three different 
concentrations of cyclohexanone: 15 mM (blue trace), 50 mM (green trace), and 100 mM (red 
trace).  
 
Prior to GC analysis, samples taken from whole-cell biocatalytic 
experiments were transferred to ethyl acetate in order to prevent any potential 
damage that a aqueous solution would have on the stationary phase of the column. 
For this purpose a set volume of sample was mixed with an equal volume of ethyl 
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acetate in a sterile 1.5 ml Eppendorf tube. The resulting solution was incubated in 
a Confort thermomixer (Eppendorf) for a range of times at room temperature and 
900 rpm. After incubation, samples were centrifuged for 10 seconds at max speed, 
and the resulting top layer containing the ethyl acetate solvent was subsequently 
transferred into a sealed chromatography tube, which prevented evaporation of the 
solvent and any transferred volatile compounds. The optimum time of incubation 
for achieving maximum transfer of cyclohexanone and ε-caprolactone from the 
aqueous Tris-HCl buffer to the organic solvent was determined by running ethyl 
acetate samples incubated for different times in the GC chromatograph. Figure 15 
shows the results from one such experiment conducted, in which samples with the 
same concentration of cyclohexanone were incubated with ethyl acetate for a 
range of different times. From the results, it could be determined that the optimum 
incubation time was 1 hour.    
 
 
 
 
Figure 15-  2D spectra obtained from samples incubated with ethyl acetate for 
different time frames: 5 minutes (black trace), 15 minutes (blue trace), 30 minutes (light blue 
trace), 1 hour (green trace), and 2 hours (red trace). 
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2.3.7- Substrate/Product Tolerance Assays 
 
The tolerance of the different bacterial strains to the substrate 
cyclohexanone, the product ε-caprolactone and the solvent cyclohexane, was 
tested by growing cell cultures in the present of these compounds. For this 
purpose, several different protocols were conducted, in which the compounds were 
added at different time points of bacterial growing.  
For the cyclohexane tolerance assays, 50 mM and 100 mM of the 
compound were added from a stock solution of 1 M to 250 ml falcon tubes 
containing 50 ml of NB2 medium with the corresponding selective antibiotic. 1 ml 
inoculates from 5 ml overnight cultures were subsequently transferred to the shake 
flasks, and the resulting cultures were incubated for for 10 hours in a Inova 4330 
shaking incubator at 37 0C and 250 rpm. 1 ml samples were taken at specific time 
point during the incubation for measurements of the cell density, using a 
spectrophotometer set at a wavelength of 600 nm. 
In an alternative protocol, which was used for cyclohexane as well as 
cyclohexanone and ε-caprolactone, 50 mM and 100 mM of the different samples 
were added to growing 50 ml shake flask incubations during exponential bacterial 
growth, between OD600 1 and 2. Samples were also taken from the growing 
cultures at regular intervals to measure the effect of the different compound 
concentrations on cell density.  
 
2.3.8- Gentamicin Resistance Assays 
 
Gentamicin resistance assays were conducted on cultures grown in 2 ml v-
bottom 96- microwell plates (USA Scientific). Aliquots from over-night cultures were 
transferred to 96-well plates containing 1 ml of growth medium (NB2 for E. coli and 
B2 for S. carnosus) with increasing concentrations of the gentamicin antibiotic. The 
plates were sealed with alluminium foil and subsequently incubated for 24hours in 
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a Confort thermomixer set for a temperature of 37 0C and a shaking speed of 900 
rpm. At the end of incubation, bacterial tolerance to the different concentrations of 
gentamicin was correlated to the final OD600 of samples. Figure 16 shows a typical 
set-up for this experiment.  
Alternatively, the response of different bacterial strains was also measured 
by plating diluted aliquots of over-night grown cultures in 2% agar plates containing 
increasing antibiotic concentrations, as well as plates without any antibiotic. In this 
case, results were expressed as % of surviving colonies, which has already been 
described previously in this chapter (see section 2.2.6).     
 
 
Figure 16- Gentamicin resistance assay performed on 2ml 96-well plates 
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Chapter 3: Results- 
Assessment of pQR493 as 
an Expression Vector for S. 
carnosus. 
 
 
3.1- Previous Work on an Expression System 
for S. carnosus and Creation of pQR493   
	  
As it was described in the first chapter, some work had already been done 
previously to validate the use of S. carnosus as a host for heterologous protein 
expression, which resulted in the construction of several expression vectors 
tailored specifically for this bacterium. The initial idea behind this project was to use 
one of the expression systems previously constructed and adapt it for expression 
of CHMO. The chosen expression system was the vector pNW21, which had been 
used for the expression of the S. aureus protein hysA (Williams et al. 2002). This 
shuttle vector contained elements for replication and selection in both the Gram-
negative bacteria E. coli and the Gram-positive S. carnosus, thus making it very 
versatile for cloning between the two species. In addition, the vector contained the 
promoter for the lipase gene from Staphylococcus hyicus, which by now had been 
used extensively as the standard promoter for protein expression in S. carnosus. 
The promoter worked well in Gram-positive strains, but it was shown not to be a 
very effective promoter for the Gram-negative counterparts (de Vos et al. 1997) 
(Demleitner & Götz 1994) (Samuelson et al. 1999). Thus, even though the 
replication and selective elements in the vector allowed for easy genetic exchange 
between different strains, pNW21 was constructed with the strict purpose of protein 
over-expression in S. carnosus. 
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In the work that immediately preceded this project, pNW21 was modified to 
accommodate the protein CHMO. This new construct, designated pQR493, was 
the primary expression system to be used for intracellular biocatalyst production. 
However, this system had not been expressed or characterized in S.carnosus, and 
this work needed to be done before proceeding with the main line of enquiry of the 
project.  
 
 
3.2- Regressive Analysis of the Restriction 
Map of pQR493 
	  
The early studies conducted on pQR493 did not give very encouraging 
results. Not only attempts to clone the vector into S. carnosus were unsuccessful, 
but the restriction maps created for the vector did not seem to coincide with the 
predicted results. Therefore the initial aim for this project was to investigate the 
genetic integrity of pQR493 and access if it could still be used as an expression 
system for over-expression of CHMO.  
The most direct way to access the integrity of small-scale genetic material is 
via restriction analysis. Restriction maps outline the restriction endonucleases that 
can cut a sequence, where they cut it, how often they can cut it, and the distance 
relationship between the restriction sites. Indeed, restriction maps are useful metric 
sequence representations that can be readily tested empirically by using cocktails 
of commercially available endonucleases. Differences between a theoretical 
restriction map of a sequence and the size distribution of bands on an agarose gel, 
when cutting the latter with specific endonucleases, can be used to access the 
genetic integrity of a mapped sequence. Thus restriction maps provide an easy 
and straightforward method to screening a segment of DNA for genetic instability, 
mutations, and recombination.  
Following this approach, it was decided that the first step in trouble-shooting 
pQR493 would be to look at its restriction map. Previous experiments had already 
indicated that the empirical restriction map did not coincide with the expected 
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results, but these experiments were base on a very limited number of restriction 
sites (Figure 17) that did not allow for a detailed assessment of the vector’s 
integrity. Therefore, the initial task would be to complement the predicted restriction 
map of pQR493 by regressive analysis, i.e. by mapping out the carry-over of 
restrictions sites from the precursors of pQR493.  
However, producing a clear picture of the restriction map was not a 
straightforward task. Due to the fact that most of the precursor for pQR493 were 
constructed in the 80s and 90s, and in that period a culture of extensive 
documentation of genetic constructs was not yet established, we have very limited 
information about any sequences of these constructs.  
Thus, it was only possible to re-create in-silico a small portion of the 
restriction map by analyzing the literature of previous work done on the precursor 
vectors, thereby rationally drawing up a history of the restriction sites that were 
maintained and discarded throughout all the engineering steps done to reach 
pQR493.  
 
 
 
Figure 17- Restriction map of the vector pQR493 as it was available before the in-silico 
analysis of its restriction map. 
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The in-silico analysis of pQR493 focused primarily on the regions around 
the lipase promoter and CHMO gene, as these seemed to be the most relevant 
when accessing the expression capability of the vector. If these regions carried 
mutations or sequence insertions/re-arrangements, the vector’s ability to express 
the biocatalyst could be compromised, and therefore it was imperative to find out if 
any detrimental events had occurred to the genetic material in the vicinity of 
CHMO.  
The pQR493 vector is a product of four generations of genetic engineering 
on a couple of basic vector designs, not all of which was done by the same group 
or in the same study (Figure 18).  The starting point (or first generation) was the 
vector pLipSP1, which in turn is a pC194 derivative in which the lipase promoter 
and gene from S. hyicus were cloned via a PstI linker region. The main use of 
pLipSP1 was as tool for the study of the lipase promoter and gene in Gram-positive 
bacteria. Introducing extra restriction sites in the N- and C-terminus of the lipase 
gene allowed for the identification of a signal-peptide sequence at the start of the 
lipase gene that promoted secretion and surface display of the lipase protein or 
any other fusion protein in-frame with the signal pro-sequence of the lipase gene 
(Demleitner & Götz 1994).  This derivative, pLipSP17, representing the second 
generation of vector constructs, was used subsequently as the basis of several 
different protein display systems in S.carnosus.  The restriction sites were 
introduced into the lipase gene sequence through site directed mutagenesis, and 
they were a BsmI site at the beginning of the lipase signal sequence, a BclI site at 
the end of the signal sequence, and a BglII at the end of the lipase pro-peptide 
sequence.  
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Figure 18- Schematic the genetic history of the vector pNW21. Some intermediate steps are 
not represented in this diagram. These steps were not considered significant for the 
resulting restriction map of pNW21, and were therefore disregarded.  
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The next step in the production of pQR493 was joining the vector pLipSP17 
with the replication and antibiotic selection part of a Gram-negative vector, pRIT28, 
via a SalI-HindIII restriction and insertion, thus creating a third generation construct 
that was able to replicate in both Gram-positive and Gram-negative organisms. 
This fusion vector, pSPP, allowed for a greater flexibility in cloning between the two 
types of bacteria, and streamlined the genetic manipulation of subsequent vector 
derivatives by taking advantage of the more simple-to-use E.coli cloning system. It 
is important to note that the insertion of the pRIT28 fragment led to the loss of the 
C-terminus of the lipase gene, which included the BglII site previously introduced 
into pLipSP17. However, this region of the gene was subsequently reconstructed 
via PCR and re-introduced into pSPP through a SalI-BamHI restriction and 
insertion.  pSPP was then modified to pSPPΔHindIII via a deletion of an HindIII 
site upstream from the gene, and this derivative was then used in several 
subsequent shuttle vector constructs.  
The last genetic manipulation step that has relevance to the construction of 
pQR493 was the introduction of a synthetically made multi-cloning site (MCS) into 
pSPPΔHindIII via a BsmI-BglII restriction and insertion. The resulting vector, 
pNW21 does not suffer any further significant changes, and therefore most of the 
restriction map of pQR493 is the same, expect the restrictions sites introduced by 
the CHMO gene, which will be discussed later. The insertion of the MCS added 
several unique sites to the restriction map of the vector, most important of which 
are the EcoRI, SmaI, and XhoI sites.   
During the in-silico analysis of pQR493’s restriction map, several sites were 
identified that could not be mapped reliably or that conflicted with the reasoning 
behind the construction of the vectors. For instance, there are two sites in pRIT28, 
BglII and ScaI, which could not be specifically allocated around the region that is 
subsequently taken from the vector to ligate with pLipPS17. Since there is no 
reference to them in the description of pSPPΔHindIII, it was impossible for us to 
know if these sites were carried over into any of the subsequent generations.  
In another instance, a BglII site upstream of lipase promoter (pLip) that was 
maintained throughout every generation conflicts with the last step in the pNW21 
creation. In this step, the multi-cloning site is insertion into pSPPΔHindIII via a 
BsmI-BglII restriction (Williams et al. 2002), but there is no reference to the fact 
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that BglII is not a unique site. Cutting the vector in the way the study described 
would have excised out the region the authors were targeting as well as the pLip 
region upstream, generating a linear fragment with BglII over-hangs. The fact that 
there is no reference to this problem make us assume that either the authors used 
a partial restriction to clone the MCS, or that the BglII site upstream has been lost 
around the third generation of vector precursors.  
The insertion of the CHMO gene into pNW21 also introduced a legacy of 
restriction sites that were not intrinsic to the gene. This was because CHMO was 
not cloned as a clean PCR-product, but instead was cloned from a precursor 
vector that had also undergone a series of modifications. Fortunately, all the steps 
that led to the final version of CHMO were previously well documented in a study 
that describes the creation of the E.coli TOP10 expression vector pQR239 
(O’Sullivan et al. 2001).  
 
Figure 19- Restriction map of the vector pQR239 taken from O’Sullivan et al. (2001). Black 
restriction sites indicate unique sites around the CHMO gene, while colored restriction sites 
indicate the presence of more than one of these sites around or within the gene.  
 
The restriction map of this vector (Figure 19) shows the complexity of restriction 
sites around the CHMO gene that underpins a major problem of the cloning strategy 
described in the study. Indeed, the legacy of restriction sites that accumulates after 
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each ligation step reduce the potential of pQR239 for further genetic engineering by 
decreasing the population of unique sites that could be used without jeopardising the 
overall structure of the vector. In the end, for the creation of pQR493 the CHMO gene 
could only be lifted from its parent vector using the endonucleases XhoI and BamHI, a 
limitation that partially motivated the insertion of MCS into pSPPΔHindIII in order to 
accommodate a more flexible region of unique sites. 
 
 
Figure 20- Restriction map of the vector pQR493 after the in-silico analysis. The color-coding 
indicates the uniqueness of restriction sites: black corresponding to sites that are unique 
within the vector, while the colored sites represent redundant or repeated sites.  
 
With the information from the vector pQR239 and the in-silico re-creation of 
the area around the promoter and MCS of pNW21, a more detailed version of the 
restriction map of pQR493 was created (Figure 21). The qualitative nature of the 
representation of the distances between restriction sites is mainly due to the fact 
that there is very little information about the position of these sites on any of the 
pNW21 precursors, and therefore it was impossible to confirm the metric distances 
between different sites.  
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While the analysis did not provide numerical data for the positions of the 
restriction sites, it was still crucial for a better understanding of the overall layout of 
the vector’s restriction map and how the different restriction sites were organized 
upstream and downstream from the promoter and CHMO gene. This information 
was sufficient to allow for accurate predictions of the experimental outcomes from 
different restriction digests of pQR493. The added knowledge of the vector also 
allowed for a greater flexibility in the repertoire of endonucleases that could be 
used empirically to access the genetic integrity of pQR493.  
 
 
3.3- Restriction Digests of pQR493  
 
With a comprehensive in-silico restriction map of pQR493 constructed, the 
next step was to plan and perform several empirical restriction digests that would 
either corroborate or confront the predictions inferred from the map. Consequently, 
a list of endonucleases was chosen to digest the vector, either individuality or as a 
cocktail of two endonucleases. The vector was extracted from E. coli TOP10 
cultures that had been grown overnight in NB2 medium and subsequently lysed 
using a DNA extraction kit from QIAGEN. The plasmid samples were subsequently 
restricted by mixing a small volume of plasmid DNA with the desired mix of 
endonucleases and corresponding reaction buffer. The protocols for plasmid 
extraction and DNA restriction are described in detail in the materials and methods 
chapter (see chapter 2, sections 2.2.4 and 2.2.7).  
Table 1 shows the list of endonucleases used in the restriction digest 
experiments, as well as the predictions of how many sites these enzymes would 
cut in pQR493 when used individually and in combination with a second 
endonuclease. It’s worth noting that not all the combinations shown in the table 
were performed. Restriction sites like BglII sites were not used in the empirical 
analysis because the uncertainty regarding the position of these sites, as it has 
been explained earlier.   
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Table 1- List of endonucleases used and number of cuts corresponding to the enzymes on 
their own (white diagonal strip) or in combination with a second endonuclease.  
 
The first round of experimental restrictions focused on the restriction profiles 
of EcoRI and PstI, either used individually or in conjunction with HindIII, XhoI and 
each other.  All of the endonucleases mentioned were predicted to span most of 
the region upstream and downstream of the CHMO gene, as well as the middle 
segment from the latter, and therefore seemed to be best choice to access if any 
large scale mutation or re-arrangement had happened on that region.  Figure  
shows the results from these digests displayed in an agarose gel, where the 
vertically arranged bands correspond to different sized linearlized or super-coiled 
fragments of DNA.  Bands located outside of the detectable range window, on the 
top part of the gel, correspond to undigested DNA in different conformation, while 
most digested fragments are located within the detectable range. The presence of 
undigested DNA in lanes is an indication that the plasmid sample was only partially 
digested. In the case of first experiment run, the heavy presence of undigested 
DNA was a clear indication that the restriction reactions were sub-optimal. 
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Figure 21- Agarose gel (1% w/v) showing the restriction map of pQR493 using a list of 
endonucleases. Lane 1 and 10: hyperladder from NEB; lane 2: undigested pQR493; lane 3: 
EcoRI restriction; lane 4: EcoRI-XhoI restriction; lane 5: EcoRI-HindIII restriction; lane 6: PstI 
restriction; lane 7: PstI-EcoRI restriction; lane 8: PstI-XhoI restriction; lane 9: PstI-HindIII 
restriction.  
 
Despite low performance of the restrcition reaction, the results for the first 
run could still be analyzed and compared with the in-silico restriction map. Some of 
the results were in accordance with the in-silico predictions. For instance, the 
endonuclease PstI was predicted to cut pQR493 into two not equally sized 
linearized fragments. This was confirmed by the results on the gel, in which 
samples digested with PstI digest produced 2 bands of distinct sizes.  
On the other hand, the EcoRI digests directly contradicted the predictions 
from the restriction map, as it was expected that this endonuclease would digest 
pQR493 in at least 4 sites, but instead the gel showed a singular band 
corresponding to linearized vector.  Similarly, a digest combining both PstI and 
EcoRI resulted in linearized vector as well as 3 smaller bands, which suggested 
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the presence of an unique EcoRI site. A double digest of EcoRI and HindIII 
seemed to corroborate these results by producing two bands of similar sizes, while 
also suggesting that the sites for these two enzymes were on almost opposite 
sides. Most of the PstI digests were very hard to analyse because of the low 
reactions yields, as evident from the strong bands belonging to linearized vector. 
Figure 22 shows the revised graphical layout of some of the restriction sites within 
pQR493, taking into account the results from the first restriction digest experiment.  
 
 
 
Figure 22- Graphic representation of the sizes and putative positions of the restriction sites, 
based on the bands from the restriction map experiment. The different colored rings and 
lines represent the number of cuts produced by the different endonucleases on their own, 
XhoI (blue), EcoRI (orange), and PstI (red). The sizes of the bands produced by these cuts 
are also coded with the same colors respectively. The black ring and sizes refers to the 
distance relationship between the different sites, and how these could be organized spatially 
in the vector.   
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Together, these results suggest that the DNA sequence around and within 
the CHMO gene suffered from large-scale re-arrangements, deletions, or 
damaging modifications. In particular, the absence of more EcoRI site was rather 
worrying, as most of the EcoRI sites in the restriction map are located within the 
CHMO gene. However, the agreement between the PstI and HindIII restriction 
digests and the predictions made from the in-silico restriction map concerning the 
latter suggested that at least part of the CHMO gene sequence was still intact, 
since both the unique HindIII site and a second PstI site were located within the 
gene sequence.   
There was also the question of the size of the vector obtained from the 
restriction digests, which was different from that calculated in-silico. Although sizes 
were not mentioned during the in-silico analysis, it was clear that pQR493 should 
be 8 kb (kilobases) in total, with 6kb being from the pNW21 construct and another 
2Kb coming from the CHMO gene and adjacent upstream and downstream 
overhangs. The experimental results seemed to contradict this prediction, since the 
cases where the vector was linearized resulted in a single band at about 7 kb, 1kb 
shorter than the predicted size. However, due to the inefficiency of some of the 
reactions and the loss of resolution in the higher size ranges of the agarose gel, it 
was not possible to conclude with certainty that the vector had lost some of its 
sequence before performing a more detailed and definitive empirical analysis. 
A second round of restriction digests was therefore designed, not only to 
confirm the results from the first restriction experiment, but also as an attempt to 
acquire a more detailed picture of the sequence around the CHMO and the nature 
of the damage that might have occurred within the latter. In order to achieve this, 
the repertoire of endonucleases used in the restriction digest was expanded to 
include SacI and NdeI, as well as the other enzymes used in the previous run. 
From in-silco analysis of the restriction map of pQR493 it was concluded that the 
sites for both endonucleases had been carried over with the CHMO gene when the 
latter was ligated to pNW21. Therefore, testing for the presence or absence of 
these sites in the extracted vector constructs would give a clear indication of the 
genetic integrity of the CHMO insert.  
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Figure	  23-­‐	  Agarose	  gel	  (0.7%	  w/v)	  showing	  the	  restriction	  map	  of	  pQR493	  using	  a	  second	  set	  of	  
endonucleases.	  Lane	  1	  and	  15:	  hyperladder	  from	  NEB;	  lane	  2:	  undigested	  pQR493;	  lane	  3:	  EcoRI	  
restriction;	  lane	  4:	  EcoRI-­‐XhoI	  restriction;	  lane	  5:	  EcoRI-­‐HindIII	  restriction;	  lane	  6:	  PstI-­‐XhoI	  restriction;	  lane	  
7:	  PstI-­‐HindIII	  restriction;	  lane	  8:	  XhoI-­‐HindIII	  restriction;	  lane	  9:	  NdeI	  restriction;	  lane	  10:	  NdeI-­‐EcoRI	  
restriction;	  lane	  11:	  NdeI-­‐XhoI	  restriction;	  lane	  12:	  SacI	  restriction;	  lane	  13:	  SacI-­‐NdeI	  restriction;	  lane	  14:	  
SacI-­‐HindIII	  restriction. 
 
Figure 23 shows the results of the second set of restriction digests. The 
results from the EcoRI digests corroborated the data taken from the first run of 
restrictions, by producing what could be interpreted as a linearized vector when 
using the enzyme by itself or in the presence of XhoI. These results seemed to 
suggest that the EcoRI and XhoI sites were located close together in the backbone 
of the vector.   
On the other hand, the fact that a XhoI/HindIII restriction produced two 
bands of similar sizes corroborates the previous data showing that XhoI and HindIII 
sites stood at almost opposite sides of the vector, judging by the close size 
proximity between the two bands. The calculated distance between the two sites 
was far greater than the expected distance if the CHMO gene was indeed inserted 
into the vector. Instead, the positioning of these two sites within pQR493 was more 
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analogous to the distance between the XhoI site of pNW21 and the HindII site of 
pSPPΔHindIII prior to its deletion.  
The PstI digests resulted in good reaction efficiencies in the second run of 
restriction and corroborated the results from the first run, while also adding some 
important information. On one hand, the similar restriction profile produced by a 
XhoI/PstI restriction when compared with a EcoRI/PstI digest performed in the 
previous run re-enforced the conclusion that the EcoRI and XhoI site were located 
in close proximity.  On the other hand, the HindIII/PstI digest produced two 
distinctly sized bands, instead of the three bands that had been predicted from the 
two PstI sites and unique HindIII site located around the CHMO gene. This result 
suggested two possible outcomes: either the HindIII was in close proximity to one 
of the PstI sites, and therefore the distance between these sites was below the 
range of detection of the agarose gel; or the HindIII was non-existent. However, the 
results from the XhoI/HindIII restriction contradicted the latter possibility, by 
showing that HindIII contained a unique restriction site in pQR493. 
The SacI digests showed the absence of any SacI sites in the vector, thus 
suggesting that the N-terminus of the CHMO was absent altogether. On the other 
hand, the NdeI digests still produced linearized vector when the endonuclease was 
used individually, suggesting the C-terminus of the gene was intact. Alternately, 
combining this enzyme with either EcoRI or XhoI suggested that there was a 
distance of 500 bp between EcoRI and XhoI, with NdeI being in close proximity to 
EcoRI. This distance relationship had not been observed in any of restrictions with 
the other enzyme combination, and it did not fit with the results from the 
XhoI/EcoRI digests.  
Finally, the size of the linearized vector obtained in the second run of 
experiments was still smaller than the predicted size of 8Kb for pQR493. Figure 24 
shows a graphical representation of the revised layout of restriction sites in 
pQR493 after the second restriction experiment.  
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Figure 24- Graphic representation of the position of different restriction sites based on the 
restriction bands from the second set of digests. The colored rings and lines represent the 
number of cuts that different endonucleases generate in pQR493. The sizes of the bands 
corresponding to the cuts are also represented by the same colors. The band ring and 
numbers refer to the distance relationship between the different restriction sites, and how 
these could be spatially organized in pQR493.  
 
Together, the results from both experimental sets seemed to suggest one of 
two possible scenarios. In a worst-case scenario, most of the N-terminus of the 
CHMO gene, where the SacI sites should be located, had been deleted. This 
hypothesis was hard to fit with the overall restriction layout obtained from the 
results. In particular the HindIII site, which would be located in the C-terminus of 
CHMO, was very distant from the XhoI site, which in turn was located downstream 
of the Lip promoter as part of the remaining MCS from pNW21. If it were the case 
that only a truncated version of the CHMO gene sequence containing HindIII and 
NdeI managed to ligate into the MCS of pNW21, then one would expect the XhoI 
and HindIII sites to be in close proximity. The more likely scenario would be that 
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the vector pQR493 was in fact a version of pNW21 with an active HindIII site. This 
hypothesis seemed to fit better with the results, except for the NdeI site, which had 
not been predicted as intrinsic to pNW21 in the in-silico analysis. The close 
proximity of the XhoI and EcoRI sites would be explained by the MCS of pNW21. 
In addition, since the position of the second EcoRI site that lies upstream of the 
lipase promoter is not know, the close proximity of between this site and the EcoRI 
site located in the MCS region in pNW21 could explain why samples cut with this 
endonuclease failed to produced two discernible bands. However, the positive 
activity shown with HindIII was not expected in the case of pNW21, and suggested 
that the HindIII site from the precursor vector pSPP had not been deleted, contrary 
to previous reports of the vector.  
Regardless of which scenario corresponding to the truth, it was clear that 
the integrity of the CHMO gene was compromised and consequently the available 
vector construct could not be use to express the biocatalyst in S. carnosus. 
Therefore the project needed to re-trace a step to create a functional expression 
system.  
 
 
3.4- Ligation Attempts with pNW21 and CHMO  
	  
Once it was clear that the vector that had been provided from previous work 
on the project could not be used to express the biocatalyst CHMO in S. carnosus, 
the focus of the project shifted from the characterization of whole-cell biocatalysis 
using S.carnosus to the production of an expression system that would allow the 
intracellular expression of CHMO in the Gram-positive bacteria.  
The simplest and fastest way to achieve a working genetic system would be 
to repeat the cloning strategy that was previously used in the creation of pQR493. 
Accordingly, stocks of E.coli TOP10 containing the vector pNW21 and CHMO 
expression vector pQR239 were re-grown to create banks of DNA for use in the 
subsequent genetic manipulations.  
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As described above, the strategy used for the insertion of the CHMO 
sequence into pNW21 involved two steps: the extraction the CHMO gene from 
pQR329 through a XhoI/BamHI restrictions, and subsequent ligation with the 
XhoI/BglII restricted pNW21. Four of the six nucleic acids from the overhangs of 
BamHI and BglII are complementary to each other, and therefore can be ligated 
together, resulting in a sequence that does not contain a recognition site for either 
endonuclease. The choice of different endonucleases to ligate the C-terminus of 
CHMO to pNW21 seems peculiar in hindsight, especially after the in-silico analysis 
of pNW21 identified the presence of a unique BamHI site downstream from the 
MCS. Therefore, in this project two different ligation protocols were attempted, in 
which pNW21 was alternately restricted with XhoI/BglII and XhoI/BamHI mixes 
prior to ligation with the XhoI/BamHI restricted CHMO gene. 
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Figure 25- Agarose gel (0.7% w/v) showing a restriction digest of the pNW21 and pQR239 
with XhoI-BglII and XhoI-BamHI respectively.  Lanes 1 and 6: DNA hyperladder (NEB); lane 2:  
pNW21 digest; lane 3 to 5: pQR239 digests. Cutting pNW21 generated a single band 
corresponding to the size of the pNW21 vector, while cutting pQR239 generated two bands, 
the lower of which corresponds to the CHMO gene (1.6 kb).  
	  
Figure 25 shows an example of the digested plasmid DNA sequences from 
pNW21 and pQR239 displayed on an agarose gel. Restriction samples were 
loaded onto an agarose gel in order to screen the samples for high populations of 
un-cut vector or re-ligated vector, which would hinder the ligation process by 
increasing the number of false positives after transformation (i.e. the number of 
colonies that contained the pNW21 vector without the CHMO insert). In the case of 
the pNW21 digestion, it was difficult to access if it had been cut properly with both 
restriction endonucleases, since the restriction sites for these enzymes were very 
close together. Therefore, we could only indirectly screen for efficient pNW21 
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digestion by running it in parallel with the pQR239 digestion, which used the same 
endonucleases, and could be easily accessed in a gel because of the two bands it 
produced. The smaller of the two bands corresponded to the CHMO insert  (1.6 kb 
in size), which had to be excised and extracted from the agarose gel prior to 
ligation.  
The extraction of restricted fragments from gels was preferred to using the 
digested fragments straight after restriction partly because gel extraction was 
required to separate the CHMO fragment from the parent vector pQR239, and 
partly because after endonuclease inactivation via heat treatment there is the risk 
of samples containing residual enzyme activity, which could re-digest the ligated 
fragments. Thus, both the pNW21 vector and CHMO gene were purified from gels 
and subsequently ligated.  
There are no universal rules for a successful ligation protocols. Some 
methods can vary depending on the enzyme commercial provider in terms of 
incubation times, volumes, and concentrations, while other vary depending on the 
quality and type of DNA used. In the case of the ligation strategy used for the 
ligation of CHMO to pNW21, different commercial variants of ligase were used in 
an array of conditions with varying vector and insert concentrations and volumes, 
as well as varying ligase concentrations. A detailed description of the different 
ligation protocols used in this project can be found in the materials and methods 
chapter (chapter 2, section 2.2.3).     
Figure 26 shows an example of a ligation experiment with T4 ligase from 
NEB (New England Biolabs). This agarose gel demonstrates that after ligation the 
band profile of a sample containing a mix of CHMO and pNW21 fragments 
changes, and this change indicated that there was some degree of ligation 
between fragment and vector, as well as re-ligation of vector.	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Figure 26- Agarose gel (0.7% w/v) showing the ligation o the CHMO gene to pNW21. Lanes 1, 
4, and 5: DNA hyperladder (NEB); lane 2: un-ligated sample; lane 3: ligated sample. The un-
ligated sample contained both the linearized pNW21 and the CHMO gene fragment. The 
difference between the sample before and after ligation indicates that a change occurred 
after addition of T4 ligase.  
	  
The concentrations of DNA fragments used varied greatly between ligation 
experiments. As a rule a thumb, a molar ration of 1:1 between vector and insert 
was considered to be optimal for ligation to occur, as there would be the same 
number of molecules from each fragment in solution. However, this ratio was 
routinely increased as an attempt to switch the reaction equilibrium in favor of the 
ligation of CHMO with pNW21, as opposed to re-ligation of the vector.  
Ligation was stopped through heat-shock at 65 0C, and the ligation samples 
were subsequently transformed into competent cells, which would be selected on 
antibiotic containing agar plates for positive ligations. In theory, because of the 
selective pressure introduced by the antibiotics, only colonies containing the 
pNW21 vector would survive on the antibiotic due to the presence of a resistance 
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gene in the vector. On the other hand, the restriction of pNW21 prior to ligation with 
two different endonucleases served a secondary purpose of preventing re-
annealing of the vector ends in the absence of the CHMO fragment, and therefore 
no re-circularized plasmid should be present in surviving colonies. In practice, 
many of transformation experiments with the ligation mixes resulted in a large 
population of surviving colonies on the antibiotic selection plates. Additionally, all of 
the colonies that were subsequently screens were shown to contain the re-ligated 
pNW21 instead of the desired ligation product. The high rates of vector re-ligation 
suggested that the restriction of the latter was not efficient. However, since the 
vector was still appearing as a linearized fragment in the agarose gels, and the 
same endonuclease mix was efficiently cutting CHMO, it was difficult to assess 
which of the endonucleases was not cutting properly.  
Screening of colonies was done by re-growing them overnight and 
extracting the plasmid DNA. The plasmid samples were subsequently cut with 
specific restriction endonucleases to check for a restriction map that corresponded 
to the ligation product pQR493. For the ligation samples in which pNW21 had been 
digested with a XhoI/BamHI mix, the same endonucleases were used to screen for 
the insertion of the CHMO fragment. However, all the colonies screened with this 
endonuclease mix resulted in linearized plasmid, indicating that the insert had not 
been successfully ligated. For the ligations in which pNW21 was restriction with a 
XhoI/BglII mix, the same screening strategy could not be used, since the resulting 
ligation would not have either a BglII or BamHI site. Instead, a XhoI/HindIII 
restriction was performed to screen colonies from these ligations, since the HindIII 
endonuclease would only cut the vector if the CHMO gene was inserted. Figure  
shows the predicted restriction map from the XhoI/HindIII restriction of the ligation 
product pQR493, as well as the results from a screening experiment in which the 
same endonuclease mix was used.  Cutting the plasmid from selected colonies 
produced a very different picture from the predicted restriction map, which was 
concerning for a number of reasons. Firstly, all colonies that were screened using 
this protocol showed the same profile, which indicated that either all the plasmid 
constructs were ligation products, or more realistically, that the XhoI/HindIII 
digestion was unable to select between ligation and plasmid re-circulation of 
pNW21. The second, and perhaps more concerning reason, was the fact that the 
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restriction map produced by the cut was very similar to the restriction profile of the 
“faulty” vector pQR493 previously studied when cut with the same enzymes (Figure 
27). 
 
 
Figure 27- Screening of E.coli colonies for ligation between pNW21 and the CHMO gene. A) 
Predicted restriction map of the ligation product pQR493 when cut with XhoI and HindIII; B) 
Empirical XhoI/HindIII restriction digest of plasmid DNA isolated from colonies that had been 
selected on ampicillin-containing agar plates. Digested samples were loaded on a 0.7% (w/v) 
agarose gel.  Lane 1 and 10: DNA hyperladder (NEB); lanes 2 to 9: plasmid samples digested 
with XhoI/HindIII.  
 
The results from the screening assays of the pNW21/CHMO ligation 
suggested that HindIII site that was detected on the “faulty” pQR493 could have 
originated from the pNW21 backbone instead of as mutation randomly occurring 
during the previous ligations of pQR493. To test this hypothesis, pNW21 stocks 
that had been used in the ligation protocols were restricted with a XhoI/HindIII 
reaction mix. The results confirmed that pNW21 produced the same restriction 
profile as the one generate with pQR493 during the restriction map studies, and 
subsequently that a HindIII site was located in the backbone of pNW21, when there 
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should not be one. On the other hand, these results confirmed that the pQR493 
construct used in the beginning of this project was in fact the re-ligated pNW21 
plasmid.  
The presence of an unexpected HindIII site and the inability to clone the 
CHMO into the vector led us to believe that problems first encountered with 
pQR493 had been a legacy from previous generations of vector precursors, and 
most likely pNW21 has been a carrier to this legacy. Therefore, before we could 
carry on with the re-construction of pQR493, it was imperative to assess if pNW21 
was still fit for purpose.  
 
 
3.5- Sequencing of pNW21  
	  
It is most likely the erroneous construction of pQR493 stemmed from the 
presence of the HindIII site in pNW21. Since the precursor vector pSPPΔHindIII 
had been created by deleting the HindIII sites in the plasmid backbone, in theory 
cutting pNW21 with the endonuclease should not have produced linearization of 
the plasmid. Thus when pQR493 produced a 2-band restriction map after digestion 
with XhoI and HindIII, it was assumed that the vector was the product of the 
ligation between pNW21 and CHMO gene, which contained a unique HindIII site 
within its sequence.  
The presence of the HindIII site in the backbone of pNW21 posed a serious 
question: was the restriction site simply omitted from the literature, or was it 
symptomatic of genetic damage that occurred to the pNW21 stocks. And in the 
latter case, there was also the question of the extent of the damage . However, 
after the exhaustive study of pQR493 using a restriction map analysis, repeating 
this methodology would not add to the understanding of pNW21, and therefore it 
was decided that a more powerful approach was needed to answer these 
questions. This approach was to use AB sequencing technology to sequence 
segment of the vector that were directly related to its functionality.  
Figure 28 shows a representation of the strategy used for the sequencing 
experiments. Primers were designed to anneal with the ampicillin resistance gene 
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(BLA), the chloramphenicol resistance gene (CAM) and the MCS, and to allow the 
sequencing of DNA regions within and between these sites. One reason for this 
choice of primer location was the fact that the sequence from these primers would 
cover regions that are crucial for the functionality of the plasmid. In addition, the 
primer design strategy was limited to areas of the vector with known sequences, 
which could be subsequently compared with the resulted from the sequencing 
experiments. The sequencing experiments were outsourced to the UCL Wolfson 
Institute sequencing departments.  
Results came in stretches of 700 bp for each primer, which were 
subsequently screened for overlapping areas and correspondingly joined as longer 
segments of the pNW21 vector. These longer sequences were subsequently 
aligned to known areas of the vector in order to identify any mutations. Several 
software that allow for DNA manipulation and alignment were employed for this this 
analysis. All the fragments and alignments are shown in the appendix section 
(Appendix 1).  
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Figure 28- Schematic of the pNW21 vector with the colored arrows representing the primers 
designed for sequencing purposes. The arrows point towards the orientation of the 
sequencing from each of the primers. Since sequencing was conducted from 5’ to 3’, the 
direction of the CAM-BLA primer (blue) and the MCS-CAM primer  (yellow) were designed to 
allow sequencing of the complement strand of pNW21.   
 
Using this method, a continuous stretch between CAM and the MCS was 
successfully sequenced, as well as part of the CAM gene. The stretch of DNA 
sequenced from the BLA gene did not align with any of the other sequences, 
probably due to the fact that the BLA gene is probably too distant from the other 
known functional elements. Despite this, the location of the HindIII site was pin-
pointed to this sequenced segment of DNA upstream of the BLA gene. However, 
because the sequence did not align correctly with the vector pC194, from which the 
HindIII site was originated, it was concluded that the restriction site was not a 
legacy from any of the pNW21 precursors, but rather introduced by mutation.  
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On the other hand, most of the sequence between MSC and CAM aligned 
with the vector pC194, a result that confirmed the ancestry of the latter as a 
precursor to pNW21. The analysis of the restriction map of this sequence also 
highlight the location of the NdeI site in the stretch that aligned with pC194. This 
result corroborated the data from the restriction map experiments on pQR493, in 
which a NdeI was detected, despite the absence of the CHMO	  gene.	  	  	  
	  
 
Figure 29- Short segment of the alignment between the sequenced region of pNW21 between 
the CAM gene and the MCS and pC194. The starting codon of the chloramphenicol 
resistance gene (CAM) is located at position 1260 in the vector pC194, just upstream of the 
displayed segment.    
	  
The alignment between the sequenced DNA fragment and pC194 also 
highlighted an unexpected insertion that had occurred just before the CAM gene. 
As Figure 29 shows, the fragment from pNW21 contained a thymidine (T) –rich 
sequence in the region upstream of the CAM gene that was not present in the 
parental vector pC194. The fact that the alignment of sequences upstream and 
downstream of this segment was 100% accurate validated this sequence insertion 
as a positive result rather than an error from the sequencing data.  
The CAM gene is a crucial functional element of the pNW21 vector due to 
the fact that it is the only selection factor for the replication of the vector in S. 
carnosus. The loss of function of this gene is fatal to the functionality of pNW21 as 
an expression system for the Gram-positive bacteria, and therefore it was 
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imperative to access if the sequence insertion upstream of the gene was 
detrimental for its expression. For this purpose, colonies of E.coli TOP10 carrying 
pNW21 were grown overnight on ampicillin selective medium and subsequently 
loaded unto chloramphenicol selective plates with varying concentrations of 
chloramphenicol (from 5 to 15 µg/ml), which were incubated for 24 hours at 37 0C. 
After incubation, the number of surviving colonies was counted as a measure of 
CAM gene expression. Unfortunately, no colonies survived on the chloramphenicol 
selective plates after incubation, a result that was corroborated by subsequent 
growth experiments in which the E. coli stocks containing pNW21 failed to grow on 
NB2 medium with 15 µg/ml of chloramphenicol. From these results it was 
concluded that the sequence insertion observed upstream of the CAM gene 
knocked-out the expression of chloramphenicol resistance in E. coli, therefore 
severely impairing the use of pNW21 as an expression system for S. carnosus.  
 
 
3.6- Concluding Remarks 
  
In this chapter we described a legacy of problems that had been carried 
over from previous work on the staphylococcal expression systems pNW21 and 
pQR493. Most of the trouble-shooting and mistakes that permeated the start of this 
project could have been avoided if these expression systems had been previously 
well characterized. For instance, the miss-interpretation of pNW21 as pQR493 
originated from predictions that did not account for the presence of a HindIII site in 
the backbone of pNW21. We were also led to make the same mistake on the basis 
of an erroneous pQR493 restriction map, which was subsequently rectified through 
the empirical characterization of the vector.  
Since most of the history around the creation of pNW21 is not well 
documented, the possibility that an extra HindIII site had not been accounted for in 
the restriction maps cannot be disregarded. However, the sequencing results 
suggest that the genetic integrity of the vector might have been compromised 
through mutations and insertions of foreign DNA. Such events were damaging 
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enough to knockout the activity of the CAM gene, which in turn terminated the 
ability of pNW21 to operate in S. carnosus as an expression system.  
Therefore, after trouble-shooting pQR493 and pNW21, we were left with the 
clear understanding that the vectors we were given were not useful as expression 
systems in S. carnosus, and that we would have to either re-trace even more steps 
and work with a precursor from pNW21, or create an expression system de-novo. 
As it has been thoroughly demonstrated in this chapter, the possibility of working 
with a precursor from pNW21 would not solve the problem of having to work with 
unknown or badly characterized genetic material. On the other hand, creating an 
expression system de-novo would allow us to have full understanding and control 
over the genetic backbone of the system while granting the flexibility to re-arrange 
and change genetic elements freely without compromising its overall functionality. 
We decided on the latter option, by re-designing an expression system that would 
allow expression of biocatalysts in both Gram-negative and Gram-positive bacteria. 
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Chapter 4: Results- Design, 
Construction, and 
Implementation of a Novel 
Expression System for S. 
carnosus.  
	  
	  
4.1- The Design Strategy behind the 
Construction of a Novel Expression Vector 
	  
There were two reasons driving the decision to re-design an expression 
vector for S. carnous. On one hand, to avoid working with badly characterized 
genetic systems that would require some level of characterization prior to their use, 
as the previous chapter demonstrated. On the other hand, a total re-design would 
allow for a greater flexibility in the choice of the genetic elements making up the 
vector. Nevertheless, the design would still be limited by functionality constraints. 
As an interchangeable expression vector between Gram-negative and Gram-
positive bacteria, the design needed to cater for replication and selection in both 
bacterial types. In addition, it would also have to allow for protein expression of the 
biocatalyst in both E. coli and S. carnosus.   
The idea of creating a shuttle vector for cloning and protein expression in 
both Gram-negative and Gram-positive bacteria is not a novel concept. For 
instance, there are several examples in the literature of shuttle vectors created for 
heterologous protein expression in S. carnosus that also allow for cloning in Gram-
negative strains. One of these examples is the vector pSPPmABPXM, initially 
created as an expression system for protein surface display (Samuelson et al. 
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1995), and more recently adapted to express intracellular proteins under the 
influence of the constitutive lipase promoter (Williams et al. 2002). While these 
vectors could be used as functional expression vectors for the purposes of this 
project, they also had several limitations. One of these limitations is the inability to 
express heterologous proteins in Gram-negative strains, which means that 
successful cloning of a biocatalyst to the vectors could only be tested upon 
transformation into S. carnosus. Since the cloning step would be performed in the 
Gram-negative E. coli TOP10, due to the fact that it is a very well characterized 
cloning strain, it would be useful if the vectors allowed for expression of the cloned 
product in the latter. Another, perhaps more important limitation is the inherent low 
degree of flexibility of these vectors relative to the cloning of heterologous proteins. 
In fact, pSPPmABPXM has a very low number of restriction sites that can be used 
for protein cloning due to the fact that it is a product of several generations of 
cloning events with DNA sequences containing homologous restriction maps.     
Figure 30 illustrates the modular approach adopted for the re-design of the 
expression vector, under which the different genetic elements (modules) were 
reversibly linked together through the use of a synthetic linker. This linker was 
designed to fulfill several functions: firstly, to allow for the ligation of the different 
genetic elements together, thereby removing the need for these elements to have 
homologous restriction sites; secondly, to provide for the cloning of heterologous 
proteins by the introduction of a MCS with a range of unique restriction sites; 
finally, to cater for the expression of the cloned proteins through a combination of 
different removable promoters from both Gram-positive and Gram-negative 
bacteria.  By creating an independent unit for cloning and expression of 
heterologous proteins, this approach allows for a greater flexibility in the choice of 
the different genetic elements for replication and selection in Gram-positive and 
Gram-negative strains. Moreover, the reversible nature of the design ensured that 
the different components of the vector could be re-arranged or changed depending 
on the functional needs of the expression system, thereby resulting in a greater 
adaptability to different bacterial hosts.    
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Figure 30- Strategy for the design of a novel shuttle vector for protein design. The synthetic 
linker contains elements that allow for the sequential assembly of the Gram-negative and 
Gram-positive components. The ends of the linker (red) are initially connected to the Gram-
negative components, after which the Gram-positive components are connected via a 
restriction site within the synthetic linker.  
 
Similarly to other vector designs previously constructed for S. carnosus, it 
was decided that the staphylococcal plasmid pC194 would work as the source of 
replication and selection genetic elements for the Gram-positive bacteria. This 2.9 
kb plasmid was first isolated from Staphylococcus aureus as a small double-strand 
circular DNA that encoded chloramphenicol-induced-resistance through the 
expression of the enzyme chloramphenicol acetyl transferase (CAM) (Horinouchi & 
Weisblum 1982). The plasmid was also shown to replicate successfully in several 
Gram-positive and Gram-negative species. Thus, this plasmid contained all the 
components required for replication and selection in S. carnosus. Another 
advantage of this plasmid was the fact that all of its sequence was readily available 
in the NCBI database. pC194 is not commercially available, and consequently a 
variant containing most of its backbone sequence, pCT20, was used instead for 
the purposes of this project.   
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The vector pTTQ18 was used as the source for the Gram-negative 
components of the design. This vector is a variant of the pUC18 containing a trip-
lac promoter (pTac) upstream of a MCS, together the lac regulation represser gene 
LacI (Stark et al. 1987). Most of the backbone of this vector was used as part of the 
novel expression construct for a number of reasons. Firstly, the pUC vector series 
have been used extensively for cloning purposes, and therefore have already been 
sequenced and characterized as cloning systems in E.coli hosts. Consequently, 
pTTQ18 had already been proven as a high-copy number cloning vector that uses 
a derivative of the ColEI origin of replication from pBR322 and can be selected 
using ampicillin as the selective antibiotic. The sequence of this vector was also 
readily available on NCBI. Secondly, the pTac promoter and accompanying 
regulatory system could be used for the purpose of expressing biocatalysts in E. 
coli by replacing the MCS of pTTQ18 for the synthetic linker, which itself contained 
a wider range of unique restriction sites. The use of the promoter from the Gram-
negative components of the novel vector design went against the original 
approach, in which both Gram-positive and Gram-negative promoters and 
respective regulatory systems would be intrinsic to the synthetic linker. However, 
this change in the approach greatly decreased the complexity and length of the 
linker.    
In turn, the synthetic linker was designed around the restriction maps of the 
other components. Thus it included restriction sites at the extremities that allowed 
for the assembly of the pC194 and pQTT18, while also containing a MCS with 
unique sites that were not duplicated in the backbones of these vectors. The MCS 
region of the linker was designed to fit downstream from the pTac promoter of 
pTTQ18 and from a second, Gram-positive promoter that was part of the synthetic 
linkers. Unique restriction sites were also designed to flank the ends of this second 
promoter so it could also be re-arranged or replaced to fit the needs for biocatalyst 
expression. 
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4.2- The Modular Nature of the Promoter 
Region 
	  
The synthetic linker was designed as the centerpiece of the novel 
expression vector design. Accordingly, this component was designed to work as a 
linker that allowed for the joining of the other components, while also providing the 
ability to clone and express heterologous proteins in both Gram-negative and 
Gram-positive bacteria. Being the only synthetic part of the vector, i.e. constructed 
from scratch, allowed for a greater freedom in arranging the restriction map of the 
promoter region to fit these purposes. Figure 31 shows the representation of the 
synthetic linker as it was designed, and highlights the role of the restriction sites as 
the flexible hinges around which the other gram-positive and gram-negative 
components are reversibly connected. 
 
 
Figure 31- Design for the synthetic linker. The promoter region is flanked by unique EcoRI 
and XhoI sites that allow for the exchange between different promoters depending on the 
needs of the expression system. The MCS contains a set of unique enzymes that allow the 
cloning of genes encoding heterologous proteins, and is followed by the intrinsic 
transcription terminator rrn BT1. The 3’ end of the synthetic linker contains restriction sites 
for the joining of the other vector components. 
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One of the crucial concepts behind the design of the synthetic linker was 
this idea that it worked as the joining point between the backbone of pTTQ18 and 
part of pC194. The easiest way to guarantee this was to introduce restriction sites 
on the linker that aligned to restriction sites in each of the other components. Thus, 
the ends of the synthetic linker were designed to contain the restriction sites EcoRI 
and HindIII, which allowed for the replacement of the pTTQ18 MCS. In addition, 
the restriction site ClaI was introduced after the MCS to allow for the insertion of 
the pC194 components into the pTTQ18-synthetic linker ligated backbone.   
The decision to design the first step for the construction of the novel 
expression vector around the insertion of the synthetic linker into pTTQ18 was 
based on two reasons. Firstly, by using pTTQ18 as the starting point for the cloning 
strategy would allow for the use of E.coli as the cloning strain, which had been 
already extensively characterized as a host for genetic cloning processes and a 
large array of tools have been devised to facilitate cloning into the latter. By 
contrast, cloning and transforming S. carnosus has been shown to be a much less 
efficient process (Löfblom et al. 2007), and therefore relying on it as the primary 
cloning strain would not be ideal.  
Secondly, pTTQ18 already contained a MCS that was redundant for the 
purposes of the vector construction. Thus the synthetic linker was designed with a 
MCS segment that would replace the latter as the main cloning region for 
heterologous proteins. Thus, the restriction sites in the end of the synthetic 
promoter region were complementary to sites in pTTQ18 located upstream and 
downstream of the MCS, but still downstream from the pTac promoter of the vector 
to allow E.coli expression of the heterologous proteins.  
The MCS segment of the synthetic linker was itself designed as a cloning 
platform for heterologous proteins. As a result, the restriction sites organized within 
this segment were chosen from a bank of commercial endonucleases that are 
readily available and consequently would be commonly used in cloning processes. 
The choice of unique restriction sites was still dependent upon the restriction maps 
of the other vector components, which had to be checked for homologous sites that 
would duplicate those in the MCS region. In addition, the MCS was designed with 
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the cloning of the CHMO gene from pQR239 in mind, and therefore XhoI and 
BamHI was added specifically for this purpose.  
The final crucial component of the synthetic promoter region that allowed 
the expression of proteins in S. carnosus was the Gram-positive promoter 
sequence, which was designed to be located upstream of the MCS and 
downstream from the pTac promoter of pTTQ18. As with every other component of 
the synthetic cassette, the promoter segment was also designed with restriction 
enzymes flanking its borders that would allow for its replacement with other 
promoter sequences at will. This flexibility to replace promoters at will is the feature 
that makes this vector design novel. No previously reported shuttle vectors for 
protein expression in S. carnosus had been designed to allow the creation of 
promoter libraries for S. carnosus. In the case of this project, this feature was 
particularly important because it meant the expression of the biocatalyst would not 
be irreversibly fixed to one promoter, and could be modulated depending on the 
needs of the biocatalytic process. It would also allow us to study novel constitutive 
and regulated expression systems for S. carnosus.  
 
 
4.3- Scanning S. carnosus Genome for the 
Putative Promoters 
 
Expression of heterologous proteins in the novel vector construct was 
designed around the	  activity of two distinct promoters: the Gram-negative pTac 
inducible promoter from pTTQ18, and a Gram-positive promoter that would allow 
for strong protein expression in S. carnosus. While there is a solid database 
available for well-characterized, commercially used promoters for E. coli, the same 
cannot be said for the staphylococcal bacterium. Therefore, the choice of promoter 
for the synthetic linker was not a straightforward task. 
There are only a couple of staphylococcal promoters that have been 
characterized in the context of heterologous protein expression. One of these is the 
lipase promoter (Götz et al. 1985), which was originally cloned from 
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Staphylococcus hiycus and was used in the vector pNW21 to expressed 
heterologous protein constitutively in S. carnosus. Alternately, the inducible xylose 
promoter (Wieland et al. 1995), originally from Staphylococcus xylosus, was also 
used routinely in staphylococcal expression systems. The inducible nature of this 
promoter involves repressor XylR gene, which is co-expressed in the expression 
vector system and inhibits promoter activity in the absence of xylose.  
One valid approach for the choice of promoter would be to use one of these 
characterized promoters for the expression of heterologous proteins. However, this 
option was discarded in favor of the choice to use a promoter that was taken de-
novo from the S. carnosus genome. One reason that drove this decision was the 
fact that none of the promoters listed above are native from S. carnosus, and while 
they have been extensively characterized, they are not guaranteed to be optimized 
systems for this bacterium. Alternately, there is an high probability promoters 
native to S.carnosus are more optimized for intracellular protein expression in the 
latter. The other reason for this choice was the discovery that comes from the 
screening of the Staphylococcal genome for novel promoters. Identifying novel 
promoters that could work as units for efficient expression in S. carnosus would 
expand the list of functional promoters for staphylococcal species, while also 
increasing the general understanding of the staphylococcal genome’s expression 
and regulatory systems.    
However there was also a greater inherent risk in adopting this more open-
ended approach. In contrast with many other bacterial strains, there is very little 
available information regarding the transcriptome of S. carnosus. Additionally, 
there are very few guidelines as to what genetic elements constitute a strong 
promoter in this bacterial strain, or how they are regulated. Indeed, many studies 
have shown that Gram-positive promoters have an high degree of variation from 
the consensus sequences.  Consequently, the selection of promoters from the 
genome of S. carnosus was hampered by the fact that they could not be easily 
identified, and there was no direct means of testing for their activity and regulation.  
Therefore, focusing on the identification of specific promoter sequences in 
the genome of S. carnosus would be counter-productive, as there would be no way 
to know how efficient these sequences were or if they were natively regulated. 
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Instead, the methodology adopted in this study for the selection of native 
staphylococcal promoters was based on the use of in-silico predictive tools to 
correlate native protein expression to promoter strength, the assumption being that 
highly expressed proteins have an higher chance of being under the influence of a 
strong promoter. There were several advantages to this approach. Firstly, there are 
several open-source software available for the prediction of highly expressed 
proteins that use sequence data as the only criteria. In addition, several studies 
have been done on the proteomics of other pathogenic staphylococcal species that 
share an homologous group of core genes (Rosenstein & Götz 2010), and 
consequently data on these genes could be used to inform predictions of protein 
expression in S. carnosus.  
Figure 32 shows the graphical representation of this methodology. The 
genome of S. carnosus was initially screened for genes that had been identified as 
highly expressed proteins in the proteomics studies with other staphylococcal 
species. Predictive software was then used on these genes to predict their 
expression in S. carnosus. A library of potential native promoters was subsequently 
constructed from the DNA sequences upstream of predicted highly expressed 
genes.   
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Figure 32- Screening strategy for the identification of putative promoters from the genome of 
S. carnosus. Potential HEGs are identified via a combination of in-silico approaches, and 
regions upstream of these genes are highlighted as hotspots for strong promoters (yellow 
boxes).  *- (Reproduced from the International Journal of Medical Microbiology, vol. 300 (2-
3), Rosenstein & Gotz, Genomic differences between the food-grade S. carnosus and 
pathogenic staphylococcal species, pg. 104-108, Copyright © 2010, with permission from 
Elsevier.)  
	  
The predictive software used for the construction of the promoter library was 
based on the Codon Adaptation Index (CAI) (Puigbò et al. 2008). CAI is a 
measurement of the codon usage bias of a sequence relative to a reference set, 
which specifies the resemblance between the sequence and the reference set. 
Codon bias refers to the observed phenomenon that synonymous codons (that 
code for a specific amino acid) are not used in equal frequencies in a protein 
sequence, and this preference to specific codons can be traced to the organism 
from which the sequence originated (Sharp et al. 2005). This codon bias can be 
very species-specific, and is viewed as one of the major mechanisms employed by 
cells to regulate rates of protein expression (Plotkin & Kudla 2010). Thus, there is a 
correlation between the codon bias of a protein and how well they are expressed. 
Highly expressed proteins are more likely to have codons which are preferred and 
consequently in greater abundance in the native organism. Conversely, proteins 
that contain a high proportion of rare codons, i.e. codons that are not preferred by 
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the native species, are more likely to have a low level of expression. In fact, 
several studies have documented the optimization of heterologous protein 
expression by adapting the codon bias to that of the host organism (Gvritishvili et 
al. 2010; Kofman et al. 2003). 
The software used for the prediction of highly expressed proteins 
(http://genomes.urv.cat/CAIcal/) calculated the CAI of query sequences as a 
function of the difference between the codon bias of this sequence and that of a 
large group of sequences from the genome of the native organism, referred to as 
the reference set. The values for the CAI vary from 0 to 1, with a linear positive 
correlation between the value and similarity between query sequences and 
reference sets. The absolute CAI values are thus inherently dependent on the 
reference set, and will be interpreted differently when distinct reference sets are 
used. This is a limitation of the predictive system that warrants caution when 
choosing the reference set. For instance, when using genomic reference sets, i.e. 
composed of a broad range of genes from a genome, the CAI value indicates how 
adapted the query sequence is to the general codon bias of an organism, which is 
a more indirect measurement of well expressed the gene in the latter. On the other 
hand, using reference sets composed of genes with specific functions can 
introduce erroneous biases to the analysis by focusing the CAI on function rather 
than expression.   
There are other limitations to the CAI analysis. On one hand, the CAI can be 
affected by biases other than the codon bias of the reference set, such as biases in 
amino acid or nucleotide composition, which creates false positives in the analysis 
of the data. On the other hand, in organisms that do not display a dominant 
translational bias, the CAI will be very high (close to 1) regardless of the codon 
bias of the query sequence, and this can result in a loss of predictive power 
(Puigbò et al. 2008). To counteract these limitations, the software allows for the 
calculation of the expected CAI (eCAI) of a sequence. The eCAI is calculated as 
the average of CAIs from 500 procedurally generated sequences with the same 
amino acid composition of the query set, but random codon assignments. By 
randomizing the codon usage of this set, the software is accounting for the 
statistical noise created by mutations, amino acid or nucleotide biases. Thus eCAI 
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represents the threshold above which the values of CAI can be statistically 
attributed to correlations between codon biases instead of being a product of 
biases that are not related to codon usage.  
The reference set used for the purposes of CAI calculations in the predictive 
analysis of gene expression levels in S. carnosus was taken from the Codon 
Usage Database (http://www.kazusa.or.jp/codon/), which contained the codon 
percentages of a set of 52 proteins with a broad spectrum of activity. The diversity 
of the set ensured that we were not introducing functional biases to the analysis 
but instead looking at a protein population that represented the more generalized 
codon bias of the S. carnosus genome. Figure 33A shows the codon bias 
generated from this set of proteins, which clearly shows the preference towards 
certain synonymous codons. This is most prevalent in amino acids like alanine 
(Ala) and leucine (Leu), which can be coded by 4 and 6 codons respectively but 
show a dominating preference to a single codon.   
For the query set, 46 gene homologs to proteins that had been identified 
through in-silico prediction tools (Jansen & Bussemaker 2003) and empirical 
proteomics (Kohler et al. 2005; Suzuki et al. 2012) ,  to be highly expressed genes 
(HEG) in S. aureus were selected from the genome of S. carnosus. The list of 
proteins, together with their CAI in several S. aureus strains, can be found in the 
HEG-database (http://genomes.urv.cat/HEG-DB/) (see Appendix 2). Many of these 
proteins were housekeeping genes that have been highly conserved within 
staphylococcal species, and were therefore to have similar expression profiles 
between S. aureus and S. carnosus. Figure 33B shows the ratios between the CAI 
for each protein in the query set and the eCAI of the set, obtained through the CAI 
calculation software. Values above 1 indicate proteins with statistically significant 
CAIs.   
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Figure 13- A)  Codon usage frequencies of the set of 51 protein sequences taken from the 
Codon Usage Database. The different colors represent different synonymous codons that 
translate specific amino acids. A strong codon preference can be observed for amino acids 
with highest frequencies. B) CAI/eCAI ratio of 46 proteins used as the query set for the CAI 
analysis. Values above 1 refer to proteins whose CAI is statistically significant.  
 
Most of the proteins in the query set had CAi values above the eCAI value 
of 0.723, and thus shared more than 70% codon bias with that of the reference set. 
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Many of the highest CAI values corresponded to ribosomal subunits that, as 
house-keeping proteins, are expected to express strongly in active cells. In fact, 
the 50S ribosomal protein L7/L12, which generated to highest CAI in the in-silico 
analysis, had been previously identified as the ribosomal protein with the highest 
level of expression in both the exponential and stationary phase of S. aureus COL 
(Kohler et al. 2005). The similarities between the results from the CAI analysis and 
the proteomics data for S. aureus suggested that the CAI values could be directly 
related to protein expression levels, and consequently could be used as 
reasonable predictive tools for HEG. 
Once potential HEG were identified, the sequences immediately upstream 
of the genes were selected as potential strong promoters (Figure 34). In some 
cases, these sequences were very short, or were part of a different gene, 
suggesting that either the promoter for the selected HEG was contained within 
another gene, or that the HEG was part of an operon. Operons can be under the 
influence of strong promoters, but in many cases this activity is also strongly 
regulated. Since the initial focus of the promoter selection approach was to select 
for promoters that could induce a high level of constitutive protein expression, 
regions upstream of putative operons were discarded because they could contain 
elements of unknown regulatory activity. As a result, only sequences upstream of 
single genes were chosen.   
One such gene was the 50S ribosomal protein L10 (rplK). The sequence 
immediately upstream was a stretch of 183 base pairs that contained several 
promoter-like DNA motifs, suggesting that it could contain multiple promoter 
activities (Figure 35). Considering the potential for high activity due to the 
multiplicity of promoter elements, and the assumption that ribosomal proteins are 
more likely to be constitutively expressed throughout the bacteria cell cycle, this 
short sequence was selected as the starting Gram-positive promoter, designated 
the rplK promoter, to be included as part of the synthetic linker.   
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Figure 14-  Position and orientation of genes with high CAI values in the genome of S. 
carnosus. The sequences upstream of the genes and the spacer sequences between genes 
are represented by the yellow and green boxes, respectively. In cases like the gene tpiA or 
dltD, which generated the highest CAI, the space between these and adjacent genes is too 
small to accommodate for promoters (green boxes), which in turn suggests that the genes 
are part of an operon. This is not the case for the rplK gene, as sequences upstream and 
downstream for it  are long enough to consider this gene as an individual expression unit, 
not associated with the expression of other genes. 
	  
 
Figure 35-  Sequence upstream from the rplK gene. Regions with putative -35 and -10 
promoter elements are highlighted within red boxes. The putative ribosomal binding site is 
shown within the blue box.  
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4.4 – The Construction of the pQR1029 Vector  
	  
	  
The novel expression vector, designated pQR1029, was created in two 
steps as outlined in Figure 36. The first was the insertion of the synthetic linker into 
the backbone of pTTQ18, thereby replacing its MCS and adding the required 
restriction sites for the insertion of the Gram-positive fragment. The second and 
final step was the ligation between the product of the pTTQ18/ synthetic linker 
ligation and a fragment from pCT20 containing the chloramphenicol resistance 
gene (CAM), and the origin of replication for staphylococcal strains.  
For the first step, both pTTQ18 and the synthetic linker were restricted with 
EcoRI and HindIII. The linker was created de-novo by the company DNA 2.0 and 
provided in a cloning plasmid with the same flanking restriction sites, so that it 
could be extracted prior to ligation by using the same digest. The restricted 
fragments were subsequently purified through gel extraction and ligated with T4 
ligase from NEB. After ligation, the resulting DNA products were transformed into 
chemically competent E. coli TOP10 and selected using ampicillin selective plates. 
Colonies were subsequently screened for positive ligation through restriction 
digests. 
Being supplied by a commercial company, the synthetic cassette had a high 
degree of purity, and therefore the ligation protocol did not require fine-tuning and 
trouble-shooting to accommodate for sub-optimal conditions. In fact, only one set 
of screening assays was required to identify colonies containing the positive 
ligation.  
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Figure 36- Ligation strategy employed for the construction of the vector pQR1029. The first 
step was the creation of the intermediate pQR1028 (3), and involved the removal of a 2.3 kb 
region from pTTQ18 (1) via endonuclease restriction with EcoRI and HindIII,  and subsequent 
ligation of the remaining backbone with the synthetic linker (2), which had been extracted 
from a commercial vector using the same restriction enzymes. In the second step, the pCT20 
fragment containing the CAM resistance gene and the origin of replication is digested from 
pCT20 (4) and ligation with pQR1028, creating the shuttle vector pQR1030 (5). 
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Figure 37 shows an agarose gel with the screening results from the first 
ligation step. The plasmid DNA was extracted from colonies that had been grown 
overnight in ampicillin selection media and subsequently digested with XhoI. The 
insertion of the synthetic linker into pTTQ18 had replaced the MCS of the vector 
with a set of unique restriction sites, including XhoI, that are not present in re-
ligated or undigested pTTQ18. As a result, only the ligation product of pTTQ18 with 
synthetic linker would be restricted with XhoI, resulting in a visible size difference 
between cut and uncut vector in the agarose gel (lanes 12, and 13), while the re-
ligated vector would remain uncut (lanes 2 and 3). Sequencing of the vector 
around the pTac promoter confirmed the results from the screening assays 
(Appendix 1). 
The ligation construct, pQR1028, contained the restrictions sites from the 
synthetic linker that were required for the second ligation step.  
 
 
Figure 37- Agarose gel (0.7% w/v) with the results from the screening of the pQR1028 
construct. Lanes 1 and 18: Hyperladder (NEB); lanes 2 to 17: 6 plasmid samples from E.coli 
colonies selected on ampicillin plates in uncut and cut states, respectively. Lanes 12 to 17 
showed the profiles we were expecting to generate when cutting the plasmid pQR1028 with 
XhoI. Indeed, cutting circular plasmid (lanes 12, 14, 16) with this enzyme produced a 
linearized band about 4.5 kb in size (lanes 13, 15, 17). 
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The second step in the construction of the shuttle vector pQR1029 involved 
the restriction of both pCT20 and pQR1028 using the endonuclease ClaI, followed 
by ligation of the resulting pCT20 fragment containing the origin of replication and 
the CAM gene with the linearized vector.  
Unfortunately, this step was not as straightforward as the first. Indeed, the 
fact that the pCT20 vector ha been provided inside S. carnosus TM300 introduced 
the problem of having to extract the plasmid DNA from the staphylococcal strain. 
Due to the toughness of the peptidoglycan cell wall, extraction protocols for Gram-
positive bacteria are work intensive and often result in very low product yields. In 
addition, these protocols require the use of expensive lytic enzymes such as 
lysostaphin and lysozyme to break up the cell wall. Finally, the DNA extraction from 
the rest of the cell debris involves the use of a phenol-chloroform two-phase 
system, which is not only extremely toxic at higher volumes, but also results in low 
purity DNA samples. These protocols are therefore limited to small-scale 
extractions, and are not optimized to achieve highly concentrated and pure DNA 
products.  
Consequently, the initial attempts of extracting pCT20 from S. carnosus 
using these conventional extraction protocols produced unreliable results, with 
large fluctuations of plasmid yield that primarily depended on the fine handling of 
the phenol-chloroform gradient. Most of the extracted samples also contained a 
large quantity of ribonucleic acid impurities, making them very hard to visualize on 
an agarose gel. As a result, the samples obtained from these extraction protocols 
were not pure or concentrated enough to allow for efficient restriction and ligation. 
The low concentration of plasmid DNA in the samples was the main 
bottleneck for the ligation, due to the fact that most of the plasmid would be lost 
during the required purification of restricted fragments from an agarose gel. As gel 
extraction protocol generally produce low yields of purified product, starting with a 
low concentration of plasmid before restriction and gel purification would result in 
very low or negligible final plasmid concentration.  
As a response to this bottle-neck, two solutions were devised to ensure 
plasmid yields: the first was to develop a reproducible and less complicated 
method for extraction of the plasmid DNA from large samples of S. carnosus; the 
second was to directly purify high quantities of the desired fragment from pCT20 
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contained within un-lysed samples by using PCR amplification with primers that 
flanked the fragment of interest. 
 
(i) The plasmid extraction protocol 
  
Figure 38 shows a schematic of the type of factors that were considered 
when developing a more efficient protocol for plasmid extraction from the 
staphylococcal strain. The first stage in the protocol would be the disruption of 
cells. Previously described protocols used a mix of lysogenic enzymes to lyse the 
thick peptidoglycan and lipid layers of S. carnosus. Therefore the first line of 
enquiry was whether there was a quicker and cheaper disruption method that could 
produce high level of lysed material. One alternative would be to use physical 
methods to induce disruption of the cells, such as sonication or French-press 
induced homogenization. All the results using physical disruption methods 
indicated that some degree of chemical treatment was required to weaken the 
peptidoglycan layer of the cells for the mechanical disruption to be efficient.   
 
 
 
Figure 38- Factors that were tested on S. carnosus for the extraction of plasmid DNA. 
 
	   153	  
Several staphylococcal strains, including S. aureus and S. epidermis, have 
been reported to be resistant to lysozyme-mediated cell disruption, and thus 
addition of lysostaphyn is needed to promote efficient lysis (Wu et al. 2003). To test 
if the same was true for the genetically related S. carnosus, toxicity assays were 
conducted in which samples of S. carnosus were grown overnight on non-selective 
plates containing various concentrations of lysozyme. The results from these 
assays (Figure 39 A) showed that concentrations of lysozyme as high as 60 mg/ml 
did not seem to inhibit growth of S. carnosus, from which it could be concluded that 
the peptidoglycan wall was not sensitive to lysozyme digestion.   
The inefficiency of this enzyme to degrade the peptidoglycan wall posed the 
question of whether the presence of lysozyme in a lytic cocktail was really 
necessary. To access this, the effect of lysozyme on lysostaphin-mediated cell 
lysis in different buffers under different incubation condition was tested. Bacterial 
samples were grown overnight, pelleted, and resuspended in various lytic solutions 
containing a constant concentration of lysostaphin but different concentrations of 
lysozyme and different reaction buffers. The resuspended samples were 
subsequently incubated at 37 0C for one and two hours, after which a small volume 
of the resulting lysates was loaded unto an agarose gel to check for the release of 
plasmid DNA from lysed cells. The results (Figure 39A and 39B) showed that 
lysostaphin by itself was sufficient to promote efficient cell disruption. In fact, 
adding high concentration of lysozyme to the samples seemed to have a 
detrimental effect on the quality of DNA extracted from the lysed samples (figure 
39C).  It is uncertain why samples digested with both lytic enzymes did not show 
visible bands on the agorose gel, since these samples were still lyses by through 
the activity of lysostaphin. One hypothesis could be that lysozyme binds to the 
plasmid DNA, retaining it in the well of the agarose gel and consequently 
preventing it from migrating into the polymer matrix. One way to test this would be 
to heat-inactivate the lysis before loading the DNA onto the gel, which should 
prevent the DNA from being sequestered by active enzyme. 
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Figure 39- Different test run on the effects of chemical lysis of S. carnosus. A)  Effect of 
different concentrations of lysozyme on layers of S. carnosus spread on agar plates. Holes 
were drilled in plate sections after incubation of bacteria on plates, and various 
concentrations of lysozyme solution were loaded unto these reservoirs and incubated 
overnight. B) Table specifying  an experimental design with the different factors studied for 
chemical lysis of S. carnosus cells. All the factors were studied at two levels, except for 
lysostaphin concentration, which remained constant throughout. C) Agarose gel (0.7% w/v) 
containing the results from the chemical lysis experiment. The letters in the lanes 
correspond to the letters outlined in the experimental design table (B).   
 
The other part of the extraction protocol that needed to be addressed was 
the purification step. As mentioned above, in the standard protocol this was 
achieved by applying solvent gradients that required delicate handling and involved 
the use of hazardous phenol-chloroform based compounds. On the other hand, 
easy-to-use kits have been developed for plasmid DNA extraction in gram-negative 
bacteria that applied a solid phase chromatography column technology to bind and 
purify DNA using vacuums or the centrifugal force of a bench-top centrifuge. The 
columns were designed to work on standard lab equipment, and had the added 
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advantage of being optimized for plasmid extraction.  Therefore, the possibility of 
using these columns for purification of plasmid DNA from lysates of S. carnosus 
was tested. Samples that were either mechanically or chemically lysed were 
centrifuged, and the supernatant was subsequently passed through the solid phase 
extraction colonies. This method resulted in samples containing pure plasmid DNA 
at high concentrations. 
Thus, after identifying the factors that were crucial to DNA extraction from S. 
carnosus, an optimized plasmid extraction protocol was developed that did not 
require complicated enzyme cocktails and took advantage of the ability of gram-
negative purification kits to obtain highly pure DNA plasmids from bacterial 
samples. In addition, this optimized protocol could easily be adapted for extraction 
of large volumes of cell lysate. The full protocol is described in the materials and 
methods chapter (see chapter 2, section 2.2.1).   
 
(ii) PCR amplification of pCT20 fragments 
 
The creation of a protocol that could reliably extract the plasmid pCT20 from 
S. carnosus only solved part of the problem. The restriction of the pCT20 and 
subsequent purification of the fragment bearing the replication and selective 
components still required running the sample on agarose gel to separate the 
different sized fragments and purify the desired components via gel extraction. This 
method is very inefficient and often results in very low concentrations of the end 
product, which in turn decrease the probability of ligation to occur. The strategy 
devised to work around this problem was based on the amplification of the desired 
fragments from pCT20 by using polymerase chain reaction (PCR). The direct 
amplification of the desired fragment from pCT20 not only took away the need to 
use gel extraction for purification of the correct fragment, but also had the added 
advantage of exponentially increasing the final concentration of the fragment 
(Figure 40). The primers used for amplification were designed to anneal 20 base 
pair (bp) sequences flanking both the origin or replication and antibiotic resistance 
gene from pCT20, and also contained overhangs with the restriction sites for ClaI 
and HindIII to allow for ligation with pCT20. 
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Figure 40- Agarose gel (0.7% w/v) containing the products from the pCT20 PCR 
amplification. The expected size for amplified fragment of pCT20 containing CAM and oriS is 
1.5 kb. Lanes 1 and 6: hyperladder (NEB); lanes 2 to 5: PCR reactions using different primer 
annealing temperatures (64.5, 65.5, 66.4, 67.9, respectively). 
 
Thus, a methodology combining the optimized plasmid DNA extraction 
protocol with subsequent amplification using sequence specific PCR resulted in 
high final concentrations of pure pCT20 fragments containing the genetic elements 
of interest.  
Subsequent attempts to ligate these the amplified fragments from pCT20 
with the linearized pQR1028 were still unsuccessful due to a second bottleneck 
that had not been accounted for when designing the vector ligation strategy. This 
bottleneck was the effect of DNA methylation of the restriction of specific sites by 
endonucleases. Methylation is a mechanism by which cells regulate several 
genetic processes, including genome replication and protein expression. 
Methylation also shields DNA from digestion by intracellular endonucleases, a 
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mechanism that selects for the degradation of foreign sequences that are not 
methylated in the same manner. One endonuclease that are susceptible to 
inhibition by methylation is ClaI. This posed a problem for the second and final step 
in the pQR1029 construction process, whereby ligation was dependent on a ClaI 
that had been specifically designed as part of the synthetic linker. Since the ClaI 
site on the ends of the PCR amplified product from pCT20 would not be affected by 
methylation, since it was not subjected to the cellular methylation process, the 
same site on pQR1028, which had been replicated in E. coli, was shield from 
restriction with the corresponding endonuclease. In fact, the ClaI site in pQR1028 
(ATCGAT) overlapped with a recognition site for the methylation protein DNA 
adenine methyltransferase (Dam), GATC (Figure 41). As a result, the ClaI site of 
pQR1028 was protected and could not be cut in the plasmid extracted from the 
E.coli TOP 10 strain, which had been routinely used as the cloning strain. To solve 
this problem, a Dam-/Dcm- E.coli strain, in which the genes for the methylation 
pathway have been knocked-out, was used as the cloning strain for pQR1028 
replication and extraction.  Switching to this strain increased the risk of DNA 
alteration, since non-methylated DNA is unprotected and more liable to damage, 
but the risk was necessary for the ligation to be possible.  
After solving all inherent problems with the second ligation step, the vector 
pqr1029 was successfully ligated. The ligations results were confirmed by 
sequencing of sequences spamming pQR1028 and one of the ends of the pCT20 
fragment. The vector was also shown to grant resistance to both ampicillin and 
chloramphenicol in E. coli TOP10, indicating that the selectivity components of the 
vector were working as intended. 
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Figure 41-  Sequence for the synthetic promoter linker, in which the different elements are  
highlighted with different colored lines:  black line: rplK promoter; blue line: multi-cloning 
site (MCS); red line: the hairpin terminator sequence. The yellow box refers to the ClaI 
restriction site, which overlapped with a methylation site (black arrow). 
	  
	  
4.5- Ligation of the CHMO Gene to pQR1029 
	  
	  
The construction of the shuttle vector pQR1029 was a milestone in 
establishing an expression system for both Gram-negative and Gram-positive 
bacteria. In the context of the project, an additional ligation step between the 
CHMO gene and pQR1029 was required to allow expression of the biocatalyst 
inside E. coli and S. carnosus. Accordingly, the MCS of the vector had been 
designed to permit the direct transfer of the gene sequence from pQR239 via a 
XhoI-BamHI restriction.  
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This ligation was also more problematic than expected, and a variety of 
ligation strategies were tested as solutions for possible problems. The standard 
ligation protocol resulted in a large number of transformed colonies, but all of those 
that were screened showed re-ligation of pQR1029. The restriction of the vector 
with both enzymes XhoI and BamHI was very hard to access, since the restriction 
sites were located very close together and resulted in a non-detectable decrease in 
the size of the linearized vector. Thus, the high rates of re-ligation suggested that 
while the vector was being linearized, one of the restriction sites could be working 
improperly. To test this, restrictions of pQR1029 with each endonuclease 
individually were performed, and the results from these tests confirmed that both 
enzymes were digesting the DNA. Therefore it was concluded that the large 
percentage of re-ligations could not be explained by a sub-optimal restriction by the 
endonucleases.   
Consequently, as a preventive measure to inhibit re-ligation of the vector 
pQR1029 before ligation, the enzyme Antarctic phosphatase (NEB) was used. This 
enzyme catalyzes the removal of 5’ phosphate groups from the exposed ends of 
double-stranded DNA, preventing self-ligation of the strands. Samples treated in 
this manner did not produce any colonies on selective agar plates, even after 
inactivation of the phosphatase through heat treatment of samples at 65 0C for 10 
minutes. On one hand, the results confirmed that the large number of transformed 
colonies seen in the first set of ligations was due to re-ligation of the vector 
pQR1029. On the other hand, these results suggest that either the Antarctic 
phosphatase was not efficiently inactivated and interfered with ligation, or that the 
CHMO fragment was not being correctly restricted from pQR239. The fact that no 
colonies could also be seen after the incubation time of heat treatment of Antarctic 
phosphatase-treated samples was increased from 10 to 20 minutes suggested that 
the problem lied of the restriction of CHMO from pQR239.      
In the conventional extraction method, the CHMO gene was purified from 
the pQR239 vector via gel extraction after restriction with a XhoI/BamHI restriction 
mix. While the process was quite straightforward, as the size of the gene (1.6 kb) 
was smaller than the vector (5 kb) and therefore can be easily identified in an 
agarose gel, the lower concentrations of the end product could have been a source 
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for the inefficiency of the ligation process. More important, the trouble-shooting 
experiments conducted of the restriction of pQR239 identified a crucial bottleneck 
with the restriction itself. In fact, restriction of the vector pQR239 with BamHI 
produced a similar restriction profile to a double-digest with a XhoI/BamHI 
restriction, which highlighted the presence of a BamHI site upstream as well as 
downstream of the CHMO. Since the restriction map for pQR239 did not account 
the presence of a second BamHI site upstream of CHMO, it was impossible to 
know if the XhoI-BamHI double digest produced the gene fragment containing the 
corresponding sticky ends, or a fragment containing BamHI overhangs at both 
ends of the gene. In the case of the latter, ligation to a XhoI-BamHI restricted 
pQR1029 would be impossible, which would explain the unsuccessful ligation 
attempts when using Antarctic phosphatase-treated pQR1029.  
To work around this problem, it was decided that the best strategy would be 
amplify the gene directly from pQR239 using primers with overhangs containing 
restriction sites that would allow for ligation of CHMO with pQR1028 in the correct 
orientation. Thus, the primer aligning to the 5’ end of the gene was designed with a 
XhoI restriction site, while the 3’ end primer was designed with the restriction site 
PstI, which ligated to an homologous site downstream from XhoI in the MCS region 
of pQR1028.  Using PCR amplification, a high concentration of the CHMO gene 
was amplified from pQR239, which had been isolated from overnight cultures of E. 
coli TOP10, and subsequently inserted into the MCS of pQR1029. The resulting 
ligation product, pQR1030, was screened by restriction analysis using a XhoI/SphI 
reaction mix, which should excise the CHMO from the vector backbone is the 
ligation was successful (figure 42). Sequencing of the area around the pTac and 
MCS of the ligation product was also performed to confirm that the gene was 
inserted in the correct orientation (Appendix 1).  
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Figure 42- Agarose gel (0.7% w/v) containing the results from the screening of E.coli 
colonies for the pQR1030 construct, together with the expected restriction profile of 
pQR1030 when digested with XhoI and SphI. Lanes 1 and 11: hyperladder (NEB); lanes 2 to 
10: plasmid samples from E.coli colonies as a circular molecule and cut with XhoI and SphI, 
respectively. The positive constructs show a distinct profile between cut and uncut smaples, 
with cut samples having to bands corresponding to the linearized pQR1029 (6.5kb) and one 
corresponding the CHMO gene (1.6kb). 
 
 
4.6- Initial Biocatalytic Studies with pQR1030 
in E. coli  
 
The expression vector pQR1030 contained the CHMO gene under the 
expression of both the Gram-negative pTac promoter and the staphylococcal 
ribosomal promoter rplK. Theoretically, the set-up would enable the vector to 
express the biocatalyst in both E.coli and S. carnosus, provided that the increased 
distance between pTac and the gene did not impair the expression of this 
promoter. Since the vector had been cloned into E.coli, CHMO expression assays 
were initially performed on this bacterial strain. The ability to express CHMO in 
Gram-negative bacteria using pQR1030 would also validate the dual-promoter 
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vector design as well as trouble-shoot the insertion of the CHMO gene into the 
pQR1029.  
Due to the enzyme’s use of the co-factor NADPH during reaction, the level 
of CHMO expression can be indirectly accessed by measuring co-factor NADPH 
oxidation rates during biocatalysis. Accordingly, biocatalytic assays were 
performed on lysates of E. coli cultures hosting the vector pQR1030. Lysates were 
produced from bacterial cultures grown in 250 ml shake flasks containing 50 ml of 
NB2 medium and 100 µg/ml of ampicillin for 8 hours or 24 hours. ITPG (1mM) was 
alternately added after 3 hours of incubation to test the induction of the pTac 
promoter. After incubation, samples were collected and resuspended in 5 ml of 
Tris-HCl buffer (pH 9), and subsequently lysed using a French-Press.   The 
supernatant from the resulting lysates was collected and subsequently used 
directly for the NADPH oxidation assays. The operating conditions of the assays 
did not deviate from previous experiments conducted by O’Sullivan et al. (2001). 
NADPH absorbs at a wavelength of 340 nm, which can be measured using 
a standard spectrophotometer. Thus the biocatalytic reactions were performed in 1 
ml-cuvettes by mixing the 0.2 ml of the supernatant from lysates with 0.8 ml of 
reaction buffer (pH 9) containing 0.161 mM of NADPH and 7.14 g/L of bovine 
serum albumin (BSA). The resulting mix was inserted in a spectrophotometer with 
temperature control and incubated for 2 minutes at 30 0C, during which time the 
NADPH levels in the sample were measured using a wavelength of 340 nm. This 
first measurement corresponded to the level of NADPH oxidation from general 
activity of cellular metabolic enzymes. After this initial period of incubation, 2 mM of 
the substrate cyclohexanone were added to the sample, and the decrease of the 
NADPH levels at 340 nm was measured for 2 additional minutes. This decrease 
corresponded to the level of NADPH oxidation resulting from the combined 
biocatalytic activity of CHMO and the activity of metabolic proteins also present in 
the supernatant. The final NADPH oxidation rate from CHMO biocatalysis was 
subsequently calculated as the difference between the two measured rates.   
Figure 43 shows the results from the NADPH oxidation assays. Since the 
vector pQR239 is the conventional expression system for CHMO expression in E. 
coli TOP10, it was routinely used in the NADPH oxidation assays as a reference 
point to CHMO expression using pQR1030.   
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Figure 43- NADPH oxidation profiles of E. coli pQR239 (A) and E. coli pQR1030 (B) lysates 
expressing the CHMO gene.  NADPH oxidation was detected by measuring absorbance at 
340 nm,  which decreases as NADPH is oxidized during metabolic activity of CHMO 
biocatalysis. The values in the y-axis are the absolute numbers of absorbance gradients. The 
substrate used was cyclohexanone (2 mM), which was added after 2 minutes of reaction in 
the absence of substrate.  IPTG was added to growing cultures at a concentration of 1mM. 
Error bars refer to the standard deviation of the experimental set-up, calculated from 
triplicates of the same assay. 
 
Lysates from pQR1030 cultures showed comparable oxidation profiles to 
those obtained with pQR239 lysates. Both cases exhibited a linear NADPH 
oxidation rate until shortly after 1 minute of incubation, at which time they start to 
plateau due to limiting substrate concentration. pQR239 lysates achieved a 
maximum oxidation rate of 44 µmol of NADPH per minute per gram of dried cell 
weight (DCW) under IPTG-induced conditions, while the pQR1030 lysates 
achieved maximal rate of 68.8 µmol min -1 g -1 (DCW). Alternately, under non-
induced condition, pQR1030 samples did not exhibited significantly higher 
biocatalytic activity when compared with the general metabolic activity in the 
absence of cyclohexanone, while pQR239 samples still exhibited a linear NADPH 
oxidation rate of 15 µmol min -1 g -1 (DCW).  
The fact that the NADPH oxidation rates of pQR1030 samples were very 
low in the absence of IPTG when compared to pQR239 samples grown under the 
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same conditions suggested that the LacI gene present in pQR1030 was working 
efficiently as a tight repression system for pTac-mediated CHMO expression. In the 
case of pQR239, the araC repressor gene is not contained within the expression 
vector, which would explain the less stringent control of CHMO expression in this 
system. On the other hand, this result also suggested that the staphylococcal rplK 
promoter downstream from the pTac promoter did not exhibit any activity in E. coli. 
Therefore, the differences in oxidation rates between pQR1030 and pQR239 was 
attributed to difference in the expression levels of the pTac and pBAD promoter, 
with the former showing a higher level of protein expression.  
One possible explanation for the lack of activity of the staphylococcal 
promoter is the presence of AT rich sequences within the latter that could form a 
hairpin structure upon separation of the DNA into single strands or in the 
subsequently transcribed RNA (Figure 44). The mechanism of protein expression 
regulation via RNA secondary structures had been previously suggested for the 
chloramphenicol resistance gene in Gram-positive bacteria (Lovett 1996), and 
therefore some promoter regions for S. carnosus could be designed to allow for 
this regulation to occur. However, if CHMO expression was indeed inhibited during 
protein translation due to secondary RNA structures, no change in enzyme activity 
should be seen between IPTG induced and non-induced samples. Consequently, 
this hypothesis was not considered as a satisfactory explanation for the lack of 
promoter activity.  
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Figure 44- Putative secondary DNA structure of the rplK promoter in the synthetic linker, as 
calculated via the OligoAnalyzer software 
(http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/) .  
 
On the other hand, the hairpin structures of the rplK promoter sequences 
could have a detrimental influence on the transcription event by preventing RNA 
polymerase binding to specific recognition sequences in the promoter. However, 
this possibility also seems unlikely, at least when E.coli is concerned, because the 
single-stranded binding protein SSB is normally employed during replication and 
transcription to prevent the formation of any intramolecular secondary structures.  
Regardless of the effect of the straphyloccocal promoter on CHMO 
expression in E.coli, the results for the NADPH oxidation assays showed that the 
vector pQR1030 allowed for the expression of CHMO expression in E.coli despite 
the presence of a second staphylococcal promoter downstream from pTac. In 
	   166	  
addition, the results also showed an improvement in CHMO expression using 
pQR1030 when compared to the previously constructed expression vector 
pQR239.  
 
 
4.7- Cloning of pQR1030 into S. carnosus 
 
The vector construction strategy for pQR1030 had relied upon E.coli as the 
cloning strain. Consequently, after confirming that the vector granted expression of 
CHMO in the latter, the next step was to transfer pQR1030 into S. carnosus.  
The transformation protocols described in previous studies for DNA cloning 
into the Gram-positive bacteria were primarily based on protoplast transformation 
(Gatermann & Marre 1989)  and electroporation (Kraemer & Iandolo 1990). More 
recently, a protocol had been optimized for the development of electrocompetent 
S.carnosus (Löfblom et al. 2007), which was subsequently been used to clone 
pQR1030 into the staphylococcal strain (see chapter 2, section 2.2.5). 
Unfortunately, attempts to clone pQR1030 using this protocol were unsuccessful, 
and required further trouble-shooting.  
Trouble-shooting the electroporation process was done by applying a design 
of experiments (DoE) approach, in which a large population of process variables 
was screened for the statistical importance of each variable on the overall process. 
Seven major variables were chosen from a list of possible factors affecting the 
electroporation protocol. These variables were growth media, starting cellular OD, 
electroporation medium, washing buffer, electroporation voltage, heat treatment, 
and incubation time after electroporation.  
Previous studies on the electroporation process of several different bacterial 
strains had highlighted the importance of the cell density before the washing 
stages, with most protocols suggesting an optimal cell density after incubation of 
0.5 OD (Gehl 2003). Alternately, in the optimized protocol developed by Löfblom et 
al. (2007), incubation time was identified as a crucial parameter, while variation in 
cell density did not have a big effect except below a certain level. Similarly, 
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incubation time after electroporation was highlighted as a crucial factor, since 
enough time had to be allowed for the cells to replicate the transformed plasmid.   
By contrast, no studies on electroporation of S. carnosus had focused on 
the composition of the cell growth media, with different protocol using different 
types of media for culture incubation. B2 medium had been routinely used 
throughout this project to culture S. carnosus, but this media contained high 
concentrations of salt that could affect the translocation of negative-charged DNA 
molecules across the cell membrane.  
There was also no consensus in the literature about the buffer used for the 
washing steps or the buffer in which the cells were resuspended for 
electroporation. Some protocols used distilled water, which increases the turgidity 
of cells and expands the cell membrane, while others used hypertonic solutions 
containing magnesium and sucrose that could be subsequently used as the 
electroporation buffer. The difference in approaches to the washing steps seemed 
to stem from different concerns that focused either on the survivability of the cells 
or on the efficiency of washing steps. 
The two last variables selected for DoE analysis, electroporation voltage 
and heat-treatment of cells prior to electroporation, had been previously highlighted 
as crucial for the success of the process. Heat treatment in particular was 
introduced to the electroporation protocol by Löfblom et al. (2007) as a means to 
reverse the inactive metabolic process that could be responsible for rejection of 
foreign DNA. Alternately, voltage was identified as a important factor for the 
migration of plasmid DNA across the thick peptidoglycan layer of the 
staphylococcal bacterium.  
A DoE two-level factorial design was conducted by running the seven 
variables concurrently at two different operational levels: a low (-) level below or 
corresponding to the optimal operation conditions of the process; and a high (+) 
level that was set at the higher extreme of the window of optimal operation 
conditions. Thus, the seven variables were combined into 32 experimental runs 
with alternative levels for each of the variables (Appendix 3). Results were 
measured as number of surviving colonies on plates containing the antibiotic 
chloramphenicol after transformation with pQR1030. Plasmid concentration, 
incubation temperature, shaking speed, and sample volumes were maintained 
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constant throughout the run. This type of factorial design is a very powerful tool for 
the optimization of an experimental process because it provides statistically 
significant data relative to the influence of individual variables to the overall 
performance of the process, while also providing a statistical map of the functional 
relationships between the different tested variables.  
Figure 45 shows a graphical representation of the results from the DoE 
analysis in the form of a Pareto chart. The y-axis of this chart corresponds to the 
effect values of the individual variables or combinations of two variables, which in 
turn relates to their statistical significance to the performance of the experimental 
proccess. Factors with high effect values are considered to be more significant for 
the process, and changes in these generate large fluctuation in the overall 
performance. The results from the analysis highlighted 3 variables that were 
significant for the electroporation protocol: initial OD, electroporation voltage, and 
incubation time after electroporation. 
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Figure 45- Pareto chart showing the effect levels of different factors individually and 
combinations of two factors to the efficiency of S. carnosus electroporation.  Effect values 
are expressed as the fraction between factors and the sum of the effect values of the whole 
factor population.  The 7 factors are designated as letters, from A to G: A- Washing buffer; B- 
Electroporation voltage; C- Growth media; D- Starting cell density (OD); E- Heat treatment; F- 
Electroporation medium; G- Incubation time. The factors B and D, together with the 
interaction between these two factors, generated the highest effect values and are 
highlighted in red.   
 
Increasing the starting cellular OD from 0.1 to 0.5 and incubating the cells 
for 2 hours after electroporation had a positive effect on the transformation 
efficiencies. The importance of these variables can be readily explained. By 
starting with a higher OD, the cell concentration of the electroporation samples was 
increased, which in turn increases the probability of successful transformation to 
occur. Similarly, the longer incubation time after electroporation allowed for more 
replication of the plasmid to occur inside of cells, thereby increasing the 
survivability of cells in antibiotic selective plates.  
On the other hand, electroporation voltage affected the system inversely, as 
raising the voltage resulted in decrease in the efficiency of electroporation. The 
optimized protocol devised by Löfblom et al. (2007) had identified the voltage of 2.1 
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kv/cm as the optimal for electroporation, and consequently increasing the voltage 
would compromise the survivability of the cells. The results from the DoE analysis 
corroborated this assumption.  
On the other hand, the DoE analysis did not identify heat-treatment, wash 
buffer, or electroporation buffer as factors that significantly impacted the 
electroporation process.  
The results from the DoE analysis led for a re-design of the electroporation 
protocol that achieved reproducible transformation of S. carnosus with the vector 
pQR1030. However, the transformation efficiencies were still very low and required 
high plasmid DNA concentrations.  
An alternative method of transformation based on sonication (L. Lin et al. 
2010) was also tested. This method was faster than the electroporation protocol, 
as it did not rely on lengthy incubation periods and wash steps prior to 
transformation. As Gram-positive bacteria, S. carnosus has a structurally robust 
cellular wall that is resilient to physical shear forces. Taking advantage of this 
natural resilience, the sonoporation protocol employed ultrasound to create pores 
on the membrane of cells without compromising the general structure of the 
bacteria.  
Using this method, cells could be directly transformed with plasmid vector 
after overnight growth in B2 medium. The resulting bacterial culture was aliquoted 
into 500 µl samples and mixed with plasmid DNA. Samples were then sonicated at 
a high frequency for 20 seconds, and subsequently re-grown in 5 ml of B2 medium 
for 4.5 hours.  
Transformation efficiencies using this method were comparable to the 
transformation rates of electroporation. Since it did not require complex and time-
consuming pre-treatment steps, this sonication-based method became the 
preferred protocol for vector transformation into S. carnosus. A detailed description 
of the protocol can be found in the materials and methods chapter (see chapter 2, 
section 2.2.6). 
 
 
	   171	  
4.8- pQR1030-mediated Expression of CHMO 
in S. carnosus 
	  
S. carnosus samples transformed with pQR1030 were initially tested for 
CHMO expression by using the NADPH oxidation assays previously described for 
E.coli. Due to the fact that S. carnosus was more resilient to physical stress than 
the Gram-negative counterpart, a higher pressure and increased number of passes 
needed to be applied in the French Press homogenization proccess, in addition to 
a chemical lysis step with lysostaphin at 37 0C. 
Figure 46A shows the results from these experiments. No activity could be 
detected in S. carnosus samples grown for 8 hours in medium containing the 
antibiotic chloramphenicol. This suggested that while pQR1030 was being actively 
replicated, CHMO was either not being expressed inside the cells or that it was not 
active. As this protein is not native for Gram-positive bacteria, there could be the 
possibility that it was not stable inside of S.carnosus and would subsequently 
aggregate into inclusion bodies or be degraded due to miss-folding. Aggregation 
could also be a result of over-expression, and since the staphylococcal rplK 
promoter was located upstream of a ribosomal gene, there was the possibility that 
this promoter was promoting strong constitutive expression of the biocatalyst.  
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Figure 15-  Biocatalysis assays  with S. carnosus TM300 containing the vector construct 
pQR1030. A) NADPH oxidation assay on cell lysates. B) GC analysis of cyclohexanone and 
caprolactone levels in biocatalytic reactions conducted on resting cells. Error bars refer to 
the standard deviation of the experimental set-up, calculated from triplicates of the same 
assay. 
 
To test these hypotheses, the supernatant and pellet fractions from the 
lysed cell cultures were loaded unto an SDS-PAGE gel. The results from this 
experiment showed no difference in the protein profiles between the samples 
containing the pQR1030 vector and the control S. carnosus samples that did not 
contain any plasmid. Over-expression of CHMO would result in a intense band 
around the 60 KB size range after staining, but not difference in intensity of the 
bands around that size were detected on the samples containing the expression 
plasmid.  
Finally, to test if the pQR1030-containing cultures could perform whole-cell 
biocatalysis of the substrate cyclohexanone, 50 ml batches of cultures grown 
overnight were resuspended in 5 ml of Tris-HCl buffer (pH 7.4) containing 10 g/L of 
glycerol and 10 mM of cyclohexanone and subsequently incubated for 6 hours. 
Production of the product caprolactone was monitored through the incubation 
period through GC analysis (figure 46B). The results showed that there was no 
production of caprolactone during the biocatalytic reaction, despite the slight 
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decrease in the concentration of cyclohexanone after the incubation period, which 
was attributed to the evaporation of the volatile compound.  
Together, the results from the GC analysis, NADPH oxidation assays, and 
SDS-PAGE suggested that either the CHMO enzyme was not being actively 
expressed inside S. carnosus , despite the presence of the putative staphylococcal 
rplK promoter upstream from the gene. It was subsequently concluded that this 
staphylococcal promoter had not been correctly selected as a strong genomic 
promoter for heterologous protein expression.    
 
 
4.9- Introduction of Reporter Gene into 
pQR1030  
 
The inability of pQR1030 to express the CHMO protein in S. carnosus 
highlighted the inherent risk in the vector design strategy employed for the 
construction of the vector. Choosing not to rely on staphylococcal promoters that 
were already characterized in the literature meant that expression of the CHMO 
gene could not be guaranteed through the methodology used for promoter 
selection. In fact, the in-silico tools used to screen the staphylococcal genome for 
strong promoters were predictive in nature and did not have a solid empirical 
database to support them. Thus the probability of choosing non-functional 
sequences or sequences that revolve around complex regulatory systems was 
very high.  Fortunately, the modular structure of the vector was designed to 
account for this risk through the inclusion of two distinct restriction sites at the end 
of the staphylococcal promoter that permitted its replacement.   
Therefore, the most accessible solution to the non-expression of CHMO in 
S. carnosus would be to select and test new set of genomic promoters that would 
replace the rplK promoter as active variants. However, using CHMO as a reporter 
gene for the screening of strong promoters was not ideal. As pointed out 
previously, most direct ways to measure CHMO activity required some amount of 
downstream processing that involved time and work-intensive lysis steps. A more 
rapid an immediate way to screen for active promoter sequences in S. carnosus 
	   174	  
would rely on a reporter gene that gave a phenotypical feedback, such as GFP 
(green fluorescent protein) or an antibiotic resistance gene. The feedback would 
provide a quick and direct method of measuring the strength of a promoter without 
the need for downstream-processing protocols.  
A variant of pQR1030 was thus constructed, in which the CHMO gene was 
replaced by the gentamicin resistance gene, aminoglycoside N(3’)-
acetyltransferase I. This gene was chosen because it was readily available, and 
although not being a visual reporter like GFP, it granted a phenotypical change to 
the bacteria that can be directly measured by using gentamicin as a selective 
antibiotic in the growth medium.  
The cloning strategy for this reporter variant, designated pQR1031, was 
slightly different from the method used to construct pQR1030 (Figure 47). The 
gentamicin resistance gene (GenR) was amplified from the vector pR26 using 
primers with XhoI and SphI site overhangs that allowed for cloning into the MCS of 
pQR1030, but the PCR product was subsequently cloned into a commercial TOPO 
vector (Invitrogen) prior to insertion into the expression vector, instead of directly 
cloning the amplified fragment into pQR1030. This extra step was done for two 
reasons: firstly, some restriction endonucleases require extra base-pairs upstream 
and downstream of the restriction sites to cut the DNA efficiently, and the primers 
used for the PCR amplification were not designed with this in mind; secondly, the 
PCR amplification of GenR was not very efficient and resulted in low 
concentrations of the amplified product. Thus, using the blunt-end high-copy 
number TOPO commercial plasmid as a carrier for GenR ensured that the 
restriction with XhoI and SphI worked, and also maximised the concentration of 
GenR by using E. coli cultures as the source of the gene.  
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Figure 47- Ligation strategy for cloning of the gentamicin resistance gene (GenR) into 
pQR1030. The first step involved cloning the PCR-amplified gene into the commercial pCRTM-
BluntII-TOPO® plasmid, which allows for blunt-end cloning. Upon ligation, the inserted gene 
disrupts the expression of the suicidal gene ccdB, thus allowing the survival of cells 
transformed with the positive ligation. The GenR gene is subsequently cut with XhoI and 
SphI  and ligated to the pQR1030 construct, which had been cut with the same enzymes in 
order to remove the CHMO gene. 
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In turn, the ligation of the gene into the expression vector was aided by the 
fact that the restriction of pQR1030 with XhoI and SphI was easily accessed, as it 
generated two distinctly sized bands corresponding to the backbone of pQR1030 
and the smaller CHMO gene. After endonuclease restriction, restricted samples 
were loaded unto an agarose gel and purified by gel extraction. Ligation reactions 
of the pQR1030 backbone with GenR were performed with T4 ligase (NEB) and 
incubated for 1 hour at 37 0C. The ligation samples were subsequently transformed 
into chemically competent E. coli TOP10 cultures, which were selected on 
gentamicin containing plates. In theory, only successful insertion of GenR into 
pQR1030 would grant the gentamicin resistance phenotype through pTac-
mediated expression of GenR. 
Figure 48 shows the screening results from plates of E.coli colonies 
transformed with the ligation product. Cutting the ligation product pQR1031 with 
XhoI and SphI generated two bands of different sizes that corresponded to GenR 
(533 bp), and the plasmid backbone (6.5 kb). Samples containing the correct 
restriction map were also sequenced to confirm that GenR was ligated in frame.   
Once the ligation was confirmed, the vector was transformed into S. 
carnosus and selected on chloramphenicol plates. Since the vector pQR1030 did 
not express the CHMO gene inside the Gram-positive bacteria, it was not expected 
that colonies transformed with pQR1031 would be gentamicin resistant. 
To test if the gentamicin resistance gene could work as a reporter gene to 
measure promoter strength, both pQR1031- containing E.coli and S.carnosus 
cultures grown overnight were plated on agar plates with increasing concentrations 
of gentamicin. Results were expressed as number of surviving colonies after 
overnight incubation (Figure 49), and demonstrated that this gentamicin resistance 
assay was sensitive enough to detect variations of protein expression over small 
gentamicin concentration gradients.   
The colony survival rates for pQR1031-containing E.coli mirrored previous 
expression assays with pQR1030, in which the tight control of the pTac promoter 
by LacI resulted in very low levels of CHMO expression under non-induced 
conditions.  
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Figure 48-  Agarose gel (0.7% w/v) showing the results from a restriction digest of plasmid 
samples from E.coli TOP10 transformed with the ligation products. The predicted restriction 
map of the positive construct pQR1031 is also displayed. Positive ligations would be 
expected to genereate 2 bands when cut with the XhoI- SphI restriction mix, the lower of 
which corresponds to the GenR gene. 
 
On the other hand, the results obtained from the S. carnosus samples 
were unexpected.  Indeed, S. carnosus strains containing the pQR1031 vector 
were not only able to express gentamicin resistance, but they were also able to 
survive higher gentamicin concentrations than their E. coli counterparts. Contrary 
to the studies conducted on pQR1030, these results suggested that the 
staphylococcal rplK promoter was active inside S. carnosus. 
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Figure 49- Gentamicin resistance assay with E. coli TOP10 and S. carnosus  TM300 
containing the pQR1031 construct, as well as with strains not containing any antibiotic 
resistance. The resistance to the antibiotic is expressed in number of colonies in plates 
containing increasing amounts of gentamicin.  Error bars refer to the standard deviation of 
the experimental setup, calculated from triplicates of the same assay. 
 
More relevant to the project was the fact that replacing CHMO with the 
gentamicin resistance gene allowed for the detection of expression from the rplK 
promoter in S. carnosus. While this promoter could not be considered a high 
expression constitutive promoter, the difference in levels of gentamicin resistance 
between the vector-containing S. carnosus strain and un-induced E.coli strain 
suggested that CHMO activity should have been detected in lysates of pQR1030-
containng S. carnosus. The inability to detect any CHMO activity from 
staphylococcal lysates favoured the hypothesis that CHMO was not being stably 
expressed inside S. carnosus. 
Regardless, the gentamicin resistance assays validated the vector 
pQR1031 as a reporter system that could be used for the screening of libraries of 
staphylococcal genomic promoters.  
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4.10- Designing Efficient S. carnosus 
Promoters 
 
The newly constructed reporter vector pQR1031 provided the required tools 
to rapidly and accurately screen large libraries of staphylococcal genomic 
promoters. In order to create these libraries, the promoter selection strategy 
needed to be revised to account for some of its limitations. 
The initial promoter selection strategy relied upon the use of sequences 
upstream from the predicted HEG that could potentially contain strong promoters. 
These sequences were not screened for specific promoter elements but instead 
used entirely as a single expression unit. This was the case of the rplK promoter, 
which was actually the upstream sequence from an putative operon containing the 
ribosomal 30S subunit L-11. The motivation to use entire sequences upstream 
from HEGs was twofold: on one hand it was difficult to pin-point specific promoter 
elements within the sequences because these elements varied greatly from 
consensus bacterial elements in Gram-negative bacteria; on the other hand, these 
sequences upstream of HEGs could contain multiple promoters that would add up 
to the overall transcription activity of the sequence.  
However, there was also a risk associated with the inadvertent selection of 
sequences containing regulatory regions of unknown function that could interfere 
with promoter activity. Since the transcription regulation of S. carnosus has not 
been well characterized, the probability of selecting for un-identifiable regulatory 
sequences was high.  
To mitigate this risk, the promoter strategy was re-designed by applying 
analytical filters to the promoter selection analysis done previously. Sequences that 
had been highlighted previously as potential promoters were actively scanned for 
promoter consensus motifs using promoter recognition software  (BDGP- 
http://www.fruitfly.org/seq_tools/promoter.html, BPROM- 
http://linux1.softberry.com/). In particular, the software searched for regions within 
sequences that shared similarities with the consensus -35 and -10 elements of a 
bacterial promoter that operated under σ70 RNA polymerase transcription. In 
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addition, it also accounted for the optimal distance between these elements, 
whereupon only segments of sequences that contained -35 or -10-like elements at 
17 base pair distance from each other would be considered as potential promoters.  
In reality, there is a broad range of variation to promoter regions outside the 
Gram-negative based consensus used by the software. There have been some 
studies in the literature pointing out the fact that promoter regions in Gram-positive 
bacteria are not as tightly conserved and elements other than the -35 and -10 
recognition sites within the promoter might be more crucial and conserved within 
the Gram-positive promoter (Voskuil 1998; Schofield et al. 2003). For instance, an 
A-rich region upstream of the -35 element and a smaller TXTG motif just upstream 
of the -10 element have been reported to have a function in promoter recognition of 
gram-positive expression systems, and also have been related to the inability of 
promoters with tightly conserved -35 and -10 elements like pTac to express in 
Gram-positive bacteria. One could thus argue that using software that is based on 
a Gram-negative promoter consensus is inadequate to identify promoter regions 
within gram-positive genomes. 
However incomplete this in-silico analysis might be, it was still useful as a 
tool to highlight windows within S. carnosus genomic sequences that might contain 
promoter activity, which could then be complemented with the knowledge of the 
other motifs that are also present in Gram-positive promoters. 
Figure 50 shows the revised promoter selection strategy. In the first steps of 
the strategy, the library of HEGs identified during the first run of promoter selection 
was re-used to identify sequences upstream that could be used as potential 
promotes. These sequences were subsequently filtered through open-source 
software that screened specifically for smaller fragments containing promoter 
elements that fitted several sequence-specific criteria, such as the distance 
between promoter elements and the presence of secondary motifs like AT-rich 
sequences around the promoter elements. These smaller promoter-like fragments 
were then re-designed with additional genetic elements to fit a more conventional 
promoter structure. In many cases the addition of a ribosomal binding site (RBS) 
and restriction enzymes was required. 
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Figure 50- Strategy for screening the S. carnosus genome for putative promoters, in which 
an intermediate step is applied to filter sequences upstream of putative highly expressed 
proteins (HEPs) for specific promoter elements. The shortes sequences containing these 
elements are subsequently designed as 80 to 90 bp promoters by including a RBS 
downstream and restriction sites to allow for the cloning into the synthetic promoter region 
of the shuttle vector. 
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Using this approach to promoter selection, two putative promoters were 
designed with sequences taken from areas of genomic DNA upstream of the 50S 
ribosomal protein L11 (rplK) and the 50S ribosomal protein L10 (rplJ). The choice 
to continue working with the sequence upstream of the protein rplK , even after the 
poor performance of the vector pQR1030, was based upon the idea that the 
revised in-silico screening strategy should be able to identify shorter sequences 
within the rplK upstream region with promoter activity. Therefore, re-designing the 
rplK promoter used in pQR1030 was a way to validate the novel promoter selection 
strategy. In addition, comparison between the activity of the rplK promoter used in 
pQR1030 and the smaller re-designed iteration would be valuable in accessing the 
elements within the staphylococcal region that inhibited pQR1030-mediated CHMO 
expression. 
The sequence immediately upstream of the protein rplJ had been previously 
highlighted as an area of potential strong promoter activity during the first run of 
promoter selection. The high CAI values calculated for rplJ and another ribosomal 
protein, rplL, in close proximity (Figure 51) indicated that the area just upstream of 
both proteins could arbor promoters that catered for two highly expressed proteins. 
In fact, the close proximity between the two genes and the same direction of the 
open reading frames (ORF) suggested that these proteins might in fact operate as 
an operon unit. If this is the case, there is a possibility that a strong promoter was 
inducing the simultaneous transcription of both ribosomal proteins.  
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Figure 51- CAI levels of a set of proteins from S. carnosus , together with the graphical 
representation of the ribosomal proteins rplJ and rplL as organised in the genome of S. 
carnosus (highligted by the red outline). These genes are highlighted in the barchart as a red 
and yellow bar, respectively.    
 
Both of the re-designed promoters were made up of a main fragment 
selected from the genome of S. carnosus, and a RBS, which was also lifted from 
sequences immediately upstream from the starting codons of the rplK and rplJ 
genes. This site was designed 7-8 bps upstream from the protein starting codon to 
allow for efficient translation. EcoRI and XhoI restriction sites were also added to 
the ends of the promoters to allow for the replacement of the rplK promoter in 
pQR1031 (Figure 52).  
In addition to the -35 and -10 promoter recognitions sites, sequences 
upstream of HEGs were also actively screened for nucleotide motifs around these 
sites that had been previously identified as relevant for Gram-positive promoters. 
These include a poly-A sequence located 42 bps upstream from the start of 
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transcription (-42), and a dinucleotide TG motif located around at 16 bps upstream 
from the start of transcription.  
 
 
 
Figure 52- Sequences of the designed rplJ and rplK promoters. The -35 and -10 promoter 
elements are contained within red boxes, while the RBS sequences, which were taken from 
upstream of the respective ribosomal genes, are highlighted by the blue boxes. The green  
boxes contained short-sequence elements that had been previously identified as important 
elements in gram-positive promoters.  
 
The promoters were commercially synthetized as single-stranded short 
oligos that self-annealed upon incubation at 55 0C. To ensure efficient restriction of 
the ends of promoters with the XhoI and EcoRI endonucleases, the promoters 
were subsequently self-ligated using a blunt-end ligation protocol. This step 
resulted in continuous DNA strands of repeating promoter units, separated by 
restriction sites that had enough extra base pairs at the ends to allow for restriction 
with the corresponding endonucleases. 
After restriction, the re-designed promoters were ligated into the EcoRI/XhoI 
restricted backbone of pQR1031, which was gel extracted prior to ligation. Ligation 
was performed with T4 ligase, with ligation reactions being incubated for 1 hour at 
37 0C.  Ligation products were transformed into chemically competent E. coli, 
which were subsequently selected for positive ligations in ampicillin selective 
plates. Positive ligations were confirmed from sequencing of the area around the 
staphylococcal promoter region of the vector (Appendix 1), as the insertion of the 
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smaller promoters into pQR1031 was impossible to access through restriction 
maps due to their size.    
The new constructs pQR1032 and pQR1033, containing the re-designed 
rplK and rplJ staphylococcal promoters respectively, were subsequently transferred 
into S. carnosus and tested for promoter activity.  
 
	  
4.11- The Expression Profiles of pQR1032 and 
pQR1033 in E. coli and S. carnosus 
 
After successful transformation into S.carnosus TM300 and E.coli TOP10, 
the new promoter designs were tested for expression of GenR. In a similar assay 
to the antibiotic resistance assay developed for pQR1031, individual colonies 
containing pQR1032 and pQR1033 were incubated in 2 ml square 96-well plates 
containing liquid media with increasing concentrations of the antibiotic gentamicin 
for 24 hours at 37 0C and 900 rpm. The levels of bacterial resistance to the 
antibiotic were measured as a function of OD at 600 nm.  
As shown in Figure 53, this assay produced very different results from the 
tests done with pQR1031. Accordingly, E. coli strains containing the new 
constructs were able to survive in media containing higher concentrations of 
gentamicin than the pQR1031-containing strain. Since the experiments were 
conducted in the absence of IPTG, and under these conditions pTac-mediated 
expression is greatly inhibited by LacI, it could be concluded that levels of 
survivability observed were a product from the activity of the re-designed 
staphylococcal promoters.   
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Figure 53-  Gentamicin resistance assays performed on E. coli TOP10  (A) and S. carnosus 
TM300  (B) containing the pQR1032 and pQR1032 constructs. Values on the y-axis are 
expressed as optical density of cultures grown overnight at 600 nm. Error bars refer to the 
standard deviation of the experimental setup, calculated from triplicates of the same assay. 
 
The activity of the rplK and rplJ promoters in E.coli was unexpected, since 
the core of these promoters had been lifted from a Gram-positive genome, which is 
a genetically distinct system from its Gram-negative counterparts. However, the 
design of the new promoters was informed by a promoter consensus structure that 
had been based primarily on similarities between Gram-negative promoters, and 
therefore the sequences lifted from the S. carnosus genome might have promoter 
recognition sites that are easily recognized by the E. coli transcription apparatus. 
These results also corroborated previous studies in which E.coli was shown to 
have enough plasticity to work with Gram-positive expression systems.  
The constructs pQR1032 and pQR1033 also resulted in an almost 10-fold 
increase in S. carnosus resistance to gentamicin compared to the pQR1031 vector. 
These results not only validated the revised promoter selection strategy as an 
efficient way of constructing libraries of strong constitutive promoters based on the 
genome of the host cell line, but also corroborated the previous hypothesis that the 
longer staphylococcal promoter sequence in pQR1031 contained genetic elements 
that were detrimental to protein expression.  
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Comparison between the levels of survivability of pQR1032 and pQR1033-
containing S. carnosus indicated that the re-designed rplK promoter was more 
active than the rplJ counterpart. This disparity might be explained by differences 
between the sequences of the promoters. The rplK sequence contains the 
complete  -10 TATAAT box as well as TG motif at position -16 that has been 
previously linked with successful transcription in the Gram-positive Bacillus subtilis 
Inversely, the rplJ promoter contains an intact -35 box (TTGACA), while most other 
promoter elements in the sequence are not as well conserved. This suggests that 
the -10 and -16 recognition sites are more important for promoter strength in S. 
carnosus than other elements further upstream.  
On the other hand, a comparison between the survivability levels of E. coli 
and S. carnosus strains highlights the advantage of using promoter systems that 
are native to the host organism. Despite being active in E. coli, the pQR1032 and 
pQR1033 exhibited higher GenR expression level in S. carnosus, from which the 
rplK and rplJ promoters are native to.  
In the end, by using a combination of in-silico tools that focused on highly 
expressed proteins and on elements that form the structure of a bacterial promoter, 
a library of short genomic promoters was created that could be used for strong 
heterologous protein expression in both E. coli and S. carnosus. This ability to 
screen the host genome for strong promoter elements has immense potential as a 
tool for the creation of promoter libraries that fit a variety of protein expression 
requirement, but unfortunately that potential lies outside of the initial aims of the 
project, i.e. to provide an efficient expression system for CHMO in S.carnosus.   
Consequently, the better of the expression constructs, pQR1032, was 
subsequently used as the expression vector for the CHMO gene.  
 
 
4.12- Concluding Remarks 
 
The construction of a strong expression system for CHMO expression in S. 
carnosus was more time-consuming and problematic than first expected. Part of 
the problem stemmed from the quality of the genetic materials that composed the 
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system. For instance, the first step in the ligation process involved the ligation of a 
synthetic promoter cassette to the vector pTTQ18, and since the synthetic 
component was provided commercially as a pure product ligation was successful 
on the first attempt. On the other hand, subsequent ligation steps required the 
development of several additional protocols to ensure that the genetic material 
being handled was provided in sufficient amounts or with sufficient purity for 
ligation to occur. In particular the handling of genetic material in S. carnosus 
required the creation of efficient processes that would facilitate plasmid extraction 
and transformation. While the development of these processes was time-
consuming and required extensive trouble-shooting, they allowed for an extensive 
characterization of the operational limits of S. carnosus as a cloning system, and 
provided us with tools that could be reliably used. For example, establishing a 
method for the transformation of S. carnosus via sonication proved to be an 
essential for the subsequent transfer of the different expression vectors into the 
Gram-positive bacteria.  
Another problem with the vector construction strategy was the decision not 
to rely on promoters that already been proven to work in S. carnosus, like the 
lipase promoter from the vector pNW21 or the inducible xylose promoter used 
routinely in many other expression systems (Wieland et al. 1995). The choice to 
screen for novel promoters in the genome of S. carnosus originated for a resolve 
not to be constrained by the limitations of these conventional systems, but as a 
consequence increased the risk of ending up with promoters that did not fit the 
necessary requirements, as was the case with the long rplK promoter.   
In-silico tools that allow for the screening of particular elements in the 
genome have an important role in mitigating this risk. The fact that we needed to 
revise our initial screening approach is a testament to limitations of in-silico models 
as predictive tools when trying to account for complexities of a biological system in 
the absence of experimental evidence.  However, by coordinating different in-silico 
approaches we were able to increase our predictive ability, and as a result 
succeeded in discovering sequences in the S. carnosus genome that could work 
as strong constitutive promoters.  
In the end we fulfilled the goal of creating an efficient expression vector, 
while also creating in the process several derivatives of this vector that could be 
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used as rapid screening tools for the mining of promoters from S. carnosus and 
other related bacteria. The next step in the project was to re-clone the CHMO gene 
into the expression vector pQR1032 and to characterize its expression in S. 
carnosus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   190	  
Chapter 5: Results- Study of 
S. carnosus as a Viable Host 
for CHMO Biocatalysis 
 
5.1- Expression of CHMO in E.coli TOP10 
using the Expression Vector pQR1034.   
 
The cloning of the CHMO gene into the vector construct pQR1032 was a 
straight-forward process that involved the replacement of the GenR gene with the 
amplified CHMO gene via a XhoI/SphI restriction and subsequent ligation. A similar 
cloning strategy to the construction of the reporter vector pQR1031 was employed 
for this ligation (see chapter 4, section 4.9). The CHMO was amplified from the 
vector pQR239 with primers containing the necessary restriction sites at the ends, 
and cloned into a pCRTM-BluntII-TOPO® plasmid (Invitrogen) prior to restriction in 
order to maximize restriction efficiencies. After the XhoI/SphI restriction, both the 
CHMO gene and the backbone of pQR1032 were gel extracted, and subsequently 
ligated using T4 ligase (NEB). Ligation reactions were incubated for 1 hour at 37 
0C. The new CHMO expression construct, pQR1034 (Figure 54), was transformed 
into E. coli TOP 10 and confirmed via restriction maps and sequencing (Appendix 
1).  
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Figure	  54-­‐	  Diagram	  of	  the	  pQR1034	  expression	  vector.	  The	  genes	  and	  promoters	  	  in	  the	  diagram	  do	  not	  
represent	  the	  actual	  size	  of	  the	  genetic	  elements.	  The	  CHMO	  gene	  was	  cloned	  into	  the	  plasmid	  pQR1032	  
via	  a	  XhoI-­‐SphI	  restriction	  and	  subsequent	  ligation	  (sites	  highlighted	  in	  red).	  	  
	  
The efficiency of the novel expression vector was subsequently tested on E. 
coli TOP10 to access if the promoter change had indeed resulted in optimized 
expression of CHMO . From the gentamicin resistance assays done previously 
(see chapter 4, section 4.10), it was expected for the re-designed rplK promoter to 
be constitutively active in E. coli, consequently adding to the levels of CHMO 
already expressed under the pTac promoter. The levels of CHMO expression were 
measured by performing NADPH oxidation assays on the lysates of vector-
containing cultures. The detailed protocol for these assays can be found in the 
materials and methods chapter (see chapter 2, section 2.3.4). Figure 55 shows the 
results from NADPH oxidation assays done on E. coli TOP10 containing pQR1034, 
together with results obtained for pQR239 and pQR1030 constructs under the 
same experimental conditions (see chapter 4, section 4.6). 
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Figure 55- NADPH oxidation assays with E. coli TOP10 containing the vectors pQR239, 
pQR1030, and pQR1034. A) NADPH oxidation profiles of biocatalytic reactions performed 
with the lysates of the different expression strains. The y axis expresses the absorbance 
gradient between different time points of the reaction as an absolute number. In reality, the 
gradient is negative because of NADPH oxidation. B) Specific enzymatic activity of CHMO in 
the lysates, calculated as µmol of NADPH oxidized per minute per gram of dry cell weight 
(DCW). Error bars refer to the standard deviation of the experimental setup, calculated from 
triplicates of the same assay. 
 
The activity profiles of the different constructs highlighted the effects of the 
different staphylococcal promoters on CHMO expression. As discussed previously, 
the CHMO activity profile of pQR1030-containing cultures was comparable to the 
control pQR239 strain under IPTG-induced conditions, while in the absence of 
inducer the LacI repressor gene echibited a tight control on the activity of pTac in 
pQR1030 (see chapter 4, section 4.6).  
By contrast, the pQR1034 construct resulted in a significant increase to the 
activity of CHMO in E. coli lysates, at around 88 µmol min-1 gDCW-1 two-fold higher 
than pQR239. This reflected the results obtained with the gentamicin resistance 
constructs, and corroborated the previously drawn conclusion that the re-designed 
rplK vector expressed constitutively in E. coli. Furthermore, the addition of the 
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smaller staphylococcal promoter negated the tight expression control observed 
with pQR1030, as there is no difference in activity between pQR1034 samples in 
the presence or absence of IPTG.  
The differences in activity between the pQR1034 and the pQR1030 lysates 
might account for the individual activities of both pTac and rplK promoters. Since 
the former is tightly controlled by the LacI repressor system, the CHMO activity 
observed in lysates of the pQR1034 construct might be conclusively attributed to 
the combined activity of the pTac and rplK promoter.  
While CHMO has not been previously reported to be toxic to E. coli when 
overexpressed, there was still the possibility that the increased expression of 
CHMO using pQR1034 could be inhibiting to cell growth. To study this hypothesis, 
the growth kinetics of E. coli TOP10 containing the expression vector pQR1034 
were compared to the same strain containing the plasmid construct pQR1030. 
Colonies containing the different vector constructs were grown overnight in 5ml of 
LB medium, and subsequently transferred to 250ml baffled shake flasks containing 
50 ml working volume of LB medium with 100 µg/ml of ampicillin. The inoculated 
shake flasks were then incubated at 37 0C and 250 rpm for 8 hours.   
Figure 56 shows the growth curves of E. coli TOP10 strains containing the 
CHMO expressing vector pQR1034 and the tightly controlled vector pQR1030. As 
it can be seen from the results, the maximum growth rates (µmax) were comparable 
between the two strains, albeit the pQR1034 took longer to start exponential 
growth. Alternately the total biomass concentration was lower for the pQR1034 
strain, at 0.73 g DCW when compared to 0.93 g DCW achieved by the pQR1030 
counterpart. Together, these results suggested that the increased constitutive 
overexpression of CHMO induced by the staphylococcal rplK promoter negatively 
affected the growth of the E. coli host. This could be explained by a stronger 
metabolic burden exerted by the constitutive protein expression on the cell.  
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Figure 56- Growth profiles of the E. coli strains containing the expression vectors pQR1030 
and pQR1034. The µmax values were 0.787 h-1 and 1.068 h-1, respectively. Error bars refer to 
the standard deviation of the experimental setup, calculated from triplicates of the same 
assay. 
 
Another parameter that could be affected by the increased expression of 
CHMO was the stability of the biocatalyst inside the cell. In most of the NADPH 
oxidation assays, the lysate samples had been collected 8 hours after incubation, 
in a period when bacterial growth is transitioning from exponential to stationary 
phase.  This is the period in which cellular density has reached its maximum. As 
the fermentation progresses into the stationary phase, several nutrients in the 
medium that are used as a carbon source become limiting and bacterial cells shift 
the metabolic machinery from protein expression to stress-induced survival, thus 
stopping bacterial growth and heterologous protein expression. Under these 
conditions, the active population of over-expressed heterologous proteins is 
expected to decrease, as a combined result from the decreased metabolic 
production and the cell-mediated degradation of proteins into constituents that can 
be used as raw material for other metabolic processes.  
The results from Figure 57, obtained from NADPH oxidation assays 
conducted on pQR1034 E. coli lysates after 8 and 24 hours of incubation, showed 
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that after 24 hours of bacterial growth in shake flasks, in which no extra carbon 
source was added, the activity of CHMO was dramatically reduced in both strains. 
This clearly indicated that the biocatalyst was not stable inside bacterial hosts after 
a prolonged period of stationary growth. On the other hand, pQR1034 still exhibited 
a higher biocatalyst expression after 24 hours of growth, from which it could be 
concluded that the increased expression induced by the rplK promoter was not 
detrimental to the stability of CHMO.  
  
 
Figure 57- NADPH oxidation profiles of the pQR1034 E. coli lysates collected after 8 and 24 
hours of bacterial growth. The specific enzymatic activity was reduced from 88 µmol min-1 
gDCW-1 to 2 µmol min-1 gDCW-1 after 24 hours of incubation. Error bars refer to the standard 
deviation of the experimental setup, calculated from triplicates of the same assay. 
 
To check if the increased protein expression resulted in the production of 
inclusion bodies, SDS-PAGE protein gels of the supernatant and pellet fractions 
from lysed bacterial cultures after 8 hours and 24 hours were performed (see 
chapter 2, section 2.3.3). Unfortunately, the results (Figure 58) did not show a 
significant difference in expression profiles between cultures containing the vector 
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pQR239, pQR1034, and an E. coli strain that did not express CHMO.  The inability 
of the SDS-PAGE to differentiate between the expression levels of pQR1034 and 
pQR239 might be due to the fact that CHMO concentration inside the cells did not 
account for a large proportion of total protein content and therefore could not be 
discerned from other metabolic proteins of similar molecular weight. Regardless, 
the NADPH activity results clearly indicate that the increased protein expression 
from pQR1034 is not detrimental to the stability of CHMO inside E. coli TOP10, 
and therefore it was assumed that any increase in inclusion body formation would 
be counteracted by increasing levels of active biocatalyst.  
 
 
Figure 58- SDS-PAGE gel with fractions from E. coli cultures containing the expression 
plasmids pQR1030, pQR1034 and a control that did not express CHMO. Lanes 1 to 6 
correspond to the supernatant fractions of lysates from the cultures, while lanes 7 to 12 
correspond to the pellet fractions. Lanes 1, 2, 7 and 8: E. coli control; lanes 3, 4, 9 and 10: E. 
coli pQR1030; lanes 5, 6, 11 and 12: E. coli pQR1034. The red traced line indicates the 60 Kb 
threshold, below which one would expect to see over-expression of the 59 Kb biocatalyst.  
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5.2- NADPH Oxidation Profiles of S. carnosus TM300 
Transformed with pQR1034. 
 
The gentamicin resistance assays with S. carnosus TM300 containing the vectors 
pQR1032 and pQR1033 indicated that the introduction of the smaller rplK and rplJ 
promoters had resulted in 7 times increase in protein expression level compared to 
the initial construct pQR1030 (see chapter 4, section 4.9). As a result, similar 
results were expected when testing for CHMO activity in staphylococcal strains 
transformed with pQR1034. NADPH oxidation assays were performed on lysates 
of S. carnosus using the same reaction protocols as those used in previous 
biocatalytic assays. Despite the use of several different protocols for the production 
of lysates, no biocatalytic activity was detected on the supernatant fractions of the 
staphylococcal lysates (Figure 59). These results suggested that either CHMO was 
not being expressed or that the lysis methods used were detrimental to biocatalytic 
activity 
 
	  
Figure 59- NADPH oxidation profiles of lysates from S. carnosus cultures containing the 
expression vector pQR1034 in the presence and absence of the substrate cyclohexanone. 
The y axis expresses the absorbance gradient between different time points of the reaction 
as an absolute number. Error bars refer to the standard deviation of the experimental setup, 
calculated from triplicates of the same assay. 
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In fact, the use of mechanical disruption methods did not produce efficient 
breakage, and required the use of extreme shearing conditions. Efficient sonication 
of cells was only achieved using a frequency of 20 KHz for periods of 30 seconds, 
which not only generated high levels of shear stress but also resulted in an 
increase of the overall sample temperature. Samples were sonicated in an ice 
water bath to prevent overheating, but even with this precautionary measure, the 
temperature of samples still rose above 37 0C during the sonication process. 
French Press induced cell lysis is a less stressful alternative to sonication that 
relies on cell disruption by pressure gradients, and thus generates less shear 
stress on cells. In addition, the cylinder cell that holds the sample is pre-chilled, 
preventing any over-heating that might occur during the disruption process. As a 
result, French press homogenization was the preferred mechanical lysis method to 
minimize any stress to the proteins in the supernatant that could kill CHMO activity. 
However, using the French Press to lyse the samples at a pressure of 1500 bar 
resulted in a very low degree of disruption when compared to the sonication 
protocol (data not shown). The supernatant obtained from this procedure also did 
not exhibit any biocatalyst activity, which suggests the lack of CHMO activity was 
due to translation or transcription problems, rather than detrimental effects from the 
lysis steps.  
Alternately, staphylococcal samples were also treated with a lysostaphin 
containing buffer prior to mechanical lysis in order to weaken the cell wall structure, 
and consequently facilitate lysis. Similarly to results obtained with the other 
protocols, the supernatant fractions from samples disrupted in this manner did not 
exhibit any CHMO activity.  
Together, the results from the NADPH oxidation assays hinted at the 
possibility that either CHMO was not being correctly expressed in S. carnosus 
TM300, or that it is not intracellularly stable. Alternately, another explanation for the 
lack of activity in the supernatant fraction of S. carnosus could be that the assay 
developed for measuring CHMO activity through NADPH oxidation raters was not 
applicable to the staphylococcal system. This possibility was unlikely, since 
reaction buffer used in the assays is optimal for activity of the CHMO, and the ratio 
in which the buffer was added to the supernatant fractions (4 volumes of buffer to 1 
volume of supernatant) would be sufficient to dilute and negate any detrimental 
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effects that the supernatant environment might have on the activity of CHMO. On 
the other hand, there was very little information about proteins natively expressed 
in S. carnosus that could compete with CHMO for binding to NADPH, or that could 
work as a efficient NADPH recycling system.  
In order to access if the results obtained in the oxidation assays were due to 
shortcomings in the methodology, or were the result of inherent limitations of the 
S.carnosus host, whole-cell biocatalytic studies were conducted on both E.coli and 
S. carnosus strains containing PQR1034. Analyzing the activity of CHMO in 
growing cells would give a clear indication of whether the biocatalyst was not being 
expressed at all, or if it had a very short half-life upon translation and folding. 
 
 
5.3- Whole-Cell Biocatalysis of E. coli and S. 
carnosus containing pQR1034. 
	  
Most of the enzyme activity data produced for the expression vector 
pQR1034 had been obtained from measuring the oxidative activity of biocatalyst in 
lysates, which while being a fast and reliable assay to measure for activity, does 
not represent the conditions in which CHMO would be operating in a whole-cell 
biocatalytic process. As a result, in order to get a clear picture of how the 
biocatalyst expression profile of pQR1034 would affect the efficiency of whole-cell 
biocatalysis, whole-cell biocatalytic assays were performed on vector containing 
bacterial strains. In addition, as stated above, performing whole-cell biocatalysis 
with growing S. carnosus cells would give a stronger indication of whether the 
CHMO was expressed and stable in the intracellular environment.  
Whole-cell biocatalysis was done using E. coli and S. carnosus strains in 
both active growth and in the resting state. For biocatalysis with growing cultures, 
colonies of the bacterial strains were inoculated in 5 ml of NBn2 and grown 
overnight, and subsequently transferred to 500ml shake flasks containing 100ml of 
working volume of NB2 medium with the respective selective antibiotic and 20 mM 
of the substrate cyclohexanone. The inoculated flasks were incubated for 24 hours 
at 37 oC and 250 rpm, with samples being taken at specific time points during the 
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fermentation. These samples were subsequently used for the GC analysis of 
cyclohexanone and ε-caprolactone concentrations present in the supernatant of 
grown cultures (see chapter 2, section 2.3.6). Results from the whole-cell 
biocatalysis of growing cultures were expressed as substrate and product 
conversion rates.  
From the NADPH oxidation assays, it was expected for the E. coli TOP10 
strain containing the vector pQR1034 to exhibit a biocatalytic activity profile that 
was linearly correlated to the strain’s growth profile. The results from Figure 60B 
show that this prediction was correct. The highest rate of substrate conversion was 
observed during the exponential phase of bacterial growth, in which intracellular 
protein production was at its highest level. Similarly, as bacterial growth reached 
the stationary phase, the substrate conversion rate was also dramatically 
decreased, but not halted completely. This result re-iterated the hypothesis that 
CHMO has a short half-life inside of E. coli strains. 
Alternatively, the decrease in the conversion rates could be due to product 
inhibition, as it has been previously reported that increasing concentrations of 
caprolactone inhibit CHMO activity (Doo et al. 2009). However, the total 
caprolactone concentration generated from the biocatalytic reaction did not reach 
the threshold at which it starts being inhibiting to cyclohexanone conversion.  
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Figure 60- Cyclohexanone and caprolactone concentration levels in whole-cell biocatalytic 
reactions performed on E. coli cultures containing the expression vector pQR1034, in the 
resting state (A) and actively growing  (B). The growth profile cultures performing 
bioconversion under active growing conditions were also included in the plot chart. Initial 
concentration of cyclohexanone was 20 mM.  Error bars refer to the standard deviation of 
the experimental setup, calculated from triplicates of the same assay. 
 
By contrast, the GC analysis of samples from the biocatalytic reaction using 
the S. carnosus strains showed that no substrate conversion took place during the 
24 hours incubation (Figure 61B). The slight decrease in cyclohexanone 
concentration observed in the first hours of the reaction can be attributed to either 
measurement errors or evaporation of the substrate cyclohexanone, which has a 
low boiling point.  The inability of the S. carnosus strain to convert the substrate 
corroborated the results from the NADPH oxidation assays, and hinted at several 
possible limitations of the S. carnosus pQR1034 biocatalytic system   
One possible limitation would be for the biocatalyst to have a very short half-
life inside the staphylococcal strain. If CHMO was actively expressed but suffered 
from a short half-life inside the cells, a small level of caprolactone conversion 
should still be detected in the first hours of the fermentation. However, the thick 
peptidoglycan cell wall might also work against cyclohexanone conversion by 
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imposing a barrier to the diffusion of the substrate into the intracellular space. A 
slow diffusion rate across the membrane coupled with the short half-life of the 
biocatalyst could account for the absence of any product formation.   
Alternatively, the expression vector pQR1034 might not be stable inside the 
staphylococcal cells, even under antibiotic selection, thus preventing CHMO 
transcription. This possibility seemed unlikely, since both precursor vectors 
pQR1032 and pQR1333 still granted the staphylococcal host with a gentamicin 
resistant phenotype, in spite of any possible genetic instability.  Unfortunately, the 
data obtained from the biocatalysis experiments was not sufficient to clear picture 
of what factors might be contributing to the lack of CHMO activity in S. carnosus.  
 
 
Figure 61- Cyclohexanone and caprolactone concentration levels in whole-cell biocatalytic 
reactions performed on S. carnosus cultures containing the expression vector pQR1034, in 
the resting state (A) and actively growing  (B). The growth profile cultures performing 
bioconversion under active growing conditions was also included in the plot chart (B).  Error 
bars refer to the standard deviation of the experimental setup, calculated from triplicates of 
the same assay. 
 
The resting state biocatalysis was performed using bacterial cultures grown 
under similar conditions to those described above, with the exception that cells 
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were grown in the absence of the substrate cyclohexanone and collected after 8 
hours of growth at the point of transition from the exponential to stationary phases.  
Cells were subsequently resuspended in a tenth of the initial volume of reaction 
buffer (50 mM phosphate buffer, pH 7) containing 10 g/L glycerol and 20 mM 
cyclohexanone. The resulting reaction samples were re-incubated for 8 hours at 30 
oC and 250 rpm, with samples being taken at time points throughout the incubation 
for subsequent GC analysis. Figure 60A shows the results obtained from this 
biocatalytic process. Reactions done with the pQR1034-containing E.coli TOP10 
strain achieved total conversion of cyclohexanone after six hours of incubation, 
with a maximum specific whole-cell CHMO activity of 8.7 µmol of caprolactone min-
1 g DCW-1. Since NADPH consumption is stoichiometrically linked to caprolactone 
production, with a 93% to 100% molar yield of caprolactone on NADPH 
consumption (O’Sullivan et al. 2001), the activity obtained from this assay could be 
compared to the  NADPH oxidation rate obtained from the NADPH oxidation 
assays with the same bacterial strain, which was calculated to be 87.8 µmol  min-1 
g DCW-1 This comparison revealed an 10 times activity loss when biocatalysis was 
performed in the whole-cell system, which also had been reported for the pQR239 
whole-cell biocatalytic system (Doig et al. 2003).   
S. carnosus cultures used in the resting-cell biocatalysis did not produce 
any lactone product during the 8 hours of reaction (Figure 61A). This was to be 
expected from the previous assay using actively growing cells. SDS-PAGE gels of 
these samples did not indicate overexpression of the CHMO protein in either the 
supernatant or pellet fractions, further suggesting that the biocatalyst was not being 
expressed in the cells or only at very low level. However, these results were 
inconclusive and unreliable, as no overexpression could be detected in the SDS-
PAGE gels of E.coli samples as well. 
Faced with the inability to generate biocatalytic activity in S. carnosus 
TM300 containing pQR1034, it was decided that the best course of action would be 
to focus on some of the possible factors that could be responsible for this lack of 
activity.  
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5.4- Toxicity of Cyclohexanone and 
Caprolactone on E.coli TOP10 and S. 
carnosus TM300  
 
One of the possible factors affecting cyclohexanone bioconversion in S. 
carnosus is the permeability of the cell wall to the substrate.  The affinity of a 
chemical compound to the cell’s lipid membrane and to the extracellular medium 
dictates its rate of diffusion across the cell wall into the intracellular space, where 
the biocatalytic process is performed.  In many biocatalytic processes the cell wall 
becomes the main barrier to substrate accessibility, and therefore its affinity to the 
lipid membrane becomes a major limiting factor in the efficiency of whole-cell 
biocatalysis (Ni & Chen 2004). However, a compound’s affinity to the lipid 
membrane is also directly related to its toxicity. Lipophilic compounds will 
inherently have a tendency to accumulate in the lipid membrane, which in extreme 
cases can cause pore formation, as well as loss of membrane function and 
structure (Sardessai & Bhosle 2002; de Bont 1998; Leon et al. 1998). Thus, the 
toxicity of a compound can be used indirectly as a measure of membrane 
permeability to that compound. 
Several cyclic ketones used in CHMO-mediated oxygenation have been 
previously reported to be moderately toxic to E. coli biocatalytic process (Doo et al. 
2009; Hilker et al. 2008) due to their lypophilic nature. To test if the permeability of 
staphylococcal cell wall to these compounds was comparable to E. coli, the 
tolerance of E.coli TOP10 and S. carnosus TM300 to cyclohexanone and 
caprolactone was measured by growing both strains in the presence of inhibitory 
concentrations of these compounds. Similar tolerance profiles between the strains 
would suggest that they have similar permeability to the compounds involved in 
CHMO biocatalysis. 
For this purpose, colonies we cultured overnight in 5 ml of NBn2, and the 
resulting cultures were transferred to shake flasks containing a working volume of 
100ml. The shake flasks were incubated for 8 hours at 37 oC and 250 rpm, and OD 
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measurements (600nm) were taken at specific time points during the incubation. In 
an first set of experiments, different concentrations of the cyclohexanone 
precursor, cyclohexane (C6H12), were added at the beginning and during shake 
flask incubation. Cyclohexane is a cyclic compound with a log P of 3.4, which lies 
within the window of toxic compounds that can diffuse and accumulate in the lipid 
membrane. In fact, cyclohexane is more aggressive to the cells than either 
cyclohexanone or the product caprolactone, and therefore using this chemical 
compound would give a good indication of difference in the permeability of the 
difference strains to this type of compounds. Figure 62 shows the results from the 
tolerance assays with cyclohexane. In the bacterial batches where cyclohexane 
was added at the beginning of the shake flask incubation, bacterial growth was 
completely halted upon addition of 100mM of the cyclic compound until after 6 
hours of incubation. Once cultures started growing, S. carnosus showed a faster 
recovery rate (0.25 h-1) than its E. coli counterpart (0.08 h-1).  
 
 
Figure 62- Growth profiles of E. coli TOP10 (A) and S. carnosus TM300 (B) cultures grown 
with increasing concentrations of cyclohexane, which was added at the beginning of 
incubation. Error bars refer to the standard deviation of the experimental setup, calculated 
from triplicates of the same assay. 
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This suggested that the Gram-positive bacterium is either less permeable to 
cyclohexane or it contains faster mechanisms of adaptability to the toxic effects of 
the cyclic compound. On the other hand, the different growth rates observed after 
hour 6 might have resulted from a decrease of cyclohexane concentration in the 
medium due to evaporation, together with the different inherent growth profiles of 
the two bacterial strains 
The data obtained from the tolerance assays using lower concentrations of 
the toxic compound is more conclusive in showing the tolerance differences 
between the two strains, as in these cases bacterial growth is affected but not 
stalled. Indeed, as cyclohexane concentrations added were increased, a more 
pronounced decrease of the maximum growth rates of E. coli cultures was 
observed, from 3.86 h-1 to 1.96 h-1.  By contrast, the maximum growth rate of S. 
carnosus cultures incubated with increasing concentrations of cyclohexane was not 
as severely affected. A concentration of 50 mM of the compound resulted in a 
small decrease of the maximum growth rate from 2.89 h-1 to 2.52 h-1. Together, 
these results corroborated the suggestion that S. carnosus is more tolerant to 
cyclohexane, either through cellular mechanisms that allow for adaptability to toxic 
lipophilic compounds, or through differences in cell wall permeability to these 
compounds.  
Similarly, adding an inhibitory concentration of cyclohexane to actively 
growing cells produced a stronger effect on the E. coli cultures. Cyclohexane was 
added after 3 hours of incubation, at the beginning of the exponential phase. At this 
time point, cells were in a state of high metabolic activity and consequently their 
ability to rapidly adapt to toxic compounds was greater than during the lag phase. 
Conversely, the addition of cyclohexane during the exponential phase had a 
stronger effect on bacterial growth of both strains than addition of the compound at 
the beginning of incubation (Figure 63).  
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Figure 63- Growth profiles of E. coli TOP10 (A) and S. carnosus TM300 (B) cultures grown in 
the absence and presence of 50 mM of cyclohexane. The compound was added after 
cultures reached a specific OD (as indicated by the red arrow).  Error bars refer to the 
standard deviation of the experimental setup, calculated from triplicates of the same assay. 
 
Adding 50 mM of cyclohexane after 3 hours of incubation had a strong negative 
effect on E. coli growth, as its growth rate became negative after the addition. 
Conversely, cyclohexane had a stationary-phase-like effect on the growth of S. 
carnosus cultures by stalling the growth rate. However, a pronounced decrease in 
cell density was only observed after 5 hours of incubation, at which point cultures 
were transitioning from exponential growth to the stationary phase.  
Alternately, a correlation could be drawn between the effect of cyclohexane and 
the overall growth of the bacterial strains. The fact that S. carnosus cultures 
showed higher growth rates than the E. coli counterpart under the experimental 
conditions of these assays could explain the lower rates cyclohexane-induced 
growth inhibition. Therefore, the increased tolerance of S. carnosus to cyclohexane 
could be the result of the better overall growth of this strain, instead of differences 
in permeability or adaptability mechanisms.  This directly contradicted the results 
from experiments in which cyclohexane was added at the beginning of incubation, 
wherein the two bacterial strains exhibited similar growth rates.  
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It is worth noting that cyclohexane was not very soluble in aqueous solution, and 
consequently to facilitate homogeneous mixing of the latter 1% (v/v) of the 
surfactant X-Triton 100 was added to the cultures. At this concentration, the 
surfactant was shown to be toxic to cells on its own, and as a result the toxicity 
observed in the cyclohexane assays is in fact the combined effects of cyclohexane 
and X-Triton 100. 
A second set of tolerance assays was done on the compounds directly used in the 
CHMO biocatalysis assays throughout this project, cyclohexanone and ε-
caprolactone. With a log P value of 0.81 and 0.61, respectively, these compounds 
are water miscible, and therefore no surfactant was added to the cultures. In 
addition, these compounds are much less lipophilic than the precursor 
cyclohexane, and consequently less toxic. The assays were performed under 
similar conditions to those described for the cyclohexane tolerance assays, but the 
compounds were only added during the exponential phase of bacterial growth. 
Figure 64 shows the results obtained from these assays. Unlike the cyclohexane 
assays, strong inhibition was only observed around 2 hours after addition of the 
chemicals. Even so, the results showed that the E. coli strain was generally less 
tolerant to increasing concentration of the compounds than the staphylococcal 
counterpart. In particular, bacterial growth of E. coli was completely stopped after 
the addition of 100 mM of cyclohexanone, which was not the case for S. carnosus. 
In addition the disparity between the tolerance of the bacterial strains to 
cyclohexanone and ε-caprolactone could not be explained by differences in growth 
rates, which were comparable throughout the assays.   
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Figure 64- Growth profiles of E. coli TOP10 (A) and S. carnosus TM300 (B) cultures grown 
with increasing concentrations of either cyclohexanone or caprolactone. The compounds 
were added to cultures after reaching a specific OD (as indicated by the red arrow). Error 
bars refer to the standard deviation of the experimental setup, calculated from triplicates of 
the same assay. 
 
   The tolerance to caprolactone was higher in both strains than tolerance to 
cyclohexanone. This corroborates predictions based on the log P values of the 
compound, under which caprolactone is the less lipophilic compound, and 
therefore should not accumulate in the cell membrane as readily as 
cyclohexanone. Together, these results indicated that S. carnosus is more tolerant 
to the substrate and product from CHMO biocatalysis that had been used in whole-
cell biocatalytic assays. This higher tolerance when compared to E. coli might be a 
result of either better mechanisms for neutralization or adaptation to the toxic 
compounds, or lower permeability to the compounds. However, the results also 
suggest that the cell wall of S. carnosus is not completely impermeable to the 
diffusion of cyclohexanone and caprolactone, otherwise no toxic effect would be 
observed on bacterial growth of this organism. However, these results don’t rule 
out the possibility of low diffusion rates of these compounds across the 
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staphylococcal membrane being a limitation for CHMO-mediated whole-cell 
biocatalysis. 
 
 
5.5- Plasmid Stability Assays with pQR1034  
 
Another factor that could affect expression of CHMO in S. carnosus is the 
instability of the expression vector pQR1034 inside the staphylococcal strain. 
Transformation of hybrid plasmids into S. carnosus had been previously reported 
to be difficult due to the fact that the organism has mechanisms in place to degrade 
DNA it recognizes as foreign (Löfblom et al. 2007). Therefore, there is the 
possibility pQR1034 is genetically and structurally unstable in S. carnosus due to 
the Gram-negative portion originated from the pTTQ18 vector, which encompasses 
a large percentage of the vectors’ genetic content. 
Correspondingly, the total GC content of pQR1034 is 46.1%, which is 
around 12% higher than the native genome of S. carnosus. A similar argument 
could be made for the GenR expression vectors pQR1032 and pQR1033. 
However, the fact that these vectors allowed for the phenotypic expression of 
gentamicin resistance in S. carnosus, together with the fact that the 
chloramphenicol antibiotic used in all the biocatalytic assays as a selection factor 
were strong counter-arguments to vector instability being the reason for lack of 
CHMO activity. Nonetheless, this possibility was tested by growing S. carnosus 
cells containing the vector pQR1034 for 3 days under non-selective conditions.  
Samples were taken at different time points throughout the process and 
plated on plates with and without chloramphenicol, which were subsequently 
incubated overnight. The percentage of plasmid loss during the incubation period 
was derived from the difference between the number of colonies grown on plates 
with antibiotic selectivity and the total number of colonies, which were grown on 
plates without antibiotic. These assays were conducted with E. coli pQR1034 and 
pQR1030, as well as the staphylococcal vector pCT20, which was used for 
comparison of a genetic system containing the same origin of replication as 
pQR1034. Cultures from the different strains were grown in 50 ml Falcon tubes 
	   211	  
containing 5ml of NB2 medium, which was replaced every 24 hours by inoculating 
1 ml of the overnight cultures into fresh media. No antibiotic selection was used 
throughout the incubation period.    
 
 
Figure 65- Plasmid stability assays with bacterial cultures incubated for 3 days in the 
absence of antibiotic selectivity. A) E. coli  TOP10 cultures containing the expression 
vectors pQR1030 and pQR1034. B) S. carnosus TM300 cultures containing the expression 
vector pQR1034, as well as the staphylococcal plasmid pCT20. Error bars refer to the 
standard deviation of the experimental setup, calculated from triplicates of the same assay. 
 
Figure 65 shows the results from the plasmid stability assays with the 
different bacterial strains. From these results, it could be observed that the vector 
pQR1034 was relatively stable in E. coli, with levels of surviving colonies 
fluctuating between 20 and 25 % of total number of colonies after 16 hours. If it 
was assumed that at the start of the experiment the total number of colonies would 
be equal to the number of colonies containing the vector, it could be subsequently 
concluded that there was a large plasmid loss in the first 16 hours of incubation. 
However, this initial instability cannot be attributed to overexpression of the 
biocatalyst CHMO, as the tightly controlled expression vector pQR1030 also 
exhibited a similar degree of plasmid loss during the first 16 hours of incubation. 
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Despite the initial drop, the levels of plasmid-containing colonies was maintained at 
around 20% of total number of colonies throughout the rest of the incubation 
period, suggesting that the plasmid constructs were stable in the E. coli strains 
after the first 16 hours of incubation.  
Similarly, the results showed that the pQR1034 vector was stable in S. 
carnosus throughout the incubation period, with around 80% of the total number of 
colonies still containing the plasmid after 3 days of incubation. This stability 
outperformed results from assays conducted on the native staphylococcal vector 
pCT20, which was present in less than 40% of the total colony population by the 
end of the incubation. Therefore, from these results it could be concluded that the 
expression vector is stable in S. carnosus despite the presence of foreign DNA and 
the different GC content. As a result, the lack of CHMO activity in S. carnosus 
could not be explained by vector instability.   
 
 
5.6- Trouble-shooting CHMO Expression in S. 
carnosus 
 
Both the whole cell biocatalytic assays and NADPH oxidation assays 
suggested that CHMO was either not stable in the intracellular environment of S. 
carnosus, or that the gene was not being correctly transcribed or translated. 
Conclusions could not be drawn either way due to the fact that the supernatant and 
pellet fractions of samples loaded unto SDS-PAGE gels were inconclusive as to 
whether CHMO was present. This was even the case in the E. coli strains where a 
high degree of activity could be observed.   
Correspondingly, one of the first and crucial experiments to be done in 
trouble-shooting the expression of CHMO in S. carnosus would be to perform 
western blots of the E. coli and S. carnosus strains containing the expression 
vector pQR1034. Western-blots are quantitative experiments that allows for the 
quantification of a protein fraction in a protein gel by using fluorescent antibody 
markers that bind to specific recognition sequences on the target protein. A 
common practice is to use an anti-poly histidine monoclonal antibodies that target 
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his-tags on proteins, and are attached to a horseradish peroxidase that allows for 
the subsequent detection of the bound protein by converting a soluble substrate 
into a visible product that accumulates around the area where the protein diffused 
in the gel. A linear correlation can then be established between the intensity of the 
visible signal and the amount monoclonal antibody body bound to the tag of the 
protein, which in turn is proportional to the amount of protein in the samples. Thus, 
Western blotting is a very important experiment to conduct, because it would allow 
not only for the detection of CHMO in the different fractions of S. carnosus cell 
lysates, but would also give an estimate of the biocatalyst concentration in these 
fractions. 
To this effect, the CHMO gene in pQR1034 was replaced with an his-tagged 
homolog, which would serve as the marker for binding of anti-poly histidine 
monoclonal antibodies to the protein during the western-blot protocol. The 
positioning o f the his-tag in the C-terminus of CHMO has been shown previously 
not to be detrimental to its activity, and therefore introducing this tag should not 
interfere or change our previous characterization of CHMO activity in the different 
expression constructs. Unfortunately, the western-blot experiments could not be 
conducted due to time constraints, and therefore would have to be performed in 
future studies with the S. carnosus constructs.  
Western blots of S. carnosus cultures containing pQR1034 would answer 
several questions. Primarily, they would allow for a direct assessment of the levels 
of pQR1034-mediated CHMO expression inside the staphylococcal strain. 
Subsequently, the results would enable the analysis of the stability of the 
biocatalyst in the intracellular environment by measuring the distribution of CHMO 
within the different fractions of lysate samples. Correctly folded and stable protein 
would be primarily present in the supernatant fractions, whereas aggregates would 
be partitioned into the pellet fractions. Inclusion bodies, which are highly dense 
miss-folded protein aggregates, would be mainly present in the insoluble fraction of 
lysates.  
Western blots would be conducted not only on samples after 8 hours of 
incubation, but also on samples taken at time points throughout culture 
fermentation in order to test the theory that the CHMO is being actively degraded 
by native proteases. If this theory is correct, we would expect to see a low 
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peroxidase signal in the first hours of growth, followed by either a decrease in 
signal throughout the rest of the incubation period or a stable, non-fluctuating 
signal that corresponded to an equality between the rates of protein expression 
and the rates of proteolytic digestion. Depending on the results of the Western 
blots, several other experiments would be performed (Figure 66).  
 
 
 
Figure 66- Diagram representation of the outcome of the western blot experiments and the 
factors that could be studied dependent on these out-comes.  
 
One possible outcome of the western blots could be for most of the 
overexpressed CHMO to be either miss-folded or aggregated into inclusion body. 
This could be symptomatic of a high level of rplK-mediated constitutive expression, 
as the native chaperone activity would not be able to cover for the correct folding of 
increasing levels of heterologous proteins. A way to test the effect of native 
chaperone concentrations on the folding of the overexpressed CHMO would be to 
grow cultures at different temperatures, or after heat-shock treatment. Chaperones 
are housekeeping genes that are highly expressed in situations of stress to the 
native organism as a measure to protect the integrity and stability of native 
proteins. This increase in expression can be triggered by heat-shock events, i.e. 
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when there is a sudden temperature fluctuation, or by growing cultures in sub- or 
above- optimal growth temperatures. Since the temperature used in all growth and 
biocatalytic assays in this project was maintained constant at 37 oC, the effects of 
native stress response in S carnosus to the expression of CHMO has not yet been 
tested.  
Correspondingly, one experiment to be conducted would involve using a low 
temperature in the initial lag stages of S. carnosus shake flask incubation, followed 
by a drastic shift of temperature during the exponential phase, which expectedly 
would trigger chaperone overexpression. Incubation of bacterial cultures at lower 
temperatures than 37 oC could also be conducted as a means to decrease the 
rates of protein over-expression, thus increasing the time window for the proteins 
to be properly folded. Temperatures such as 30 oC and 25 oC have been routinely 
used for E. coli cultures wherein heterologous proteins are highly expressed, or are 
unstable and consequently require a longer post-translation processing time to be 
folded properly. 
The composition of media used for bacterial growth could also be a factor 
contributing to the levels of protein expression. Thus, another experiment could 
revolve around the effects of different media, such as NB2 or B2, and other more 
minimal media, on the expression of CHMO. Subtle differences in the medium 
composition, such as the salt concentrations, carbon source levels, and pH, 
change the manner in which cells react to the extracellular environment, and 
consequently their ability to express stable heterologous proteins.  
For instance, the pH of external media might have a direct impact on the 
stability of intracellular biocatalysts by affecting the internal pH of cells. Studies 
done on lactic acid bacteria have shown that the intracellular pH (pHi) of these 
strains changes depending on the pH of the extracellular media, and in most cases 
the shift in pHi reflects similar shifts in the media. 
More importantly, the faster growth rates and higher densities of S. 
carnosus, when compared with the E. coli counterpart, result in a faster depletion 
of oxygen levels during shake flask incubation, which was the preferred method for 
biomass production in this project. In turn, oxygen starvation promotes the 
production and excretion of acetic acid through anaerobic fermentation, which 
would consequently result in the acidification of the external medium. If S. 
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carnosus behaved in a similar fashion to lactic acid bacteria, the growth-induced 
acidification of external pH would correspond to a decrease in the pHi of growing 
cultures. The fact that the staphylococcal strain is tolerant to lower pH may partly 
explain why it can maintain high growth rates even in high levels of anaerobic 
fermentation. However, the decrease in the pHi would be detrimental to the activity 
of CHMO, which has been shown to greatly decrease at pH lower than 9 (Doig et 
al. 2003). 
The incubation of staphylococcal cultures with buffered media at different 
pH would allow us to test this hypothesis. Conversely, there are methods for the 
direct measurement of pHi. One such non-invasive method relies on a GFP 
variant, ratiometric GFP (Olsen et al. 2002; Webb et al. 2001), which alters its 
excitation spectrum depending on the pHi. By replacing the CHMO gene in 
pQR1034 for this reporter gene, we would be able to test if, under the conditions 
used for the biocatalytic assays, the pHi of S. carnosus is significantly more acidic 
than the E. coli counterpart.    
The acidification of the external environment during bacterial incubation was 
not helped by the limitations of the shake flask containers used for the incubations. 
The shake flask incubation experiments conducted throughout the project are 
involved the use of conical flasks that were completely sealed and consequently 
did not permit gas exchange between the exterior and the shake flask air pocket. 
Therefore, cultures growing using this apparatus had a limited supply of oxygen. 
The study of aeration is rather limited in conical shake flasks. Different flask 
geometries could be used to generate different oxygen mass-transfer rates 
between the air pocket and the growth media. Alternately, a more detailed analysis 
of the effects of aeration, including mass-transfer rates and oxygen concentrations, 
would require a fermentation reactor set-up, containing an impeller system for 
modulation of mixing and a gas input for modulation of oxygen concentration in the 
fermentation medium.  
Figure 67 shows a DoE two-level factorial experimental design to test the 
effect carbon source concentration, growth temperature, heat-shock treatment, 
aeration, and external pH on the expression of CHMO in S. carnosus. This 
experiment would cover many of the factors that could have an influence of protein 
production, but they require the setting-up of 32 shake flask incubations. A 
	   217	  
simplified and more efficient alternative would be to use 96-microwell plates, which 
have a proven record as tools for scale-down modeling (Baboo et al. 2012; Lye et 
al. 2003). In addition, a recent methodology has been developed to allow for the 
non-invasive measurement of oxygen levels in microwells (Ferreira-Torres et al. 
2005), thus increasing the value of microwell systems as a better alternative to 
shake flask experiments As a result, the whole experiment set-up could be 
performed using 96 well plates with different wall conformations and incubated at 
different temperature, thus saving the time-consuming an cumbersome procedure 
to prepare and manipulate 32 conical shake flasks.  
All the experiments discussed above have been designed with the 
assumption that CHMO was being overexpressed but not stable in the intracellular 
environment of S. carnosus. On the other extreme of the hypothetical outcomes, 
the Western blot results could indicate that very little or no biocatalyst expression 
was occurring during incubation. In this case, both the strength of the expression 
vector and the codon bias of the protein become the most important factors to 
trouble-shoot.  
The gentamicin resistance experiments have suggested that both small rplK 
and rplJ promoters allow for a high level of GenR constitutive expression (see 
chapter 4, section 4.11), and thus expression pQR1034 should have a similar 
expression profile. However, it is possible that the resistance to gentamicin is not 
linearly correlated with the levels of GenR, and that low levels of the enzyme are 
enough to produce a strong response against the antibiotic. One way to test this 
theory would be to optimize gene expression, either by changing the 
staphylococcal promoter in pQR1034 for those already described in the literature, 
or by conducting another round of genome mining for strong constitutive 
promoters. In the next section of this chapter, we discuss in more detail this 
optimization.  
Codon bias also becomes a potential trouble-shooting factor due to its effect 
on protein translation. The codon bias of a protein gene sequence becomes rate 
limiting in translation when codons that are rare in the host organism are employed 
repeatedly in the sequence, since the concentrations of the available tRNA for 
these codons are low in comparison with codons that are used more routinely in 
the host cells. Consequently, long strings of rare codons in gene sequences would 
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greatly inhibit the rates of translation. Since the CHMO is not native from S. 
carnosus, a valid line of enquiry would be to test if the optimization of the codon 
bias of CHMO to fit the codon preferences of the staphylococcal host would 
improve the expression of active proteins.  
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Figure 67-  DOE design for the study of  the effects of five factors  on the expression of 
CHMO simultaneously. The factors A to E correspond to glucose concentration, temperature 
of incubation, heat-shock of cultures before incubation, the use of different geometries of 
96-well plates (oxygen levels), and the pH of the medium, respectively.  Each factor would be 
explored at two levels, high (+) and low(-).  The results of the DOE experiment would be 
expressed in amount of protein expressed per gram of DCW.  
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In conclusion, the execution of the experiments described above would 
depend upon the results from the initial Western blot. Without the input that this 
experiment would give, we would have multiple directions in which to tackle the 
CHMO expression problem but no clear direction as to which would be the correct 
approach. It is worth noting that all the experiments described in this section were 
designed using my current empirical knowledge about the S. carnosus expression 
system, and therefore are not by all means an exhaustive list of all possible 
experimental studies that could be conducted. Rather, they are the experiments we 
found to be the most pertinent in the context of answering the question of CHMO 
expression in S. carnosus.  
 
 
5.7- Optimization of the pQR Expression 
System  
 
One factor that could be directly related to the lack of CHMO expression in 
S. carnosus is the strength of the staphylococcal promoters in the pQR expression 
systems. These promoters were either taken directly or iterated from putative 
promoter regions for highly expressed genes in the genome of S. carnosus, and 
therefore assumed to be natively useful constitute protein expression. Accordingly, 
the gentamicin resistance assays suggested that this was indeed the case for the 
smaller re-designed promoter variants (see Chapter 4, section 4.11). However, we 
did not have any means to compare the performance of these promoters with 
previously reported systems such as the lipase promoter or the xylose promoter, 
and therefore categorization of promoter strength for the promoters used in this 
project was subjective at best. Moreover, the bank of promoters used in the project 
is too small to reach any conclusions about their optimization in S. carnosus. We 
only tested three sequences, two of which were variants of the same promoter. 
Following the underlying principle behind the construction of the vector pQR1030, it 
should have been possible to study a much larger number of genomic promoters, 
which would provide a better understanding of how different sequences affect 
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promoter strength, but also a larger database of expression systems from which to 
compare the strengths of individual promoters.  
Therefore, one approach to optimizing expression of CHMO in pQR1034 
would be based on the random selection of a large number of putative promoter 
sequences from the genome of S. carnosus. Using the ability of the pQR1031 
reporter vector for promoter interchangeability, large number of genomic 
sequences could be screened for promoter activity, thus creating a database of 
both constitutive and regulated native promoters from which an optimized 
expression variant could be more easily identified. One advantage of this approach 
is that it bypasses the need to use statistical in-silico models for the identification of 
genomic pockets of potentially highly expressed genes that have not been 
confirmed for S. carnosus. However, this shotgun approach to promoter screening 
would require extensive trial-and-error studies that would be both time and 
resource consuming.  
Another approach to promoter optimization would be analogous to 
methodologies used in this project, in which sequences upstream from HEGs are 
re-designed into smaller promoter units. Several of these were designed in this 
project but not tested (Figure 72). As highlighted previously, the creation of smaller, 
more concise versions of the promoter regions upstream of putative highly 
expressed genes has the advantage of filtering out sequences of unknown 
regulatory functions, thus creating promoter units that are capable of inducing 
constitutive transcription. However, the constitutive nature of these units can 
become detrimental to the overall expression and stability of heterologous proteins, 
either by inducing the formation of inclusion bodies or by triggering stress-related 
proteolysis.  
Therefore, a more efficient approach would be to design hybrid synthetic 
promoters that combined native genomic promoter elements from S. carnosus with 
regulatory sequences that have been previously characterized (Figure 68). 
Recently, software for the comparison and inference of genomic regulons called 
RegPredict (http://regpredict.lbl.gov/regpredict/) has assembled together 
databases of DNA binding sites for known transcription factor involved in the 
regulation of metabolic pathways, including several palindromic sites identified in 
staphylococcal species that could be used to moderate the expression of strong 
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genomic promoters. By combining the sites recognized in this database, which are 
allocated specifically to particular regulatory pathways, with the smaller sequences 
identified from the upstream promoter regions of HEGs, a comprehensive 
catalogue of inducible staphylococcal promoters could be constructed. Small 
promoters with high constitutive activity could be combined with different regulatory 
elements in order to modulate the method of regulation to fit different biocatalytic 
requirements.  
 
 
Figure 68- Representation of the different strategies  used for the optimization of the 
promoter system for heterologous protein expression in S. carnosus. One strategy for 
choosing strong promoters would be to screen the host’s genome for sequences upstream 
from HEG.  These sequence can either be lifted directly into the promoter cassette or further 
processed (dotted line) through promoter prediction software to design smaller core 
promoter sequences. Regulation and TF binding sites can be added separately by using 
online databases such as the Registry for Standard Biological Parts.  Finally, restriction 
sites can be designed around the different promoter and regulatory elements to allow for 
rapid and straightforward interchange between different elements.    
 
The choice between the different approaches would depend largely on their 
limitations. Optimization through random sequence screening would require a large 
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number of different constructs due to the statistical noise of many promoters that 
would be natively regulated, and sequences that would not carry promoter activity. 
On the other hand, a more focused approach combining the in-silico selection of 
promoter elements within genomic sequences and the introduction of known 
regulatory elements would depend on the accuracy of in-silico predictions. 
 
 
5.6- Concluding Remarks 
 
The use of the expression vector pQR1032, which contained the shorter 
staphylococcal promoter rplK, for the expression of CHMO resulted in an increase 
in the biocatalyst activity of the E. coli whole-cell system when compared with the 
previously established pQR239 expression system. This optimization was achieved 
through the constitutive transcription of the rplK promoter in E. coli , which negated 
the negative control of the Gram-negative pTac promoter, while allowing for the 
constitute expression of CHMO. The strong activity of the staphylococcal promoter 
in E. coli was a surprise, considering that the majority of its sequence was lifted 
directly from the Gram-positive S. carnosus. Using this optimized expression 
vector, pQR1034, we achieved maximum conversion rates of 0.55 g caprolactone 
L-1 h-1 while using E.coli TOP10 cultures in resting state conditions, with a specific 
whole-cell activity rate of 9.7 µmol caprolactone min-1 g DCW-1. Total conversion of 
20 mM of cyclohexanone was achieved after 6 hours of incubation.  Performing 
whole-cell biocatalysis with actively growing cultures did not achieve total 
conversion of the ketone after 24 hours of incubation, and the caprolactone 
conversion rates were much lower than in resting-state biocatalysis. This is due to 
the fact that cultures used for the resting-state biocatalysis were at an higher 
concentration. The highest conversion rates were observed during the exponential 
phase, thus suggesting that the CHMO expression is at a maximum level during 
this period. On the other hand, the fact that total conversion was not achieved hints 
at the instability of the biocatalyst in the intracellular space during the stationary 
phase of bacterial growth.   
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The values from the resting-state biocatalysis are lower than activities 
calculated in other studies using pQR239 (Doig et al. 2003), and these difference 
might be due to changes in the experimental set-up that can be perceived from the 
total concentrations of cell cultures achieved by the end of incubation. In previous 
studies, E. coli concentrations of around 5 g DCW L-1 are achieved, whereas in our 
experimental protocols we obtain final cellular concentrations between 0.5 and 1 g 
DCW L-1. A better comparison between pQR1034 and pQR239 can be observed 
through the NADPH oxidation studies, wherein culture lysates with pQR1034 
exhibited 2 times higher NADPH oxidation rates than pQR239.   
Unfortunately, the presence of the smaller staphylococcal promoter did not 
result in positive CHMO activity in S. carnosus cultures transformed with the 
expression vector pQR1034, despite the expression of the GenR in cultures cloned 
with pQR1032 and pQR1033. Correspondingly, neither whole-cell biocatalysis 
assays using resting or activity growing cultures generated any lactone products. 
No overexpression of CHMO could be detected on SDS-PAGE of supernatant and 
pellet fraction of growing cultures, hinting that perhaps the biocatalyst was not 
being expressed. However, similar protein gels done with E. coli cultures were also 
inconclusive in showing CHMO overexpression.  
Cell wall permeability to cyclohexanone and caprolactone, as well as 
plasmid stability, were also assayed as factors contributing to the lack of CHMO 
activity. Substrate/product tolerance assays showed that S. carnosus TM300 had a 
higher tolerance to the ketone and lactone than E. coli TOP10, which could be 
attributed to a lower permeability of the former’s cell wall to the compounds. 
However, the small difference in tolerance between the two strains does not 
account for the lack of biocatalytic activity. Indeed, if S. carnosus cell wall was 
impermeable to the substrate cyclohexanone and prevented its diffusion across the 
membrane, we would not observe ketone- mediated inhibition of cell growth. 
Plasmid stability assays showed that the vector pQR1034 is stable in S. carnosus, 
even after 3 days of incubation. Therefore, we also cannot attribute the lack of 
CHMO activity to vector instability.  
The work we conducted on S. carnosus and the expression vector pQR1034 
is only a superficial look on the characterization of the organism as a potential 
biocatalytic host or of the vector as a expression system for heterologous 
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biocatalyst expression. Unfortunately, due to time constraints, we were not able to 
extensively trouble-shoot the lack of pQR1034-mediated CHMO expression in S. 
carnosus. Indeed, factors such as the growth conditions of bacterial cultures could 
be crucial to the expression of active biocatalyst. We are also not certain if other 
metabolic processes within the bacterial strain outcompete CHMO for the ketone 
substrate. Using other ketone substrates in biocatalysis could test this hypothesis. 
Another factor that might dictate the rates and efficiency of CHMO activity is the 
codon usage bias of the protein. It is possible that optimization of the biocatalyst 
sequence to fit the codon bias of S. carnosus would improve its expression. All 
these enquiries will need to be considered in future work done on this project.  
Despite the embryonic stage of the work done on S. carnosus, some of the 
results and trouble-shooting issues encountered throughout this project hint at the 
difficulties of this bacteria as a biocatalyst host. One of the potential problems is 
the physical robustness of the bacteria, which becomes undesirable when trying to 
extract active proteins from the intracellular environment. Directly related to this 
issue is the handling of genetic material, which as previous chapters highlighted, is 
cumbersome and requires methods that are either shear-intensive or require 
expensive chemical treatments. Finally, as the tolerance assays showed, the cell 
wall of S. carnosus did not generate a significant increase in tolerance to the 
biocatalytic substrates and products to justify its advantage in CHMO biocatalysis 
over E. coli strains. Of course, in order for us to give a definite answer regarding 
the suitability of S. carnosus as a biocatalytic host, we would need to test other 
biocatalytic systems. Also, there is also the possibility that pQR1034 could be 
further optimized for expression in the bacterial strain. However, the results from 
the biocatalytic experiments suggest that S. carnosus is not suitable for whole-cell 
CHMO biocatalysis. 
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Chapter 6: Conclusions  
  
6.1- The Production of a Shuttle Vector for the 
Expression of Biocatalysts in E. coli and S. 
carnosus 
 
One of the milestones of this research project was the production of a 
shuttle vector that allowed for the expression of heterologous proteins in both 
Gram-negative and Gram-positive bacteria. While the construction of this vector 
was initially motivated by the necessity to find solutions for problems generated by 
constructs used in previous studies, the ability to re-design a vector de-novo 
allowed us to expand on the designs that already existed for protein expression in 
S. carnosus. In fact, previous designs had focused on the integration of a couple of 
well-characterized promoters into a backbone that allowed for selection and 
replication in the staphylococcal strain, thus creating rigid expression systems that 
relied on the flexibility of these promoters for reproducible protein expression. The 
fact that the promoters had been extensively studied meant that these expression 
systems could be reliably used with ease in in-vitro and in-vivo conditions, thus 
reducing any need to change or search for better alternatives. Consequently, the 
constructs for protein expression in S. carnosus centred on the use of either the 
constitute lipase promoter, or the inducible xylose promoter for heterologous 
protein expression. While these promoters have been used for the expression of a 
myriad of different proteins, they had not been applied in the context of 
biocatalysis, where often a high level of protein expression is required.  
Efficient whole-cell biocatalytic systems depend on the systematic 
optimization of the factors that directly or indirectly influence the performance of 
biocatalysis, and these include intracellular expression levels of biocatalyst. 
Subsequently, there is a constant pressure to engineer expression systems that 
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resemble those encountered in the biocatalytic host in order to minimize the 
negative effects of introducing novel or foreign metabolic circuits. Thus promoters 
are engineered to fit the requirements for optimal expression in the host organisms, 
while proteins sequences are re-shaped to reflect the codon bias of the latter. In 
this context, the lipase and xylose promoter systems are not optimized for 
biocatalyst production in S. carnosus. On one hand, these promoters are not native 
to S. carnosus, and while the genetic similarities between the latter an the 
staphylococcal species from which the promoters originate seem to hint at a 
common genetic mechanistic background, it is not a guarantee that these 
promoters are adapted for optimal expression in S. carnosus.  On the other hand, 
the rigidity of the shuttle vectors containing the lipase and xylose promoters works 
as an antithesis to the adaptability required from engineered biocatalytic systems. 
As a result, we attempted to address these potential limitations by designing 
a shuttle vector as a modular assembly, composed of functional elements that 
could be easily manipulated and replaced depending on the functional pressures of 
different biocatalytic systems. Essential to this design was a synthetic linker, which 
was designed as a reversible anchoring point for different staphylococcal 
promoters, thus allowing for the screening of the best promoter for biocatalyst 
expression. The addition of a flexible promoter region to allow for promoter 
screening and optimization is not a new idea, as the vector pCX15 (Wieland et al. 
1995), used to characterize the xylose promoter in S. carnosus, was designed for a 
similar purpose. However, the design developed in this project expanded on this 
idea by adding the ability to optimize and screen promoter activity in both Gram-
positive and Gram-negative bacteria. In addition, the modular nature of the design 
allowed for a fast adaptability to biocatalytic pressures not only in S. carnosus and 
E. coli, but also for other whole-cell systems by changing the replication and 
selection elements of the vector as required.  
Figure 69 shows the different constructs produced from the initial vector 
design.  The expression vector pQR1029 was created by joining the 3 main 
components of the vector design: the E. coli plasmid pTTQ18, a sub-section of the 
vector pCT20 containing the chloramphenicol resistance gene (CAM) and the 
staphylococcal origin of replication (oriS), and the synthetic promoter linker. The 
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construction of this vector was hindered by bottlenecks in the extraction of and 
manipulation of pCT20 from S. carnosus.  
One of the problems was the fact that the thick peptidoglycan wall around S. 
carnosus rendered the latter extremely resilient to physical and chemical lysis. 
After trouble-shooting the methodologies that are routinely used to lyse Gram-
positive bacteria, we were able to develop a simple protocol for DNA extraction that 
involved a single chemical lysis step with lysostaphin, followed by purification via a 
commercially available silica-gel membrane. This protocol was faster and more 
reliable than the alternatives, and we were subsequently able to use it routinely for 
plasmid and protein extractions with S. carnosus.     
	  
	  
Figure 69- Diagram outlining the progression of the vectors constructed throughout this 
project. The arrows highlight the design strategy underlying the construction of each vector 
construct. For instance, the construction of pQR1029 revolved around the jointing of 
pQR1028 and the staphylococcal vector pCT20.  
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The other bottleneck in the restriction and ligation of pCT20 with pQR1028 
related to a fault in the design itself. This ligation step relied on the restriction of 
both vectors with the endonuclease ClaI, which was inhibited by methylated sites 
on the target DNA. We did not account for this inhibition, and the ClaI site of the 
synthetic linker was designed with an overlapping methylation site, which 
subsequently prevented the restriction of pQR1028. This problem could only be 
solved by using a different E. coli cloning system that did not contain the 
methylation pathway.   
The shuttle vector pQR1029 was transformed into both E. coli TOP10 and 
S. carnosus TM300, and shown to grant the adequate resistance phenotype to 
both species. Once the vector was proven to replicate and express the selective 
phenotype in both strains, the next step was to clone the CHMO gene into the 
MCS region of the vector, thus creating the third construct, pQR1030.  
The CHMO expression profiles from pQR1030, as inferred from the NADPH 
oxidation assays, showed that the vector could be used to express the biocatalyst 
in E. coli through the activity of the pTac promoter from pTTQ18, but neither this or 
the staphylococcal promoter designed into the synthetic linker were active in S. 
carnosus.  While we were expecting the pTac promoter not to show any activity in 
the latter, we were hopeful that the staphylococcal promoter, designated pRplK, 
which had been extracted from the staphylococcal genome as the region upstream 
of the ribosomal protein rplK would exhibit high promoter activity in the 
staphylococcal strain.  
Exchanging CHMO for a gentamicin resistance gene (GenR) (pQR1031) 
challenged these results, by showing that pRplK had some, albeit low, level of 
activity in S. carnosus. Using the antibiotic resistance gene as a reporter, we were 
subsequently able to screen the genome of S. carnosus for stronger constitutive 
promoters. A shorter version of rplK promoter (pQR1032), in which both ends of 
the sequence were deleted, generated high levels of resistance to gentamicin in 
both E. coli and S. carnosus. This supported the assumption that genetic elements 
around the ends of the pRplK repress the expression of the rplK ribosomal protein, 
and are responsible for the lack of CHMO expression by pQR1030 in S. carnosus.  
The staphylococcal genomic sequence upstream from the putative operon 
containing the ribosomal protein rplJ also generated a shorter promoter sequence 
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that could induce high levels of constitutive GenR expression (pQR1033), 
comparable to the shorter rplK promoter. Comparing the sequences for the two re-
designed promoters highlighted sequence motifs around the promoters -35 and -10 
RNA polymerase recognition sites that had been previously identified as conserved 
promoter elements within Gram-positive genomes: specifically, and A-rich area at 
position -42 from the transcription start, which was present in both promoters, and 
a TG motif just upstream from the -10 box, which was only present in the rplK 
promoter. In addition, the -10 box was mostly conserved between the two 
promoters, while the -35 box showed a greater degree of variation.  
The pQR1032 vector, which inducing the stronger response to gentamicin, 
was subsequently used as an optimized version of pQR1029 for the expression of 
CHMO (pQR1034). 
In the end, the different constructs produced throughout the project 
validated the principles behind the vector design strategy we used, by 
demonstrating the versatility of the core vector structure of pQR1029. In fact, 
through several simple modifications we were able to change the primary function 
of the vector from biocatalyst expression vector to reporter system for screening of 
promoter libraries. In addition, we also shown that this vector can be used as a 
powerful exploration tool that can be used to increase the general understanding of 
how genetic systems are regulated in organisms like S. carnosus. 
 
 
6.2- The Promoter Region Upstream of the 
staphylococcal rplK Protein.  
 
The results generated by the expression vector pQR1029 highlighted the 
role of the staphylococcal rplK promoter in the regulation of the expression of the 
50S ribosomal protein L-10 in S. carnosus, which had not been previously 
reported.  
In the gentamicin resistance assays (see chapter 4, section 4.11) the vector 
pQR1032, which contained a trimmed-down version of the rplK promoter region, 
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induced an estimated 7-fold stronger response to the antibiotic gentamicin than the 
precursor pQR1031. On their own, these results clearly indicate a difference in 
promoter strength that is not related to sequence differences in the core units of a 
promoter, but instead suggest the presence of areas within the region upstream of 
the rplK protein that exert a negative effect on the expression of this ribosomal 
protein. Indeed, since the shorter rplK promoter in pQR1032 is contained within the 
larger rplK promoter of pQR1031, we would expect both constructs to induce 
comparable responses to gentamicin in the absence of additional regulatory 
elements. 
By complementing these results with the sequence analysis of the longer 
rplK promoter (Figure 70), we can start building a picture of the genetic elements 
surrounding the core promoter that could be responsible for protein down-
regulation.   
 
(i)- Catabolic repression 
 
The area upstream of the -35 box contains a 36 bp stretch of palindromic 
DNA that could be involved in transcription regulation. A similar palindromic 
sequence had been previously identified upstream of the inducible xylose promoter 
(Wieland et al. 1995) characterized as a catabolite responsive element (cre) 
responsible for the glucose-mediated repression of the promoter (Figure 70).   
Catabolite repression is a mechanism used by several bacteria and yeast to 
down-regulate the expression of specific catabolic genes in the presence of 
multiple carbon sources as a means to decrease the translation and transcription 
load and to maximize the conversion of specific catabolites (Hueck et al. 1994). In 
low G+C Gram-positive bacteria, catabolite repression works through the global 
regulator catabolite control protein A (CcpA). This protein is activated in the 
presence of glucose and other fast metabolized catabolites by association with the 
co-repressor Hpr, and binds to palindromic cis-acting sequences in promoter 
regions once activated, resulting on the up-regulation or down-regulation of 
transcription, depending on the location of the binding sites (Titgemeyer & Hillen 
2002).  Recently, a study of CcpA-mediated regulation in S. aureus (Seidl et al. 
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2009)  demonstrated that CcpA acts upon several metabolic, transport, and 
virulence pathways of the cell. In addition, proteins involved in the xylose, sucrose, 
and lactose metabolic pathways were shown to be repressed by CcpA activation in 
S. xylosus (Jankovic & Brückner 2002). However, there is no evidence of a similar 
regulation occurring for proteins from the metabolic translation pathways in 
staphylococcal species.  
 
 
Figure 70- Graphical representation of the promoter regions from vectors pCX15 and 
pQR1030. The palindromic sequence previously identified by Wieland et al. (Wieland et al. 
1995) as a CcpA binding site is highlighted by black horizontal lines. Black horizontal lines 
also outline a similar palindromic region in the rplK promoter of pQR1030, which we have 
defined as palindrome 2. In addition, another palindrome, highlighted by red lines, was also 
identified upstream, with one side of the palindrome overlapping palindrome 2.   
 
It is thus surprising to see a cre-like sequence in the promoter region of the 
rplK protein, as it suggests that this ribosomal protein is also controlled by the 
presence or absence of specific catabolites. While there have been reports of 
ribosomal proteins being up-regulated in the presence of glucose in E. coli and 
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Bacillus subtilis (Gosset et al. 2004; Lorca et al. 2005) there hasn’t been any 
conclusive evidence to establish a link between this effect and the CcpA regulation 
system. In addition, ribosomal proteins are essential components of the translation 
machinery, without which protein translation cannot occur, and thus it would be 
expected for these proteins to be maintained at a steady level of constitutive 
expression.  
There are two possible hypotheses for the presence of a catabolite 
regulatory site upstream of the rplK promoter. The first hypothesis is that this site 
works in a positive manner, by allowing CcpA-mediated up-regulation of the 
ribosomal protein rplK, which fits with recent reports suggesting that CcpA binding 
sites upstream from the promoter elements are used as anchors that increase the 
affinity of RNA polymerase to the promoter (Titgemeyer & Hillen 2002), as opposed 
to CcpA sites within the promoters, that induce transcription repression (which is 
the case with the xylose promoter). However, this hypothesis contradicts the 
results we obtained from the gentamicin resistance assays, in which the presence 
of extra elements upstream and downstream from the promoter clearly had an 
inhibitory effect on protein expression levels.  
Instead, the results seem to suggest that the cre sequence upstream of the 
promoter works as a repressor that induces down-regulation of rplK as levels of 
glucose increase. This hypothesis fits with the theory that bacteria and yeast down-
regulate protein expression to maximize catabolite conversion. As the overall level 
of protein expression decreases, ribosomal proteins are also down regulated to 
avoid wasteful surplus. Therefore, it is possible that, in order for the glucose down-
regulation signal cascade to be fast and effective, some ribosomal proteins are 
directly repressed by CcpA and become a limiting factor for ribosome assembly.  
The theory that rplK is directly repressed by high glucose levels also supports 
reports in which addition of glucose to growth media had an inhibitory effect on 
growth of S. carnosus (Tjener et al. 2004). Comparison between the expression 
levels of pQR1031 and pQR1032 in S. carnosus suggests that this repression is 
not maintained throughout the growth cycle of bacterial cultures, and could be 
directly related to the starvation of the carbon source in the media. Figure 71 
shows the proposed mechanism for CcpA repression of the rplK promoter.  
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Figure 71- Diagram outlining the proposed mechanism by which the rplK promoter might be 
down-regulated by catabolic regulatory protein CcpA . The regulation depends on the 
phosphorylation state of a energy coupling protein of the phosphotransferase system  
(PTS), HPr. Depneding on the residue in which phosphorylation occurs, HPr can function as 
either a triggering factor for the transport of the carbon source by the EIIABC complex, or as 
an activator of CcpA. The two phosphorylation states complement each other as follows: 
The phosphorylation of a histidine residue in HPr is phosphoenolpyruvate (PEP)- dependent 
process that involves the pyruvate kinase EI. The histidine-phosphorylated HPr 
subsequently triggers  the intake of the carbon source. In turn, the increasing levels of 
metabolites from glycolysis of the transported carbon source, such as fructose-1,6 
biphosphate, stimulate another kinase, HPrK , which phosphorylates HPr in a serine residue. 
Seine-phosphorylated HPr will function as activator of CcpA. Thus, histidine 
phosphorylation of this protein triggers a positive-feedback loop that fuels self-regeneration 
through glycolysis, and induces activation of CcpA via HPrK.  
 
By comparison, the native rplK promoter region exhibited very little or no 
activity in E.coli TOP10. Correspondingly, the tight regulation of pTac was not 
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negated by the insertion of the staphylococcal promoter, as can be seen from the 
NADPH oxidation assays with pQR1030 (see chapter 4, section 4.6). One reason 
for this outcome could be the fact that the transcription machinery of E. coli is not 
well adapted to operate with foreign Gram-positive promoter sequences and 
therefore could not induce expression using the rplK promoter. The genetic 
difference between the two systems might have created a barrier that would 
prevent any interchange of sequence functionality. However, by removing most of 
the rplK region to create a shorter promoter, we were able to not only increase the 
level of CHMO expressed in E. coli as compared with the pQR1030 and pQR239 
constructs, but also bypass the inducible nature of pTac by generating constitutive 
expression of the biocatalyst.  
Thus by showing that the smaller re-designed genomic rplK and rplJ 
staphylococcal promoters in pQR1032 and pQR1033 were active in E. coli TOP 
10, these results suggest that there is a common genetic language that can be 
used by both the Gram-negative and Gram-positive bacteria to induce 
transcription. In addition, the results also indicate that rather than being inactive, 
elements within the rplK region in pQR1030 are actively preventing the E. coli 
mediated activation of the core rplK promoter, perhaps by employing a similar 
regulatory mechanism to that which was proposed for S. carnosus.  
The catabolite regulatory pathway in E. coli works via the activation of the 
catabolite activator protein (CAP) (Titgemeyer & Hillen 2002). CAP exists as a 
dimer that is activated upon association to cyclic AMP, which in turn is converted 
from ATP by adenylate cyclase. Upon activation, the CAP dimer binds to a 22 bp 
palindromic sequence upstream from the promoter and induces transcription by 
association with the CTD domain of the RNA polymerase (Lawson et al. 2004).  
Alignment of this consensus sequence with the region upstream of the rplK 
promoter does not show significant homology between the two sequences. In 
addition, as an activator protein, CAP functions as a positive inducer of 
transcription, which does not account for the inhibition of CHMO expression in 
pQR1030. Since catabolite inhibition in E. coli involves a negative feedback loop in 
the activation of CAP, it is therefore improbable that the rplK promoter region is 
affected by homologous regulatory systems in E. coli and S. carnosus.  
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The involvement of Ccpa in the inhibition of the rplK promoter could be 
tested by incubation S. carnosus cultures containing the reported vector pQR1031 
under different concentrations of glucose. If CcpA was indeed responsible for the 
repression of the rplK promoter, cultures grown with higher concentrations of 
glucose would be less tolerant to the antibiotic gentamicin as a result. Conversely, 
a different carbon source could be used to test if the repression signal is solely 
glucose sensitive. The present literature on S. carnosus is unclear as to what 
alternative carbon sources could be used for bacterial growth, and thus some 
experimentation would be require to access the best alternatives. However, since 
the genome of the staphylococcal strain contains Lac genes involved in lactose 
metabolism, we would hypothesize that this compound would work as a suitable 
replacement for glucose. Acetate could probably also be used due to the ability of 
staphylococcal bacteria to grow in high concentrations of the compound, with the 
caveat that pH of the extracellular environment would have to be tightly controlled 
to prevent expression variations resulting from media acidification.  
 
(ii)- Unconventional DNA secondary structures    
 
Another possible source of rplK-mediated inhibition in E. coli and S. 
carnosus may be the A and T-rich inverted repeats (IR) of the palindromic 
sequence upstream of the promoter core, which under physiological conditions can 
form cruciform secondary structures in double-stranded (ds) DNA, and hairpins in 
single-stranded (st) DNA and RNA (Figure 72). The mRNA generated from pTac 
transcription would include the whole rplK region, including the IR element, so it is 
possible for the latter to form a hairpin secondary structure that would inhibit 
translation of CHMO. However, this hypothesis was disregarded because the 
inhibition of CHMO expression was not observed at the translation level, as 
induction of the pTac promoter with IPTG still generated levels of CHMO activity 
that were comparable to the control pQR239.  
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Figure 72- Graphical representation of dsDNA cruciform formation during the transcription 
process. As the DNA gyrase unwinds the area around the promoter region to allow for RNA 
Polymerase binding, it generates extra tension in the DNA sequence around this area: DNA 
downstream of the gyrase will be positively super-coiled , while the DNA upstream will be 
twisted in the opposite way through the longitudinal  axis of the molecule (negative super-
coilling). The relaxation around the promoter area will allow the palindromic region to for a 
cruciform structure that will prevent the binding of the RNA polymerase complex to the -35 
element of the promoter.   
 
Alternatively, cruciforms are DNA structures in which the two 
complementary IR elements form cis-annealing hairpins that extrude from the 
double-stranded DNA. These structures are not genetically stable and only occur 
through openings in the double-strand, which allows for intra-strand base pairing. 
Thus, cruciform formation is favored in events where negative supercoiling occurs, 
such as replication and transcription (Bikard et al. 2010). During transcription, DNA 
topoisomerases are employed to relieve the positive supercoiling occurring 
downstream of the transcription site by unwinding the ds DNA. As this unwinding 
occurs, the conformation of the DNA changes, so that areas downstream of the 
transcription machinery are positively supercoiled, while areas upstream are 
negatively supercoiled (Wang & Lynch 1993). There is evidence to suggest that IR 
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extrusion occurs in transition areas between the negative- and positive- 
supercoiled DNA in a transcription-dependent manner in E. coli (Dayn et al. 1992; 
Rahmouni & Wells 1992). In addition, this cruciform formation also seems to be 
dependent on the thermodynamic kinetics of IRs, with long (dA-T)n strands being 
more prone to form self-annealing hairpins structures in conditions that allowed for 
DNA negative supercoiling (Dayn et al. 1991) .  
More important to our analysis is the association between DNA extrusion 
and transcription regulation. Several reports have highlighted that the presence of 
IR in the promoters regions led to promoter inhibition under physiological 
conditions, suggesting a mechanism wherein the negative supercoiling occurring at 
the start of transcription promotes the formation of cruciform structures, which in 
turn occlude the promoter recognition sites from binding to the RNA polymerase 
complex (Figure 72) (Horwitz 1989; Singh et al. 1995). Therefore, there is a 
possibility that a similar mechanism is occurring around the -35 region of the rplK 
promoter. The 36bp  (dA-T)n IR sequence upstream of the promoter would be 
thermodynamically favorable to the formation of a cruciform structure, which would 
prevent the -35 box from binding to the RNA polymerase.  This would also partly 
explain the fact that only rplK-mediated expression is affected, while the pTac 
promoter that lies upstream from IR region can still be induced in the presence of 
IPTG, as there is no indications that cruciform formation downstream of a promoter 
reduces transcription. On the other hand, if the IR sequence upstream from the 
rplK promoter was a binding site for regulatory proteins in E. coli , one would 
expect pTac-mediated expression to be precluded, as the presence of a regulatory 
protein would physically clash with the progression of the transcription complex. A 
similar process could also be occurring in S. carnosus. 
 
(iii)- Transcription factor (TF) recognition sites 
 
We also cannot rule out the possibility of negative interactions between 
other transcription factors of the bacterial hosts and the sequences around the 
staphylococcal promoter that could down-regulate transcription. In fact, screening 
of the pQR1030 rplK promoter with 81 consensus sequences for transcription 
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factors in E. coli K12 and S. aureus COL (taken from the RegPredict database) 
identified several small sequences upstream and downstream from the -35 and -10 
RNA polymerase recognition sites that could acts as potential binding sites for 
transcription repressors (figure 73A). 
One of these repressor is the EbgR protein, which belongs to the LacI/GaIR 
family of transcription regulators, and acts by repressing the ebg operon (Hall et al. 
1989).  The ebg operon codes for a β-galactoside that is homologous to the LacZ 
but much more inefficient, not being able to promote bacterial growth on lactose in 
its wild-type form (Hall 2003). The Ebg repressor itself has very low sensitivity to 
lactose, and no known strong inducer for this protein is known. In the comparative 
analysis of the rplK promoter, the putative EbgR binding site was pin-pointed to a 
sequence several base-pairs downstream from the transcription start site, so it is 
unclear if binding of the repressor to this sequence would preclude transcription in 
the same manner as the LacI repressor, by inhibiting the formation of a stable 
transcription initiation complex. Regardless, it is plausible to assume that the 
presence of the repressor on the path of the RNA polymerase would generate 
enough conformational clashes to hinder transcription, and that the inactivation of 
EbgR by IPTG is required to allow for the strong activity observed in IPTG –
induced cultures.  
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Figure 73- Homology between sites in the rplK promoter and TF binding sites for E. coli  (A) 
and designs for truncated promoters that could be used to study the importance of these 
sites to transcription repression in E. coli strains (B).  The homologies between the different 
TF sites and the promoter sequence are highlighted in different colours. Two of the sites, 
EbgB (purple) and PurR (red) , are situated downstream from the promoter region and 
overlap each other. The IclR site (blue) overlaps the -35 box, and subsequently the Δ-IclR 
construct is not a truncated version of rplK, but rather the -35 box of the promoter (TTGATT)  
is replaced for the consensus sequence TTGACA, which has a lower degree of homology to 
the rest of the palindromic sequence. By doing this, the IclR site is disrupted while avoiding 
the deletion of the core promoter.  
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Another palindromic sequence identified in the rplK promoter region that 
overlaps the putative EbgR binding site is homologos to the recognition site for the 
purine repressor PurR. This repressor actively suppresses several genes involved 
in pyrimidine and purine biosynthesis, as well as the conversion of adenosine 
monophosphate (AMP) (Anon 2011). Unlike LacI or EbgR, PurR requires the 
binding of a co-repressor, in this case guanine and hypoxanthine (Swint-Kruse & 
Matthews 2009). Strong repression was also shown to be elicited by an exogenous 
adenine stimulus (Cho et al. 2011). Since the co-repressors are compounds 
actively used in metabolic pathways, repression by PurR fluctuates between 
different stages of bacterial growth depending on the intracellular concentrations of 
these compounds, and as a result we would expect to observe intermittent strong 
CHMO expression via the rplK promoter throughout bacterial incubation. Since the 
levels of activity of non-induced pQR1030 culture are very low, it is unlikely that 
PurR would be the sole factor responsible for rplK repression.  
The third transcription factor with a potential binding site in the rplK region is 
the IcIR repressor. This factor actively prevents constitutive expression of proteins 
involved in acetate processing (Donald et al. 2001). In this case, acetate is the co-
factor that binds to the repressor, thereby inactivating the repression of the 
aceBAK operon (Donald et al. 1996). As described previously, acetate becomes 
more prevalent during later stages of bacterial growth, when the oxygen becomes 
limiting and cells enter anaerobic fermentation in order to produce energy. 
Consequently, we would expect a spike of CHMO activity around the later stages 
of exponential and stationary growth if IcIR was the sole factor responsible for rplK 
repression. The results from the biocatalytic assays suggest that this might not be 
the case, as biocatalytic activity still remained low after prolonged incubation.  
The complexity of the feedback loops that regulate the different factor 
highlighted above makes it difficult to devise an experimental method to study each 
one individually. Both PurR and IcIR use co-factors that are products of indirectly 
related metabolic processes. Correspondingly, it would be impossible to study the 
effects of one co-factor on the expression of CHMO without effecting the 
concentrations of the second. For instance, to study the possible binding of IcIR, 
an experiment would be conducted in which E. coli cultures containing the vector 
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pQR1030 were grown in the presence of different acetate concentrations. 
However, the metabolic response generated by the presence of acetate in the 
extracellular medium would inevitably effect the concentrations of purines present 
in the intracellular medium. Consequently, it would not be possible to conclude if 
the biocatalytic activities observed under different acetate concentrations were a 
product of IcIR binding to the rplK promoter region, or if the guanine fluctuations in 
the cell during the metabolic response to acetate-mediated acidification of the 
extracellular medium also affected the binding of PurR to the promoter. Likewise, 
the similarities between the EbgR and LacI make it impossible to use external 
stimuli for the study of one factor without triggering the other. The only known anti-
repressor for EbgR, lactose, would also have a similar effect on pTac expression.  
Therefore, a more direct method of accessing the relevance of the putative 
transcription factor (TF) binding sites to the expression of the rplK promoter would 
involve the production of truncated version of the staphylococcal promoter DNA 
sequence so that the different binding elements are deleted sequentially. This 
would result in the construction of 3 variant of pQR1030, each containing a single 
TF binding site deletion, corresponding to each of the repressor proteins 
highlighted above. Change in CHMO expression in each of these constructs would 
directly correlate to the independent activities of the different repressors (Figure 
73B).  
The discovery of rplK repression in both bacterial strains used in the project 
is important for two reasons; firstly, it re-iterated the paradigm that bacterial 
promoters use a universal language that is valid between Gram-negative and 
Gram-positive bacteria; secondly, it highlighted the presence of genetic elements 
that can carry similar regulatory activities between different bacterial species. 
Discovering the nature of these activities would not only inform how the ribosomal 
protein subunit L-11 is regulated in S. carnosus, but would also highlight the 
parallelism between the genetic languages used for gene regulation in both E. coli 
and S. carnosus. In biotechnological terms, the discovery of regulatory elements 
that generate analogous responses in distinct bacterial species is very valuable 
because it informs the construction of universal promoters that can be used for 
heterologous protein expression cross-species. 
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6.3- The Promoter Screening Strategy 
 
The choice of promoter for expression of CHMO in S. carnosus was 
primarily informed by the requirements of the biocatalysis systems, specifically that 
expression systems should be adapted to the cellular host to permit optimized 
biocatalyst expression. Therefore, instead of relying on promoters from related 
species that had been previously characterized, we decided to build a methodology 
for promoter selection that would allow for the use of promoters that are native to 
the biocatalytic host, and therefore offer optimized protein expression.  
The initial approach to this problem was to search for regions upstream of 
proteins in the S. carnosus genome that were highly expressed and therefore could 
potentially be under the influence of a strong promoter. To identify these regions, 
we used the CAI analysis as a tool to predict highly expressed proteins, wherein 
the CAI values of a set of proteins were interpreted as estimates for the expression 
levels of that set. While the CAI analysis generated results that compared favorably 
with previous experimental studies on related species, employing this analysis on 
its own failed to produce a strong constitutive promoter from the genome of S. 
carnosus, as could be seen from the expression levels of pQR1030 in the 
staphylococcal strain (see chapter 4, section 4.7).   
One limitation of the CAI analysis as a predictive tool for promoter strength 
is fact that CAI values are directly related to translation events. The analysis of the 
codon biases of different sequences is specifically related to the ease at which 
these sequences would be translated in organisms with strong codon selectivity. 
Thus, rather than accounting the level of transcription, CAI predictions are primarily 
focused on translation efficiencies of proteins.  
This problem directly feeds into the second, and larger limitation of the CAI 
analysis. While attempting to give a broad overview of protein expression levels 
inside the cell, CAI uses a metric that is very heavily correlated to the specific 
cellular process of translation. However, protein expression is a multi-layered 
process that is regulated at various levels.  For instance, the stability of mRNA is 
an important factor that is used as a means of controlling the gen population 
available for translation. The affinity of ribosomes to the mRNA is also tightly 
regulated, involving several factors and feedback loops that dictate how strongly 
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the ribosome binds and dissociates from the target sequence. As a result, the CAI 
analysis provides a very narrow window into gene expression that does not 
represent the totality of the factors that effect this process. It is therefore expected 
that the estimates from the CAI values do not represent the real levels of protein 
expression in cells.  
Despite these limitations, we were still able to obtain valid estimates for the 
levels of expression of some of the proteins of the set we chose. Of the 46 proteins 
composing the query set, 39 generated CAI values that could be attributed to an 
high level of protein expression. Most of these are proteins concerned with 
housekeeping functions in the cell, such as translation or glycolysis, and therefore 
are expected to be present in high levels in cells at different stages of cellular 
growth. Proteins such as the ribosomal protein L7/L12 (rplL), which generated the 
highest CAI value in our analysis, had been previously shown to be one of the 
most abundant proteins in the cytoplasm of growing and stationary S. aureus cells 
(Kohler et al. 2005). Other translational oriented proteins such as the trigger factor 
Tig and the transcription initiation factor IF-2 (infB) that had previously been shown 
to be abundant in S. aureus also generated high CAI values.  
Conversely, the glycolysis protein triosephosphate isomerase (tpiA) was 
estimated as HEG from the CAI analysis, while proteome studies showed that this 
protein was only present in high levels in growing S. aureus, but did not exhibit the 
same levels in stationary cells. This case re-iterates the limitations discussed 
previously, as the CAI analysis does not account for the regulation that inevitably 
occurs for glycolysis proteins. However, we did partly account for such limitations 
when selecting promoters. Thus proteins that were associated with catabolic 
networks, such as glycolytic proteins, or proteins that are directly implicated in 
responses to extracellular stimulus, as is the case of membrane transporters and 
chaperones, were not considered as potential candidates after the CAI analysis.  
In the end, the correspondence between the CAI analysis and the proteomic 
evidence from related species gave us the confidence to use the results from the 
former as the basis for the promoter screening strategy.  
The inability to extract a promoter from the genome that would generate 
high constitutive levels of expression in the first screening highlighted another 
limitation with the approach we used that is not directly relate to the software tools 
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applied in the screening. This limitation was the lack of knowledge about the 
systems that regulate gene expression in S. carnosus. As a result, by lifting whole 
sequences upstream of putative HEG as potential promoters, we were exposed to 
the risk of lifting not only promoter regions, but also other regulatory elements that 
would interact with the host in an inhibiting manner. Indeed, this was the case of 
the region upstream of the rplK gene, which as we discussed previously might 
contain regulatory elements involved in a glucose negative-feedback loop.  
Only by employing promoter prediction software that filtered through the 
sequences upstream of putative HEG for specific promoter elements, were we able 
to generate short promoters that allowed for higher levels of constitutive 
expression. Therefore, by combining the predictive ability of the CAI analysis with 
the promoter screening software, we were able to optimize gene expression in S. 
carnosus. Thus the combination of these tools is a valid strategy for extracting 
strong promoters from the genome of the cell host for biocatalytic purposes.  
 
 
6.4- The Expression Profiles of the Re-
Designed rplK and rplJ Promoters 
 
 
As described in the previous section, the two shorter promoters designed 
from the regions upstream from the rplK and rplJ genes were composed of 
fragments from the S. carnosus genome that had been screened for specific -35 
and -10 RNA polymerase recognition sites. In addition, the promoters were 
designed with restriction site overhangs that allowed for cloning into the vector 
construct pQR1031, as well as RBS elements downstream from the transcription 
starting point that were also lifted from the area upstream of the ribosomal genes. 
The resulting ligations products of these promoters with the reporter vector 
pQR1031 generated gentamicin resistance profiles that were not only an 
improvement from the expression profile of the precursor pQR1031 in both E. coli 
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and S. carnosus, but also hinted at transcription mechanisms that might be 
interchangeable between S. carnosus and other Gram-positive bacteria.  
The comparable activities of the smaller rplK and rplJ promoters suggest a 
universal structure for S. carnosus promoters, which is very similar to the 
consensus recognition sites for Gram-negative bacteria. In fact, the rplJ promoter 
contained an intact -35 box (TTGACA) and a partially intact -10 box (TATATT), 
whereas in the case of the shorter rplK promoter the opposite is observed.  In 
addition, the distance between these elements is 17 bp, which agrees with that 
stipulated in Gram-negative promoters. However, the fact that pTac did not show 
any activity in S. carnosus indicates that additional upstream elements (UP) are 
required as recognition sites for the transcription machinery of the staphylococcal 
strain.  The presence of UP elements in Gram-negative bacteria such as E. coli 
has been widely reported, but the affect they have on transcription depends on the 
affinity between the RNA polymerase complex and the main promoter -35 and -10 
recognition sites (Rhodius et al. 2012)  . By contrast, strong transcription in the 
Gram-positive Bacillus subtilis seems to be dependent upon the presence of A- 
and T- rich sequences upstream from the -35 promoter element that theoretically 
binds to the C-terminus of the RNA polymerase (Meijer & Salas 2004).  Another 
UP element, a -16 TG motif, was also identified as crucial for strong expression in 
Bacillus subtilis (Voskuil et al. 1998). Our results suggest a similar requirement for 
transcription in S. carnosus, as both small promoters contained these UP 
elements. In fact, by doing a comparative alignment of the sequences upstream of 
the genes with the highest CAI values, we also observed that UP elements 
highlighted above are present in most of the sequences (Figure 74).  
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Figure	  74-­‐	  Sequences	  of	  putative	  promoter	  regions	  contained	  in	  the	  sequences	  upstream	  from	  5	  predicted	  
highly	  expressed	  genes.	  The	  gene	  selection	  was	  based	  on	  the	  CAI	  analysis	  and	  the	  spacing	  between	  
different	  genes	  in	  the	  genome.	  Thus,	  only	  sequences	  with	  a	  span	  longer	  than	  40	  base	  pairs	  between	  genes	  
were	  considered.	  The	  promoter	  -­‐35	  and	  -­‐10	  elements	  are	  enclosed	  within	  the	  red	  boxes,	  while	  UP	  
elements	  such	  as	  the	  -­‐16	  TG	  motif	  or	  the	  AT	  rich	  sequence	  upstream	  of	  the	  promoter	  are	  outlined	  by	  
green	  boxes. 
 
The difference in GenR expression between the two short promoters used in 
this project further elucidates the unequal relationship between the different UP 
elements and transcription strength. In fact, the UP element upstream of the -35 
promoter element is more extended in rplJ, containing an extra 5 thymine residues. 
Despite this, a slightly higher resistance to gentamicin was observed in colonies 
containing the vector construct pQR1032. The fact that the rplK promoter contains 
an intact -16 TG motif, as well as an intact -10 TATAAT box, might account for the 
increased activity of the latter. On the other hand, the results clearly indicate that, 
while the presence -16 UP element resulted in an increase in promoter strength, it 
was not as essential to the overall expression as the UP element upstream of the -
35 box, which was present in both promoters. Furthermore, the fact that extending 
the latter region did not produce a change in activity suggests the presence of 4 
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adenine residues immediately upstream from the -35 box is enough to induce 
strong transcription. 
The fact that the two staphylococcal promoters allowed for constitutive 
expression of GenR in E. coli was surprising, albeit not all together unexpected. 
Since we used promoter prediction software tools that had been modeled on 
Gram-negative expression systems to filter through the S. carnosus genome, the 
probability of selecting sequences that could also be recognized by the E. coli 
transcription machinery was high. Nevertheless, the ability of E.coli to use 
promoters from the S. carnosus genome has not been previously reported. 
In addition, the lack of protein expression from the longer staphylococcal 
promoter RplK in both E. coli and S. carnosus suggests a common negative 
regulatory system between these bacteria that interacts with regions upstream of 
the rplK promoter, resulting in promoter inhibition. Once these sequences were 
deleted from the core promoter, in the case of pQR032, both organisms were able 
to generate high levels of constitutive expression. 
More importantly, the results with pQR1032 and pQR1033 clearly 
demonstrate how reverse engineering of genomic promoters from S. carnosus 
allowed for the creation of hybrid promoters that can be efficiently used in both 
Gram-negative and Gram-positive bacteria.  
 
 
6.5- Expression of CHMO in E. coli TOP10 
 
Previous studies of CHMO-mediated whole-cell biocatalysis have mainly 
focused on E. coli as host cells. In turn, the best characterized vector system to 
work in this bacterium for the expression of CHMO is the vector pQR239. Thus, we 
based the qualification of the performance of the vectors pQR1030 and pQR1034 
on the direct comparison with pQR239, which was considered to be the standard 
for CHMO expression in E. coli.  
However, the comparison studies done on the CHMO-mediated NADPH 
oxidation of lysates containing the different constructs presented some doubt about 
the nature of the pQR239 stocks used throughout this project. Specifically, the fact 
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that pQR239-mediated CHMO expression could be modulated by IPTG suggested 
that the plasmid was in fact different from that reported in the literature (O’Sullivan 
et al. 2001). CHMO is under the regulation of the pBAD promoter in pQR239, 
which is an L-arabinose promoter. This promoter is tightly regulated by the protein 
araC, which exerted a strong repression of protein expression in the absence of 
the activating substrate L-arabinose (Khlebnikov et al. 2002). In the presence of L-
arabinose, the promoter is activated in a non-linear fashion, and therefore 
modulation of protein expression using this promoter is not possible. Despite this, 
the pBAD promoter was chosen for CHMO expression because it did not allow for 
leaky expression of the biocatalyst, and activation required the inexpensive 
substrate L-arabinose.  Contrary to the results obtained in the NADPH oxidation 
assays, very low or no CHMO activity from pQR239 should be expected in E. coli 
cultures grown in the absence of L-arabinose. Additionally, IPTG should not induce 
an increase in pBAD expression. It is therefore possible that the pQR239 bacterial 
stocks contained instead the precursor vector pQR210, from which CHMO was 
lifted up to create pQR239. In this plasmid, CHMO is under the influence of the 
pTac promoter, which would explain the results from the NADPH oxidation assays. 
Unfortunately, we were not able to confirm this due to time constraints.  
The possibility that pQR239 was in fact pQR210 offers a new perspective on 
the activity of the long rplK promoter in pQR1030. Since both vectors contain the 
same promoter and origin of replication (ColE1) for E. coli, we should expect the 
specific activity of cultures containing these vectors to be very similar under fully 
induced conditions. Consequently, the fact that pQR1030 exhibited higher specific 
activity hinted at the possibility that the longer rplK promoter is actually active in E. 
coli, providing for the extra CHMO expression. However, the assumption that 
pQR210 and pQR1030 have similar copy numbers inside cells and therefore 
express the same level of CHMO is not certain, since the vector pQR1030 also 
contains the staphylococcal origin of replication, which could contribute for the 
replication of the vector in E. coli.     
Otherwise, the results from the NADPH oxidation assays corroborate the 
results from the gentamicin resistance assays with pQR1031, pQR1032 and 
pQR1033, and confirm that the smaller rplK promoter in pQR1034 allows for high 
levels of constitutive expression in E. coli.  
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They also showed that smaller staphylococcal promoter cancelled out the 
negative regulatory influence of the lacI repressor on pTac expression. This result 
is difficult to interpret because it suggests that the small rplK promoter is 
exclusively responsible for the high CHMO activity observed in pQR1034, and that 
the IPTG-mediated activation of pTac does not add to the overall expression of 
CHMO. In other words, the results suggest that the presence of second promoter 
upstream of a strong constitutive promoter does not add to the expression of 
downstream heterologous proteins. Further experiments would need to be 
conducted to confirm these results. 
The whole-cell biocatalytic experiments done on resting and actively 
growing cells (see chapter 5, section 5.3) have a limited use for comparison with 
previously studies on CHMO whole-cell biocatalytic systems (Doo et al. 2010; Doig 
et al. 2003), due to the fact that the bacterial densities generated in these 
experiments were not comparable to the higher bacterial densities achieved in the 
previous studies. As a result, whole-cell activity of 9 µmol min-1 g DCW-1 calculated 
for resting state E. coli cultures containing the pQR1034 expression vector were 
much lower than activities of previously characterized strains (Doo et al. 2010; 
Doig et al. 2002).The disparity between activities might be a result from the sub-
optimal conditions used. 
However, the whole-cell biocatalytic experiments on actively growing cells 
were valuable to show that highest rate of CHMO activity occurs during the 
exponential phase. Additionally, the results show that CHMO activity significantly 
decreases during the stationary phase, which agrees with activity assays done on 
lysates after 24 hours of incubation. It is possible that, upon reaching stationary 
phase, constitutive expression of the biocatalyst is not viable, and the latter is 
either digested or forms inclusion bodies as a consequence of protein miss-folding. 
Alternatively, previous studies have hinted that the lower CHMO activity in actively 
growing cells might be a result of the inherent half-life of the protein (Walton & 
Stewart 2004), or due to competition for oxygen, which is also used for the general 
metabolic activity of the host and becomes a limiting factor during the later stages 
of bacterial growth (Baldwin & Woodley 2006). Another study conducted by Doig et 
al.(2003) suggested that the intracellular pH of bacterial cells could have an 
important role in the stability and activity of CHMO, which operates under an 
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optimum pH of 9. Correspondingly, decreasing the pH of a biocatalytic reaction 
from 9 to 7 resulted in a 5 times decrease in CHMO activity of cell lysates. The 
effects of pH would certainly partly account for the 10 times lower activity observed 
in resting cells (9 µmol min-1 gDCW-1) when compared to the specific enzyme 
activity in lysates (88 µmol min-1 gDCW-1). 
 
 
6.6- Expression of CHMO inside S. carnosus 
TM300 
 
No CHMO activity was observed in either the NADPH oxidation assays or 
whole-cell biocatalytic reactions performed with S. carnosus TM300 strains 
containing the expression vectors pQR1030 and pQR1034. Since the gentamicin 
resistance gene GenR had been expressed inside the staphylococcal strain using 
the same promoter constructs, the results led us to suspect that the lack of 
biocatalyst activity was a result of inherent limitations in the expression of the 
protein inside S. carnosus.  
There are several factors that could contribute to this lack of protein 
expression. On the translation level, successful CHMO translation could be 
hampered by differences in codon biases between the protein and the host 
organism. Previous studies have shown the importance of codon biases as 
modulators of heterologous protein expression (Gustafsson et al. 2004; Gvritishvili 
et al. 2010). 
CHMO is native to Acinetobacter sp. NCIMB 9871, a Gram-negative 
bacterium with a distinct genetic make-up from S. carnosus. Despite that, CHMO 
has been shown to be actively expressed in the Gram-positive bacterium 
Corynebacterium glutamicum (Doo et al. 2010), suggesting that the Gram-
negative/Gram-positive codon bias disparity is not an important factor in the 
translation of the biocatalyst. However, C. glutamicum is in many respects more 
suited to express Gram-negative proteins than S. carnosus. Firstly, Gram-negative 
expression systems such as the pTac promoter can be used in C. glutamicum, 
thus removing the need for a dedicated promoter system for protein expression. 
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Additionally, looking at the codon preferences of C. glutamicum and S. carnosus, 
we observed that the former matches more closely to the codon bias of CHMO 
(Figure 75). Accordingly, the protein sequence contains several high frequency 
codons that are not prevalent in S. carnosus. For instance, the codon GCC, which 
codes for 12 of the 46 alanine amino acids in CHMO, is used in less than 10% of 
synonymous sequences coding for alanine in S. carnosus, and therefore could be 
considered to be a rare codon (Gustafsson et al. 2004). Other examples of S. 
carnosus rare codons that are significantly present in the CHMO sequence include 
CUG, which codes for 6 leucine amino acids in the protein, UCC, which codes for 3 
serine amino acids, and ACC, used 12 times to code for threonine. Together, these 
correspond to 6 % of the protein being coded by codons with a very low prevalence 
in S. carnosus. By contrast, only 2.7% of CHMO is coded by rare codons in C. 
glutamicum. Although the percentage of rare codons used in the translation of the 
biocatalyst is not high, it is possible that it could represent a burden to successful 
translation, specifically If the rare codons are clustered together.  
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Figure 75- Codon bias barcharts for C. glutamicum (A), S. carnosus (B), and the protein 
CHMO  (C). The different coloured bars correspond to different synonymous codons for a 
specific amino acid, and are displayed as a percentage of the total number of codons for that 
amino acid. The colours are consistent throughout the three charts, i.e. they correspond to 
the same codons in the three plots.  
 
Post-translational events could also contribute to the inability of S. carnosus 
to produce active biocatalyst. Intracellular proteases that degrade mis-folding and 
aggregating proteins could play a role in the possible degradation of CHMO. One 
of these proteases is the ATP-dependent ClpP protease, which is highly conserved 
in Gram-positive genomes (Frees et al. 2007). This protease is an oligomer that 
depends on the binding of Clp ATPases to specific targets that are subsequently 
carried into the ClpP complex and digested. Different ATPases are normally 
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expressed at distinct points in the bacterial life cycle and recognize protein targets 
that are involved in regulatory and stress-response networks (Frees et al. 2007). 
More recently, the CLpP protease complex has been associated with the 
degradation of non-native proteins. Proteome studies with Bacillus subtilis have 
shown that overexpression of heterologous proteins triggered an increase in ClpP 
expression (Jürgen et al. 2001), while deletion of the protease gene in Lactococcus 
lactis resulted in an increase in expression of active heterologous protein (Frees et 
al. 2001; Loir et al. 2005). ClpP has also been shown to have a similar function in 
S. aureus, suggesting that it could actively hindering protein expression in the 
genetically-related S. carnosus (Michel et al. 2006; Frees et al. 2003).  
The current proposed mechanism for ClpP-mediated degradation of non-
native proteins involves the ATPase ClpC, which is coded by the ctsR repressor 
operon. Upon protein denaturing conditions, ClpC is titrated from a regulatory 
complex to bind to specific mis-folded or non-native proteins, and subsequently 
binds to the ClpP core oligomer to promote total unfolding and denaturation of the 
target (Frees et al. 2007). The uncoupling of the ClpC from the regulatory complex 
also triggers the binding of the complex to the repressor CtsR, which auto-
regulates the ctsR operon. Thus ClpC expression works as positive feedback loop 
that is triggered by the presence of miss-folded proteins in the intracellular space. 
By analyzing the genome of S. carnosus, we were able to identify a putative CplP 
gene with high homology to the L. lactis and B. subtilis counterparts (Figure 76A). 
In addition, a CplC gene homolog was identified in an operon-like genomic 
segment that also contained the CtsR gene (Figure 76B). Thus, it is possibly that 
the CplCP complex acts in S. carnosus to prevent the accumulation of non-native 
proteins, and could consequently be responsible for the denaturation of CHMO.  
Another ATP-dependent protease that could contribute to the degradation of 
overexpressed proteins is the membrane bound FtsH, a metaloprotease that is 
highly conserved through the bacterial genera and recognizes and digests unusual 
or unstable protein conformations (Ayuso-Tejedor et al. 2010; Li et al. 2004). A 
homolog of this enzyme can be found in the genome of S. carnosus, so we cannot 
rule out its possible role in the degradation of miss-folded CHMO. 
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Figure 76- Analysis of the ClpP and ClpC protease subunits in the genome of S. carnosus.  
A) Protein sequence alignment between the ClpP of S. carnosus and counterparts found in 
L. lactis and B. subtilis . B) Graphical representation of the operon-like region in S. carnosus 
genome containing the ClpC ATPase. The repressor CtsR can be found upstream from ClpC, 
at about 187 K base pairs. 
	  
Finally, the presence of competing metabolic pathways that use the 
substrate or product of CHMO-mediated biocatalysis is also a possible factor in the 
lack of conversion observed in whole-cell experiments. Side reactions have been 
previously reported to be problematic for CHMO biocatalysis in bakers yeast, a 
problem that led to the shift to E. coli as a host for CHMO biocatalysis (Stewart et 
al. 1996).  Analysis of the S. carnosus genome did not generate any positive hits 
for cyclohexanone dehydrogenases or lactone hydrolases. A 3-oxoacyl-ACP 
	   256	  
reductase with 46% homology to the cyclohexanol dehydrogenase from 
Acinetobacter sp. NCIMB9871 was identified, but it is unlikely that this enzyme 
would compete with CHMO for cyclohexanone or caprolactone. On the other hand, 
the reductase uses NADP+ as an acceptor, which could interfere with the oxidation 
rates of the monooxygenase. However, since E. coli strains also contain this 
enzyme, it is unlikely that it would contribute to the negative results.  
As stated above, the data obtained in this project is insufficient to answer 
these queries, and further experimentation is needed to trouble-shoot the lack of 
biocatalyst activity.  
	  
	  
6.7- S. carnosus as an Alternative Host for 
CHMO Biocatalysis 
 
Whole-cell biocatalytic processes are complex systems involving several 
factors that are independent from the biocatalyst or biocatalytic reaction. Therefore, 
as this project exemplified, the choice of host is not straightforward and often 
involves the consideration of multiple criteria. While these criteria are heavily 
dependent on the choice of biocatalysis and biocatalytic reaction, some are 
general enough to be valid for most whole-cell systems. For instance, the ability of 
the host to stably express the biocatalyst intracellularly, and the genetic expression 
systems that are available for use in the host are important considerations to make, 
regardless of the biocatalyst. Likewise, the growth profile and optimum growth 
conditions of the host are factors that will directly affect the performance of the 
whole-cell process independently from the biocatalyst used. Other criteria, such as 
the permeability of the cell wall to substrates and products, or the presence of 
competing metabolic networks, are criteria that will be more or less impactful with 
regards to the choice of biocatalyst. For instance, when employing biocatalytic 
reactions where toxic substrates and/or products are used, the permeability and 
resistance of cells to exposure to these compounds becomes a major 
consideration for the choice of host.  
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From the results obtained in this project, we are able to make some 
conclusions about the fitness of S. carnosus TM300 as a host for CHMO 
biocatalysis (Figure 77). Growth studies showed that under similar conditions, S. 
carnosus reached faster growth rates and total growth than E. coli TOP10. This 
characteristic would be advantageous for whole-cell biocatalysis, as either biomass 
densities would result in increased total yields of the biocatalytic reaction. In 
addition, S. carnosus was not only shown to grow efficiently in conditions used for 
the Gram-negative counterpart, but it was also adaptable to more aggressive 
conditions that severely impaired E. coli growth. In fact, optimum S. carnosus 
growth was observed in media containing 2.5 % (w/v) sodium chloride (NaCl), 
which would be naturally selective against other bacteria species. The fact that 
high-salt, low pH media are already used in food industry to hinder contamination 
by pathogenic bacterial demonstrates the advantage of using S. carnosus as 
bacteria capable of growing in harsh environments. 
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Figure 77- Graphical representation of factors that affect whole-cell biocatalysis and their 
relation with the two bacterial strains used in this project. The direction of the arrows and 
colours of the lines highlight the advantage of the strains in relation to the factor. The red 
directional lines indicate that S. carnosus TM300 is more advantageous as a biocatalytic 
host when considering bacterial densities and tolerance to toxic metabolites. By contrast, 
the green arrows indicate factors that favor the use of E. coli TOP10 as a host system. The 
blue bi-directional blue arrows indicate that neither organism has the upper hand when 
considering the strength of the cell wall, i.e. there are advantages and disadvantages to 
using either.  
 
Directly related to this is the shear-resistant nature of the Gram-positive 
bacterium, observed throughout the bacterial lysis protocols conducted in this 
project. This characteristic could be advantageous in retaining the stability and 
activity of intracellular biocatalyst in shear-intensive reaction conditions, such as 
when high levels of mixing are involved. However, the hardiness of the 
staphylococcal cell wall also works against the system, as it has been shown in 
several experiments where cell lysis was required. The harsh shear conditions 
used in this experiments were often inefficient without the pre-treatment with 
expensive enzymatic cocktails, and risked the stability of the biocatalyst due to 
over-heating or enzymatic interference. Additionally, the thick peptidoglycan wall 
greatly hindered attempts to clone and manipulate genetic material in S. carnosus. 
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In fact, all the protocols used routinely for transformation of E. coli were ineffectual 
for cloning into S. carnosus, and the protocols that resulted in positive clones had 
much lower yields. DNA extraction also required protocols that could potentially 
harm the integrity of the genetic material and made it difficult and cumbersome to 
analyze the plasmid content for the staphylococcus strain. 
Other factors were also undesirable for biocatalysis. The lack of general 
knowledge about the staphylococcal host and the absence of a wide range of well-
characterized genetic systems for the expression of heterologous proteins were 
responsible for the extensive amount of time devoted in this project to the 
construction of an efficient expression vector. On one hand we see this lack of 
knowledge as an advantage rather than a disadvantage in scientific terms, as our 
study of promoters from the staphylococcal genome has contributed to the general 
understanding of what promoter systems can be used for heterologous protein 
expression in this bacterium. However, the time investment and the cost that such 
studies demand is not economically viable to projects that rely on fast creation of 
highly efficient biocatalytic systems. This is one of the reasons why most of the 
current efforts regarding biotechnological advances in whole cell biocatalysis have 
focused on the optimization of already well-established systems, as opposed to 
searching for novel bacterial hosts. And while there is an argument for the latter 
approach as a means to bring biotechnological novelty to whole-cell biocatalysis, 
the lack of understanding about the operating rules and limits of novel cell systems 
can still be seen as a disadvantage, particularly when the benefits from using these 
systems are not inherently apparent. Such a case could be made of S. carnosus.  
Even considering the higher tolerance to cyclohexanone and ε-
caprolactone, together with the higher bacterial densities that would result in higher 
biocatalytic rates, the inability to express active CHMO in S. carnosus makes it an 
undesirable host for CHMO biocatalysis. In fact, the results from the biocatalytic 
assays suggested that intracellular expression of non-native proteins in S. 
carnosus is not as straightforward as in more conventional systems, and requires 
careful consideration of factors such as the codon bias of the protein gene and the 
proteolytic degradation of overexpressed proteins.  
In conclusion, the advantages of using S. carnosus as a host for CHMO 
biocatalysis do not seem to out weight the disadvantages of working with a poorly 
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characterized system that is difficult to clone and manipulate, particularly when no 
biocatalyst expression was observed. However, the results from this study are only 
preliminary, and a more in-depth trouble-shooting process would have to be 
conducted to give definite conclusions about the expression of CHMO in S. 
carnosus.  
 
 
6.8- Future Perspectives  
 
6.8.1- The Use of Alternative Biocatalysts 
 
The PhD project described in this manuscript focused on CHMO as the 
biocatalyst. And while the results from this study heavily infer that S. carnosus 
might not be suitable for whole-cell biocatalysis with this protein, the study of a 
single biocatalytic system is insufficient to conclude that the staphylococcal strain 
is inadequate for whole-cell biocatalysis in general. Correspondingly, to answer 
such a query would require the expression and study of the performance of several 
other biocatalysts in S. carnosus. 
CHMO is the most widely studied Baeyer-Villiger monooxygenase, but it is 
not the only one to be cloned and expressed in bacterial systems. Five other 
monooxygenases have been studied in the context of recombinant bacterial 
systems. Two of these, the steroid monooxygenase (STMO) and the 
cyclododecanone monooxygenase (CDMO) were encountered in Gram-positive 
Rhodococcus species and subsequently cloned into E. coli (Kostichka et al. 2001: 
Morii et al. 1999). 
CDMO, first cloned from Rhodococcus ruber CD4 and SC1, was shown to 
be able to efficiently convert long chain cyclic ketones in recombinant E. coli. This 
monooxygenase is an interesting and potentially valuable candidate biocatalyst, as 
it not only catalyses the degradation of compounds contained in petroleum 
(Kamerbeek et al. 2003), but also produces lauryl lactone, which functions as a 
pharmaceutical building block and is not currently chemically produced (Yang et al. 
2009).  Additionally, the bulky aliphatic nature of substrates for CDMO represents a 
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big shift in size from the single and dual ring substrates of CHMO, and therefore 
would allow us to study the permeability of S. carnosus to different substrate sizes.  
Two variants of the STMO that performed conversion of steroid compounds 
were first identified in Rhodococcus rhodochrous and Cylindrocarpon radicicola, 
but only the formers’ monooxygenase was implemented in a whole-cell biocatalytic 
system with E. coli as the host (Kamerbeek et al. 2003). E. coli BL21 (DE3) 
cultures expressing the STMO were able to achieve protein yields about 40 times 
greater than STMO expression in its native strain (Morii et al. 1999). However, no 
further biocatalytic studies were performed on whole-cell conversion of steroids 
such as progesterone.  Thus, on one hand the study of STMO in S. carnosus as a 
biocatalytic system would be very valuable in the categorization of the enzyme as a 
biocatalyst. On the other hand, the lack of information about this protein does not 
fulfill the purpose of comparing S. carnosus as a biocatalyst host to other 
established whole-cell systems. It is worth noting that although STMO and CDMO 
are native from Gram-positive Rhodococci, these strains are genetically distinct 
from S. carnosus, with GC-rich genomes, as opposed to the AT-rich 
staphylococcal counterpart. Correspondingly, the both monooxygenases code 12 
to 17% of their sequences with S. carnosus rare codons, which is twice as much as 
the CHMO sequence. As suggested above, this disparity between protein codon 
biases and host codon preferences might create bottlenecks for the subsequent 
expression in the host, and correspondingly codon optimization of both protein 
sequences would have to be performed before expressing them in S. carnosus.  
Another Baeyer-Villiger monooxygenase, cyclopentanone monooxygenase 
(CPMO) that was isolated from Comamonas sp. NCIMB 9872, has been shown to 
share an substrate specificity overlap with CHMO, although with different enantio-
selectivities (Kamerbeek et al. 2003). Since this enzyme has mostly been studied 
in the context of whole-cell systems (Iwaki et al. 2002; Bes et al. 1996), there is 
enough data from which to compare the performance of S. carnosus  as a 
biocatalytic host for CPMO biocatalysis. Another aspect also makes this 
monooxygenase an interesting candidate. There is a high degree of disparity 
between the codon bias of the CPMO gene and that of the staphylococcal host, 
with 43% of the sequence being composed of rare codons in S. carnosus. This 
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difference could be exploited as an alternative way to access the impact of codon 
bias to heterologous protein expression in S. carnosus.  
Finally, the 4-hydroxyacetophenone monooxygenase (HAPMO) was initially 
encountered in Pseudomonas fluorescens ACB growing on 4-
hydroxyacetophenone. This enzyme was characterized as the first Baeyer-Villiger 
monooxygenase able to catalyse aromatic ketones, as well as a broad range of 
aliphatic compounds (Kamerbeek et al. 2003). Due to the fact that its native host 
contains enzymes that degrade the products from HAPMO oxygenation, this 
enzyme has been cloned and overexpressed in E. coli under a T7 promoter system 
(Kamerbeek et al. 2001). Another study was able to demonstrate the use of this 
monooxygenase as a biocatalyst in a E. coli whole-cell system with a range of 
different cyclic ketones (Anon 2007). Of all the monoxygenases discussed in this 
section, HAPMO seems to be the best candidate, due to the fact that there is 
already extensive literature about its substrate specificity and performance as an 
whole-cell biocatalyst. Additionally, it provides the lowest codon bias disparity with 
the S. carnosus host compared with the other Baeyer-Villiger monooxygenases, 
except for CHMO.  
Another type of monooxygenase that is relevant for the study of whole-cell 
biocatalysis due to its catalytic importance and requirement for NAD(P)H and co-
factor regeneration, is cytochrome P450s. Cytochrome P450s are heme containing 
oxygenases that have been found in most living organisms and are able to 
catalyse oxidation reactions a broad range of substrates, including steroids, 
prostaglandins, carcinogens and xenobiotics (Urlacher & Schmid 2002). Most 
P450s are mechanistically dependent on redox proteins such as a iron-sulfur 
ferrodoxin and flavin adenine dinucleotide (FAD)- or flavin mononucleotide (FMN)- 
reductases to perform the electron transfer from NAD(P)H (Guengerich 2007).  
This dependency on co-factor regeneration allied with better stability and activity 
rates when expressed intracellularly makes P450s very valuable candidates for 
whole-cell biocatalysis.  
One of the most studied and characterized cytochrome P450s is the 
CYP102 from Bacillus megaterium, which is unique due to the fact that it is 
cytosolic, as opposed to membrane bound), and it is also self-sufficient, i.e. it 
contains both FNM/FAD reductase and monooxygenase domains in one single 
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chain (Narhi & Fulco 1986). Additionally, this enzyme has shown to have the 
highest reaction rates for reported activities in P450s, with turnover frequencies of 
more than 1000 min-1 (Schewe et al. 2008). These factors, together with the fact 
that the native host is a AT-rich Gram-positive bacteria, make the argument for 
CYP102 as an ideal candidate for expression in S. carnosus. Additionally 
hydrophobicity and related toxicity of long chain fatty acids and terpenoid 
substrates for CYP102, which are the most common limiting factors for biocatalysis 
with P450s (Urlacher & Eiben 2006), can be used as objective  measurement in 
comparing the performances of S. carnosus and previously used recombinant E. 
coli strains (Schewe et al. 2008).  
It is noteworthy to mention that the biocatalysts discussed in this section are 
a small sub-set from a much larger list of possible candidates. Our selection was 
done by choosing systems that seemed immediately relevant in the context of 
whole-cell systems, such as the dependency on co-factor regeneration, as well as 
the ease at which expression could be achieved in a recombinant bacterial strain. 
Thus, all the biocatalyst systems chosen were composed of a single gene of 
bacterial origin, and had been historically shown to be expressed in other 
recombinant bacterial systems. Consequently, there are many other candidate 
proteins that have been excluded from this selection that are probably more 
relevant for the biocatalytic industry. Regardless, we are confident that the selected 
set encloses a broad range of protein conformations, codon compositions, and 
substrate specificities that would allow for the study of several different aspects of 
whole-cell biocatalysis.  
 
6.8.2- Towards the Creation of Universal Expression 
Systems 
 
The construction of a vector system that could replicate and express 
proteins in Gram-positive and Gram-negative strains gave us the unique 
opportunity to test how promoters from the different strains could perform in foreign 
environments and interact with each other. Correspondingly, we found that the 
genomic promoters of S. carnosus are not exclusive systems that do not permit 
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protein expression in foreign systems. Thus, as a bio-product from the vector 
design strategy used in the project, we stumbled upon a new and alternative 
source for E. coli promoters in the genome of S. carnosus. We also found that 
genetic regulatory elements active in the staphylococcal genome could translate 
into a similar function in E. coli. These findings, which hint at a common genetic 
language between E. coli and S. carnosus, point toward the prospect of creating 
promoters that could operate in both bacterial strains, and even perhaps function in 
a broader range of Gram-negative and Gram-positive hosts as biocatalytic 
expression systems.  
Correspondingly, one direction this project could take would be to elucidate 
the common transcription language between bacterial species by using the 
reporter vector pQR1031 as a genomic mining tool and to create ‘universal’ 
transcription systems that could work across Gram-negative and Gram-positive 
bacteria. In a similar approach to the optimization of promoter expression in S. 
carnosus, a library of different promoter constructs would be generated by mining 
both the staphylococcal and the E. coli genomes for regions upstream of house-
keeping or well expressed genes. These genes are more likely to be conserved 
throughout the bacterial fauna due to their importance for survivability, and 
therefore are good targets as areas with a high level of genetic information 
conservation. Due to the interchangeable nature of the promoter system in 
pQR1031, the library of constructs would be easily produced by amplifying 
fragments from the genomes with EcoRI and XhoI sites at the ends, which would 
subsequently ligate with the vector cut with the same endonucleases. Additionally, 
the output of the different constructs could be easily assayable by measuring the 
tolerance level to gentamicin, thus providing an high-throughput method to screen 
a large promoter library.  
The first stage of screening would be concerned with the selection of 
promoter areas that would provide a good base level for protein expression in both 
E. coli and S. carnosus, with the focus on constitutive expression. The results from 
this run would help us identify the elements within a promoter that are common 
between the bacterial species and can translate the same information regardless of 
expression hosts. The second stage would focus on the genetic analysis of 
elements in the proximity of the promoters that would carry the same functionality 
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across strains. This would involve the study of constructs that perhaps with low 
protein expression that could contain within their sequences elements that would 
potentially bind to TFs or form secondary structures, like cruciforms. Thus, this 
phase of the screening would allows us to build a catalogue of several regulatory 
elements that could be used interchangeably between bacterial species to produce 
similar inducible effects on protein expression systems.  
While there have been several approaches focused on cataloging 
constitutive and inducible promoter systems for several bacterial species, such as 
Registry of Standard Biological Parts, there hasn’t been to our knowledge any 
study conducted on the genomic level concerned with the cross-compatibility of 
promoters across different bacterial strains. Thus, we believe conducting such a 
study would add to the general understanding of the universal genetic language 
that can be used across different bacteria to promote and regulate gene 
transcription (Figure 78), while also adding to the current list of promoter modules 
that are used in the design of synthetic promoters. 
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Figure 78- Principles underlying the construction of a library of universal promoter elements 
for use across bacterial species. Bacteria with different genetic biases use a majority of 
transcription elements that are unique to that bias. However, a small percentage of elements 
is cross-compatible between the species (blue shapes) , performing either the same or 
homologous functions in each of the strain. These  intercepting points (blue shapes) can be 
used to construct  a library of universal promoters that could be implemented in multiple 
bacterial strains.   
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6.8.3- Beyond the Biocatalytic Bubble: Adding to the 
Transcriptome of Staphylococcal Species 
 
In the last sections, we described how the pQR1031 reporter vector could 
be used to develop novel promoter designs for biocatalytic expression within a 
bacterial strain and cross-species. However, the screening strategy proposed in 
these studies could be applied to fields outside biocatalysis. More specifically, the 
pQR1031 reporter vector could be applied to the area of bacterial pathology. The 
fact that S. carnosus is phylogenetically related to the pathogenic staphylococcal 
species, the most notorious and relevant to current health research being the 
methicillin-resistant Staphylococcus aureus (MRSA), makes the former a prime 
model system for the study of the biology underlying the pathology of these 
organisms and to test drug therapies against them.  
Thus, by taking advantage of the non-pathogenicity of S. carnosus and the 
close homology between it’s genome and that of pathogenic staphylococci, we 
could apply the screening strategies described above to map the activity and 
regulatory mechanisms of genomic promoters from the more pathogenic 
staphylococcal species.  
There are already several powerful techniques that can be used to measure 
and map the levels of protein transcription (i.e the transcriptome) in bacterial 
genomes under different growth conditions. These include high-throughput 
methods such as DNA microarrays or Whole Transcriptome Shotgun Shotgun 
Sequencing (RNA-seq), both of which focus on the mRNA levels produced by 
cells. Transcriptomes are very valuable because they are a snapshot of genomic 
expression, and can be used to detect even slight changes in protein transcription 
under conditions that lead to pathogenicity of bacteria such as MRSA. However, 
while giving a general overview of the extracellular stimuli that affect mRNA levels 
in bacterial cells, transcriptomes do not communicate any information about the 
specific rates of transcription of the different proteins and the regulatory 
mechanisms that might be involved in this process and subsequent variations 
between transcription rates and translation rates.  
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Figure 79- Genome mining strategy for the mapping of the promoter landscape of 
staphylococcal genomes. Sequences upstream of genes are lifted from several 
staphylococcal genomes and cloned into an hybrid vector with a interchangeable promoter 
region and a reporter gene. The Library of different promoter constructs is subsequently 
cloned into S. carnosus and promoter strength and regulation is analyzed by the phenotype 
of the reporter gene. In the case of the vector pQR1031, the level of expression would be 
measured as the level of tolerance to the antibiotic gentamicin (external stimulus)., as a 
function of growth in micro-well plates with increasing concentrations of the antibiotic.  (*)-
(Reproduced from the International Journal of Medical Microbiology, vol. 300 (2-3), 
Rosenstein & Gotz, Genomic differences between the food-grade S. carnosus and 
pathogenic staphylococcal species, pg. 104-108, Copyright © 2010, with permission from 
Elsevier.). 
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Thus we believe that by focusing on the genomic promoters, their activity 
and means of regulation in pathogenic staphylococcal strains would add to the 
current transcriptome data by mapping the levels of mRNA expression to specific 
genetic sequences and regulatory elements. This is not a novel approach to 
studying how genes are transcribed. Several groups have focused on specifically 
studying promoters of proteins that been involved in the pathogenicity of 
staphylococcal strains. However, as described previously, the interchangeability of 
the staphylococcal promoter in the pQR1031 reporter vector allows for an high-
throughput approach in which a library of MSRA genomic sequences containing 
putative promoters could be easily constructed and characterized  (Figure 79).  
The characterization of a large population of genomic promoters would allow 
us to build a more in-depth picture of the different transcription systems involved in 
the pathogenicity of MRSA and perhaps highlight genetic targets for drug therapy. 
It is worth noting that the approach we are suggesting works under the assumption 
that S. carnosus and its pathogenic relatives employ similar transcription 
mechanisms, and that promoters lifted up from the pathogenic genomes would be 
under the influence and affected by the same factors in S. carnosus. This is 
perhaps a simplistic assumption, considering that some factors and proteins that 
trigger pathogenicity in S. aureus and S. epidermis are not expressed in S. 
carnosus. However, we believe that the majority of transcription factors and RNA 
polymerases involved in protein expression are equally present and preserved in 
most staphylococcus species, and as a result most promoters could be transcribed 
across different staphylococci.  
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Appendix 
 
Appendix 1: Sequencing results 
 
• Comparison between oriS of pC194 and sequencing from 
pNW21 
 
 
 
Where Seq_1 is the sequenced pNW21 fragment, and Seq_2 is the oriS from 
pC194.  
 
 
 
 
Alignment of Sequence_1:  [MCS-oriS.xdna] with  Sequence_2: [oriS.xdna] !
!
Similarity : 383/1723 (22.23 %)!
!
Seq_1  1723  AATTAGCTTTATATAATTTCTGTTTTCTAAAGTTTTATCAGCTACAAAAGACAGAAATGT  1664!
                                                                         !
Seq_2  1     ------------------------------------------------------------  0!
!
!
Seq_1  1663  ATTGCAATCTTCAACTAAATCCATTTGATTCTCTCCAATATGACGTTTAATAAATTTCTG  1604!
                               ||||||||||||||||||||||||||||||||||||||||||!
Seq_2  1     ------------------ATCCATTTGATTCTCTCCAATATGACGTTTAATAAATTTCTG  42!
!
!
Seq_1  1603  AAATACTTGATTTCTTTGTTTTTTCTCAGTATACTTTTCCATGTTATAACACATAAAAAC  1544!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  43    AAATACTTGATTTCTTTGTTTTTTCTCAGTATACTTTTCCATGTTATAACACATAAAAAC  102!
!
!
Seq_1  1543  AACTTAGTTTTCACAAACTATGACAATAAAAAAAGTTGCTTTTTCCCCTTTCTATGTATG  1484!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  103   AACTTAGTTTTCACAAACTATGACAATAAAAAAAGTTGCTTTTTCCCCTTTCTATGTATG  162!
!
!
Seq_1  1483  TTTTTTACTAATCATTTAAAACGATACATTAATAGGTACGAAAAAGCAACTTTTTTTGCG  1424!
             |||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  163   TTTTTTACTAGTCATTTAAAACGATACATTAATAGGTACGAAAAAGCAACTTTTTTTGCG  222!
!
!
Seq_1  1423  CTTAAAACCAGTCATACCAATAACTTAAGGGTAACTAGCCTCGCCGGCAATAGTTACCCT  1364!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  223   CTTAAAACCAGTCATACCAATAACTTAAGGGTAACTAGCCTCGCCGGCAATAGTTACCCT  282!
!
!
Seq_1  1363  TATTATCAAGATAAGAAAGAAAAGGATTTTTCGCTACGCTCAAATCCTTTAAAAAAACAC  1304!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  283   TATTATCAAGATAAGAAAGAAAAGGATTTTTCGCTACGCTCAAATCCTTTAAAAAAACAC  342!
!
!
Seq_1  1303  AAAAGACCACATTTTTTAATGTGGTCTTTTATTCTTCAATGTGGTCTTTTATTCTTCAAC  1244!
             |||||||||||||||||||||||||||||                     ||||||||||!
Seq_2  343   AAAAGACCACATTTTTTAATGTGGTCTTT---------------------ATTCTTCAAC  381!
!
!
Seq_1  1243  TAAAGCACCCATTAGTTCAACAAACGAAAATTGGATAAAGTGGGATATTTTTAAAATATA  1184!
             |||                                                         !
Seq_2  382   TAA---------------------------------------------------------  384!
!
!
Seq_1  1183  TATTTATGTTACAGTAATATTGACTTTTAAAAAAGGATTGATTCTAATGAAGAAAGCAGA  1124!
                                                                         !
Seq_2  385   ------------------------------------------------------------  384!
!
!
Seq_1  1123  CAAGTAAGCCTCCTAAATTCACTTTAGATAAAAATTTAGGAGGCATATCAAATGAACTTT  1064!
                                                                         !
Seq_2  385   ------------------------------------------------------------  384!
!
!
Seq_1  1063  AATAAAATTGATTTAGACAATTGGAAGAGAAAAGAGATATTTAATCATTATTTGAACCAA  1004!
                                                                         !
Seq_2  385   ------------------------------------------------------------  384!
!
!
Seq_1  1003  CAAACGACTTTTAGTATAACCACAGAAATTGATATTAGTGTTTTATACCGAAACATAAAA  944!
                                                                         !
Seq_2  385   ------------------------------------------------------------  384!
!
!
Seq_1  943   CAAGAAGGATATAAATTTTACCCTGCATTTATTTTCTTAGTGACAAGGGTGATTAAATGG  884!
                                                                         !
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• Comparison between the CAM of pC194 and sequencing from 
pNW21   
 
 
Alignment of Sequence_1:  [CAM.xdna] with  Sequence_2: [MCS-oriS.xdna] !
!
Similarity : 446/1723 (25.89 %)!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  1723  AATTAGCTTTATATAATTTCTGTTTTCTAAAGTTTTATCAGCTACAAAAGACAGAAATGT  1664!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  1663  ATTGCAATCTTCAACTAAATCCATTTGATTCTCTCCAATATGACGTTTAATAAATTTCTG  1604!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  1603  AAATACTTGATTTCTTTGTTTTTTCTCAGTATACTTTTCCATGTTATAACACATAAAAAC  1544!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  1543  AACTTAGTTTTCACAAACTATGACAATAAAAAAAGTTGCTTTTTCCCCTTTCTATGTATG  1484!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  1483  TTTTTTACTAATCATTTAAAACGATACATTAATAGGTACGAAAAAGCAACTTTTTTTGCG  1424!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  1423  CTTAAAACCAGTCATACCAATAACTTAAGGGTAACTAGCCTCGCCGGCAATAGTTACCCT  1364!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  1363  TATTATCAAGATAAGAAAGAAAAGGATTTTTCGCTACGCTCAAATCCTTTAAAAAAACAC  1304!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  1303  AAAAGACCACATTTTTTAATGTGGTCTTTTATTCTTCAATGTGGTCTTTTATTCTTCAAC  1244!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  1243  TAAAGCACCCATTAGTTCAACAAACGAAAATTGGATAAAGTGGGATATTTTTAAAATATA  1184!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  1183  TATTTATGTTACAGTAATATTGACTTTTAAAAAAGGATTGATTCTAATGAAGAAAGCAGA  1124!
!
!
Seq_1  1     ---------------------------------------------------ATGAACTTT  9!
                                                                |||||||||!
Seq_2  1123  CAAGTAAGCCTCCTAAATTCACTTTAGATAAAAATTTAGGAGGCATATCAAATGAACTTT  1064!
!
!
Seq_1  10    AATAAAATTGATTTAGACAATTGGAAGAGAAAAGAGATATTTAATCATTATTTGAACCAA  69!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  1063  AATAAAATTGATTTAGACAATTGGAAGAGAAAAGAGATATTTAATCATTATTTGAACCAA  1004!
!
!
Seq_1  70    CAAACGACTTTTAGTATAACCACAGAAATTGATATTAGTGTTTTATACCGAAACATAAAA  129!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  1003  CAAACGACTTTTAGTATAACCACAGAAATTGATATTAGTGTTTTATACCGAAACATAAAA  944!
!
!
Seq_1  130   CAAGAAGGATATAAATTTTACCCTGCATTTATTTTCTTAGTGACAAGGGTGAT-------  182!
             |||||||||||||||||||||||||||||||||||||||||||||||||||||       !
Seq_2  943   CAAGAAGGATATAAATTTTACCCTGCATTTATTTTCTTAGTGACAAGGGTGATTAAATGG  884!
!
Seq_1 183   -----AAACTCAAATACAGCTTTTAGAACTGGTTACAATAGCGAC--GGAGAGTTAGGTT  235!
                   ||   | | |    |||||  |||||||| ||||||||   |||||||||||||!
Seq_2  883   TCTCGTAAA-TACAGATTCTTTTTATCACTGGTTATAATAGCGAACTGGAGAGTTAGGTT  825!
!
!
Seq_1  236   ATTGG-G-ATA-AGTTAGAGCCACT-TTATACAATTTTTGATGGTGTA------------  279!
             ||||| |   |    ||||  | || ||||||||||||||||||||||            !
Seq_2  824   ATTGGTGATAACGTATAGATTCTCTATTATACAATTTTTGATGGTGTACTCTAGAACAAT  765!
!
!
Seq_1  280   ----T-CTAAAACATTCTCTGGTATTTGGACTCCTGTAAAGAATGACTTCAAAGAGTTTT  334!
                 |  | |||   |    |    |   |         |  ||   |   |    ||| !
Seq_2  764   TCTCTGGT-AAATTATGGACGTATCTGTCAAAGTAAATGACGATTCGTAATAGAGTTTTA  706!
!
!
Seq_1  335   ATGATTTATACCTTTCTGATGTAGAGAAATATAATGGTTCGGGGAAAT---TGTTTC-CC  390!
              ||||||||  |||| ||||||||||| ||||||||||||||||||||   | |  |   !
Seq_2  705   CTGATTTATGTCTTTTTGATGTAGAGACATATAATGGTTCGGGGAAATCTGTTTCCCATT  646!
!
!
Seq_1  391   -AAAACACC--TATACCTGAAAATGCTTTTTCTCTTTCTATTATTCCATGGACTTCATTT  447!
               |        |  |  ||    | ||     |  | ||||||||| |||||||||||||!
Seq_2  645   GTACCTGTAGTTGGAAATGCTTTTTCTGGCGGTTATGCTATTATTCTATGGACTTCATTT  586!
!
!
Seq_1  448   ACTGGGTTTAACTTAAATATCA----------ATAATAATAGTAATTACCTTCTACCCAT  497!
             ||||||||||||||||||||||          ||                 |        !
Seq_2  585   ACTGGGTTTAACTTAAATATCAGGATAGATTGATTGATGCTAATTACCTTCTACTTATTA  526!
!
!
Seq_1  498   TATTACAGCAGGAAAATTCATTAATAAAGGTAATTCAATATATTTACCGCTATCTTTAC-  556!
             |  |||||| |      |  |||  |        |     |  ||         ||||  !
Seq_2  525   TGCTACAGCTGTGTTTATTGTTATAACTATGCCATATGGTTGATTCAGATATGGTTTATC  466!
!
!
Seq_1  557   ---------------------------AGGTACATCATTCTGTTTGT-------------  576!
                                        ||||||||||||||||||||             !
Seq_2  465   TCCTAGCTATCAATTTGCAACATTAAAAGGTACATCATTCTGTTTGTCAAGAACTAGAAC  406!
!
!
Seq_1  577   -----GATGGTTATCATGCAGGATTGTTTATGAACTCTATTCAGGAATTGTCAGATAGGC  631!
                   |||    |  ||      | |  |  |    |          |        | |!
Seq_2  405   GTTATCATGCAGGTATTGTT-AGATATGAACTACTATTCAGTGAATTGTCAAGATAGGCC  347!
!
!
Seq_1  632   CTAATGACTGGCTTTTATAA----------------------------------------  651!
               ||||||||||| |  ||                                         !
Seq_2  346   TGAATGACTGGCTATATTATCAAATCAACTGCGATTGCAAAATTATTAATGTCACTTACT  287!
!
!
Seq_1  652   ------------------------------------------------------------  651!
                                                                         !
Seq_2  286   CAAGATAAATGGATGGGTATATTGCTCACATTGGTGCCGAAACCTATTCGCAATTTCGGT  227!
!
!
Seq_1  652   ------------------------------------------------------------  651!
                                                                         !
Seq_2  226   TACGATTTATTCGCAAACAATCGCGATAAAATGTGGCATGCAATTGAACACTTAGGAAAT  167!
!
!
Seq_1  652   ------------------------------------------------------------  651!
                                                                         !
Seq_2  166   GTGTTTTGACAGTTAGGCAAAAAATATGCGTAACTGTTTGGAGAAAATAGTGTTTTTCAA  107!
!
!
Seq_1  652   ------------------------------------------------------------  651!
                                                                         !
Seq_2  106   CAGTTACGCATGCAAATCTAACAGTTAGGCAACTTTACAATATTTTAAATGAAATTTGGT  47!
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Where Seq_1 is the CAM sequence pC194, and Seq_2 is the sequenced pNW21 
fragment.  
 
 
• Comparison between sequencing results and the predicted 
sequence for pQR1030 
 
 
 
Where Seq_1 is the sequenced pQR1030 fragment, and Seq_2 is the predicted 
sequence for pQR1030 around the CHMO gene.  
 
 
 
 
Alignment of Sequence_1:  [Sequence Window #7] with  Sequence_2: [Sequence Window 
#6] !
!
Similarity : 800/1903 (42.04 %)!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  1     TCGCAACCAATCGGCAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCATGAATT  60!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  61    AATTCTCATGTTTGACAGTAAGGCGACTGCACGGTGCACCAATGCTTCTGGCGTCAGGCA  120!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  121   GCCATCGGAAGCTGTGGTATGGCTGTGCAGGTCGTAAATCACTGCATAATTCGTGTCGCT  180!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  181   CAAGGCGCACTCCCGTTCTGGATAATGTTTTTTGCGCCGACATCATAACGGTTCTGGCAA  240!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  241   ATATTCTGAAATGAGCTGTTGACAATTAATCATCGGCTCGTATAATGTGTGGAATTGTGA  300!
!
!
Seq_1  1     ---------------------------------AATTCATGTTTTGCTTTTAGTCAACAT  27!
                                              |||||||||||||||||||||||||||!
Seq_2  301   GCGGATAACAATTTCACACAGGAAACAGCGATGAATTCATGTTTTGCTTTTAGTCAACAT  360!
!
!
Seq_1  28    ACACTAAAAAAGCAAAATAGTATTGATTTTACATTTTTTAAATGATATAATACTGTGGTC  87!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  361   ACACTAAAAAAGCAAAATAGTATTGATTTTACATTTTTTAAATGATATAATACTGTGGTC  420!
!
!
Seq_1  88    GTGCTCGTAAAGGGTAGGCCATTTCGTCACGAAATGTTTTATGAGTGGGAGGGCAAAAAT  147!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  421   GTGCTCGTAAAGGGTAGGCCATTTCGTCACGAAATGTTTTATGAGTGGGAGGGCAAAAAT  480!
!
!
Seq_1  148   GAGCCCTGTGACCACATCACGATATCAACTCGGGGGTACCCTGAGATGTCACAAAAAATG  207!
             ||||||||||||||||||||||||||||||||           |||||||||||||||||!
Seq_2  481   GAGCCCTGTGACCACATCACGATATCAACTCG-----------AGATGTCACAAAAAATG  529!
!
!
Seq_1  208   GATTTTGATGCTATCGTGATTGGTGGTGGTTTTGGCGGACTTTATGCAGTCAAAAAATTA  267!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  530   GATTTTGATGCTATCGTGATTGGTGGTGGTTTTGGCGGACTTTATGCAGTCAAAAAATTA  589!
!
!
Seq_1  268   AGAGACGAGCTCGAACTTAAGGTTCAGGCTTTTGATAAAGCCACGGATGTCGCAGGTACT  327!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  590   AGAGACGAGCTCGAACTTAAGGTTCAGGCTTTTGATAAAGCCACGGATGTCGCAGGTACT  649!
!
!
Seq_1  328   TGGTACTGGAACCGTTACCCAGGTGCATTGACGGATACAGAAACCCACCTCTACTGCTAT  387!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  650   TGGTACTGGAACCGTTACCCAGGTGCATTGACGGATACAGAAACCCACCTCTACTGCTAT  709!
!
!
Seq_1  388   TCTTGGGATAAAGAATTACTACAATCGCTAGAAATCAAGAAAAAATATGTGCAAGGCCCT  447!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  710   TCTTGGGATAAAGAATTACTACAATCGCTAGAAATCAAGAAAAAATATGTGCAAGGCCCT  769!
!
!
Seq_1  448   GATGTACGCAAGTATTTACAGCAAGTGGCTGAAAAGCATGATTTAAAGAAGAGCTATCAA  507!
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• Comparison between sequencing results and the predicted 
sequence for pQR1032 
 
 
Where Seq_1 is the predicted pQR1032 sequence around the rplK promoter and 
GenR, and Seq_2 is the sequencing result 
 
 
 
 
 
 
 
Alignment of Sequence_1:  [Sequence Window #13] with  Sequence_2: [Sequence Window 
#12] !
!
Similarity : 625/960 (65.10 %)!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  1     GGGGAGGCAATCCGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCTTAATGCAGAATTA  60!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  61    ATTCTCATGTTTGACAGCTTATCATCGACTGCACGGTGCACCAATGCTTCTGGCGTCAGG  120!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  121   CAGCCATCGGAAGCTGTGGTATGGCTGTGCAGGTCGTAAATCACTGCATAATTCGTGTCG  180!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  181   CTCAAGGCGCACTCCCGTTCTGGATAATGTTTTTTGCGCCGACATCATAACGGTTCTGGC  240!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  241   AAATATTCTGAAATGAGCTGTTGACAATTAATCATCGGCTCGTATAATGTGTGGAATTGT  300!
!
!
Seq_1  1     ----------------------------------GAATTCAAAATAGTATTGATTTTACA  26!
                                               ||||||||||||||||||||||||||!
Seq_2  301   GAGCGGATAACAATTTCACACAGGAAACAGCGATGAATTCAAAATAGTATTGATTTTACA  360!
!
!
Seq_1  27    TTTTTTAAATGATATAATACTGTGGTCGTGCTCGTAGGAGGTACTCGAGATGTTACGCAG  86!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  361   TTTTTTAAATGATATAATACTGTGGTCGTGCTCGTAGGAGGTACTCGAGATGTTACGCAG  420!
!
!
Seq_1  87    CAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGGTGGCTCAAGTAT  146!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  421   CAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGGTGGCTCAAGTAT  480!
!
!
Seq_1  147   GGGCATCATTCGCACATGTAGGCTCGGCCCTGACCAAGTCAAATCCATGCGGGCTGCTCT  206!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  481   GGGCATCATTCGCACATGTAGGCTCGGCCCTGACCAAGTCAAATCCATGCGGGCTGCTCT  540!
!
!
Seq_1  207   TGATCTTTTCGGTCGTGAGTTCGGAGACGTAGCCACCTACTCCCAACATCAGCCGGACTC  266!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  541   TGATCTTTTCGGTCGTGAGTTCGGAGACGTAGCCACCTACTCCCAACATCAGCCGGACTC  600!
!
!
Seq_1  267   CGATTACCTCGGGAACTTGCTCCGTAGTAAGACATTCATCGCGCTTGCTGCCTTCGACCA  326!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  601   CGATTACCTCGGGAACTTGCTCCGTAGTAAGACATTCATCGCGCTTGCTGCCTTCGACCA  660!
!
!
Seq_1  327   AGAAGCGGTTGTTGGCGCTCTCGCGGCTTACGTTCTGCCCAGGTTTGAGCAGCCGCGTAG  386!
             ||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||!
Seq_2  661   AGAAGCGGTTGTTGGCGCTCTCGCGGCTTACGTTCTGCCCAAGTTTGAGCAGCCGCGTAG  720!
!
!
Seq_1  387   TGAGATCTATATCTATGATCTCGCAGTCTCCGGCGAGCACCGGAGGCAGGGCATTGCCAC  446!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  721   TGAGATCTATATCTATGATCTCGCAGTCTCCGGCGAGCACCGGAGGCAGGGCATTGCCAC  780!
!
!
Seq_1  447   CGCGCTCATCAATCTCCTCAAGCATGAGGCCAACGCGCTTGGTGCTTATGTGATCTACGT  506!
	   287	  
 
 
 
•  Comparison between sequencing results and the predicted 
sequence for pQR1033 
 
 
 
Where Seq_1 is the predicted pQR1033 sequence around the rplJ promoter and GenR, 
and Seq_2 is the sequencing result. 
 
 
 
 
 
 
 
Alignment of Sequence_1:  [Sequence Window #3] with  Sequence_2: [Sequence Window 
#2] !
!
Similarity : 618/950 (65.05 %)!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  1     CGGGAGCATCGCAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGAATTAATT  60!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  61    CTCATGTTTGACAGCTTATCATCGACTGCACGGTGCACCAATGCTTCTGGCGTCAGGCAG  120!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  121   CCATCGGAAGCTGTGGTATGGCTGTGCAGGTCGTAAATCACTGCATAATTCGTGTCGCTC  180!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  181   AAGGCGCACTCCCGTTCTGGATAATGTTTTTTGCGCCGACATCATAACGGTTCTGGCAAA  240!
!
!
Seq_1  1     ------------------------------------------------------------  0!
                                                                         !
Seq_2  241   TATTCTGAAATGAGCTGTTGACAATTAATCATCGGCTCGTATAATGTGTGGAATTGTGAG  300!
!
!
Seq_1  1     -------------------------------GAATTCTTTTTTTAAAACATATTGACATA  29!
                                            |||||||||||||||||||||||||||||!
Seq_2  301   CGGATAACAATTTCACACAGGAAACAGCGATGAATTCTTTTTTTAAAACATATTGACATA  360!
!
!
Seq_1  30    TCACATCCAAACCGTTATATTGGTTAATGTGATTAGGAGGTTCTCGAGATGTTACGCAGC  89!
             |||||||||||||||||||||||||||| |||||||||||||||||||||||||||||||!
Seq_2  361   TCACATCCAAACCGTTATATTGGTTAAT-TGATTAGGAGGTTCTCGAGATGTTACGCAGC  419!
!
!
Seq_1  90    AGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGGTGGCTCAAGTATG  149!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  420   AGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGGTGGCTCAAGTATG  479!
!
!
Seq_1  150   GGCATCATTCGCACATGTAGGCTCGGCCCTGACCAAGTCAAATCCATGCGGGCTGCTCTT  209!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  480   GGCATCATTCGCACATGTAGGCTCGGCCCTGACCAAGTCAAATCCATGCGGGCTGCTCTT  539!
!
!
Seq_1  210   GATCTTTTCGGTCGTGAGTTCGGAGACGTAGCCACCTACTCCCAACATCAGCCGGACTCC  269!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  540   GATCTTTTCGGTCGTGAGTTCGGAGACGTAGCCACCTACTCCCAACATCAGCCGGACTCC  599!
!
!
Seq_1  270   GATTACCTCGGGAACTTGCTCCGTAGTAAGACATTCATCGCGCTTGCTGCCTTCGACCAA  329!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  600   GATTACCTCGGGAACTTGCTCCGTAGTAAGACATTCATCGCGCTTGCTGCCTTCGACCAA  659!
!
!
Seq_1  330   GAAGCGGTTGTTGGCGCTCTCGCGGCTTACGTTCTGCCCAGGTTTGAGCAGCCGCGTAGT  389!
             |||||||||||||||||||||||||||||||||||||||| |||||||||||||||||||!
Seq_2  660   GAAGCGGTTGTTGGCGCTCTCGCGGCTTACGTTCTGCCCAAGTTTGAGCAGCCGCGTAGT  719!
!
!
Seq_1  390   GAGATCTATATCTATGATCTCGCAGTCTCCGGCGAGCACCGGAGGCAGGGCATTGCCACC  449!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  720   GAGATCTATATCTATGATCTCGCAGTCTCCGGCGAGCACCGGAGGCAGGGCATTGCCACC  779!
!
!
Seq_1  450   GCGCTCATCAATCTCCTCAAGCATGAGGCCAACGCGCTTGGTGCTTATGTGATCTACGTG  509!
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• Comparison between sequencing results and the predicted 
sequence for pQR1034 
 
 
 
 
Where Seq_1 is the predicted pQR1034 sequence around the rplJ promoter and GenR, 
and Seq_2 is the sequencing result. 
 
 
 
 
 
Alignment of Sequence_1:  [Sequence Window #5] with  Sequence_2: [Sequence Window 
#4] !
!
Similarity : 621/1781 (34.87 %)!
!
Seq_1  1     ---------------------------------------------------GAATT----  5!
                                                                |||||    !
Seq_2  1     CCGGGAGCATCGCAACCGCCTCTCCCGCGCGTTGGCCGATTCATTAATGCAGAATTAATT  60!
!
!
Seq_1  6     ------------------------------------------------------------  5!
                                                                         !
Seq_2  61    CTCATGTTTGACAGCTTATCATCGACTGCACGGTGCACCAATGCTTCTGGCGTCAGGCAG  120!
!
!
Seq_1  6     ------------------------------------------------------------  5!
                                                                         !
Seq_2  121   CCATCGGAAGCTGTGGTATGGCTGTGCAGGTCGTAAATCACTGCATAATTCGTGTCGCTC  180!
!
!
Seq_1  6     ------------------------------------------------------------  5!
                                                                         !
Seq_2  181   AAGGCGCACTCCCGTTCTGGATAATGTTTTTTGCGCCGACATCATAACGGTTCTGGCAAA  240!
!
!
Seq_1  6     ------------------------------------------------------------  5!
                                                                         !
Seq_2  241   TATTCTGAAATGAGCTGTTGACAATTAATCATCGGCTCGTATAATGTGTGGAATTGTGAG  300!
!
!
Seq_1  6     ------------------------------------------------------------  5!
                                                                         !
Seq_2  301   CGGATAACAATTTCACACAGGAAACAGCGATGAATTCATGTTTTGCTTTTAGTCAACATA  360!
!
!
Seq_1  6     -----------CAAAATAGTATTGATTTTACATTTTTTAAATGATATAATACTGTGGTCG  54!
                        |||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  361   CACTAAAAAAGCAAAATAGTATTGATTTTACATTTTTTAAATGATATAATACTGTGGTCG  420!
!
!
Seq_1  55    TGCTCGTA--------------------------------------GGAGGT--------  68!
             ||||||||                                   |||||         !
Seq_2  421   TGCTCGTAAAGGGTAGGCCATTTCGTCACGAAATGTTTTATGAGTGGGAGGGCAAAAATG  480!
!
!
Seq_1  69    --------------------------ACTCGAGATGTCACAAAAAATGGATTTTGATGCT  102!
                                       ||||||||||||||||||||||||||||||||||!
Seq_2  481   AGCCCTGTGACCACATCACGATATCAACTCGAGATGTCACAAAAAATGGATTTTGATGCT  540!
!
!
Seq_1  103   ATCGTGATTGGTGGTGGTTTTGGCGGACTTTATGCAGTCAAAAAATTAAGAGACGAGCTC  162!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  541   ATCGTGATTGGTGGTGGTTTTGGCGGACTTTATGCAGTCAAAAAATTAAGAGACGAGCTC  600!
!
!
Seq_1  163   GAACTTAAGGTTCAGGCTTTTGATAAAGCCACGGATGTCGCAGGTACTTGGTACTGGAAC  222!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  601   GAACTTAAGGTTCAGGCTTTTGATAAAGCCACGGATGTCGCAGGTACTTGGTACTGGAAC  660!
!
!
Seq_1  223   CGTTACCCAGGTGCATTGACGGATACAGAAACCCACCTCTACTGCTATTCTTGGGATAAA  282!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  661   CGTTACCCAGGTGCATTGACGGATACAGAAACCCACCTCTACTGCTATTCTTGGGATAAA  720!
!
!
Seq_1  283   GAATTACTACAATCGCTAGAAATCAAGAAAAAATATGTGCAAGGCCCTGATGTACGCAAG  342!
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  721   GAATTACTACAATCGCTAGAAATCAAGAAAAAATATGTGCAAGGCCCTGATGTACGCAAG  780!
!
!
Seq_1  343   TATTTACAGCAAGTGGCTGAAAAGCATGATTTAAAGAAGAGCTATCAATTCAATACCGCG  402!
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  781   TATTTACAGCAAGTGGCTGAAAAGCATGATTTAAAGAAGAGCTATCAATTCAATACCGCG  840!
!
Seq_1 403 GTTCAATCGGCTCATTACAACGAAGCAGATGCCTTGTGGGAAGTCACCACTGAATATGGT  462!
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  841   GTTCAATCGGCTCATTACAACGAAGCAGATGCCTTGTGGGAAGTCACCACTGAATATGGT  900!
!
Seq_1 463 GATAAGTACACGGCGCGTTTCCTCATCACTGCTTTAGGCTTATTGTCTGCGCCTAACTTG  522!
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  901   GATAAGTACACGGCGCGTTTCCTCATCACTGCTTTAGGCTTATTGTCTGCGCCTAACTTG  960!
!
Seq_1 523 CCAAACATCAAAGGCATTAATCAGTTTAAAGGTGAGCTGCATCATACCAGCCGCTGGCCA  582!
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||!
Seq_2  961   CCAAACATCAAAGGCATTAATCAGTTTAAAGGTGAGCTGCATCATACCAGCCGCTGGCCA  1020!
!
Seq_1 583 GATGACGTAAGTTTTGAAGGTAAACGTGTCGGCGTGATTGGTACGGGTTCCACCGGTGTT  642!
        |||||||||||||| ||| |||||||||||||||||||||||                  !
Seq_2  1021  GATGACGTAAGTTT-GAA-GTAAACGTGTCGGCGTGATTGGT------------------  1060!
!
Seq_1 643 CAGGTTATTACGGCTGTGGCACCTCTGGCTAAACACCTCACTGTCTTCCAGCGTTCTGCA  702!
                                                                    !
Seq_2  1061  ------------------------------------------------------------  1060!
!
Seq_1 703 CAATACAGCGTTCCAATTGGCAATGATCCACTGTCTGAAGAAGATGTTAAAAAGATCAAA  762!
                                                                    !
Seq_2  1061  ------------------------------------------------------------  1060!
!
Seq_1 763 GACAATTATGACAAAATTTGGGATGGTGTATGGAATTCAGCCCTTGCCTTTGGCCTGAAT  822!
                                                                    !
Seq_2  1061  ------------------------------------------------------------  1060!
!
Seq_1 823 GAAAGCACAGTGCCAGCAATGAGCGTATCAGCTGAAGAACGCAAGGCAGTTTTTGAAAAG  882!
                                                                    !
Seq_2  1061  ------------------------------------------------------------  1060!
!
Seq_1 883 GCATGGCAAACAGGTGGCGGTTTCCGTTTCATGTTTGAAACTTTCGGTGATATTGCCACC  942!
                                                                    !
Seq_2  1061  ------------------------------------------------------------  1060!
!
Seq_1  943   AATATGGAAGCCAATATCGAAGCGCAAAATTTCATTAAGGGTAAAATTGCTGAAATCGTC  1002!
                                                                         !
Seq_2  1061  ------------------------------------------------------------  1060!
!
!
Seq_1  1003  AAAGATCCAGCCATTGCACAGAAGCTTATGCCACAGGATTTGTATGCAAAACGTCCGTTG  1062!
                                                                         !
Seq_2  1061  ------------------------------------------------------------  1060!
!
!
Seq_1  1063  TGTGACAGTGGTTACTACAACACCTTTAACCGTGACAATGTCCGTTTAGAAGATGTGAAA  1122!
                                                                         !
Seq_2  1061  ------------------------------------------------------------  1060!
!
!
Seq_1  1123  GCCAATCCGATTGTTGAAATTACCGAAAACGGTGTGAAACTCGAAAATGGCGATTTCGTT  1182!
                                                                         !
Seq_2  1061  ------------------------------------------------------------  1060!
!
!
Seq_1  1183  GAATTAGACATGCTGATATGTGCCACAGGTTTTGATGCCGTCGATGGCAACTATGTGCGC  1242!
                                                                         !
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Appendix 2: CAI values for HEGs in S. aureus strains 
 
 
The CAI values are arranged from the highest to lowest values for each strain. HEGs 
highlighted in grey correspond to genes that were also used in the CAI analysis of S. 
carnosus.  
 
 
• S. aureus COL  
 
 
GeneName	   Function	   CAI	  
- hypothetical protein 0.905 
- hypothetical protein 0.854 
- hypothetical protein 0.853 
hup DNA-binding protein HU 0.851 
- PTS system, sorbitol-specific IIB component 0.844 
rplA 50S ribosomal protein L1 0.837 
eno enolase 0.833 
trxA thioredoxin 0.831 
atpE ATP synthase subunit C 0.83 
- alkaline shock protein 23 0.827 
gapA1 glyceraldehyde 3-phosphate dehydrogenase 0.826 
isaA immunodominant antigen A 0.823 
rpsO ribosomal protein S15 0.821 
- hypothetical protein 0.818 
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rplL 50S ribosomal protein L7/L12 0.817 
- hypothetical protein 0.817 
rplU ribosomal protein L21 0.813 
rplM 50S ribosomal protein L13 0.813 
tuf elongation factor Tu 0.807 
rpsD 30S ribosomal protein S4 0.804 
rpmJ ribosomal protein L36 0.802 
- cold shock protein, CSD family 0.798 
ahpC alkyl hydroperoxide reductase, C subunit 0.797 
deoD2 purine nucleoside phosphorylase 0.797 
glyS glycyl-tRNA synthetase 0.795 
fbaA fructose-bisphosphate aldolase 0.794 
rpsK 30S ribosomal protein S11 0.794 
- hypothetical protein 0.793 
rplT 50S ribosomal protein L20 0.791 
- hypothetical protein 0.791 
tig trigger factor 0.789 
- peptidyl-prolyl cis-trans isomerase, cyclophilin-type 0.786 
- NADH dehydrogenase, putative 0.784 
rpsT ribosomal protein S20 0.783 
clpP ATP-dependent Clp protease, proteolytic subunit ClpP 0.783 
pflB formate acetyltransferase 0.783 
rplY ribosomal Protein L25 0.781 
rplS 50S ribosomal protein L19 0.781 
pdhD dihydrolipoamide dehydrogenase 0.78 
rpsR ribosomal protein S18 0.78 
tpiA triosephosphate isomerase 0.777 
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rpsU ribosomal protein S21 0.776 
fusA translation elongation factor G 0.776 
lacD tagatose 1,6-diphosphate aldolase 0.774 
- hypothetical protein 0.773 
rpsI ribosomal protein S9 0.773 
agrD accessory gene regulator protein D 0.772 
rpsH ribosomal protein S8 0.772 
rpsP ribosomal protein S16 0.77 
- LysM domain protein 0.769 
tsf elongation factor Ts 0.767 
pgi glucose-6-phosphate isomerase 0.767 
- hypothetical protein 0.766 
rpsB 30S ribosomal protein S2 0.766 
rplK ribosomal protein L11 0.766 
pdhC 
pyruvate dehydrogenase complex E2 component, dihydrolipoamide 
acetyltransferase 0.766 
glmS D-fructose-6-phosphate amidotransferase 0.765 
- sceD protein, putative 0.764 
pdhB pyruvate dehydrogenase complex E1 component, beta subunit 0.764 
sodA2 superoxide dismutase 0.762 
rpoZ DNA-directed RNA polymerase, omega subunit 0.762 
rplQ ribosomal protein L17 0.761 
pyk pyruvate kinase 0.761 
rpmF 50S ribosomal protein L32 0.761 
- hypothetical protein 0.759 
rplF 50S ribosomal protein L6 0.759 
serS seryl-tRNA synthetase 0.759 
acpD acyl carrier protein phosphodiesterase 0.758 
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rplJ ribosomal protein L10 0.757 
dltC D-alanine--poly(phosphoribitol) ligase subunit 2 0.756 
rpsN2 ribosomal protein S14 0.756 
ilvC ketol-acid reductoisomerase 0.755 
- staphyloxanthin biosynthesis protein 0.755 
acpP acyl carrier protein 0.755 
rpmA 50S ribosomal protein L27 0.755 
dnaK dnaK protein 0.753 
rpsE ribosomal protein S5 0.753 
- cold shock protein, CSD family 0.753 
rplX 50S ribosomal protein L24 0.753 
efp elongation factor P 0.753 
fdaB fructose-bisphosphate aldolase 0.752 
- HIT family protein 0.752 
rpsG 30S ribosomal protein S7 0.75 
- cold shock protein, CSD family 0.749 
- hypothetical protein 0.749 
pdhA pyruvate dehydrogenase complex E1 component, alpha subunit 0.748 
- thioredoxin, putative 0.748 
- hypothetical protein 0.748 
rplC ribosomal protein L3 0.747 
- transferrin receptor 0.746 
- hypothetical protein 0.746 
gnd 6-phosphogluconate dehydrogenase 0.745 
atl bifunctional autolysin 0.744 
femC glutamine synthetase FemC 0.744 
greA transcription elongation factor GreA 0.744 
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fmtB fmtB protiein 0.744 
- hypothetical protein 0.744 
rplE ribosomal protein L5 0.744 
ppaC putative manganese-dependent inorganic pyrophosphatase 0.743 
- staphyloxanthin biosynthesis protein 0.742 
- fumarylacetoacetate hydrolase family protein 0.741 
- hypothetical protein 0.741 
- hypothetical protein 0.739 
- iron compound ABC transporter, iron compound-binding protein 0.738 
- hypothetical protein 0.738 
- copper ion binding protein 0.737 
pgk phosphoglycerate kinase 0.736 
- hypothetical protein 0.735 
- phosphate ABC transporter, phosphate-binding protein 0.735 
rplR ribosomal protein L18 0.734 
- hypothetical protein 0.734 
guaB inosine-5'-monophosphate dehydrogenase 0.733 
fabG1 3-oxoacyl-(acyl-carrier-protein) reductase 0.733 
- hexulose-6-phosphate synthase, putative 0.732 
lacB galactose-6-phosphate isomerase 0.732 
rplN ribosomal protein L14 0.731 
- ferritins family protein 0.731 
infB translation initiation factor IF-2 0.731 
rpmG2 ribosomal protein L33 0.731 
icd isocitrate dehydrogenase 0.731 
- IgG-binding protein SBI 0.73 
- hypothetical protein 0.73 
	   294	  
rpsQ 30S ribosomal protein S17 0.73 
purA adenylosuccinate synthetase 0.728 
- ABC transporter, substrate-binding protein 0.728 
mqo2 malate:quinone oxidoreductase 0.727 
rpmH ribosomal protein L34 0.727 
rpsM 30S ribosomal protein S13 0.727 
- Dps family protein 0.726 
- nucleoside diphosphate kinase 0.726 
sdhB succinate dehydrogenase 0.726 
sucD succinyl-CoA synthetase alpha subunit 0.726 
tal transaldolase 0.725 
groEL chaperonin, 60 kDa 0.724 
tyrS tyrosyl-tRNA synthetase 0.724 
 
 
 
• S. aureus Mu50  
 
 
GeneName	   Function	   CAI	  
- hypothetical protein 0.905 
asp23 alkaline shock protein 23 0.864 
- similar to sigmaB-controlled protein 0.853 
hu DNA-binding protein II 0.852 
- hypothetical protein 0.85 
rplA 50S ribosomal protein L1 0.837 
eno enolase 0.832 
trxA thioredoxin 0.832 
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atpE ATP synthase subunit C 0.83 
- putative transcriptional regulator 0.822 
gap glyceraldehyde-3-phosphate dehydrogenase 0.82 
rpsO 30Sribosomal protein S15 0.819 
rplL 50S ribosomal protein L7/L12 0.818 
rplU 50S ribosomal protein L21 0.813 
rplM 50S ribosomal protein L13 0.813 
isaA immunodominant antigen A 0.812 
rpsD 30S ribosomal protein S4 0.805 
tig trigger factor 0.804 
tuf elongation factor Tu 0.803 
- PTS system, galactitol-specific enzyme II B component 0.802 
cspB cold shock protein 0.799 
rpmJ 50S ribosomal protein L36 0.797 
ahpC alkyl hydroperoxide reductase subunit C 0.797 
fbaA fructose-bisphosphate aldolase 0.795 
rpsK 30S ribosomal protein S11 0.792 
- general stress protein-like protein 0.792 
glyS glycyl-tRNA synthetase 0.791 
rplT 50S ribosomal protein L20 0.79 
deoD purine nucleoside phosphorylase 0.789 
- putative NADH dehydrogenase 0.784 
rplY 50S ribosomal protein L25 0.784 
rpsT 30S ribosomal protein S20 0.782 
clpP ATP-dependent Clp protease proteolytic subunit homolog 0.781 
rplK 50S ribosomal protein L11 0.78 
- hypothetical protein 0.78 
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tpi triosephosphate isomerase 0.778 
pflB formate acetyltransferase 0.778 
rpsR 30S ribosomal protein S18 0.778 
pdhD dihydrolipoamide dehydrogenase 0.778 
- putative pit accessory protein 0.774 
glmS D-fructose-6-phosphate amidotransferase 0.774 
rpsU 30S ribosomal protein S21 0.773 
- peptidyl-prolyl cis-trans isomerase homolog 0.772 
fus translational elongation factor G 0.77 
rpsH 30S ribosomal protein S8 0.77 
rpsI 30S ribosomal protein S9 0.769 
rpsP 30S ribosomal protein S16 0.769 
- hypothetical protein 0.768 
rpsB 30S ribosomal protein S2 0.768 
- secretory antigen SsaA homolog 0.767 
rplJ 50S ribosomal protein L10 0.766 
pykA pyruvate kinase 0.766 
- hypothetical protein 0.764 
- hypothetical protein 0.764 
tsf elongation factor Ts 0.764 
- similar to SceD precursor 0.763 
serS seryl-tRNA synthetase 0.762 
phdB pyruvate dehydrogenase E1 component beta subunit 0.761 
rplS 50S ribosomal protein L19 0.761 
sodA superoxide dismutase 0.76 
rplQ 50S ribosomal protein L17 0.76 
pgi glucose-6-phosphate isomerase 0.758 
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- probable DNA-directed RNA polymerase omega chain 0.758 
rpsG 30S ribosomal protein S7 0.758 
rpmF 50S ribosomal protein L32 0.757 
rplF 50S ribosomal protein L6 0.756 
hmrB HmrB protein 0.755 
rpsN 30S ribosomal protein S14 0.755 
dnaK DnaK protein 0.755 
pdhC 
dihydrolipoamide S-acetyltransferase component of pyruvate 
dehydrogenase complex E2 0.754 
dltC D-alanine--poly(phosphoribitol) ligase subunit 2 0.754 
rpmA 50S ribosomal protein L27 0.753 
- elongation factor P 0.752 
gnd 6-phosphogluconate dehydrogenase 0.752 
rplX 50S ribosomal protein L24 0.752 
rpsE 30S ribosomal protein S5 0.752 
cspA major cold shock protein 0.752 
hit Hit-like protein involved in cell-cycle regulation 0.75 
lacD tagatose 1,6-diphosphate aldolase 0.75 
- hypothetical protein 0.749 
ssaA secretory antigen precursor SsaA homolog 0.749 
ilvC ketol-acid reductoisomerase 0.748 
glnA glutamine-ammonia ligase 0.747 
fmtB(mrp) FmtB protein 0.746 
- lipoprotein 0.746 
cspC cold-shock protein C 0.746 
- 5-oxo-1,2,5-tricarboxilic-3-penten acid decarboxylase 0.745 
acpD acyl carrier protein phosphodiesterase 0.745 
pdhA pyruvate dehydrogenase E1 component alpha subunit 0.744 
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rplE 50S ribosomal protein L5 0.744 
- phenylalanyl-tRNA synthetase homolog 0.742 
greA transcription elongation factor 0.742 
csbD sigmaB-controlled gene product 0.741 
- fructose-bisphosphate aldolase 0.741 
dps general stress protein 20U 0.739 
- partial autolysin 0.739 
pgk phosphoglycerate kinase 0.738 
- similar to secretory antigen precursor SsaA 0.737 
- similar to ferric hydroxamate receptor 1 0.737 
- hypothetical protein 0.736 
- hypothetical protein 0.736 
- putative manganese-dependent inorganic pyrophosphatase 0.735 
- similar to mercuric ion-binding protein 0.734 
- thioredoxine reductase 0.733 
guaB inositol-monophosphate dehydrogenase 0.732 
fabG 3-oxoacyl-(acyl-carrier protein) reductase 0.732 
lacG 6-phospho-beta-galactosidase 0.731 
rplN 50S ribosomal protein L14 0.731 
infB translation initiation factor IF-2 0.731 
- hypothetical protein 0.731 
- hypothetical protein 0.73 
rplR 50S ribosomal protein L18 0.73 
lacB galactose-6-phosphate isomerase 0.729 
- putative hexulose-6-phosphate synthase 0.729 
citC isocitrate dehydrogenase 0.729 
sbi IgG-binding protein 0.729 
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- ferritin 0.728 
rpmG 50S ribosomal protein L33 0.728 
rpsM 30S ribosomal protein S13 0.728 
groEL GroEL protein 0.728 
pyrE orotate phosphoribosyltransferase 0.727 
rpsL 30S ribosomal protein S12 0.726 
rpsC 30S ribosomal protein S3 0.725 
rplI 50S ribosomal protein L9 0.723 
- similar to ABC transporter substrate-binding protein 0.723 
purA adenylosuccinate synthase 0.723 
sdhB succinate dehydrogenase 0.723 
- hypothetical protein 0.723 
rpmH 50S ribosomal protein L34 0.722 
- hypothetical protein 0.722 
- similar to thioredoxin 0.721 
tyrS tyrosyl-tRNA synthetase 0.721 
mqo2 malate:quinone oxidoreductase 0.72 
- alpha-acetolactate decarboxylase 0.718 
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Appendix 3: DoE design for optimization of the 
staphylococcal electroporation protocol 
	  
	  
	  
	  
A B C D E& F
1 hypertonic& 21&kv/cm&1.1ms&B2: 0.1 : Sucrose&
2 water 21&kv/cm&1.1ms&B2: 0.1 : no&sucrose&
3 hypertonic& 2.5&kv/cm&2.5ms&B2: 0.1 : no&sucrose&
4 water 2.5&kv/cm&2.5ms&B2: 0.1 : Sucrose&
5 hypertonic& 21&kv/cm&1.1ms&B2 0.1 : no&sucrose&
6 water 21&kv/cm&1.1ms&B2 0.1 : Sucrose&
7 hypertonic& 2.5&kv/cm&2.5ms&B2 0.1 : Sucrose&
8 water 2.5&kv/cm&2.5ms&B2 0.1 : no&sucrose&
9 hypertonic& 21&kv/cm&1.1ms&B2: 0.5 : no&sucrose&
10 water 21&kv/cm&1.1ms&B2: 0.5 : Sucrose&
11 hypertonic& 2.5&kv/cm&2.5ms&B2: 0.5 : Sucrose&
12 water 2.5&kv/cm&2.5ms&B2: 0.5 : no&sucrose&
13 hypertonic& 21&kv/cm&1.1ms&B2 0.5 : Sucrose&
14 water 21&kv/cm&1.1ms&B2 0.5 : no&sucrose&
15 hypertonic& 2.5&kv/cm&2.5ms&B2 0.5 no&sucrose&
16 water 2.5&kv/cm&2.5ms&B2 0.5 : Sucrose&
17 hypertonic& 21&kv/cm&1.1ms&B2: 0.1 + Sucrose&
18 water 21&kv/cm&1.1ms&B2: 0.1 + no&sucrose&
19 hypertonic& 2.5&kv/cm&2.5ms&B2: 0.1 + no&sucrose&
20 water 2.5&kv/cm&2.5ms&B2: 0.1 + Sucrose&
21 hypertonic& 21&kv/cm&1.1ms&B2 0.1 + no&sucrose&
22 water 21&kv/cm&1.1ms&B2 0.1 + Sucrose&
23 hypertonic& 2.5&kv/cm&2.5ms&B2 0.1 + Sucrose&
24 water 2.5&kv/cm&2.5ms&B2 0.1 + no&sucrose&
25 hypertonic& 21&kv/cm&1.1ms&B2: 0.5 + no&sucrose&
26 water 21&kv/cm&1.1ms&B2: 0.5 + Sucrose&
27 hypertonic& 2.5&kv/cm&2.5ms&B2: 0.5 + Sucrose&
28 water 2.5&kv/cm&2.5ms&B2: 0.5 + no&sucrose&
29 hypertonic& 21&kv/cm&1.1ms&B2 0.5 + Sucrose&
30 water 21&kv/cm&1.1ms&B2 0.5 + no&sucrose&
31 hypertonic& 2.5&kv/cm&2.5ms&B2 0.5 + no&sucrose&
32 water 2.5&kv/cm&2.5ms&B2 0.5 + Sucrose&
